var title_f41_32_42496="T3 esophageal cancer EUS";
var content_f41_32_42496=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77939&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T3 esophageal cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 404px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGUAcEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5topabQA6kpKdQAlFJRQA6kpaKAAUUq0mKAEopaKBiHnrzRS0UCExRTu3SkoGL2ppAPUUtFAgooptA7C4pRxjHam0UCFopabQMd06UZI70UUBYXe394/nSU2nUCD1optFACrjuBS02igBQAO1LRRQAmAev0oHHSkp1A7BSUtFAgoptOoAKKKbQMWloptAC0UlFAh1JSU6gApKWm0ALXS+DOW1LPOLRmHsfWubrpPBP+s1P/rzegDn4wplAfOK+lvDHwA8P6nolnez6hqIaaMPgFK+aE/1gr728Bn/AIpHSv8Ar3WgDzN/2cfDYjJXUtTz77f/AImvmzxdpcGja/e2FuzskEhQE9TX39uBFfB3xIH/ABW+sf8AXc0IDmKKKKBhSUlOFAWEpaWkoASlFFL9KBCUtGKReOtAxVoozQOaBBQKWnJGdueKAGgBulIanjTHQCrIswIN8hANAGf2pKWkoHYKKbTqACkrU0vw9rGrR79N0y7u0HUwxM38qg1HS77TJfK1G0mtZf7sqFf50BcpUUtNoEOpKWm0AOAzVm1t/MOGViPaoo1Fb2nN5Medo/E0AZsljGOUfn3qjImw8n8q0L64aZ/kKj6Vmk5680AJRS0UAJRS02gB1FNooAWlptOoAKKKKBiUtFFAgpKWigApKWm0DFopabQIWloptADqSkp1ACqpcgJyTXb+FPD2sWkGo3Nzpl7FbmzbEjwsAf0rh1LL9xirDuDiu78NeJdbv7HUrK61W9kthZviNp3Kj8CcUAcQn+sFfeHgRv8AiktK/wCvda+D4/8AWJX3X4Gb/ik9L/64JQB0ZbivhT4j/wDI7av/ANd2r7kLHHWvhn4ic+M9X/67tQgOaooooASlqXyWI6cetRdKBiin7BTM0uT6mgLDadH9KkiVT1FShQnYE+lADEQyNgCpJrdU4702F9h3k4qXJnbrx60CKNSImepxT2jUHCgml8l1GSOaB2E2LT44zty3C+lWktcxgucH2qEwyO+0ZxQBFLIP+WefwqVZS0exyW/GnmzaNM9v1qukbK/H60CIvKJ6jFRlcVqrblxuJwKq3ChTjAoHcqYpUAzzT1AHUClyvpQB9P8A7KXOhamTyVlwD6CvOv2mePiCVXhfKU4HTNdh+zFr+laXomorqepWlqWl4Esqrn864f8AaHv7PVPH3maddQXMflD5o3DD9KBHlFGKtfYpgm7aMVBsagdiOkp+PakxQA6LrycVuW21YwHj3j86xYIxI20sF963IbGWO2zFdQt7ZoAhu4YduUttp9jiso27da0pBNjhS1MWTbH8/wCq0CMrFHSppcZ+UCoaBi9qbS0UAL2ptOwB3pKAEpaKbQA6iim0CHUU2nUDCiheOtFAWCkpaKAuFJS02gQ6kpKdQMSloooCwldL4K+/qf8A15tXN10ngv72p/8AXo9AHPp/rBX3P4JP/FKaX/1wSvhhP9YK+4fBL/8AFLaX/wBcFoA6Bm4618PfEL/kc9X/AOu5r7bZ+K+JPiF/yOWq/wDXc0Ac3RRRQBbSYtGI+B71E6qRwBUQ9qTJ9TQAooopKYEsXHNTwjd8zdKqAnHWrcRyAp6UgsPaAGPcTTMFRhGP4VeBQqAR8tIVUfdX8qBFa0+/h+TWpAsJJMilj6CqCMkPO3mrFjcDdk8GgCVVdjll2g9KvwaaeG3c1fht4JFVnZdoqRrxI/uAH8KAKMmkyHLnJFZMthKj5KmupgvPOXZupssQ48xzQBz9ujMdrA4qPVNPC4YKa6RrL5QYQD+FSPY3F1DswmR3oA4JIWeTaqce4q09ntABUbvYV0DaU0b8kYHdaYLSRGzEmPqMmgDn7WDy9wIKgnJ9zTmtmd94OTjGfauhj0qV0zKrc+1KmliPgnGfWgDAKyuNm8AVHLbeUgbGRW1JpyJIAzJt9RTbuOFY9oO8D2oHcwCg2ZEX5mqPerl1knCggVWC7etADKsWjyo4CYIqDBHUVPbMA4boKYHTaYZWHCx/8CFRatFeMOLeMj/ZAqO0kkcf6sY+tbNkJ5Iv9YtIRxZtbkc+Q/5VD5Ei/fUr9RXeXNybcbXKkmsPUiSAW2D8KAOcK02rska4zx+FVSE/h/WgY0Uce9KnHUVoRPaNDl1Ab6UBYzQCe1Ltb/Iqx5iJJkKCPTFalu1pLBuZQG9KAMqCDfjJ/Sp7jTnjTchDCo1ufs9xmMZX0PStJdStnIJTbnqMUxGGyFeopK0r5I25hII9qzSCOoNIdgooooC4UUUUAFJS0UAJS0UUAFFFFABXSeC/v6n/ANebVzddJ4L+/qf/AF5tQFjnk++lfbvgo/8AFL6X/wBcEr4jT7619reDG/4pfTP+uCUCOgY/LXxR4/8A+Rw1X/rua+0C3y9a+LvH3/I3ap/13NAHO0UtFAwAoopFBp2C4UCgU/AJ4FFguCD0Gamg+ZvSmRVZh27TxzSES8/KM8U9WcLkLmoRIPlBrShIaL5V/SgCi6MeZDzSQxFGz2q6YGJyy1NFbq0ee9AEEVzIBt3NtHvW3YQLPHk8VlwWbvJgKStaU8n2GILGc0AXIIFWXCjmrzWjS8Z5FYOj3skl3+8J/E11sTfaHxC2AOpFAGdH5kTeWSceuaSKQwqcOTW2LMFMSL+NUpLNQCFdTQA3Tkhcfv1JzXQ2On6ftMpTJHY81z2lzrHcKsuMCtie4IGLdCSaAE1F1mUFQqovXAxXL3ssZkXIb8K2JGfzDGZVOfUVn3gS3Odqn8KAKCQxypn7x96Sytzkx+Qr+5GaFZGG4sQf0pbTUJYWJGD70AVr/So8HfGqmuWvYBHLjHFdLcXpuZMvkfWsS/RG6tQBTjghdd285qLCIMEGi3DDoCfxqYRedIMHHsaALtkhEP7vke5q/a3LQjBH5VmQM8U23gL61c3oeN4zQB0Gm2kWonMkWPrTtT8Po5+Xyz+NZ2nXMkbDbOcV0lhD9pAd23L9aAOcTww0aEuFK1z17pM0ZxHGxH0r0x7e0ZSq3TD2JrIl81JNq7JF9aAOD/s6Yc4wfeohayk8xn8q6i5uEJw4Kt60y2vR2jV/rTuBznkfLgqwb6VAUaPpmuoMgkfPkhD9azztRvnCn8KQGDz6mjNaFwbcPzHt+nFVHRA3B4oGMjdkPBOKlnlSRcgYPtULADoaSgBtFLSUBYKdTaKAHU2nUlAhKKKWgBabTqSgByFFIMgYj2r1DRI/Bkej376YdabUTZnIk8vy68uro/BIG/U+P+XNqAOfT/WCvtHwY3/FMaZ/1wWvi1P9YK+zfBrf8Uzpn/XBKAN8txXxj48P/FW6p/12NfY+44618ceO/wDkbNT/AOuxoA5+iiigY8KMdaZUkgKuQUePno4wRUdAC1LGu7qcVGBmp4xuUAA5oAkhhJX5eafFGw65q1bgRRVAzu5+Xj6UBYiucNIPLX8q1LJ9qhcNmqtnDkgEFjXQ2UAC5ZCT9KAsRABysSj5j1NO8kQtg10Gj6SJCZCmT64q0uiCaT5hn6igRkWbxiNVA/HFQ3FmZhkDNdE+jC3XbuANQLZtF3zQMw9P0l0uBsUsT19q6yKxe2iGMD6Uumgxo5AO76VMJj5WZySx6CgDOu5Hb+JifTNVYg/mbMEt9anEbSz8lvzprxypMNgI/wBrvQImXTSgVhtDe5q1Oq2tsrG6w3pVQ7/tEYdmI9M0/WLb7UuyAc47UDKSvEzbkfefUmq1xmVvX61DaaLfWx3ujGP0LVP9oVhxC6H2FAiKSzL2/PyfTiqEfk267WjbFbyRytCWdsj3FZlxbNMmVBP6UAZN5JbnHBBrPSx8wgnLCrlzZSiQAgE1ZsZ47dj5i5oAxpLBlm+WBwlLH5aS42qT7iu6trjT7uH95laoXlppUfKsSfWgZzEke+LcqoDTFRWPzAL9BVmZ1ZtsJwv0qu8TgDfmgC/bqirhea3NNkkWDYH21zMUZU/KT+da2nO+3IkwR70CNq5ik2BkRGPrWY9rMed236GtCEM6fOAR7Gqs4LjCsRQM5jUd+4hmyPrUDqwgBt8giti7sCFw68+uax4nMDlckH8xQFiETNtBcsPwps54BDmrguGIxLGCPpVSYqR8qkUAVjGHXLnn3qvs445qd93pSLgR570AVqSppAoHAqNsdgKAG0lLRQAlFLRQA2ilooASilooAWm06koEJXTeCvv6n/15tXNV0vgn/Wan/wBebUDsc+n3xX2L4Pb/AIprTv8AritfHKffFfYHhBj/AMI3p3P/ACxWgDfLcV8e+O/+Rs1P/rsa+u9xx1r5C8cf8jXqf/XY0IRg0UUUDLN+jpdSea7u+7lnJJNVxU1zcG8uJZiCFdsgGo0WgBUUgitS0VdpIXJrOkPzAKDWrp4ZE+YCgBCP4Mc+lPjtGHTNEfDPK3PpmtXS4mfbu5+tAEmi2SrKm8Z+tdja6ekqblVQPYVm2GmvJPlcha6xIY7WFVjYGgCvAfJgEUQIY+1STTx2CjznzIetXrNo2mEj42p7da5nxFdK92GIBBoA2bTOpSgRqCPerT6c3nnO3HpWLoN+9uCUAUY6ntVi28QtNNhY9woA27W1RYslMn6VTazLuSUC/Wrc2rRR2yl8AjrXPXWsvcEeUrbPWgDShgh3fLjd6mrhtbeSPkpx6CuZaa4C8yKn0NRB7o8RTNj6mgDZmt7YTYWRcimxwxKfllO761hSIUyWm+YehzUcJkWQF5yD6UAdLcQObXiXd7E81jrvt0JMYbHTNRzreSJuinBPuaqQ3l3FKqXYDr+dAFqO6kMJVwR9BVNXbbgM2PetRp4Zvu4X6VTuYHiOVDMKAIrvT4hbhwcye9c7NbOhA2cn1rpIpgy4kYjPTIqKW3845DZI9TQFjDKNBH+8yv0qosqynbLuA9elaNxDL/E3A9eaoSwbz+8ZcD0oAClvHD8kzn8KridZYiGcA+uKXaoGAtMKKxCqvPsMUCEt8qoO8mrFqzLNgAYqoH2+vFXbMq0eSOaBm3bOANqgr+NS3COsWUYE+tUrPIcZOa04gJBgDC0AYt0JzHjIA/OsllcEAx8/SusltkEfCk1nzwAJkDn1oEYOdilSBmqpIbvV+6gOzfzmqMceD3NAyBlG2qmSepq6wJB4qvtAGCOaAKwYk4J4pGFSLCzZxUZBB+YmgBFFJS4PYmkxjrQAlFFFABRRRQAUUUUAFFFFAWCuk8Ff6zU/+vN65xVLkBBkmu38KeHtYtYdRubnTLyKA2bYkeFgD+lAHEp98V9eeEj/AMU5p/8A1xFfIg++PrX1t4UbHh3T8f8APEUAbu7ivkfxt/yNOpf9djX1juOOtfJvjT/kaNS/67GgDCopaKAJVj+Uc1NGmIyQM4qvGSWAycVftl+cpQAyBR5g+XNXYxJwCpxV2BYkOSg/Kp4QJi3AAFAiK4twERUXn2rpvCmmySH51yPes3RLdr25XOTubAr0tbE6ZaARABu5xQMqFEtV2oo3ewp1lZuxLTPgD1rHl1FWvMFiffNWP7V32UpU4PagRV13XRb77e12n3Fc/Hcee6NOSx9M1lahLtuPkO5q0PD9rLPKjSjA+lAG9OdkAA+UH0pdKjS3HmFMgdBjrVqVYFbGQ+KjiKgFpJNqjoKAGyyGfm4GxT2pgnUsIYwqp6gYqOaRZCTIxOPeqyJ+9DZO2gZfjSLBEnSk+0JH8sY4PpUJuE8nGz8cVAm7dlRkUAPhtsk/KBnvTLiGTOQwqVPNkYAnbVgxjyjnFAjMt3kjOCciiR2aYsQdo7VLtVZFCgEflUxCsny/nQBlx7w3BI9qs213OW2spI96aI/LmznIpwmZX/dn9KBlvzBOV3IAKswWqSNuYnHtWXF8g2vLuPoK1tOuvIO1kBHqaBBcaQrRPtDflXJXNi8NyAF4PXNegjUnZlUFRu9qz57FZN5f5iemBQBxx06dTlVUj1qAW8xlYCPn6V1S2bRHBLYpiWm1xIshwe1AHMvapHFmRST7Cn21vbGIncwPpXSSwErgKv5VlC1ZSy7QreuKBhDa4ZXDHA9614YQ0O9CN3pWdBDJGMOSQfQ1at28o4Vm+maBGhBCNuXkOfQiqN7bOi5VQQfatTyWYho/1qJnbcYpccd6AOae1aRCpA/Ksy4tW2kEbW9RXXhIw27dxWZdBcONgfNAHKRR/uzhdzepqlcRSKucVuLtiIXHGelLqFiEAyeG6YoGc7HuC7s1BKS3VRV2SHacDtTHgZl3qOKBFEcGkqcpk8gVHx6CncCLFFPIz0plIY2inClxQAyilooASilooAMsv3GKt6g4rvPDPibWr+y1Gxu9UvZLUWb4jadyo/AnFcJXSeCv9Zqf/Xm1AHPL98V9Y+FD/wAU9p//AFxFfJ6ffFfVfhZv+KfsP+uIoA293FfKPjP/AJGfUP8Arsa+p93HU18r+Mv+Rm1D/rsaAMSilooAltxtO49KvWTgN5j1Qj+YYHStFI8Jk9KALUcjyDAzVyKORYgEJy/vWdBKMqEGDXS6NbLcXKLvHHSgLHbfDuwjLRuVBCHJJFX/ABnqnlxmKJhvb0rQ0e2j0XTJGZgCehrk9bgM5E/Jx60Ac6qsj4ZiQO5NbNvB51gWThR1NZ93GwTA4Hc1DLrJgsBbw9O5oAom1H9ojC7h7iumjnSBFVVAPqBisG1uVdY2AJf1rTtHFySG60ASxDcSSSCamlVEtwjklj600qqlWUEgVGokup+ccdKAHRWjMq5XAPqKvrEqqFKgj6VejVTAElABFRD5LnBwUoAxpoHUYVSR9KjiSUHAyAPSugkkULjAqvZ27ysxIXafagCpFCzMHxxSPG5OWJCjqKtbmSTYWXb6AVXld89Tj0oAqXDYVcBc1GuBFtPyn2q+ArjkA/UUS26MOFX8qAMoQ7yCrtmta102IR7ps/jUccRTBC9Ku/a1fAfIA7etAGVPbBXP2dQT64qoqTqPmZq3ZJlTb5YAJ9BUKkMTujZqAK+nTruHnAjHeuksQjR5BGPfrWIbcBwsmFPpVoP9mxyW+lAG9/Z8bcyEbaiuNOtwuI1yPpVa11QEbZVbHvWta3NvJwrY9jQBzV3YssgC/d9RVE2pTcAMmuyltd0J2/NWRe2bp9zPFAHMIjpkleRSrGPMyRWqtmz9A341V8qSKUKV4oAtRN+6XbgVVkCiTe7ZFALg428VASjR8Bhj1oARpIimDtGOnvWPOj7gVIH1rUZi5xtqkYjIhDjDUAY08RXl8N9KikkMigGRmxWpFBiH5sZqm6tHyV4+lAGRKNjDeOKWP5ImUc56Vdu0Hl9BVFmKL06dPegDMbIk+aoZF544rRkUFfmAz64qqwVeDjNAWKfI702pmAxUZAoAbRS0UAJRS0lABRRRQAV0ngv7+p/9ebVzddJ4L+/qf/Xm1AHPp98V9S+GG/4kNhz/AMshXyyn3xX1D4Zb/iQ2H/XIUAbJb5a+XPF/PiTUP+upr6d3fLXzD4t/5GO//wCupoAx6KKKALVqq7TV+1bzIxxnNZtmpJxW1pxQBc44oALG23tg9a6/w3osjXKMpIx6Vz2ngPJ8o716n4bgWGw81vvmgC5q4BhtrbJJNU79ESMRBenWtCba0yStzjpmmX6ANvYDpQFzgNblMQaNGG5qyLW0LwyO5yB61pXtu09/lVLnoAKvHw/rLaUpstMvZs9SkBP9KAMO0lVRtUKMdOKuWbMpRQcOeuKWz8K6++P+JNqB29T9nekt7aa3u5DdRvG68ESDBFAGpvZYJc7jj0pNO5i8xWw3vUSXCQjYw3b+tQKrNxGSoPoaANu1M753SA1Ntdm6/nWfYSPGvzHp1NVptUP2jar5/GgLm2o8zgDJqVmNtDGq9ayINVWOVFz1q8bpJpVyp2igCv5TM/mljmnsyxj5yT9afJIu44yB6VTuTng9PrQBaiwpwU4PvS8rHk461Rjfd1J46c1MCxGCTtoAfJcqBsVfxxVV3YqpyMD160jYPTdTzEHAIBH1oAgikL/cY/hWzptrdOvyDJ9TTNE0cF90sh2e5ran1CKzh2xhVHt3oAZ/ZEIIe7lBanSf2ZDgb1P41yWqazdXMmLcN+FVGtLqRAfKYn8aAO4C2M0eVlXd9aBZMBviII/WuANtqUHz7HC+mTWtpOt3seDM749DmgDtLS6mtlCyAkHrmtMwRXEO+JgR6YrLtL+HUIcKq7veltLuWxmVWUbDQA6a28teP5VmXcAfBTlhXXzpHc26tEME9cVi3FkinKNhqAOYFs398fjUE8UjRNtVa3msiXz82B7U10AGxQBQBzERkEgDpg/SoWEpJOz9K6C7th5AbA3D2rNbe3CqcUAZJhBOePzqG4UMQhX5fpWtabfNxMrAGo9RiVACq0AcxeWyjd1xWdMm9FIHP1rp5bbzFHArEurcxTYA4oC5jSNITtKDjvVcgbemT6mtLy2ZmyT+NVpUCgBRzQBQlQhQw6VEuM/NVzaSuxxTHhVuhoAqYpMVJjHXtTfvnigBlFPKYptACUUUUAFdJ4L+/qf/AF5tXNoUUgyhivotenaDF4Ni0jUJdNl1xtRNmcrN5RT9BQB5onUV9OeGm/4kVl/1yFfMS/fFfS/htv8AiR2X/XIUAa+44618z+Kv+Rhv/wDrqa+k93FfNnir/kYL3/rqaAMiiiigDSsocEN2xWja23yFieKraajSQ9TWgAwjAHTNAGr4dsgz7sHAr0SxYMqRIeBXP6PbC108Oyjc3tWpbzG2G4csaAN1dpjj5zzVHxNeJaae7Mw3HpVzSE8yOMyEZ964v4ksy3Hlq58v0zxQAmjXSiyur8LvMI+UDrmrvhjX9bW1voYdQvEjji3gCZgM/nXL+E74WreTP80Eowy9vritLSdVit21KPawEkWxeO9AGx4e1rXbm7Maa7dxqPmYPcuMj86oX8j3eo3Eszuxds/MSat+HofDsQ8/Un1NLpOAIioB+tUJ7kXmpO9rGUhY8AigCkimWTaDg1oMgRMqM/SqjW7JJ3De1XAzRoqqwJx6UAU5JW8gquQx71mGzdRuBJPrW8LdZCGJBFDLDGmKAMO1jkVlaTJI9a3Yrobc96z4mDEkgY9KMcq3b2oAtC7OSOtRbmcYJJPoaVY/m3KBgdc1LaFZCxAyRQFx9umSPlq8iHjg/jT7KPzCGxge1XJlUhcEDHpQBTSElTnANLHE8vyD9Kn8sAEs5yfSt3RraOG1Msig56ZHNAGZcEWkKRjJJ9OtQrp8Tp514/lJ6d6uai8VkPOcB52+6hGcVlQLd3z7p1JHpQBYgvdHsz+5tGkb1YZrUh1yMQ8WEJ/4DTrTRZ5cDyBj1bitWPRSqbXubdfyoAxn1y38vZc6dEf90AVl+dp1w21QYifUcV0s/hQ3A3LNG7eimsXVPDrWwwVZT60AY0kc2nPvgz5fqK6CyulvbZQ7AyD15NYkV1PYfu7uPzID1zzir1vAIW8+1AaI9h2oA6Gyu3jfaCcDsasXsSyIrxng9aoxzCW3E6gB16j1p6SStDhSAPYUATFSU4YCsl438/DEFfWrgJa3K7vm9TVbywIsknPtQBFexNhRkc1mzgp93AA9K12VpI1K4Y+9Y1zycDBGaBELc8HB96dLbh4fm5pnKybVUbfWprcExckmgdyn9njV8Kcr61g6hB87bRwPWuq2KicgH8K53WXDDCAjPXHegDDuYfMi3RIFNZoT5TuUGtO4ZkXGTgVmp5h5A49DQFyk3zSZNU3BR8EmtSWPftwAMdcCq17b4wV5oApMM1EvyVOSVG0j5qrnkc0ALuO2mCpM/LUdABRRRQAZI6Guk8F/f1M9/sbVzddJ4L+/qf8A15tQBzq/fFfSXhxv+JJZ/wDXIV82r98V9G+Hm/4k1n/1yFAGruOOtfOXin/kPXv/AF1NfRG6vnbxP/yHr3/rqaAMqiiigDpNKUeQvHWtS3iDiIMON1QaTatJaRui8AVpJH+9jjB6UAdZdsBDCkfGO1PkABiZulUJpt8kSDnHU0uo3LsiRwqTjvQB0+ms8kYYZG01xfjmCWSfc+dhrp9LupVsyACC1ZniBvtUflSDJWgDjLBEgQknmp4xhvMC5A61RdWe4KpkAdq1JVMen5U/MaAIbi7SXlGwfrWrY3MQQIHy4HWuVhgeTpmtzSrX/SVX5uRQBtyNG6mTI4HWq1gVL5Zt/wCtQToyYhVzyeajhxbsVGaALs+4thThfQVA0nmcd6pPfqLn7xP406Bjv3/1oAheVkmEa8D1qcbtoKNwPWqt0d0maWzIkOH3Y96AL87mDTlctl2qTRJDJuxG2TWfqGWIRGO1a2fDaSRRNKVyvvQBsxTrHDhF5+lR2+SCXORWf5xeXCuQPSrSxSNHjNAFqyYXFztx8tbz3CwWzTS8QxcKPWsi0iEKKRwemRU3iEF47azjJIzlqAIbKNtQkFzOMlugIzXV2dpDYwefcbQeykVS0G35VSAI0GTWL4x1twSUb/ZVfegCbxB4ujt32tKT/sJXLS+IbmeTdBpl26fjTlSw8O2C6rr6C4upeY4n/wAKwLn4r6+X/wCJellaQf3PsqMf/HhQB1Om+LWtpMTwXVsfVs12+n6/DqMQS6KSIejjrXlek/EePV2Fn4psbaQPwJoowjD8q0LqBtBu42gcyafPyrZ4FAHfano0ckRHDIehxXN6ZI9hd/ZZsmM+tdJ4avjf2LRMSWT7pJzWP4gt2VhIq/MtAF6wG24kjYfKwpbRv3hT5jjtmq1sS0UMxJBPBqexyt/gnigCQMVyCvNCw5TgED61NckKx561BE+RgkH6mgCoZXibaVIX1rPhgSSblulaGpsAIwpIJ9DWVApXr19RQAt0qxo2w022fKDpSzhQAGJ5qkm5E4JoAvlRsxkdPWsLUUVRlSDU7zPsHrWfduideaAMydUOM4qsfLjGD8wpLgMzcE7R0OetUWLL1JoAfkelLcCFYkI606LLSZx8uKpXc2RtFAFWZR5mcCs9/pViWR9+TmoGYnnFADMUUdqO1ABRTc0ZoAWuk8F/f1P/AK82rma6bwX9/U/+vNqAOeHUV9EeHyf7Hs/+uYr52H3hX0JoLH+x7Tn/AJZigDTzxXz34m/5Dt5/10Ne/bjjrXgHiT/kN3n++aAMyiiigD1Lw0kf9ix9NxWoMLHKWIqt4bn8qyg3Nnjoash98mTyM0Bc29NijKF5Dn0J7VNDtxgAE1kxySMdkedvtXSaRYF4gz8mgDQtYBHYoSADmuX1GRlv5EJOa7Oe3MNjliTXGXwMmpKxGWPUCgDH8mNohIIz5hPPFGwmFFkQj6VpX8iW06AU2UKscWfrQBk2VmVfcPu+hrUtWMdx5qJx9KisCHzljgGtOHbEuMce9AXKdx90uvX1qjHIWtnd4z161K0sgG1h8pNIJGWDa5ytAGHsBdi3Bq6FVLAMWO72qG8QeYPL7+gq1PBi1TB6daAKcLNcc7SFHc1fijIKEcY6+9V7YMIGUMePerIaRRkKD+NAEptTJ05/SultIvs3hxyBls9axrPdIuW4Nakdyw0trZh1oAyY3bdnaV+lbkYRbZSSSaZolsjbndBj3pJJF5BHA7UAW7HElzBGWY5PQmpZ5g2suvXHT2rO0O8WTWEHHB4q3coF1uTruPSgDqrJjDpMsijnO3NcHqy/a/FWn2jKApOSMda7fTy0ukzRAncD61xGvsbDxPp964PlqcE0AcR8VLyW58VTwEnybX5FTPGfpXHYrvPivpMkHiCW/jBa3uv3iuOea4OgBuK9X0CZ9V+GkpuDukspNoYnJ/OvLI0MjBVGSfSvV9PtjoPw5eK44uL594j70Bc6rwFL/o9lIM89fetXxAoLSqBzWd4Jt3gtbSMjkDNWNWulkv5AGyB1FAFexR205xn7p71Np3mPdjevenWTD7FLxjNS6LbSSz7gQB70ALqxMExD9B+NUjcFRwOTVvU5S87hh+dVWCbdxBxQBmXO5nVmL5+tRZ2OTk4+tWGfIz3rNld16nigB0rlpAC4Kjv3qMEyRlgSAKiW45x1oDs0DZXb9KAIrh0TkOOKzL7EqsUHXpVh0hYMCCc1RuWONi9RQBSkDqmDjFQGJXizxuHappSTKoJ4I5FQCURk5GQeMUANtmBj69Kzb9OQUFbFmITlelZc8kaPhgaAuZxUtGSetQMNqVf3qU6CqLncfagCEUlKpxwaSgBKKSnUALGhcgAZJrvvC3hTXrO21G7utIvY7Y2RPmNCwFef5YfcYhvUGu98M+JNav7DUbG71S8ktfsbfunncr+ROKAOFXhua990Fv8AiUWnP/LMV4EOor3jQ2/4lFp/1zFAGrnivA/EX/Iau/8Afr3Xccda8K8Q/wDIZuv+ulCAzaKKKAOx0aKT7NA3OK2hbvGq5B5qTw/bD7DbkgFSmea1J/mVMAEUAS6TYZUEnmuu0aAww7WJJ96wdMJC5OMiumtSjeXhsZoAv6tGv9hq2OfWvPmCw6iskxyMV6ZPH52meSRkY615d4iV4rjAGKAMWdWu7t3ySo6AmrbHhA/P1qrZhvO3g/L3FOuZc7MNQBat7eM3G2M4U+lT64kkMK+WT9c03TY1M0eXx+Na2uxJbQp5rblPegDCsAtzBlwSRVKRZJAyIhwK6LT4om2rgDcPSr0tiiAFVXnr70AceLcuVPTFXkswUEbEk+9WHgEbbcda07eFWtd7pg+uKAMix05VyGxg+1Lc2LxSBVPy/SrqkIGBbOOlPXEkYZloAqwp5eF7+tOwyvl+np1rRWyUw/eqj8wPlkc57UAbEheCCMRAcjnFYd9IDA5XIf2rZvQbe08xm4xXIJqSPfFXbKnigB+h3iwyiQ/eB6966vWH+eG9iHDjrXEPGbWYrj5TXVaBdJeWYtJm+ZfuZ7UAdJ4cudkn777snXNR+KPD/wDaEDJnBXlGzWVFPJaz+VNnb2Nb+nakk8XkXZYL2fPNAHDJqKWdsNJ8WWjT2yfcmxkj6Gs9vBvhC9bzLXxFNar/AHHgD/1Feo3ejR3Vv0S5T361zEng3TWfEthJ+FAHO2mneDvDvzieXVbgdAyYWr9nbXfiXUY7vUY/Ks4v9XH2/AV0Fn4SsYCGt7Mj/frejjs9PRXnZfl/gXtQFh9rDHp1mZnAHy4UY6Vz0Vs1xdHaMseprSlu7jVpgoTZCvpwKvLFFaR5jwT64oC5j3NuYmESZPritHT4jDCSrEH3NWbG2BBupunoao3Vyu3O4AdgO9AFC+Z92TtJ9aqGUtGd46e9M1C4C4J/lWU8zM5CZwaALbTL5OcDOetZs8uWIHNEjOBtOazwxBLMx/OgCdQMx8davyWzGIsDgYqjZyCWZV9OlbWsny9P3I43egoA5ZGLH0qmQUlbcd2akikdRzmq8pIkCDgnv6UAQTY3A8ZNZZDi5zyVrQu8IFxmq1qxZ9u2gBbfiXvWbqccnmZJHNa6OqStke1Yl9IXlIck496AIGJWOqualMmY9p61BQAUlFNoAWloooAK6TwX97VP+vN65uuk8F/e1P8A682oA50feFe5aK3/ABK7X/rmK8NH3xXtuit/xK7b/rmKANPdx1rw7Xv+Qxd5/v17Xu4rxTXv+Qtc/wDXSgDPopKKAPT9CnP9lWmCeFrXjJ4BHy1g6CSukwZx0raiZvsY559aBF1JVjbIbitrT7xRtOelcrbo7RNuJ/GtTS1JJLnA9KB3PQNJuDcx7F71wvxBtXhuVKj611GhTNHKigYHtR4xsvN+d13bqAueW2P7qI+aagkZt6jqCa6R9JRgR0rnriNopACOBQFy5bW88NxECTg85rd1+JriyWPOWHQ1kzXT5t8L261ryCWXT/NHzEUBcgtsW7xGTjjFXd+5Bz3rLtrlL2ArICJEPFatuqtaZU/MvrQIcbYNNlkGCODirKDbb7CAfrVaLUlbIIyRUkFyJRGV4B9aAMjV4ts6qiYB64NJG4C7TnAqW8kDzZIyPalEcRX5S2fSgdy7bPuj4H61D5YE6nANRRyeWuMYFW7FA1xGGY4NAXG+ISUsPvfJ715hLc7Lr92O9ep+MYGfT8RNjHbFeVTQlF3pguO1AXOnDpqFuu0gSD9ait5JLO6DcjPpWDpOoeVcfOSPxro52S5gVlxvHegR02n6lb6gvlXm1Jh0arksbWw6bo/Va4RlZ48lmRvXNdFomsvBCIpm8xf9o5oHc27DVCrfu5XGOxJrTOsOwybh/wAqy7c6XcDdtkhb2qXyLNT/AMhA8+q0BcfJqNw7YNzKw9qLK3a9mH3j6moI3tI34ld/wrV0i8VW2W8JX3bmgLmrBZvCAsXC+1K1uiD9++0DoPWpW1WG2g+8DLXMXt1c3kvDGgC3f6mxi8qOQKPQHisRZpWAZgWA75pGtQg3TNn61kXt+Yw8VuDj1BoC4l9fFyEyc/WoIJJEZWYZz6motqRqHcgsPU5qLzGlulMbfL6UBc1tQ3LEJQg59q51pG2cgn8a09U1YCJIBj5etYTXaiPhQaBFqyn2Tb8sMelWNSv96qokz/s5qjbThjzz9KqsqG8D4496ALxJA69Kz7u5DS7h1qWWQ85cfhWTO+1smgdyeWcyNtJFO0tnN0SQCo71mKDuL5NW4ZzDCxB60BckkcHzCRgetYE2WlJyc1ol38obs89aoswYfKvP0oEVwAAQetRU4/epAOM0DuNpKWm0AOoptFADq6TwV/rNT/683rma6bwX9/U/+vNqAOdH3q9o0Vv+JZbf9cxXiw6ivY9Hb/iW23+5QFzS314zrv8AyFrn/rpXr+7ivH9d/wCQrc/79AXKFFFFAXPQNNd00u2AHG2tq3lJtwvesrSZ4jpMAfHyrVqG+gQZUg0BY3rO2d4xubGetXLNMORngVgHWFCYU/lUaarMjHGTn0oEeiafcIknDCt4XUeoJskALDpkV5hZX0ilWYn866nSr0b1JbBHQ+tAE15pu2SQKCMdDXHapbFHbcgKjuRXrdj9m1C1CnG7171yWvaO4mljCjaenFAHEwhXjgbHy5xXSWOEXywAYz2qhFZmG0COmMcjiponMEwY52lfWgCEWaW0zME569KsWiAXJOf3Mgxj0qO4uHkG+Plh2p0+YoVdBx/KgCteWhgbEZNWLK2by1BbJ96YLwXs0aIPmPFQxXM1rd+VIpK+tAD5EEJPlruogJjOWbOevtVm3wTkg025gLQboc5+lAFeVUKfxU22HlzRsWbFQQzeW+2Xn681clwSjRZIoA6fWLQXmmZUFjt9K8ant2t75t+cA9K9j0C6Jg2zkgehrmPFvheVpmuLX5o27CgDzTU4Yi261I3jsKLLUriBMPkj0NaEuhXMUu4QyVdtNCkn5lgINAxdPv4rpfLlRmzW5aaWEbodvvUun6CsJQ7c/hWyqsF5YYHtQIrI+z5YlUCnyTBdoeIE1NcyRwAE+Xn2rKe9cnPkpj3oAvQy5kBKcfSni/mTJgfbWDNqsybQQqgVn/2m56uR+NAHY6ek11NumkB/GtGSWCz5EgY/WuBtdVeEKI52yfSrdnNLNIBNICPTNAF+7lkujLl2CDpzWKsqR7wxXP1rduYw9uVgXAPcVg6qiQ7cgZPXigCiZd4+Ziee9V/tyWhIVstUE9/jOwAY9KyJ5Q53E8mgdi1LeNJIzMc59TTUZtuP61meYOik/jT1kbOS5AoCxsLdLEMIeaZ9oNxPtTcF9QayhMd/Sr1i7s37sflQIWedxIAMiqsjFpMMTj602SSRrjkGo5XfPK80DsWAcqq96kmiI4GMVnxM46sc/WrDzPjGaBC3BcInuKobjE3Umpp5XOCTkDoM9KpFtx5OaB2EpuTjGTTjxUdADqSkooC4tJRRQIeuxSDKHK/7NeoaHF4Li0bUJNNm1ttRNmcrLHHs/nXlw46V0ngr/W6me/2NqAOd/jr13SG/4l9v/u15D3r1nSm/4l9v/u0DsaGeK8j1r/kKXH+9Xqu44615TrH/ACE7j/eoCxSooooEdJpzyfZtu75dtTWmDD948GqmmH92AelTgLCSqk4NA7l7zVUVftJQWAyM1jCF5D3q1aW0nm5BNAjoBdE/IOtadleSboyc1lwwIrKXb8autPCkYCEZFAHY6TeSQMAHwM9jXabYdQs0fePMHfvXj9nqEr7OvXtXcaBcyEEEt+dAEms6U0ULADIrLFqptU8xfxIrvWhF9pmRy9cxfQCJhDLlRQM46aM2rGQdKnkkiuLQrHIQxHTNdHNosUtvs3bifWuSm0q4gmXCkfSgRDpEZtrtWfkjua1L94J23xuEb3FZs0ohmXzUdc02Ro7kEKdqe9AFi3vlIwD+QqUXA2HDYx2BqDT44kPRT74p8kFu+RHJhvQUAVcJMxY/e+tTQSmJ0Ung1QeN435IH0q022SMEdR0NAGrBPPHJtKgoe9a9hqMseEljZk/2mzXP6fHcuQJAdtbFxFNHH8ke4e1AFu7ltXGVQCqsccLw5SVM/lWKTNMSq5z6U77LIsGCCKBmo0wgHyNv+tUmuZJOUXiq8L3Ak5ClfQ1oJJGsW0RYb2NAjJuyrfMwbArnb68QKQGK/jWjrt1JGHCMyiuKuZjJ2JPuaAL8l4DDy4NV3miZVxuJ9qxvM+cAg49Kkhl2NuViD7UDNyJ2EsYDqq+9aemzxfaOG3H3rlFcyt85JPb2qdJHt2BzhvY0CPSJtSt7aw8vIaWuSv7w3J5+9WdbXrSP85L1ckeFIc8bvzoAx54WjUlitZ5UhhkgirF9M0suwnAqq3DcfNigY1QD1FNycY5/OkVs/eGPxpmCDxuNAXFWTGOtaGmXPlvtXkmstTng5zV/SECz7n6e9AjobGwWSX5gD9RVbW7H7NgqASfauitTD5WY0w2PSud1O6k+07ZiT6Z7UAYhhYZcjAqFZAX554rVWMyQ7c8msiaLypKAI3Yleai70rHPemZNAxetNpe1NoAWikooAWikooEOrpPBf39T/682rma6bwX9/U/+vNqAOc716ppbf6BB/u15X3r03TWP2GDn+GgDQ3cV5bq/wDyEJ/96vS91eZar/yEJ/8AeoAq0UUUAa9i5AQDpW5Jag25lXAIrn7bKxKwJGK2oNREsZjPTFAE2nNi1Jc5PqamW+EZyoqrZD93s+Y1oWWmNKnzCgCq9zcTJhWPPStXSbG5mt/3m7d6k07T7ERvtkIx71vxXCwsFUALQBPpGnrEyh/1rqbKRI2JBx9K5H7aVPDYP1pIdQniPMu5fegD0ex1Vo49iOvFaObTV4wXwJh0968xgvXMoZGIX0Brbsb5oGUox/OgDpruwcYEZIcdKybhfNGyUbZB371p2GsJPGDI4Zl6c5pNR+zy2/noMN60AczcWiGImRNxHcjNZE+mpON0B2KOuOK6GG+WdvLEY/Oq7Wu272xnap7UAcaqT2115Ls2D3zWxaaLKQJQwz9am1nSJjMpQ8nvmqkjXtjgM5C/WgC7Ho/lsDId315q4LO0WPadik+lYv8AbbzKY1zv9TVSCedz++kJP1oA7C1mjhG2ZAU9c0j63bqP3ceR6EVy3nShQSzFfSrERaRR8uAOtAGpNPHI26BREfY1WmmuPKOG3e5NVxGo5Y44qhNqLIuwDFACtctDJuYiq1zqW77jlSfTiqbuGi+dm/KqE1ygTK8H6UAU9UviD85c/U1j7wG3jP0qzeyLKwU5Pviq8dsxJwx/OgChvYncxOPamtPt6E49auizeNAGQHPqarPA46qCPrQBE8vGd7bqlDOy5bJ+pqJgrnC0YIGATQBYivHiXO3mp7GYzSgyMdvuazjuL4LHFWrQ/NjIUUAXZ7bzJC0YyPWqLqYhlwM1tS3lvb2WyJgZfXFc3MXPzE5HvQAxwB0OaFJHeo8kmpoxvIAH50ARZx71oaQA90oZ+PSqUqqhCqcmr2n8XEaoPm9aAPRpYoYrPenXHUVyRgE96JJgSvoa7TyA+krv4OKxLqKMbBxQBlJBlXaJc46e1YV7bybMvnPrXYxOkEbRqBvPtWXqEC/ZMswLUAciRj3qPFaBhQA45qnIhQ7SOaAIqSlooGNopaKBCUtFLQAldL4L+/qf/Xm1c2iliAvJNdx4T8Paxaw6jcXWmXkVubN8O0JAP6UAcQOtekac3+gwf7tebjg16Hpx/wBCh/3aALu/3rzjU/8Aj/m/369BzxXnupf8f031oArUUUUAaloHaLy1QnPetjT9HlHzuvFaXhy0jNkjuoJI6kV0WUSPBA/KgZS03TY0ILAH6irytFAWTIGehqmt35Zxnis65nOc7sj1oEPup2WTCt+OajXUWiGJDu/GsZ7t2bAyTmlBy+JM0AaJ1KRpu/0zWrZ3Kyx7SMkVzkDDz8lTV2O7RSCmAT2oGdRZNiMgVbS7LJgHDVzFtfMXJR8e2amjupDLzkr60AdZorOLgoxO31zXYSx/atGKxviQDsa4qyuI1jRgfmPWtjT9UGXihc596AKunxCA5Zjn3qxc3KvFkSHevQ55NZ13eATbZl8se1NdRbsjviSI9cUAXDcy3NuEEigj35pFVWj23bBwO5Oa5/UI/n8y1dh7A4rKiu7rdtkL7R1yTQB0N2IIpd0EWB7Cq0l9ZOABG6t602OVxtKvkemao6nkxny/kY9DQBq22o28Xy3ce6M9CBzVqW6sli3WtxlfQiuYsN6DbdMGX1rYsxYlwAEdKAEe8+X76sazjJ+9+UHHvWxfWWnhd0LGNvTNYjQsJceaWzQBPDcRyPtZlXHtVPU7XKfuo1x7Uklmyj5Sc+uKYknljZJvP1NAGKLWWJfmG73qoZXUbFyD6119rAk8JUEZ96yZtM2SbZUOD/FQBy8ryEjLsce9QySMU749a257CFGxJMy++2q91b2kUIWOUufYUCMmJwjDbzU21lPIp8SQY/1b8dKcVeQcq496AICzBwcUhYM3FSPGVxkkj60zCp93mgYv1qMMpTk0bX+9k4qTZEsQGMmgCIRkOMYp4Gx+KhV2VuAT70+3Ys2WNAhrFd2SK2PD1u0txG2Oc1m7GmkwiAD6V3/g7RZNyl9oRR1xQM6J8NGkJUbB3rD1CJTKMAAD2reu7VFU7ZCT7GufdjCFR8sWPU80AZciP55KZJ9fSql4vyiPmtqRkCnaAGY1Uns23gseMc0AYS2SRw7z0rGmYyykkYrau5W7Z8sfkaoBAeeM0AZWKSppgFbgCoaAuFFFFABRRRQA3LdVYqw7g4rufDGvate2mpWdzqV9JbizbEb3Dso/AnFcPXS+C/8AWan/ANeb0Ac5XfWD/wCiRfSuB7129i3+ixfSgC9u964LUf8Aj7l+tdturiL7/j7l+tAFeiiigDutJvPLsIx/s1I+plhy5/OucW8MdvCAevWkJJPUkUCNJtSG4DccfWrtgFuMrvzXNKMkEDj3q9ZzGKf5CV9s0AXGg8qRgyfjVaV383cgyK1Zh50SyY69azAfKm2c/jQA6C7Vl6ANSSA/eAA+lU75vLcYXA9RUaTMv3myvvQBpqzGPcuQw9KuWt8wwMEisK3u+cbiR9asWl6Fl2nOKB2Ok0+6k8xN8jBfrXStcRQoskDjzD1rjDcBUXbVy0uw3BG6gRqXuqFzmTk1Zt7x5IMI2V9CaxJVWZMocN6VHaSvGduSD9aANqOUrxISKdtUxMxAI+lV2jcATOd0fvzTo5iEwnMfpmgCV4SLfKAj6VXJMy7ZecVr2V6F+R4UaP1Kg1WlEAcvGVAoAzhD8m0Dj3quUa1IkXJFX3VJsbXK/Q1n3SyxrgvuT0NAEE92ZzuExUinQXDiPzFlYt9azXUngnHvSQHyiMy8fWgDR/taYcEk5rNuL6ZpNwZifSop7lD0k/8AHafYOk84xzQBctLq4jhJSMk0sutyhAJVJA9Tmug0/TpGi+QD8RWNqegytyFwPagCnPeGdAWiGTTI1h8jcYcn3FUrm3uouEdh+NV2vLtcLigC/HIG+7bgfhUDpO7fNGAv1qBr+VCMnFRSXkrrw5+maACREX75yPaq4ZeqAZ+lOGVQ7x+ZqsjAt/FigCTzJSNuVFRbtvSpGWMEc1GAB2zQA0yER4AGaapwMA1KsMksoWNGYn+6M113h/wlLKQ95EwP90imBU8NaSbpd8jMAenFeiWaraWywRMxP8RqS1sIrCFY0hBfsAOlSQKY5TkAkdaQFaUYR2OR7VjyqskoDfw1rLKZHk38VgyCQPK+7A+tADYIRNdA4yi+tM1Us4YIwUeo4qWyulWzYD73rVDAP32JHpmgDMlhj+zjg4rDmUxvlSSK6m/UhAqx4z6Csu5ijigBZQW9xQBjNEvk+Y/f1qiKtz5xtycelVgu3rQA2mU8U3FACUUtFA7CV03gv7+p/wDXm1c1XS+C/v6n/wBebUCOc712Vm3+jR/SuNrrLRv9Hj+lA7FzfxXG3n/H1J9a6zNcldf8fMn1oCxDRS0UCLtqquqq9WJFaIYBOKgt2HA7ipJJsuFPIoHYlVwyKCeRT3ICbxyfWqxIHSkGSMZOPSgLGrb3TyKFRiB6Zp8/3d78kd+9Z9uMKrKTkVeZvMg2jrQIqtNvTZKgIPQ1SKgrjNTGN1KhyBUbLtk7baB2H2EIJGQK03sUCZjwDWXHI6NhTViCS5Knc2fYmgCRGkBQFuR1Ga0g7DaycViGR94ITmtKOZ9oyKBGhHJMp3YGKnWVQwcgVQ+0cbMmoYroqdjruX1PNAHWNPG9rtRgfrWagaL5ix2+xqrbtEy7S7DPvUkDsimNnJ+poA1opiRkPn2zVOa5MafvIjj2NUDN8p3ZH402O7KttJV4/egCVb7amVZQfrUc2qF1xwTVad7d+g2/QVmTDyz+7YUDsXFuGm4wVNTiNQMSbfxNZEd2y43Ci7lDcg0CLE8jsMKY8euKXQpQZsHOaztyjGCMVpWiRhQ8Um0+woGelaVewxRjec/WrzTWchydrL6E158t+8ce08mmxXdxOwESMfxoEdlqFtY3RxHHGh9gK5ufQ4w+ck1FYi/348mXPrtNbtpb6gIt80Xyj1oA5C70USLvAZQOmRWU+mzKcorGvU4ohfR7CoX6iqV1ZRwcMFA9hQB5hLBL0cPn0pgXEeBx+FelQ6VZ3B+aTDerAVpQ+GdLEf7yeNm9AooA8ihtpJPuq7fUVs6P4bu76UCTKCvT4PD9oi4jIB9lq1AkVqwSNQSO5oAXwh4QsbBUYrGz/wB+QA1005tInEcEayz93x8orEimhWXfdXJKjooNXH1S2ubfyLceX/tDg0AVtZkt7GAmNvNun9O1c9EXRslm3Hrk1JfNsuP3Lb8epzSRQM43TTDJ64GaAILqVIonZcFq5Weea4Yx78A1vX8RUnY+R9aybgW8KbgPmoApPP8AZ4dqc1Np8XmASSOAo7etZzkv8wwB7UiSMu0ZOPrQBrzs8kqg8CqN+kbDkZqwLpZBuIHFVyA37yU/L6UAc+9uWbkYX1NZ82d3TitnUJiy7Ix+VZmw8B6AK0QHemMcnipChzx+tR4oAZRS0UDErpvBf39T/wCvNq5xDGpBkBK+1eo6JF4Lj0TUJNMl1htRNmcrIE2UCPLu9dPat/o6fSuYrordv3CUDLW/3rl7r/j4f610Wa524/1z/WgRFRRRQBPE2MYp5G6kVU2jmkDbFwetAxd7beppElbbjPNRBj60g4p2AtW8rocEn86sidkPyvmqDMT3NS22G4ZiKQFybLkM/Sq5kI4xke9OMpQbTz9aYg/KgCa1TeMg4PvU029CGXOKZHtSQc8VOsoL84K+9AAG8vB/nS+awXr+VTzRwyw8MKpSKVX5aAsaenqsyZYjPvSSxiPsQf0rNhlfZtbINaCyt5fznI9TQBJE6seOtLO7dQxB9c1nmXy2+Tn6UjTFo/lJ3ehNAFjzHkGGYj8ahYKrf6w/nUSO+OvP1qlKT3JoAsmcDgO2PWq7yD3qBAp4JOKRjj7xJoEXEnTb8wBPuKZJPGyY2DNVWao1p2GSYG7GTVu0uGUdf1qivHWgEjoSPpRYDZ+1NL/rOPoasWWoNbsDE7fnWRb578n0NWc7cbQgpAenaB4wDQbZkG4dytSS+IllOAmF9Aa87t7tyv8Arkj+gxTTdNDKGMhYfWgR3dtrUUTln3Ae9XFuLbUVyu7FefNeJJgyI2Pc10GjajDbAAkCgDensNybYUZT71paZpE0MG6Z1LeprPj12N4sxkBq57VfEOoF8JJMF9iaAO8kWW3tsq5ZvY1S0+G5lYu6OR6tXO6TrV1MNpZj9a3hd3LJhpSo+tAFqWyBOSy5rNeURT7N3H+zU32qJF+dmc1kPMDLu3H8KAL5SIDcC2akju1ELbV2j1NQ2EkUikO351NK0Bh2Ku4/SgDJeRJX+Qtn61i3yhZNrSk/jW3cxbBth6+1ZlxalSDJ973oAoFEVMDBqlOXdsKMD2q3OAOAcCod4C/L81AEavsGzPA60rz9MmqpU43MTmoXkG4DmgdiwwUHIBx61Rcq8vX5RU5mYrySKoOT/DQFhkzgvgdKjQCgUDC9adgGGmU6kpAGTXS+Cvv6me/2Nq5qul8F/f1P/rzagDnO9bsL/ukrCrXiP7taAuWd/vWFcf61q181kS/6xqBEdFFFAxevSgknqc0LxSUAFGaKUUALg0i5A6mn5pM0ATGbK5I5qWBs9aqDOO1T27LtzzmgLkshweKtWqgjDd/Ws4N83JNWoZiO1AicMsR2EH86l+RouDWe7eYd3NSQdMZOKB3FEvz7ScmrH2lHi2HINV5IsHdjn1quJCp+bBoAnO6IgxtmmzTEjIHPrUaTBByKY0m77uPxoETwFSmd2D71ACRJgYYe9RFhSI3OTwaBjj+VIGGMYpGz60gAPSgBVx/EM0gHp+tNBK9zRknvQAZpYyAfmyfrSUUBc2Le5tVTIiBPuKYs8c0oMiAD0FZWSKXcfU0CLd88RbEQOKrbz6k/jTAS33iaPu9KBk6yuT8zmrdpdyebg81TjYnqF/KrULFHGwAUAdfo7+aPnJH4V0lnpVm4HnebJ+FcNYX6wld7D8K6Cw8RurbVJIoEdh9k0/T4N6W2D7nmudvbp2mzHJtT0xUsl294oMuQPQmsfVrxAAikA+wFAFvddyj5GVhVyO38q33Sspb0HNN0e4tTbgFMn3FbVvJujzDaqT/tCgDHtoI48M5J9qvSTRiPEaBR71Lcxlo90u0H0ArAubl2XYw2E0AQ3t9skHlkhvY1FzcczNg+9Q21oY2aRySB61M8OYt5c4/WgDLuIFDYEhI+tRB4YUOwZHqan8osvBz9aoXg/hAwvtQA1yrJndWZ5g83rVhgOBuwBVGVV3ZQ0DuPlnHbJqPzNw+UYqI0A/hTsAbWHQ00+9O3bRgcmmUgG0UtFACV03gv7+p/9ebVzVdL4L+/qf8A15tQBzlaUbfIKzauo3yigCfd71mS/faru6qLffoASiiigBf4KanvS08ICOtADaCB60lFACjmgHB5oFJQBIiZFNQleaAxHQ0maALKOKchIb2qvFx16VPG3GCaAsPiZVbHUUZwfkzVfawPWpY2cEcUBYsCViMSGo54gBkYNRMzbs4ppBPGRQAwgnqSabt4peV605CD1p2AjXg8802lopAOHSmgUmTS0AJRRRQAU2nUlAC9KKKKAG0UtFACrTlY5602igC9Gowvyk/jWnayuuNoUGsWGRweCfzqzGX3ZwaAOxtp5JYMOWb6GsnUrNwd5yfxqXSJif8AWO34cUajK8vAJA+tAixpN4bfG5s/Wujj1CeRVCS4HoK5GxhG7EhBFdhphs9g+UGgdiYmR8bnP50w20CtvmYNTb64CcqFVazXnDQ7t5oET3R88FYlCJ7cZqqZFhXEuWHvVWK+LDbEjO3vUVyzlcyHaaBjhcwytjBxVS8XzlxAg2+uKqxuyt7U99T2R7IwB70CMS6WRGwTiq2do4qxdyF+SxJqox4oGNpKKKACinBcik2460AMopaKAFVWcgJyTXceFPDusWsGo3Nxpl5FbmzOJHhYA/pXDAspGxirDuDiu88M+JdbvrLUrK71W9ktRZtiNp3Kj8CcUAcKetTq3A5qCnK1AE+6qx607dTKACiiigQUDjpW/D4L8TSxq8egaoynoRavUn/CDeKv+hd1b/wEegDnOnWm106eBfE5cB/D+rhfX7I9Xta+HXiGzvmhtdD1aVABz9mY/wDstAHGU2ul/wCEF8Vf9C7q3/gI9H/CC+Kv+hd1b/wEegDnKUCui/4QXxV/0Lurf+Aj0L4H8V/9C7q3/gI9AHPKcUZPrXZaH8PPEN7d+Td6Hq0SbSd32Zh/7LVE+B/E6thfD2rMPX7I9O4HPI4PD5BqXJC5B5rbHgfxVnnw5qx/7dHqZvBHifA2+HtX/wDAR6QHO8gZJb86R/LxkZzXSf8ACG+Kdv8AyLmq/wDgI9MHgfxOw/5F7Vv/AAEegDmMk9SaSu2h+HevNo8102i6sJkcKqfZm5FZv/CD+Kv+hc1b/wABHp3A5qiuj/4QbxV/0Lurf+Aj/wCFL/wgvinH/Ivat/4CPSA5uiuj/wCEG8Vf9C7q3/gI9PTwJ4p/i8Par/4CPQO5zNFdtqvw71+2jtDBomqu0se5h9mbg/lWd/wgvin/AKF3Vv8AwEf/AAoEc1RXR/8ACC+Kv+hd1f8A8BH/AMKP+EG8Vf8AQu6t/wCAj0Ac5Ta6X/hBvFX/AELurf8AgI9WdN+H/iS4voIbjQtVjjdvmb7M3H6UAcjTq6y+8AeJIbuWODQNXdFbAP2R/wDCq3/CDeKv+hd1b/wEegDmqeorov8AhBfFX/Qu6t/4CPS/8IP4q/6F3Vv/AAEegDn4lbPBxVtJWjHzE/nWqvgjxWDx4e1f/wABHrV034feILq3u2udG1dHiTco+zPyf++aAOftbsg53tj61ca4WTG6T8qsr4E8UBONB1T/AMBXq3beA/Eq4LaFqZ+tu1AFOIF0xGpVf71SwSmAYDsPxrSl8MeKwNqaDqar7WrioR4T8UBM/wDCPaoT/wBer0APhkSVMySlz70yZlRdpPy0+08JeJ/vS6Fqn0+yPWje+Dde/sq3uV0jVmkkJyn2ZuKAOeN6U5hXI9elVXu3n5k6e9aw8J+Jjw+g6wB7Wj0kngzxGUwNC1YD/r0egDB89mHBqlICzcE4rpP+EM8TAYHh/Vfr9kemnwb4mEWB4f1bP/Xo9AHLMfWqx5rq4vAnid3Ak0LVQvr9lerGt/DzxDZ37QWuiatLGP4vszf/ABNAHF4pyxuexrq4PAXiU/e8Pap/4CvWo3gbX7e240HUnlP/AE6vQBw+1UTk81BurpX8D+KmP/Ivat/4CPUf/CDeKv8AoXdW/wDAR6AOcptdrofw78Q3t35V1oerRLtPP2Zv/iaonwL4nzhfD+rEf9ej0DuczXS+Cv8AW6n/ANeb0n/CDeKP+he1b/wEetXw/wCHtY0iPUptU0y8tIjaMA08LJk/iKBHD0lLSUAJTqSloGNopaKAsdJF458URIFi8QaqijoFu5AB+tH/AAn3i3/oZNX/APAyT/GiigQ0+PvFp6+I9XP/AG+Sf40f8J/4tyT/AMJJq+T3+2Sf40UUAL/wn/i3/oZNX/8AAyT/ABo/4T/xb/0Mmr/+Bkn+NFFAB/wn/i3/AKGTV/8AwMk/xo/4T/xb/wBDJq//AIGSf40UUAIPH/i0HI8SauD6/bJP8aB4/wDFo6eI9XH/AG+Sf40UUAH/AAn/AIt/6GTV/wDwMk/xo/4WB4u/6GTV/wDwMk/xoooGL/wn/i3/AKGTV/8AwMk/xpP+E/8AFv8A0Mmr/wDgZJ/jRRQIP+E/8W4/5GPV8df+PyT/ABo/4T/xb/0Mmr/+Bkn+NFFAw/4T/wAW/wDQyav/AOBkn+NL/wAJ/wCLf+hk1f8A8DJP8aKKBCf8J/4t/wChk1f/AMDJP8aP+E/8W/8AQyav/wCBkn+NFFAw/wCE/wDFvH/FSavwMD/TJOP1o/4T/wAW/wDQyav/AOBkn+NFFAg/4T/xb/0Mmr/+Bkn+NH/Cf+Lf+hk1f/wMk/xoooAP+FgeLf8AoZNX/wDAyT/Gj/hP/FuQf+Ek1fI/6fJP8aKKAAePvFgzjxHq/Jyf9Mk/xo/4T/xb/wBDJq//AIGSf40UUAL/AMJ/4t/6GTV//AyT/Gk/4T/xb/0Mmr/+Bkn+NFFAC/8ACf8Ai3/oZNX/APAyT/Gk/wCE/wDFvP8AxUmr89f9Mk5/WiigA/4T/wAW/wDQyav/AOBkn+NL/wAJ/wCLf+hk1f8A8DJP8aKKAE/4T/xb/wBDJq//AIGSf40f8J/4t/6GTV//AAMk/wAaKKAF/wCE/wDFv/Qyav8A+Bkn+NJ/wn3i3AH/AAker4HT/TJOP1oooAP+E/8AFv8A0Mer/wDgZJ/jS/8ACf8Ai3/oZNX/APAyT/GiigBP+E/8W/8AQyav/wCBkn+NH/Cf+Lf+hk1f/wADJP8AGiigAPj7xYeD4j1fH/X5J/jR/wAJ/wCLck/8JJq+T1P2yT/GiigYf8J/4t/6GTV//AyT/Gj/AIT/AMW/9DJq/wD4GSf40UUCD/hP/Fv/AEMmr/8AgZJ/jR/wn/i3/oZNX/8AAyT/ABoooGA8f+LQcjxJq+fX7ZJ/jQPH3iwdPEerj/t8k/xoooEH/Cf+Lf8AoY9X/wDAyT/Gq2p+LPEGpWTQ3+tajcxMMFZbl3B/M0UUDMWiiigQU6iigBtFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic ultrasound image showing stage T3 esophageal cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John R Saltzman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42496=[""].join("\n");
var outline_f41_32_42496=null;
var title_f41_32_42497="Normal SPEP";
var content_f41_32_42497=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Normal pattern on serum protein electrophoresis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 556px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIsAf4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiikAUUUUAFFFFABXFfGbxXfeCPhtrHiHSoraa9s/J8tLlWaM75kQ5CkHox7jmu1ryr9qP8A5IT4m/7df/SqKgB8X/C7PNTzv+FceXuG7b9tzjvj3r1KiigAooooAKKKKACiiigDhZPG1zH8Vb3wq1pCbSHSo79Z9xDbmkKFT1GPTjrXSjV+f+Pdic42hst/u4x98dSvYd68uuv+Tk9TIzu/4RuHGBk/6854+nU9hz2ru8AjDbdmNuC2F2dhu/uZ6P1J4oAy/if46u/CfgTVdb06xgubq0RGSORyUbMiqW4wSgDHnjnAx3ru4JVnhjljzskUMM+h5rx/45xib4TeJllBb/RvMO75PnDAgnHRuPudMc16h4WmNx4Z0iZmDtJZwuWHQ5QHPFAGpRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUwCiiigAooooAKKKKQBRRRQAUUUUAFeVftR/wDJCfE3/br/AOlUVeq15V+1H/yQnxN/26/+lUVAHqtAoooAKKKKACiiigAooooA8Z1AGL9pa8Rhkz+F45UwccLclTk9vp36d67zIHJIA6525GPXb6f9M+3WuD1Q+b+0xO+AFg8KJE27kEtdlhx/nBwa7znOBv3ZxhTh93cbv7/q3ccUwOU+K8TSfDLxUoIUjTLgnd8+CIy2Pc4H+s/Cux+Gkon+HHhSZQQsmk2jgH3hQ1zPxBiE/gHxLESQsml3K5j+X5TEwyPRP9n15rZ+DUrTfCbwez4yNKtk49FjUD9BSA7GiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/AOSE+Jv+3X/0qir1WvKv2o/+SE+Jv+3X/wBKoqAOsT4ieCXdVTxh4cZmOABqcBJP/fVdTXLJ8O/BKOrJ4P8ADispyCNMgBB/75rqaACiiigAooooAKKKKAPGATL+0f4hcnDQaFbxIF+9tLlj/wDX9s13hxs52bNg+9/q9uePfy/TvnrXAaXiT9oDx8WJby7LT0GfuqChbGexzyB3NegAkPuG7duLfKuX3d/l6b/VOgHNMDK8WosnhjWUlBZWtplYP1LGNuv/AE0x+GKX4COz/BzwkXYsRYqOfQEgfpVrUlzpl0oCkG3dAFOQVweM90/2+ueKx/2bGDfBHwsVII8mUcHuJpKQHplFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooopAFFFFABRRRQAV5V+1H/yQnxN/wBuv/pVFXqteVftR/8AJCfE3/br/wClUVAHqtFFAoAKKKKACiiigAooooA8U8KnzPjh8VZEyYy2mJu6/MtsQRt7/Xt1r0H3xnvjft/Df2/66fxdK898BkzfFL4nzqCFbULeIc4bKQ4bB7D19RxXoJIC7jt27Q3zLlNvb5euz0TqDzTAPx9s7Mf8C2/+0u/WuV/ZcOPgZ4cT+NDdKy91P2mXg+hrq8HODu3btvLZbd9f+en+30A4rkv2Y+PhPar/ABLe3YYE8g+e/B96APV6KKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooopAFFFFABRRRQAV5V+1H/AMkJ8Tf9uv8A6VRV6rXlX7Uf/JCfE3/br/6VRUAeq0V5bF/wuzzU87/hXHl7hu2/bc474969SoAKKKKACiiigAooooA8Q+GR83xj8TLhio3a+0RU9BsUAE+5zx716KM+YMb9+8/d/wBZuxzjt5mOvbHSvOvhDmTU/iLOxcyHxZfx5C/wrsAx68Hn0HNeiHGMHZtxjDNhNvb5v7no3c8UwAY28bNvl9vu7M/+ivXvmuS/ZpP/ABQN+v8AEus3oYdwfM6Guu5z/HnOeV+bd64/56eidMc1x/7OBH/COeKVyMr4lvgQOxyvFAHrVFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/wCSE+Jv+3X/ANKoq9Vryr9qP/khPib/ALdf/SqKgD1WiiigAoooPSgAooooAKKKKAPD/gziRvHk4H7u48WahInzYyuUxn+7yD/vdK9FyRyCQ3XO3Jz67fX/AKZ9utec/BIr/ZvivlePEl9u+TplxjP97np/dPNejgEnC7t+duFbDb+43f38dX6EcUwEwOmBj7uN2ePTd6f9NO3SuQ/Z4OIPiCjH5x4uv2IIwcER4OO2a6/IxkFduN3C4Gz1x/cz/wAs+pPNcd8Bcrq3xHjfcso8RSsVY5bBRcH8aAPXKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRTAKKKKACiiigAooopAFFFFABRRRQAV5V+1H/wAkJ8Tf9uv/AKVRV6rXlX7Uf/JCfE3/AG6/+lUVAHqtFFFABRRRQAUUUUAFFFFAHh/wQy2leJ3XzCkniK/ZGB4Ybxkp7f3vbpXopxtydm3aD8w/d7e2R18v0HXNeb/AYL/wiOp8R86xebuT2lON3pz93HU9a9JBYNuXf5m4tlRl9/c46eZjqvQCmAHOed+7djk/Nu/+O+h6YrivggwXxr8TYfkDrqsUhCD5cNFxj8jXaYXGBs27dvB+Xy+4z/zzz1brmuM+ELOnxY+KtvL5hkWfTpSXGCQ8DEDH0FAHr1FFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/5IT4m/7df/AEqir1WvKv2o/wDkhPib/t1/9KoqAHxfAH4ZwypJH4aw6MGU/b7ngj/tpXqVFFABRRRQAUUUUAFFFFAHhvwDbf4IuZ1z5c2qXkifJ/CZSPx6c/3etej4yMYHTbgtgfTd6f7ffpXm37PJ3fDGzdclHurtkYPww89+V9B6/wB7pXpPGOSNuMZK5XHY7f7vpH260wFzznnru+7g/XHr/wBM+/WuI+F/7j43fEuJQNs8GmynD7sFYmXg/j+HTtXb856HOc43ZO70z/e/6adB0zXDeAcR/H7xkkZXZLpVnI+1NoLAkA47cZHv170Aex0UUUgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiimAUUUUAFFFFABRRRSAKKKKACiiigAryr9qP8A5IT4m/7df/SqKvVa8q/aj/5IT4m/7df/AEqioA9VooooAKKKKACiiigApGYKpZiAoGSScAUtU9adY9HvndgqrBIST0A2mgDxb9nL5fgx4f3BBjz85B73MuN3/svoevFelgEybRv37yvynEm7HPPTzPU9MdK8/wDgCGT4QeGQQ4PkyEYHrI+dvrx970HSu/IBQqdmzYF+Y4j25456+XnoeuaYACNuRs2+WW4Hy7Pp/wA8vVeua4fwqCn7SGtr8wLeHYWcMfmJ87gtjgnHT2wK7ok7snfu8wPyPm3/AE/56+g6YrgtDwv7TRC7QP8AhDzjZ93/AI/f4T1PfPvntQB7NRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKYBRRRQAUUUUAFFFFIAooooAKKKKACvKv2o/wDkhPib/t1/9Koq9Vryr9qP/khPib/t1/8ASqKgB8PjT4mNKiyfCbYhYBm/4SS2O0euNvNepUUUAFFFFABRRRQAVjeM5Vg8H67LJnZHYTs2PQRsa2a5n4oSmD4aeLZlALR6RduAe5ELmgDhfgtG0Xwp8MLIBk2SNycZByVz6deP73Su2Gc8Z3ZxkLlt3c7f73qnbrXK/CuLyPhn4VTOf+JXbPyN2N0an8evH93rXVYycc5ztwGwfpu9f9vv0pgJxjoMYzjdkbfTP93/AKadR0zXCWv/ACcppmfvf8I3NkkbSf346r/D/Uc967vPGcjpu+7gfXHp/wBM+/WuCm4/aL8LDuNHu+Dyeo6t/F/Tp2oA9oooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiikAUUUUAFFFFABXlX7Uf8AyQnxN/26/wDpVFXqteVftR/8kJ8Tf9uv/pVFQB6rRRRQAUGiigAooooAK4b44zi3+EHi5znnTpU4/wBobf613NcB8fv+SNeLP+vI/wAxQBF4IhMHgzQIVCjy7CFAIeFysahtuen+16jpWySoXc2zy9oYlhlNnbjr5eei9QazfDXPhvSt3/PnBnzOD9wYz7f3PU9a0wTvyN+7cT8v+s3d8Dp5nqOmKYAQ27B37t23k/N5nYZ/56Y6N0xXAan8vx/8BSR5CS2OoJlOEYBAcKOo5znPfmu+GMYGzG3HH3dv/wAa9T1zXAa6fK+P/wAOXcZM9vqMQLf6zKwBvnHQDHTHbFAHtVFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/5IT4m/7df/AEqir1WvKv2o/wDkhPib/t1/9KoqAPVaK8ti+D3lyo//AAsT4jvtYHa2t5Bx2I2dK9SoAKKKKACiiigArgPj9/yRrxZ/15H+Yrv685/aJlMPwV8VOoBJtlTn0aRAf50AWfDHHhrSdnH+iRY2/NyUG7Hqf7w/h7VpYBGG27MbcFsLs7Dd/cz0fqTxVLQ4vJ0XT4lO4JbxoD93OFGfp9f46vZA5JAHXO3Ix67fT/pn260wDJzk7t2d3K4O/wBcf3/+mfQjmvP/ABNx8dPhSF+4P7W2gcqP9FGcN/Fz19Dkdq7/AAemDn7uN2efTd6/9NO3SuA8UHHxz+FTn7hOqgN90Em2Axt/h5/Pr3oA9qooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFMAooooAKKKKACiiikAUUUUAFFFFABXlX7Uf8AyQnxN/26/wDpVFXqteVftR/8kJ8Tf9uv/pVFQB6rRRRQAUUUUAFFFFABXmv7SP8AyRLxT/1xj/8ARyV6VXl37TsrQ/AzxOyYyVt159DcRA/oaAN3TP8AkG2mcf6lPvc9hjPqP7o/hq1znA37s4wpw+7uN39/1buOKZbRCCGKKPdtQFFx14GD+P8Af/SnHGznZs2D73+r2549/L9O+etMA4x/BjGeBhdvrj/nn6p1zzXn3jw+V8U/hhM4O1dQuImzy4Z4cLuPf29BxXoRzu537vMHX72/H/o307Yrzn4pMIPEvwzugVUDxHDArLyg8wMCF+p6579KAPcKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRR3oAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/wCSE+Jv+3X/ANKoq9Vryr9qP/khPib/ALdf/SqKgD1WivLYvjD5kqJ/wrv4jpuYDc2iYAz3J39K9SoAKKKKACiiigAryn9p/LfBzVISf3c9xaRv7r9ojP4dBXq1eTftM/N8ObeFiRHNqtnG4/vDzQcfpQB1x5znHQD5jjgdM+390/xd6UEh9w3btxb5Vy+7v8vTf6p0A5pP0/Dd/wDrz6fwUvvjPfG/b+G/t/10/i6UwEAG3A27du3hsrt+v/PP/b6g8V5z8b2MWneFr3Lg2fiSwuGbaMrtYqCy9vvcAdRya9G/H2zsx/wLb/7S79a81/aIJi+Ft9eqMGzubW4GGyVInQcN/Efm6/w/doA91ooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRXyj4lTVfFUvjP4lWGq3cN54fvmj0VEciIW9tjzSRnG1xuOO5z24r6d8O6rFrnh/TNWthiG+to7lBnOA6hgP1oA0aKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiimAUUUUAFFFFABRRRSAKKKKACiiigAryr9qP/khPib/t1/8ASqKvVa8q/aj/AOSE+Jv+3X/0qioA9VooooAKKKKACiiigAryb9o3LaD4RhQMZZ/E9hHGFOCWy5wD26HmvWa8j/aFIkPw9tiEAbxTaSln+6AiyHBA7HNAHZDnGM9SPlOOR1x7/wB4/wAXakJAXcdu3aG+Zcpt7fL12eidQeaD3zt6Lnd6fw59v7n60oz5gxv37z93/Wbsc47eZjr2x0pgGDnB3bt23lstu+v/AD0/2+gHFeeftAKsnwd8RZAZTFGy7RheJk5UfwjOMjueRXoQxt42bfL7fd2Z/wDRXr3zXDfHVFk+E/igSj/l2DHzPvbgQV3Y/i4+XHGOtAHremMz6baM5LM0KEknJJwKs1meGJGl8NaTJIdzvaQsx9SUFadIAooooAKKKKACiiigAqFLu3e6ktkuImuYwGeIOC6g9CR1Aqvr2pRaNoeo6pc/6ixtpLmTnHyopY/oK+VdM0698LeFfD/xXkM51yS+Goaw4Zj51lcybdpGcbdpQrxwSx7DAB9cUU2KRJYkkiYPG4DKwOQQehFOoAKKKKACs/xFf/2V4f1PUD0tLWW4/wC+ELf0rQriPjfdGz+EXi6UEjdps0XGP412f+zUAcJ8HNGV/gppWnzgN9utJGlJHLGdmYbj/ExD8N/D3xXSfs2Xz3vwZ8PrOf39qJbRxnODHK6gf98haseB7cWngjw9bAoUh02GMEZKECNQ2O+3+/nnrisn9nNvs+l+MtL4AsPEl5HGF6eW21lx7cnigD1yiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/AOSE+Jv+3X/0qir1WvKv2o/+SE+Jv+3X/wBKoqAPVaKKKACiiigAooooAK8j+PJ3az8N4k3eafEMUgCjJwqNkj1IyOO9euV5F8cMHxh8M14JOrvxnGR5Rzz2+vbrQB2f0z3+6M/XHv8A3h/DSHGMHZtxjDNhNvb5v7no3c8Uv15/HHTp9Mev8dJkjkEhuuduTn12+v8A0z7daYC85/jznPK/Nu9cf89PROmOa434xRrL8LPFCnO0WErDy/mHAz8p7rkfMex4rscDpgY+7jdnj03en/TTt0rlvipEJ/hn4qVj/wAwu5cknZkrGxHH8PTG3+LrQB2/gOVp/A/h2V8b3063ZsepiU1u1zPwvlM/w08JTMAGk0i0cgdiYUNdNSAKKKKACiiigAooooA8z/aPv3sfg7ryQDdc3gisokB5YyyKpA/4CWpur+GoLv4f3PhpEzE2nmyjAGWBEe0ED++MAsP4cZqh+0GftsngPRMbhfeIYJZFz96KIMzj6cjntXZ+x5HTGcDA6Dd2A/vfx9KAMn4Ca02u/CLw1dSsTPFbfZJd33t0RMfPv8oP416BXkH7Pj/YLjx34eLMf7O12WeMFdu2KdQyDHbo3516/QAUUUUAFeXftNT+T8E/ESAbpJ/IhRfUtPGP5ZP4V6jXkf7Rr+fo/hHSlJzqPiOzicBdx2AszHHfGBxQB1trEYLaKLcWKKqlsfMSBgEjs390fxcVx3wcP2X4o/FHTsjAubK7UZ6+bCSx+uQM+h4rtv5dMZ7HqM9892/g6dq4bwaxtP2ifEdtn/j+0G3u8bdv+rl8v/gXX73emB7HRRRSAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKYBRRRQAUUUUAFFFFIAooooAKKKKACvKv2o/+SE+Jv8At1/9Koq9Vryr9qP/AJIT4m/7df8A0qioAfF8HvLlR/8AhYnxHfawO1tbyDjsRs6V6lRRQAUUUUAFFFFABXkHxkI/4WZ8LQSP+Pu9JzzwIBkkdx6juOO9ev1498Uj5vxt+F0a/ehTU5D6ndCijb/tZ6e+KAO2OB1x2JyM8H7v1H90fw96UAk4XdvztwrYbf3G7+/jq/QjigZ7bup+7698e/8Af9e1IcbcnZt2g/MP3e3tkdfL9B1zTAMjGQV243cLgbPXH9zP/LPqTzXP/ESITeAPE8MhCl9MuUbeN5BaJtuT/EcdG/hHBroTnPO/duxyfm3f/HfQ9MVkeLYhP4S1qLJCSWFwuYuFA2MCVz/D/e9T0oA0fg5MZ/hP4PcgDGk2ycf7MSj+ldhXB/AiVpvg94SZgARYInHovA/lXeUgCiiigAooooAKKKKAPHPiOx1D46+A7EBmTTrG91B1BwMOojBPqBg8de3eu4OAMnGzAJJGV2n7p291/ur1U8muBYjUP2kNfuCFYaXodtYgkfdMkhlAH+16e9d+M7sDduyR8v3898H+/wD3z0I6UwOE8Ev/AGZ+0N4psixB1fRra+IY8l4X8nBP8RwevfrXsteJ+IH/ALL+Ofw91AECK+hvNOkI6Y2b49v+wWzgHng17ZSAKKKKACvHvi6xvfi18MdMQsQkt7euFO0gpEAmD2yxIz2r2GvGNeb7f+0jCnJh0vw2Xb+6ryT4O/8A2duM0Ad5xjPG3BI44wPvYHYf3l/j7VwRb7F+0d4dlyQb/Qrm1/3gjiUc+ncA9PrXfc5P3s5Gcfez2z/tf3PQYzXnfjgiy+LHwv1PkBb67si3G0maHbg/7WRz79KYHt1FFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooopgFFFFABRRRQAUUUUgCiiigAooooAK8q/aj/5IT4m/wC3X/0qir1WvKv2o/8AkhPib/t1/wDSqKgD1WiiigAoNFFABRRRQAV4748y/wAf/CCtuKJpF42P4RkgEn0BHBI5xXsVeN+Mz5v7RPhtAMfZ9CuJs565l28DuRjp36UAdycHO7HQA7jjgfdz7f3T370oLBty7/M3FsqMvv7nHTzMdV6AUDj9egz1/n7j+GkxkYwOm3BbA+m70/2+/SmAYXGBs27dvB+Xy+4z/wA889W65qvqcJurC7hZPMeWMqVfhmbaQoI6bsfdHQjrVnPOeeu77uD9cev/AEz79aToMexGAcjntu7j1b+HpQBz37Nk/wBo+CPhZwxbEUqZP+zNIuPwxivTK8o/ZjPl/Ci2sugsb67tgAcgYnZuD3Hzda9XpAFFFFABRRRQAUUUUAeIfDtvt/xI+J+r9TJqiafuHpbxbCPoM/N3AxXohwVw23ZgA7uE2j7uT12Z+6epPWvNvgGTd+DtQ1hsE6xq95qG7dndmQrk+h+TgfxfhXpXQ59ycgZPPfb3Pqv8PWmB5r8cpDp+leHNe3FBo+v2l5MzcAru2uG9HOVyo4wK90ryL4yaZ/a/wu8S2gGWFk0qjG7JixIAPUZQYfueK77wBq39u+B/D+qltz3lhBM5/wBooCw/A5FIDfooooAK8U8MsdQ+OPxGv+Slr9hsYGAzhliLOF7F93QdOucYr2uvDfg2fts/jnVyOdQ8RXYRtx+aJSqqPYdfnHTpQB6PxgDjbggZPy7T97B/u/3z2OcV5x8bT9ksvCer4IOmeIbG4dh2jDFcH/Y+bAPcda9I75+h6ent2Pov8dee/H20a7+EmviPIkgRLlGXqpSVGJHqcA5H8NMD2yiqei3q6no9jfpjbdQRzjHTDKD/AFq5SAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKYBRRRQAUUUUAFFFFIAooooAKKKKACvKv2o/wDkhPib/t1/9Koq9Vryr9qP/khPib/t1/8ASqKgB8Xx++Gc0qRx+Jcu7BVH2C55J/7Z16lRRQAUUUUAFFFFABXjOrf6R+0w7YyLXwsqAHrva6JBX0OON3br2r2avFNLb7V+0J49l+XFjp9jbHI7NGZDn1X1x296APQR7Z79Dj6/Q+p/jpOMckbcYyVyuOx2/wB30j7daDwDnb0Undzwfu59v7np3pQCZNo3795X5TiTdjnnp5nqemOlMA5z0Oc5xuyd3pn+9/006Dpmk7cY24PIGBjudvYeq/x9aARtyNm3yy3A+XZ9P+eXqvXNKchyp3b9yg7vv7j93J6b/wC4egHWgDjf2dyLe28dadkf6L4nuyuAB8jhCvH59q9crx/4Nt9n+KHxTsNwIS7srkD3khYn3zxz2z0r2CkAUUUUAFFFFABWJ441D+yfBev6jnH2Swnn/wC+Y2P9K2682/aNvmsPgx4laLJlnijtUUdWMkqIQPwY0AZHwWsRp3wq8MQhVXfZpOQB3kzIMnuTv4P8HfGa7bvxndk8A4Oe43dj6t/H0qlotmNO0bT7JANttbrCuz7uEUBtue3Hz+varh4QsduzapO77m0/dyOuz+4OoPWmBHcQx3FvJDMFaKRCjArkFDxnH93/AKZ9R1rmP2abqT/hWg0e5bN3oN/c6XNk8gpIWH5BwPwrrQDuwN+7zCnB+bf9f+evqemK4H4cS/8ACP8Axs8V6IVjSz161i1qz8sEIXU+XKFz3J5x14oA9nooopAV9RuksNPubub/AFdvE0rfRQSf5V4v+z7bvD8J9Gln/wBfd+dcysRndvmc7j6rjHydT1rv/jHenT/hT4tuAdrDTJ0U+hZCo/VhWL8O7H+zvAfhuz2srRWNvGwHB8zylJx6SdcHoBxQB0PfvnI7857c9yezfwdOMVh+OLH+0/BevWIXebiwuIlAIHzNGw4J6EHqf4vetv8AhB+XGGIz93A+9j/Z/vjqTnFDYwQ23GFzvGRg9M+39z070wKXwP1A6n8IvCVwTuI0+KEn1MY8s/8AoNdxXlH7MxMHwzOlnIOlaneWW09VxMWx/wCP+pr1ekAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUwCiiigAooooAKKKKQBRRRQAUUUUAFeVftR/8AJCfE3/br/wClUVeq15V+1H/yQnxN/wBuv/pVFQB6rRRRQAUGiigAooooAK8S+HpMnxK+J1wS5dtVgj+UDH7uLC4/2+TgdCete214h8JyJNf+JEyjMZ8TXUe4nGSoUMPp6t/D1oA9FBIIxu6sRt9T97Hv/f8ATtSEAoVOzZsC/McR7c8c9fLz0PXNB98dupx9PoPQ/wAdKM54zuzjIXLbu52/3vVO3WmApJ3ZO/d5gfkfNv8Ap/z19B0xTRwgUbdm1gNv3Np+9g9dn989QelHGOgxjON2Rt9M/wB3/pp1HTNKevOd2RyRg57Hb2Pov8fWgDh/AzG2/aC8WQHf/pejWlwNwGCEYxjb/s88Z5NexV4xpZ+z/tMQlQNt14XeNgD/ABLdBtx98cY7dO1ez0gCiiigAooooAK8i/aLb7Zp3g/RBg/2n4gtVkDZ2+Um5nJxzgfKa9drxv4iv/anx58D6aMFdLsLvU5Fz/z0xEhx/EQw4XueKAO5PLEnqSud3Xj7uff+5696UZDhhu37mI2/f3H72B03/wB8dAOlH06c9OR78989z/B7UnbnG3A4JwMdhu7D0b+PpTACBtwdm3ywvJ+XZ9f+eXo3XNea/FyT/hHvEHhDxzh1/snURb3ruACLaceW5k7bhxgDjBzXpfOepznGduTu9cf3v+mfQdcVjeMdDh8TeFNU0aYokd7bPGrZ3qh/hbceqhsNv7EYoA9DByMiivPPgP4kl8RfDuyjvyRq+ks2l36McsssXy5PuV2n6k16HSA8o/aandvhc+kwZ+0a1f2unRAdSzShsD3whrqYYo4YEiiESxJF5ahGJQJ6ZPPlep65rifizINa+LXgHw+FEkNj52uXas5VVCDZCxI6fPkZ967rnPJYnOMlNp3eu3+9/wBM+hHNMA/iJ+bOVJx97I+7n/a/uDoRjNAJBGN3ViNvqfvY9/7/AKdqT8sc9+Md+e4Pdv4Ogxig++O3U4+n0Hof46AOM/Z9P2a7+IemjywsPiSe4UR8qFlVSAp9OOK9erx34Xt9g+NnxGsHP/H5DY38YIAPCFHJHY7iOO3SvYqQBRRRQAUUUUAFFcL4++KHh7wbMLG4km1HW5B+60qwTzrh+MjIH3R3yccdM1xb3/xT8YKJPPsPBGmvgiKNBeXu0/3icIuR93GCaAPbqK8P/wCFY3VwxkvviD48mnJOGi1MxhSO6oF4b1X+EEk00eHviF4bYT+FfG8urwou42HiECdZP+24wwHbdwCeMigD3KivMvBHxZsdX1YeH/FVjL4a8UjC/Yrw/u5z6wydGz2HX0z1r02gAooooAKKKO9ABRRRQAUUUUAFFFFMAooooAKKKKACiiikAUUUUAFFFFABXlX7Uf8AyQnxN/26/wDpVFXqteVftR/8kJ8Tf9uv/pVFQB6rRXlsX/C7PNTzv+FceXuG7b9tzjvj3r1KgAooooAKKKKACvDPgQfP8L6xqJHOo63fXm4jO7MmM+v8PKnlule0avdjT9Jvbw4xbwPMc/7Kk/0rx79n+2+y/CHw7GoG5o3kbb13PK7Lk93+b5T270Aeg/8A1jyM9f5+w/hpcZOOc524DYP03ev+336UDJ+7nOSBt45H3se/949+1ISoXc2zy9oYlhlNnbjr5eei9QaYBnjOR03fdwPrj0/6Z9+tL0OPcDBOTz23dz6N/D0oIbdg7927byfm8zsM/wDPTHRumKQYK5XbswSNvCbR97A67M/eHUnpQBwN/mH9oTwS458/Tr6E9sbQG/E9s9+te014n4wYWvxn+Ft4QNomvrdjjBPm24CZP93glV+te2UgAnAyawdJ8Y+GtY1OXTtJ1/S72/jzut4LpHfjrwDk4746Vwfx31i8vF0vwJoVz9m1HxAW+13C8m1sV/1rnHTd90evzDrWP4j+EuiyeHrW28L2yaHrmmYbTr+EBZVm6qJHUZctxyegPrQB7lRXB/CLxyfGOhyw6nELPxNpb/ZdVsjwY5RxvA/utjI/Ec4yaP7OGpX2r/Bjw9fareXN9ey/aPMuLmVpZHxcygZZiScAAfQUAelV4b4HuB4n+KvjnxVH89hFJFoljJn7wiGZdvoC+CH6DNbPxd8eXP2keBvAzC68Yaivlu8bfLp0R+9LIw+62DwOvIP90NqeC/Dln4T8L2Gi6cS1vaxH94w/1nOZHP8AsliSy9fTigDb9/XPt09u3uP46ToM+wOSMjnvt7j0X+HrQeCQ33hjO7k5P3c+/wDc9O9KMlgFzvyQNvD7h97B6b/7x6EdKYBjnHPXb97B+mfX/pp36UmcjOR03ZC4H12+n+x360ZXGTs27d3I+Xy+xx/zzz0XrmlIYNtbf5m4Lhjl9/YZ6eZjo3QCgDzG+vR8L/igdflJj8J+JClvqRzlbS7A/dzn0VhkHHTJzyBXQtIi/tQmUuojHgrcXJ4x9tznPpXQ6rp1nq+nT2Go28VzZ3CMskTL8rL/ABY9ADy3cnkYr5/b4bvH8XX8L2fiXV4NGk8N73LOHcWbXIH2VGPKxlsEcEgNg55NAHoHw0uP+Et8Z+LPHhJ+yXco07TCyEj7LDwXx/EHfnb1BBNemEYOMHrtwX3H6bvX/pp26VT0XS7XRtMtdM0q3Nva2qiCGKIgFSB0z/z0x1boR71bBUrlfL2bd3yqQuzucf8APPPVeueaADtn2J6ent2Hqv8AHR/9Y8jPX+fsP4aXBzjndkA4PzZP3cn+9/cPbjNAyfu5zkgbeOR97Hv/AHj37UAee6jL/YH7QHhTUmAW31qwn0aRuOHQiVAx/iJOBu7/AIV7ZXkPxZ8Nz+I/CTHS3EWsadJHqWmzDACSxnKYz0RuVA7E5PFdT8MviDpvjjR0dHS01uD91f6ZKds1tMvDAoeduc4P9QQEB1VhqVjqP2n+z7y2uvs0zW0/kSrJ5Uq43Rtg/KwyMqeRmrdeU/ARgi/EhmICjxlqRJJwB/q60/F/xf8ACfh2QWkV9/bOsOdsWm6UPtEzt/dO3hfxIPoDQB311cQWltLcXc0cFvEpeSWVgqoo5JJPAHvXimseOfEHxIuptL+G0jab4fVzFdeI5UIaU91tgceh+c4x6qcZpz6B4p+J15Hc/EEnSfDiSZh8OWkvzTMvP+kSDqR12/yPX0u0t7aztIre0it4LWKP93HGm2NYhxwo6RZ/h655oA53wR4H0TwfbMNLgMl5KC9xf3Hz3Fwc8s7HnHqn8XXFdR/9b26/zz2/uUpDA4bfu3AfMctuP3ef7+PunoBjNHpn/axn2+/j/wBn/vdqYABk456kYDYPHbPr6v8AxdKTPGcjpuzs4+u30/6Z/jQSoXLbNu0H5hldp+7x/cz90dQcZpcNuxiTfu2/eG7f6Z/56Y/i6Y4oAw/FvhXRvFummw16xjuogfkJOHjY91ccg/7fQdDkcVxlh4m8SfCaeK28VTXPiHwOzbIdW2l7uwHQCcdXQE43fl2WvThjGRjbtLDA+XYPvcf3P7w6ntTZ4o5opIbiNZEcBJEkG7cGHyhuxyPu+negDo9L1Gz1bTre/wBMuYrqyuEDxTRMGV19QRVqvn+bTdY+EmpTaz4Mhl1DwnKzPqOgBstAQPmkgz0ZQMso4PbjGz2rwt4h0zxVoVrrGh3SXVjcruR16g91YdmB4IPSkBrUUUUAFFFFABRRRQAUUUUwCiiigAooooAKKKKQBRRRQAUUUUAFeVftR/8AJCfE3/br/wClUVeq15V+1H/yQnxN/wBuv/pVFQB6rRRRQAUUUHpQAUUUUAcj8Xrz7B8LPFtxu2sul3CqeOGaNlH6kVz/AMN7X7H8PPDNudv7vTIFPJ28xrux325zv9OcVW/aXvWHw3/sO2kVb7X76302DJ/vSBmP0wpBPvXU28S28EcUQKrGqqAByNownHYgY2r/AB96AHnHfb0H3vTtn2/uevelBO/I37txPy/6zd3wOnmeo6YoGR0z3xgZ5P3vqf7w/h7UmARhtuzG3BbC7Ow3f3M9H6k8UwAYxgbMbccfd2//ABr1PXNKc7snduyD83389sj+/wD3B0I60ZOcnduzu5XB3+uP7/8A0z6Ec0gwBgY2YIAByu0/eG7uv95uqngUAeb/ABtlGl2XhbxEzKsei67bXMxP/PJm2yY9+V3ds4rt9B8azXPjz4g6Vqn2O30nw3HZSx3ADBtksDSyNISSCBt4wBx1zUfivQ7bxL4b1HRr/Itr2ExO2Pu/3G9tpwVP8ZHNfO3hXw7401rxf4u8IapcwR28g0yHXL2B8yPBDAVijQZyWkXBbjja2ccggHq3wrEvijW9a+Id+kol1WQ22mJgboLKM4QL6SMRux0Iye9ekDGONm3aR8h+XHf/ALZ/3j1BziobO1trKzgtLSKKG0gjEMUathEiAwFB/ucD5+ueKnySctuLZB+ZcHcPunH97HROjDk0AcP4x8ETahrUPiTwtqj6H4qt4xELuNA8dxHxiOdDwynACHrjGegx5x8GNP8AH2tfCvRLHTfEdnofhoicI9hbs9/IPPkLruYgK27ccqRhcHk5Fe/fXtnGeOv3seuf4v7navNf2cQD8GPD24Lg/aA25tox9plxk9hnoe5+WgDp/BPg3RvB2nS2+kQqZJ/3lzdzuXkuW7tI/Ux59MfNniukOc/xZ3A8/e3dv+2n90dMdaMtnOX353Z2fNv9dv8Afx/yz6Y5pOOgxtwRwcjaeoz/AHfV+q0AA6DHTnG3p749v7/p2oONpB27cAfN9zHbP+x/cPUnrR356nGc8HI+7kdj/dH8felGQcjO/JIIGW3H73y92/vL/D1FAAM5437t2eB827/476jpikGNuBs27SPlP7vb3wevl+p65owMYIXbjby2Bs9M/wBzP/LTqTxSkknLbt+d2WXDb+x2/wB/HROhHNAAc993Ufe9e2ff+569680/5uTz/F/wiZ/38/bOf+Bdd3/Asdq9KGB0x3Awc8H731H94/w9q81/5uRx/B/wiWMfw4F5x83p0wf4uP71AHpRC7cHytu3Hzn5Nvb/ALZeh65pSTu583duz84+fd2/7a46DpijLA5UvvzuyqZbf3O3+/jqnQDmkwoGFCbcbcK+5dncbv7mer9QeKADt/DjB6/dx3x/s/3/AEOcUHHfb0H3vTtn2/uevel5687sgnjnI+7kdj/dX+PvQMjpnvjAzyfvfU/3h/D2oAATvyN+7cT8v+s3d8Dp5nqOmK5DxT8OPCfim5F1rGj20l2BkXMLvC3HAbchBMY9Tkg112ARhtuzG3BbC7Ow3f3M9H6k8UuTnJ3bs7uVwd/rj+//ANM+hHNAHz78Lfhd4V1w+Lhq1lc3Mdj4iu7GGN7uVR5abNoIVhuk54z1IOele0eHPC2heG49mg6TZ2ORtLW8QEjAdt3Vj/fyeO1cd8EsY8fAY2/8JZqA4ORtPl5Gf7vTLfw8HvXpfsenGc8DA+7k9h/dP8fegBO38ONoHP3dvb/tn/dPXPWlyd3/AC13bs9Bv3f/AB326YzRznIzuzu4GTuPU4/veqdFpMLjGE24243/AC7PTd/cz/H1zxQADGONm3aR8h+XHf8A7Z/3j1Bzij1/4DnH/juf/ZPXvS5JOW3Fsg/MuDuH3Tj+9jonRhyaT69s4zx1+9j1z/F/c7UAKM7sjfu3E/J97Pf/ALaf3h0Azik424/dbduOp2bf/jWe/XOaCARhgu3AHzNgbR90Z/u56P1Y8UuWznL787s7Pm3+u3+/j/ln0xzQAHOf4s7gefvbu3/bT+6OmOtIOgx05xt6e+Pb+/6dqOOgxtwRwcjaeoz/AHfV+q0d+epxnPByPu5HY/3R/H3oADjaQdu3AHzfcx2z/sf3D1J615XrVjf/AAq12fxb4Ugmn8O3Mm7W9GjH3R3njHRZF5LKOMe33fVRkHIzvySCBltx+98vdv7y/wAPUU1lRlKOEMZXYQzfKY/TP9z/AKadT0oA3NA1iw1/R7TVdIuY7qxukEkUqHII/oR0I6ggitCvn2O4ufgt4kkvoUmn+HuqTZu4FT5tJnY/fCD7qN3Udhx0APvtrcQ3dtFc2ssc1vMgkjljYMrqRkEEcEEd6QEtFFFABRRRQAUUUUwCiiigAooooAKKKKQBRRRQAUUUUAFeVftR/wDJCfE3/br/AOlUVeq15V+1H/yQnxN/26/+lUVAHqtFeNa3+0h8PNMZlt72+1Nl6iztW/nJtB/OsL/hpzRZiGs9BumiPGZ7+1hbP+6XP50AfQVFfO7/AB/1bUQq6To/hfT1b/lvqfia2IH1jQhqqv4t8Sa0M6t8X/BmiRuDvg0doJMegEkj7hn1HTvQB9JU2WRIo2kldUjUZZmOAB6k18zf8Iv8LL4+b4o8bQ+I7o8mXUvESk59F2OoGPfII6Uq+DfgerjbqWgiLgmI66xjLD+MjzckdsdfXigDooNRi+JPxiOr2ZFx4Y8LRNBaXAG6Ke7fHmSL2cKuBgdeCDg16b7d+mM9z0Ge+ezfwdO1cfpPizwDo+nQWGleIfDlnZwLiOCLUYAE+mGxv77/AM+at/8ACfeDv+hs8PY/7CMOPfA3cD+8P4u1MDpvpz+OOnX6Y9f46MgckgDrnbkY9dvp/wBM+3WuZ/4T7wd/0Nnh78dRhP5/N0/uj+HvR/wn3g/r/wAJZoOevy6nCHz/AL277/q/QjigDpcHpg5+7jdnn03ev/TTt0pfccjrnGBgdTt7Af3f4+tcz/wn3g7/AKGzw7jpxqEIXH03f6v/AGOpPNH/AAn3g/8A6GzQM/7WpQlvxbd97+638I4NAHS9OT0/Pr04757D+CvNfAn/ACWf4ojv/wASsY75+zNxu/8AZu//AAKul/4T7wf/ANDZ4f8Aw1KEH3wd3B/vf3u1efeC/F3hu3+LXxHu7jxDo8Vnd/2b9nnkvYhDNsgYNty2GUHA2j7vGelAHs2R1yMfezs7eu30/wCmf40YI4IIPTBbdyeg3ep/v/w9O1c1/wAJ94P/AOhs0PPX/kKQ7s/Xd9//AG+mOKP+E+8Hf9DZ4dx/s6hCFx9N33f7y/xHmgDpv6/jnHX6Y7/3680/ZwIHwY8O5IGPtBOV3Y/0mXt/F6Y7ferpf+E+8Hf9DZ4f/DUYfwz83P8As/3e9effALxd4b0v4S6FZ6l4h0mzvIvP3wTX8UUi5nkI4ZgVJBByeqkCgD2bB6YOfu439/Td6/8ATT8KX37dc4xx3OPQf3P4utcz/wAJ74O/6Gvw5jp/x/w7cfTd9z/Y655o/wCE+8H/APQ2aB686lCTn67vv+jdFoA6b2PX8+vTnvnsf4KT2HJ6Yzg5HUbuxH9/+PpXNf8ACfeD/wDobPD/AOGowge+Bu4H94fxdqP+E+8Hf9DZ4ex/tajCV/Fd33f7q/wnk0AdLkdcjH3s7c8eu30/6Z9utGCOCCG6Y3ZOfTd6/wDTTt0rmv8AhPvB/wD0Nmg568anCGz9d3+s/wBvoRxR/wAJ94O6f8JZ4dx0+XUIQmP93d9z1TqTzQB0305/DHTr9Men8deaf83I57f8IlnP/b5x8v5cfw5/2a6X/hPvB/8A0Nmgf8C1KE/n83X+6f4e9eff8Jd4b/4X/wD2j/wkOj/YP+EY8j7V9ti2eb9r3bPM3bd+OTz8w3etAHs+CeACT93G/bz6bvX/AKad+lGQeQQR97Ozbx67fT/pn361zP8Awnvg7/obPDmOnzX8JXH03fc9E6g80f8ACfeD/wDobNDz1+bVIS2fru+/6P0A4oA6X279MZ7noM989m/g6dqX6c/jjp1+mPX+OuZ/4T7wd/0Nnh7H/YRhx74G7gf3h/F2o/4T7wd/0Nnh78dRhP5/N0/uj+HvQB02QOSQB1ztyMeu30/6Z9utJg9MHP3cbs8+m71/6adulc1/wn3g/r/wlmg56/LqcIfP+9u+/wCr9COKP+E+8Hf9DZ4dx041CELj6bv9X/sdSeaAOa+CX/M/en/CW35zjHH7vJx6f7P8XTtXpXTk9Pz69OO+ew/grxn4P+LvDdh/wm327xDpFt9o8T31xD599EpkjbZtdSW5zg7XHA555r0H/hPvB/8A0Nnh/wDDUoQffB3cH+9/e7UAdL7d+mM457jPr/t/xdKMjrkY+9nZ29dvp/0z/Gua/wCE+8Hf9DZ4ex76jDjH03fc9F6rR/wn3g//AKGzQ89f+QpDuz9d33/9vpjigDpcEcEEHpgtu5PQbvU/3/4enal/r+Ocdfpjv/frmf8AhPvB3/Q2eHcf7OoQhcfTd93+8v8AEeaP+E+8Hf8AQ2eH/wANRh/DPzc/7P8Ad70AdNkdSQB1zt3cHodvof7n8PXtSYPTBz93G/v6bvX/AKafhXNf8J94P/6GzQc9fl1OENn67vvf3m/iHAo/4T3wd/0NfhzHT/j/AIduPpu+5/sdc80AdN79uucY47nHoP7n8XWj2PX8+vTnvnsf4K5n/hPvB/8A0NmgevOpQk5+u77/AKN0Wj/hPvB//Q2eH/w1GED3wN3A/vD+LtQB0vsOT0xnByOo3diP7/8AH0oyOuRj72duePXb6f8ATPt1rmv+E+8Hf9DZ4ex/tajCV/Fd33f7q/wnk0f8J94P/wChs0HPXjU4Q2fru/1n+30I4oA3720gvrOazvYI57eZDFLDLh1cEcqSeDkfx9uleXade6p8E7xk2XWrfDeeQsNoLz6OSeeOrRZP9ev3uy/4T7wd0/4Szw7jp8uoQhMf7u77nqnUnmkfx54NdGV/FXh9lYYIfUoWz9fm5P8AdP8AD3oA9D0TV9P13S7fUdHu4byxnXdHNC25WH9D6g8ir1fM9zH4c8O6hNq3wv8AiB4f0K7kO6bTZtQiksbo+jJu+RgOrL/wHFbOj/tI6VZXKWPjWzhtrnH/AB+aPdx31s4/vfIxZP8AdOTSA9/orgNO+Mnw81BA8HizTEB6faHMB/JwDWr/AMLH8Ef9Dl4b/wDBpB/8VQB1VFZWheItG8QLM2havp2ppCQJGsrpJghPTdtJxnB6+latMAooooAKKKKACiiikAUUUUAFFFFABVTVdNsdXsJbHVbO2vrKXHmW9zEssb4IIyrAg4IB+oFW68q/ak/5IV4m/wC3X/0qioA6v/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4muU/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA6v/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4muU/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA6v/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4muU/wCGfPhh/wBCz/5P3X/xyj/hnz4Yf9Cz/wCT91/8coA6o/DjwR/0Jvhv/wAFcH/xNJ/wrjwR/wBCb4b/APBXB/8AE1yj/s/fDFRx4Y/8n7r/AOOU0/AH4YgZPhgf+DC6/wDjlAHW/wDCuPBH/Qm+G/8AwVwf/E0f8K48Ef8AQm+G/wDwVwf/ABNcHefBP4WWoJfw0vH/AFELr/47WJcfDL4Swtg+GYz/ANxG6/8AjlK6HZnq/wDwrjwT/wBCb4a/8FcH/wATS/8ACuPBP/Qm+G//AAVwf/E15Va/C/4TTsAvhpOf+ojdf/HK3Lb4G/C24AKeGh/4MLr/AOO0JoOVnc/8K48E/wDQm+G//BXB/wDE0f8ACuPBP/Qm+G//AAVwf/E1yP8AwoD4Y/8AQsD/AMD7r/47R/woD4Y/9CwP/A+6/wDjlMR13/CuPBP/AEJvhv8A8FcH/wATR/wrjwT/ANCb4b/8FcH/AMTXI/8ACgPhj/0LA/8AA+6/+OUf8KA+GP8A0LA/8GF1/wDHKAOu/wCFceCP+hN8N/8Agrg/+Jo/4Vz4I/6Ezw3/AOCuD/4iuR/4UB8Mf+hYH/gfdf8Axyj/AIUB8Mv+hYH/AIH3X/x2gDrv+Fc+CP8AoTPDf/grg/8AiKP+Fc+CP+hM8N/+CuD/AOIrkf8AhQHwy/6Fgf8Agfdf/HaP+FAfDH/oWB/4H3X/AMdoA67/AIVz4I/6Ezw3/wCCuD/4ij/hXPgj/oTPDf8A4K4P/iK5A/AL4Yj/AJlkf+B91/8AHKT/AIUH8MP+hZH/AIH3X/xygDsP+Fc+CP8AoTPDf/grg/8AiKP+Fc+CP+hN8N/+CuD/AOJrkP8AhQPwx/6Fgf8Agwuv/jlL/wAKA+GX/QsD/wAD7r/45QB1/wDwrnwP/wBCb4b/APBXB/8AE0f8K58D/wDQm+G//BXB/wDE1yH/AAoD4Zf9CwP/AAYXX/xyj/hQHwx/6Fgf+B91/wDHKAOv/wCFc+B/+hN8N/8Agrg/+Jo/4Vz4H/6E3w3/AOCuD/4muQ/4UD8Me/hgf+B91/8AHKQ/AL4YD/mWR/4MLr/45QB2H/CufA//AEJvhv8A8FcH/wATR/wrnwP/ANCb4b/8FcH/AMTXHD4B/DA9PDI/8GF1/wDHad/woD4Y/wDQsD/wPuv/AI5QB1//AArnwP8A9Cb4b/8ABXB/8TR/wrnwP/0Jvhv/AMFcH/xNch/woD4Zf9CwP/A+6/8AjlH/AAoD4Zf9CwP/AAPuv/jtAHX/APCufA//AEJvhv8A8FcH/wATR/wrnwP/ANCb4b/8FcH/AMTXIf8ACgPhl/0LA/8AA+6/+O0f8KA+GX/QsD/wPuv/AI7QB1//AArnwP8A9Cb4b/8ABXB/8TR/wrnwP/0Jvhv/AMFcH/xNch/woD4Zf9CwP/A+6/8AjtH/AAoD4Zf9CwP/AAPuv/jlAHX/APCufA//AEJvhv8A8FcH/wATR/wrnwP/ANCb4b/8FcH/AMTXIf8ACgPhl/0LA/8ABhdf/HKP+FAfDH/oWB/4H3X/AMcoA6//AIVz4H/6E3w3/wCCuD/4mj/hXPgf/oTfDf8A4K4P/ia5D/hQHwy/6Fgf+DC6/wDjlH/CgPhl/wBCwP8AwYXX/wAcoA6//hXPgf8A6E3w3/4K4P8A4mj/AIVz4H/6E3w3/wCCuD/4muQ/4UB8Mf8AoWB/4H3X/wAco/4UB8Mv+hYH/gfdf/HaAOv/AOFc+B/+hN8N/wDgrg/+JpP+Fc+CP+hM8N/+CuD/AOIrkf8AhQHwy/6Fgf8Agfdf/HaP+FAfDL/oWB/4H3X/AMcoA67/AIVz4I/6Ezw3/wCCuD/4ij/hXPgj/oTPDf8A4K4P/iK5H/hQHwy/6Fgf+B91/wDHKP8AhQHwx/6Fgf8Agwuv/jlAHXf8K58Ef9CZ4b/8FcH/AMRR/wAK58Ef9CZ4b/8ABXB/8RXI/wDCgPhl/wBCwP8AwYXX/wAco/4UB8Mv+hYH/gfdf/HaAOu/4Vz4I/6Ezw3/AOCuD/4igfDjwR/0Jvhv/wAFcH/xNcj/AMKA+GX/AELA/wDA+6/+OU9f2ffhiRz4Z/8AJ+6/+OUAehaH4e0XQEmXQdH07TFmIMgsrZIQ5GcbtoGcZPX1rUrxX4JeHtL8K/Fj4p6NoNr9l022/sryofMaTbugkdvmYkn5mJ5PevaqYBRRRQAUUUUAFFFFIAooooAKKKKACvKv2o/+SE+Jv+3X/wBKoq9Vryr9qP8A5IT4m/7df/SqKgD1WiiigAooooAKKKKAGTHC1ha3qS2tu7E4wK2bw4iz715n8QrxorKXB7Gpk7FRVzzP4iePpIZJEjkx2615Bf8Ajq6kmY+c34VQ8eX7y3smWPJriixJJzSSG2epaL45ullXMzY+te4/D3xobrYjyZ+pr5Ds5Csi4PNexfDS5cXMfPU0NDTPsTTboXEKsO4q2z4HvXNeE5GexjJJ6VuzH5cVSYmhslztpiXeT1rOuWI71BG5z1pXA6BZxStMBWXGxNKzk96dwsaJuVHWoJb1UUms+VzWRqlwyxnrSbGkW7/xAkW4Z9qzo/FA3Y3cVwutXj+YcE1l29y2/O7mkVY9itNeWQDLcVqxakG715ZpM7YHNdVZStgc0XFZHYi8U043S5rn4ZDxnIqcyHGM07isaFxfrGvWsK/8QJDnJqvqcxVDz2rz7XrpvMYbjSuNI7lfFq7uvFbuma4lyAQa8Lju3MuNx6+tdr4YnfK5JouDR6yl0rck08TrjqKwbSQlBk9qsbz607kWNb7QnqKPtCeorIMh+lNMhx1p3Cxrm6THam/bEHesR5T61WknI9aLjsdF9tTFH22PPWuYads003DdM0rjtY6n7alL9sj9a5UXDY605bluxouLlR1Qu09aUXKeormEuD6mp4529adxWOkE6nvSiRTWFHMT35q1FIc8k4ouFjV3CnVSSQ1YQ8c0xEtFIDS0AFSR/d/Go6kj+7+NAHlnw7/5Lt8XP+4R/wCkrV6rXlXw7/5Lt8XP+4R/6StXqtMQUUUUAFFFFABRRXgngbx/8U/HtjqOqeGtP8GRWFleSWZhvTciaRkCsdpUleQ68nHOaQHvdFeefCr4iTeL7vWdG1vSzo/iTRpBHeWnmeYhBzh0b049+o5Oa898C/EH4ueO7C/v/DuneCxZ2t7JZH7UtwjllCt0Eh4w6/rQB9C0V57BrXjfRvh14o1jxjbaCmr6faXF1aR6f5rQsI4S43hmz94HOCOK1PhL4lvPGHw70XXtTjt4ry9jZ5Et1Kxgh2XgEk9AO5oA66vKv2o/+SE+Jv8At1/9Koq9Vryr9qP/AJIT4m/7df8A0qioA9VooooAKKKKACiiigCC9/1NeTfEwYspf92vWbz/AFX415L8TmzYy4/umpkXE+QfGR/0+T6muaro/GDZ1CT6mucoEyxZrmQV7J8M4Mzx4ryDTxmVfrXt3wxUecn4UMcT6b8KJtsIx7VtzfdzWT4aA+xx4HOK15fu0IHuY9z1qCMc1YuutQxj5qALUY+XmnMKI+lKwoAryjjNY2rrmNjW1IDtJ7Vkar/q2+lJlI831lf3jVm2y/PWxrX+sOfWsy2HzikUdFpI4Wuss14FcvpIwBXV2f3RQBoRjgCpiBimR44qTHrTI6mPq6/u2rzvXl/eNXo+q/6ps+lee67je1Io56JP32feu38MDG2uMiP70V2vhjGUIoA76z+6PpVnFV7P7gqzTJGkVG49KlpjcUxFZwc1WlXrVySq0g460ikVjTGXmpT3pppDIwMCnClpy0AKtWYxxUUeMjNWEFMTJY+oq3HVeMZq1EOR6UyS1H0FWk6CoI6sJ2NMTHinUlLTEFSR/d/Go6kj+7+NAHlnw7/5Lt8XP+4R/wCkrV6rXlXw7/5Lt8XP+4R/6StXqtMQUUUUAFFFFABXyr+zx8UPCngrwrr2m+IL+aHUJtZnuIbeK1llaVSkajaVUrnKngkV9VV4X+yD/wAiF4i/7GC5/wDRUNICz8FNN1XW/iF4w+Ieq6ZcaTa6wsVtYW1ypWVokVV3svbIRPxJxxyeB/Z38ReMdI8L67B4Y8C/8JDZNrU7vdf2vDabJNkQKbHBJwApz0+bHavqmvk/9n74seEvAnhnXNM8SX01veS6zPcoqW7yAoUjUHKgjqjcUAe0+JtS1vVfgr4zuPEvh/8AsC+GlXyi0+2pdZQW7YfegA5yePam/s4f8kS8Lf8AXCT/ANGvVHWPiF4d8f8Awm8fy+GLuW5Sz0e6WYvC0eC0EhH3gM9DXA/Bj43eBvC/wx0HRtY1K4iv7SJ1lRbSRwCZGYcgYPBFAH0rXlX7Uf8AyQnxN/26/wDpVFXdeDfFGl+MdAh1nQZnnsJmZUd42QkqxU8HnqK4X9qP/khPib/t1/8ASqKgD1WiiigAooooAKKKKAILz/VfjXkfxR/48pcf3TXrl5/qvxryH4o/8eUv0NTIuJ8g+Lz/AMTCT61z1dD4u/4/3+prnjTJL+m481PrXt/wyx50efavDdPP71frXtvwxJ85PwqZFRPqTw5/x5J9BWrNwtY/hYsbGPdjp2rXn+6aaB7mTddahj61LdHmoYzzQBej6e9K1MQccGnNQBDIetY+q/6pjWtIDisbVf8AVtzSZSPP9ZP7059azbcfOKv60cyNWdbE76RR1WlYwPWuqtB8q1yekscLxXVWZO0UCNVO1SHpUMZ4FS54pisZercxnPpXnmu/fbpXoWrn92a8611v3jcUhmNEMy12vhjHyDtXDwt+94rtfDB+7QB6FZ/cH0qxVazPyD6VZzTJCmN0PT2pc01iMUxET4qtLwDip3PrVaVqRSIm60w9aVvrTCeetIYtOWmA0oNAE8Y5FWU6VUUkc1ZQ+lMTLUQxVqKqkNWo+tMkuRdatJ0FVo+1WE7UxMlopAaWmIKkj+7+NR1JH938aAPLPh3/AMl2+Ln/AHCP/SVq9Vryr4d/8l2+Ln/cI/8ASVq9VpiCiiigAooooAKKKKQBRRRQAUUUUAFeVftR/wDJCfE3/br/AOlUVeq15V+1H/yQnxN/26/+lUVAHqtFFFABRRRQAUUUUAQXn+q/GvJPiembGXH90163ef6r8a8r+JSbrGXHoamRcT448YLi/k+prnTXVeNoyt/J25NcrQhMuaf/AK1frXtfwx/18f1FeKWH+sX617V8MT++jxyeKUhxPqXwyc2cf0rWm+6ayvDP/HlH9K1pvu00D3Mi6Gagi61Pddahh+9QBcj6UpB/GhOlK3TBoAryjjNY2rcxNwa2ZRjr0rI1X/VnNJlI871kYkPpWdbj5xWprP32+tZ1v98Uijo9JGQuOtdVZ52jIxXMaUPu11dnjavpQIvpggVKBxTI+3FS4wKYrmTqoBjavOteX94xr0bVB+6avPNeH7xqQ0YEK/vfxrtfDQ5WuMhA80V23hofc5oA72z+6PpVmoLQfuwanPPWmSJTH6Yp5pH5FMRWcVXkHFWnxzVeTkUikVmHXFRleambFMakMZtGKcBxQKUUASRgZqwgHaoY+tWEpiZPHVqLtVeLpVqIc0yS1H25zVlOgqCPtVhO1NCY+lpKWmIKkj+7+NR1JH938aAPLPh3/wAl2+Ln/cI/9JWr1WvKvh3/AMl2+Ln/AHCP/SVq9VpiCiiigAooooAKKKKQBRRRQAUUUUAFeVftR/8AJCfE3/br/wClUVeq15V+1H/yQnxN/wBuv/pVFQB6rRRRQAUUUUAFFFFAEc67kxXCeN9Na4s5cDqDXeydBVK7tlnjKsM8Umioux8O/EXQJYruU7D1rzaSzkRyCp/Kvt/xn4Eh1HcyIMn2ryjUPhY/nttjOPpUplNXPBtLsZXlXCnFe4fDDS5fOjOzjitbRfhkyToHT9K9d8J+EI9ORcoMijcFodNoEBjtUB7AVpSrkdKkghEUYUdKkK1VibmHcxEnpUMURz0rceAEUi24HalYdzPWMhSaUp6/hWkYVIwRSeQp607CuZEqYHbmsrUrcvGcV1htYz2qGTT43B5pNDUjxvW7RhKRjqazbe0kD9DXr174dhmJJUE+tVE8NRKeEpWK5jkNLtpBt4rqLSFgAMcVsWuipH/CBWhHYIoxiiwrmOkTdcVNsOOK1xaqPSlNsuOgp2Yro5TUoWMZ4rz/AF21k3k7TXsc9iJBWLqGgRz5ylJpjTPGI7ZxN0OK7XwzA/y5XpXQL4TXfnHQ+lbmm6IlsBgDNFimxLVDsANT7DWilsqgDFP8haqxFzJ2GmshrX8hQOKPIHpRYLowpI2x0qu8bV0ZtVPYUw2ansKVmF0c00TelRtCw7V0/wBhU9qQ2C+lKw+Y5gQv6U9YW9K6T7CuelKLJB2osHMc/HEwqdIm/u1tizUHtThaqO1OwrmXHG3erUcZPrV4QKO1PCAdqdhXII1NWFp20UUxBS0UUAFSR/d/Go6kj+7+NAHlnw7/AOS7fFz/ALhH/pK1eq15V8O/+S7fFz/uEf8ApK1eq0xBRRRQAUUUUAFFFFIAooooAKKKKACvP/j34e1TxV8J9d0bQbb7XqVz5HlQ+Yse7bPG7fMxAHyqTye1egUUAeVf8Jt8T/8Aokf/AJctr/8AE0f8Jt8T/wDokf8A5ctr/wDE16rRQB5V/wAJt8T/APokf/ly2v8A8TR/wm3xP/6JH/5ctr/8TXqtFAHlX/CbfE7/AKJH/wCXLa//ABNH/CbfE/8A6JH/AOXLa/8AxNeq0UAeUt41+JxH/JI//Lltf/iaT/hM/ib/ANEj/wDLltf/AImvV6KYHkr+L/iY/wB74R/+XLa//E1A3iT4jMefhB/5ctr/APE17DRQO54/H4m+I6HK/CHn/sZbX/4mp18Y/E1RgfCL/wAuW1/+Jr1miiwjyceMvid/0SP/AMuW1/8AiaX/AITP4nf9Ej/8uW1/+Jr1eigDyf8A4TL4nf8ARI//AC5bX/4mj/hMvib/ANEj/wDLltf/AImvWKKAPJ/+Ey+J3/RI/wDy5bX/AOJo/wCEz+J3/RIz/wCFLa//ABNesUUAeT/8Jl8Tv+iR/wDly2v/AMTR/wAJl8Tv+iR/+XLa/wDxNesUUAeTnxl8TT/zSM/+FLa//E0Dxj8TR/zSP/y5bX/4mvWKKAPJ/wDhMvib/wBEj/8ALltf/iaP+Ey+J3/RI/8Ay5bX/wCJr1iikB5R/wAJn8Tv+iR/+XLa/wDxNH/CZ/E3/okf/ly2v/xNer0UAeUf8Jl8Tf8Aokf/AJctr/8AE0h8Y/E0/wDNI/8Ay5bX/wCJr1iimB5MPGHxMB4+EX/ly2v/AMTS/wDCZfE7/okf/ly2v/xNesUUAeUf8Jn8Tf8Aokf/AJctr/8AE0n/AAmXxN/6JH/5ctr/APE16xRQB5OPGXxO/wCiR/8Aly2v/wATS/8ACZ/E3/okf/ly2v8A8TXq9FAHk/8AwmXxO/6JH/5ctr/8TR/wmfxO/wCiR/8Aly2v/wATXrFFIDyf/hMvid/0SM/+FLa//E0f8Jl8Tf8Aokf/AJctr/8AE16xRQB5P/wmXxN/6JH/AOXLa/8AxNH/AAmfxO/6JH/5ctr/APE16xRQB5R/wmfxO/6JH/5ctr/8TSf8Jl8Tf+iRn/wpbX/4mvWKKAPKP+Ez+J3/AESP/wAuW1/+Jo/4TP4nf9Ej/wDLltf/AImvV6KAPKP+Ez+J3/RI/wDy5bX/AOJpP+Ez+J3/AESP/wAuW1/+Jr1iigDyj/hM/id/0SP/AMuW1/8AiaP+Ez+J3/RIz/4Utr/8TXq9FAHlH/CZ/E7/AKJH/wCXLa//ABNKvjX4nAf8kj/8uW1/+Jr1aigDyr4R6Z4n/wCE78eeJPFfh7+wf7a+weRb/bYrr/UxPG3zIf8AdPIH3u+K9VoopgFFFFABRRRQAUUUUgCiiigAooooAKKKKYBRRRQAUUUUAFFFFABRRWT4s1qDw54Y1XWbrHk2NtJcEf3tqkgficD8aAMXw78RNE1/xrrPhawNz/aWlAmZpEAjk2sFbYQSTtYgHIHNaL+KrFPHcfhMx3H9pSaedSD7R5XlCTy8ZzndntjGO9fNXhTXtJ8OzfDPWkvLiTWXu54dcL2ksYYXrFizOyBTscr0J/HrXr9z/wAnQWf/AGKb/wDpXQB23gXxVY+NPDNtrmlR3MVpcNIqrcKFcFHKHIBI6qe9b9fOPwW8H6nrfwbt7228W63plwj3X2GKymEUMJWaQ5kUD95l8k7j0wBjHPrvwf8AEt14w+Gug67qCqLy6hPnbBgM6OyFgO2Suce9AHY0UUUAFFeT+Kde8V+JviTd+DvBOq2+hQaTax3OpanLaLcyB5BmOJI2+XlcEk47+nLfhdrPiz/hZni3wz4s1yHV00q2tXhlis0twfMBO4hRnJGMjJAPSgDqrD4jeG9S8cL4V0q+W/1H7PJcSSWrJJDCEIBRmB4fnoAcY5xXYV42dG0zR/2ldIGk6dZWIuNBuJZhawLF5jmYZZtoGT7mvZKACiiigAqjrmqW2i6Ne6nfFxa2kLTSeWhZtqjJwB1PtXlTav418f8AjTxDZeEPEFt4Z0LQbn7C9ybBLua6uQPnG1zhVXpwQenXPGl8EvEPiHVm8Y2vi7Uob650jVnslligWFFVVGcAAcZyeST70AP0n4zaJea1p2nahovibQxqUghsrrVtOMEFy5+6EbceuRjjuK9OryTWJB8WPEml2mkxhvCOhail9c6ofu3txFkLDB/eQEnc/TsPf1ukAUUUUAFIzBVLMQFAySeABS1X1L/kHXX/AFyf+RpgeIf8LN+IOseG9R8aeGdB0D/hD7TzXjivZZReXMMRIeRSuEA+U8Hn5SOeK9j8LazF4h8NaVrNtG0cOoWsd0iP1UOobB+mcV87+BvCfiXxN+zx4dXRPEEVvpqWt0LnR5rfEd/i5mJVp0YSICvy4HFe4fCjxBa+Kfh1oOr2FmtjbTW4RbVPuw+WTGVX/ZBQge2KAOsooooAKKKKACiiikAUUUjqroyOoZWGCCMgigBaK+evD/ij/hVGifELwtOzNLobm80OJuTLDcn90ijvtlYA47seOK9W+E3hdvCHgLS9LuCXvyhuL2RuS9xId8hJ74Jxn0AoA6+iiigAooooAKKKKYBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFKwBRRRRYAooopgFFFFABRRRQAUUUUAFFFFABXL/ABI8Jf8ACbeGv7Elvms7SW4ikudse8zRI4Yx9RjJA556dK6iigDnPiB4UtfGXgzUvD10/kQ3cYVJVTd5LKQyMBx0IBxkVn6f4Kmg8ead4ou9V+03Vtoi6RJH9n2CZvMDtNnccZP8ODj1NdnRQB5DoXwk1rQfC48PaT48vbbS5t/2pFsIyx3k7vJYkmLIP+1zkjGa9N8OaNZeHdCsdI0qLyrGyiWGJScnA7k9yepPqa0aKACiiigDyTxJo3i/wt8TdR8WeDdEtvENprVrFBfWDXi2ssckQ2o6u/y7duBjk/zp3wv0HxdB8TPFniPxfptnZDVLW1SL7JOJI8opBXruyBjJIAJzjIr1migDyW/+CFjea8+sv418dx6gQ6JNHqqhoo2bcY0by8qmf4c4r1lRgAZJx3NLRQAUUUUAeMx6V468B+MfE0nhPw7Z+ItF1+7OoKWv1tXs53AD79331zzhecdx0o8AfD7WbzQPiDpnjuH7AfEWpSTtJp06kMjgZMZO4gZBHzjOOor2aigDyWy+CcFjbw29n4/+IcFtCoSOGPWQqIo6AKI8Ae1etUUUAFFFFKwBVfUv+Qddf9cn/kasUUwPmf4LeBfFPiH4O6Oth8QL3SdDvknWbT4rCJ2Uec6sI5iQ6A7c8dyfWvoPwtoNh4X8PWGi6RG0djZRCKMMck9ySe5JJJ9zWrRQAUUUUAFFFFABRRRSsAUUUUWA8Q+MWg6fqHxx+FM13AJHmlulkz/GsCrLGD6gOSce9e30UUwCiiilYAooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Looking from left to right on the serum protein electrophoresis, a normal pattern has a large peak representing albumin followed by significantly smaller peaks for alfa-1, alfa-2, beta, and gamma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42497=[""].join("\n");
var outline_f41_32_42497=null;
var title_f41_32_42498="Brain MRI of a child with adrenoleukodystrophy";
var content_f41_32_42498=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Brain MRI of a child with adrenoleukodystrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 449px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHBAeADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiloJGflGBQAlFFFADmYsBnHAwOKbRRQAUUUUAFFFFABViC7mhiaJJZBGxyUDEA/hVeigC0t7OqhRI2wdF3HApDdzF9zOzc55OarU4LxkmgCZ7h3fO47qjZjnDcHvTOh4peSeaAAEinYZ2AAJJ4AFanh/w/f67dpBYQPI7HHAJr6S+GXwAUyQ3etqeMN5ZoA8H8JfD3XfEsqiytH2H+IivoLwL+znbRQwy68xlm6legr6C0Xw/pfh6yVIIo4o4x1xgV5x8QPjTpekPLp+jMLvUF+UKnKg0Adfo/hnwx4NslxDawKBgu4FY/iX4t+HtEjC2TC6kJwFhGf5V88a/r2r+L7gf8JHeSWcZ5RFO0fzrd8KWui6bbb5p45QoBLOQTQB2GqfE3xT4ggJ8PWLQIeP3i81hweHvH+tTNJq+rNBG3SNWxmtCf4oaHpn7u2VGdRyFxWBr3xugdUWGFnHcA9KANhPhfahy+pzmZm4JZs1dtPhV4cgLSupcuOMt0rzX/hZ+qXU/mQ6bM8fUAZqKX4xTQz7ZbR1kGMKT/SgDqx8HoP+EkEloXFoxJI3dK6e7+FtkjFISUkK4DZryx/jpqUFyCtsoC9Bk9K6fSfjra3mHv0aFwOuaAK978MdXtZ3eLVZY1XlcMRmo7KT4gaLMUsL03EanABOSao618ZreeV/s+9iOFzwDWZYfEzUTL9paOPyM5ODzigD1jR/izr2hRq3i3TZDCODIg4Hua7zQfil4X8UhYIpEG/gpIuDXjaeMdO8X6aUuZIwAOVY/wBKiTQdHlgH2K4it5QeGBoA9c8afB3wz4thLxRxxSsOJIuDXzn8SPgRrPhtzNpoa7tOuQMkD6V6DpnibxL4MYOlwdQsQQNu7JAHWvYPCPxD0nxLarFcsiXDcMjdRQB+fFxBJbytHKpV1OCCMYqKvu/x58FfD3iW3nuLOFIbyTJ81O59TXyf8R/hnq/g69kWW3kktQ2FlA4NAHAUUpGDzSUAFFFFABRRRQAUUUUAFFLSUAFFFFABRRRQAUUUUAFFFFABSg4pKKACiiigAooooAKKKKACiiigAooooAKWkooAKKKKACloGM80KcHNADnQqBuBBNN9qlldZMno1RqpZsAc0AKilmwOtdp8PfAGqeL9SihtYH8okb3I4Arovg98LLvxlqUckiPHYp95yCMn0r7V8IeFtM8KaTFa2cCRrGuN2OtAHN/DL4X6X4R0+LZEDd4G9yBkmuj8V+LNL8K2Re5ceYB8sY6muH+J/wAVIdFd9O0gedfngkdFrwXX/ESxmTUdevHmvDkpEzZH5UAdD8R/ibq2vH5bhtO03psB+Zh78149eajLeapGNBtmmnY/63BO41t+FvDWtfEjWhNPm3sA2CSMDFe+aF8P9K0O3hW2iTfGOS3JPvQB41p/gvW9akT+13ePjI56Vtx/Dq9tYnSG4JOMDNeyGCNclF5HGSKdDFuyzAEA9aAPEvDfwrvpryb+0SPLY8EHrXcaV8L9E0aQPcR/aHJycjOK7zAhxKJN2PajeHjWV3Bx69KAK9homjqFiSzjRfTaMVhan8NND1C7uLySyXeoyoVQM1tR6jC0hVcAg4zWjZzsj5aQBW4zQB8T+MrCTT/El7DJA0MYkIQEY+WvRPCPwsh1qytL4PIIWALqepr0f4p+ENIvtbtri6LF3YcDvmu/02zi07SLe3tkWKIAAYGOMcUAeaz/AAh8OTMDLE8AC8lWxk1e8N/B3RYPOMs5mtz9xT2r0G88m5hEOwAgdaitAYQFBZUU+tAHiviv4UNpl1NPortsbpHXl+qz6hp0xt7l5oWU9QcCvsS7uFkh2R4Le9cnr3hvSNTQf2jbxs56YGDQB88WXjjVdPtfIuS8sDdGIzW3oeuW96fM0+4MN52y2K9Jm8E6WsJtY7QG2bPzHnFeVeNPhzeaReNcaFveEc4U8rQB7N8O/jH/AGPcx6V4kl35+UTDpXutxa6P4w0XOyK5gmTg8Hg18D6DqlojSW+vWxaVeRITgg/Su++H3xbvvB2qJAzm40VmyVJ5UUAbPxj+BVxpzS6l4fjLQDLPFjkfSvne4gktpmimQpIpwQa/SXwx4k0rxfo6XFlLHKjryuRwa+f/AI9fBdpmuda0KHLnLOiDrQB8q0VNdW8trM0U6MjqcEEYqGgAooooAKKKKAFpKKKACiiigAooooAKKKKACiiigAopaBjPXj1oASiiigAooooAKKKKACiiigAooooAKKKKACiiigAoopQCelACpjcMjIr1L4LfDO78a6ujlXjsY2/eOR1Ge1ZHwq8A33jXW4rW3QiHP72Q8BRX3R4Z0LSfAXhlIYdkMMEeXduM470AXdB0bTvCmipBbpHFDEnLdM+5rxrx38XJr+8uNI0JSiKSrXBPHpXP/Fj4lX3iiSXT/D8jw6fGcPKpwX/+tXl9pBqOowSWek28jzc+ZL9fegDd1LULSGykFvL9q1N+WkPJFYXhvwFqPivWorm/L/YwcsSPet/wV4A1O1lJ1aIsWPUmvcfD9nBY2fkRqFfHXGP8mgCxoWm2OiafDaafGscajBOKlupwu8cYPAGarz3KRBo5mA9D61ml5JQxhI2DoDQAouY2nf52B6Y7VqRMosWC8t2rnZIh/C2JPU1nNqs+nTt5zbk+vSgDqo2RYT9pbntWHrWqKqGKHo2R9KzbzxNFOrJAmWxz7VkaLJcX2pgy5MYbgE5xxzQB0egWMjwvKxBJ7ZrbibYqoedv6VctoVgQCPj2rJ1UvDdKYyck8Ad6AMbxvd2w1LT1m2qTIME122pTq2mQCHD5H3gOleLfF3+0WitPLjwxYHPevSPAj3S6HbDUmDNtGPagDPfUJtN1VVuHbyHHGe1dJaXcd6f3GCo6kVk+LLaO9gdANpHQ1yFpd32jRsIyZIwfWgDvZ2Wxk8zaMdOTS3Lw3ihuM9evIrjNR1y6uoYxEoLHGQcV0OkssVpvvAQSOhNAE8YzLsJytR3CAO6MoZCO9XbaKJ42ccZHABqukZEhychjxntQBw+u+ANP1lpXSHy3YE7l614p4r8L3ehXclvskaPPyknoK+rFcIxjxk+1ZfiDRLLVrOVJIxvI5PegD5w+HPjrVPA2so9vIz2xYB4yeCM9q+3fA/jPSvGGhRSxyxkuoDxMeQfpXyb4p+H5023muoF3IBnJGeKwfAniXUfCetxXsQae0Rv3keaAPYv2hPhCL0Ta3oECoyAtIgH3vcV8pyI0TsjgqynBB7V+jngvxTpfjXQlkt2Rg64eMkZB7givmz9o/wCFK6VKdb0O3IgYkzIg6H1oA+c6KU8UlABRRRQAUUUUAFFFFABRRSnGeOlACUUUUAFFOYAHAbcPWm0ALT3j2orbgSeo9PSo6KACiiigAooooAKKKKACiiigAooooAKKKKACiiigArf8G6BdeItat9Ps0ZpJnC4A7dzWTYWst5dRwwKXkdgqqOpNfbnwD+Gdv4P0NNW1WNBqUy7mZhzGD2oA7L4eeENM8AeF0RFSJkTfNKRjJ7149428T6n8SNfk0/SGaLQLV8SyDpJirvxD8Yah478St4Y8OyGDSom23N0v8XqAa5Pxv4ttvAemJ4e8MLHNeyfIzDDcn1oAyL61gvdQTRtCcokTYkdV6eteteFtHt9C0pIolBmI+8R1NcL8IPCeuAnVNRRI/tB34Iwea9gvLYJCuPmf2oAhtOc+cAc9M9qZGF89ucHORVW5kuIQCF/DFVIb9fMIDfvaAEvbf7VdnLlfb0pzxiytSwO/+tV5ZgXLSEA5z9aRLkXIMJBAHegAsttyryyAgDoK5fxDcrGXdgCPrXRSSyQxsAAY+9cLrnm3LlVbbyeM8YoApW11bi3lII3HPAOK3PBmAzFgcMe9ctAkdvIgYbi3866/RZfKdDKpVT0KigD0DTEYsGlf5CKztdWVtThMBwgPJFTrPut1EQx2q/psa+YDOMjHpmgDivGDq+q2VvNibnpjNdHKiRQxCJdgwM4pup2ts+vLKy5298VqzWwY+Y2fLA7d6AOY1PfOuwPjPU1zV5Kis9s5BJGAcc11N8pSVnCHGe9cRrsojvi6gjFAHN211cW/iOGNncwq+CO3WvV/ErCfSoBZYVxjNeW3sg81JoSN27P0r0HwpqCXlikU5wQOpoA3NNuFjt4UnGGAGTnitaYK3zKvynnpWLqdvKqRLAeM5zWxBcLBpimZckDkmgDHNykN05kY8DgVPBL5o8xOVPNcprBfUdXUwPsj3c45ro7NGgjVEZWXvnqaAJ9WRLuzNvhdrLjBFfOesxroPjCS1ZA0MzDcuOOa+lWQJHlsluwA715T8QPBU2oSS6oFIkUEgYPbpQBnaLeal4C1eLW9NlEmmyEGaFT2r6e0PWNI+IPhYvE6TRTptdDg7T718c+F/EknmyaPrakRNlfn7Vu+BPFd58NPGa75Gk0K5PzEH5RnvQByXxn8BXPgrxJMpRzZzuXicjjntmvOq/QDx74e0n4oeBy9vsl3JvglU8g4r4O1vTJ9H1W5sLtSs0DlGBoAoUUUUAFFFLQAlFFFABSkEHBBBpKUkk5JyaAEooooAKKKKACiiigAooooAKKKKACilwcZxx60lABRRRQAUUUUAFFFLQAlKBk4FJXVfDrwrc+LPElpp1sCVkcCQ/3V9aAPYf2X/hwNX1Ia9qKH7HbnMYYcM4r1j4x+MLy7v4fCHhc/6TNxczJ0jT0rR8Xa1ZfCjwBaWWnw7ruRRDboP4mxya82tbm28FeFL3xBr0wk8QXwL8nJyR0FAFD4ja7Y+APDFvpeilW1aXh3UgsD3Jri/hf8PtR8Ta2mr64ZYod+/e/VjWX4E0LUPGPit9X1CGSW38wyHd356V9K6dOv2NLaCAQqg9OKAN8+XaWkVtasdiALgVT+0mCUiVjg9MmnRzqsaDrzVXWbU3UatGeRzQBclkhnj+ZlArJOkRrIZ1znrxWTLqDovkPk7TjNbtlP/ou3dknigDEvLCSRi5DY7c1De5tVDINhxya6aZy6pGEGT1x3rmvEtylkrpOo5HU0AYOpauIjh2yG7CsCa1F9ceau5RjoCavWywzxtJKQFOSM1RiumkumihBWMdTjigCO8tkSIPIdrLyPU1a0Z5rjq+FToCOtWRZm7bZEA79MGtvTPDjFC03yMrcYPFAGnok86sBcqpT65rpEZ52BiG0Y7cVza2rRnC5yD19a6G3eQlI1T6jNAGVPIjals3YI4rSdmYAKZCvc81heIdLvLrU0+wEo/wDERVXR38S2us/Zr6ENajgyAdvWgDVv1kOQgLL71wPiy3dCXVGPrXqwto3yvmBT6E8isTVdNVwyMu8UAeOX1v8A6OksWd2OQK2PDl4sM0cTEjoMe9W9Sshp178yoY89Otc/qlyRrEElqioinJIoA9tsHW5gjAOCBn5uc1R8V3LR6e8IwpC596zdI1dTbxtG4BHUVk+Nr4vaF0bMmBQBD4YZ7hmMeGweTXVRtHE4LZU+h7VxfgK78mLMp+djyK7GZ4bmTpz6j0oA0IHLguGzxwBUtwrTw4nA24xWZZ3AtZfLJGOgJqxcXnlXKRysDG/SgDxL4r+FZLy+F1o0JEgPzBe9ZOjzQ3OlNo2uxj7TjajE8g9q99vbKCFtwIKv1x0rzPx/4UhSN9UgwJUG75T1oA6L4A+OjoWpt4U1YeXCzE27seDntWX+1d4FSCSHxJp0XyyHbcbeR7NXnzPL4g0yK/0kGPVNPIPHDHHWvoz4d6/afFD4czafqaq12kRhnRhzux1xQB8OUVveONAm8M+J7/S51I8mQhc917Vg0AFLSUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRS0lAD4k3uFHU9K+yP2Y/Bkfh7wu/iLU4lSe4UurOPuoO/tXzb8JvCM3i7xbZ2EahoWYNKcZ2qOa+nfjv4iTwx4V0/wvpu9ZrsCI7OqRjgk0Acf4o8SnxH4mu/EerPt0DTCUtlI+8RxmuM0bRtQ+KHiB9Yvw8WkQn9zGTgYzVd5X8Rajpvg7TEcWcWGnkHQ9zmvoOGwtdE06DT7VFRI1A+UUAVvC+nWejWZghRI1HAxWtGnko77Rz6iqxaO4t9qDaVPXPWmwTu22NucHigBTJGuN5Csx9aju7kLGMHjHFPu0hkUB4+VPB9KzryymkGUbgc4zQBVlhi2+bjknPNMS4iYjyH+YdeaqXV3MkjRXKbEx2NcxaXMr38qo52Z4+lAHpFjOxjznkjG6uF+Ic7OApfLAjgVds9YlgRofmyBjdnpXOXzSXt+WmyVWgB9oAdOUSDa5HcdKdFp000yRWrbnfHOKITDJcqz5AT7vHFdb4R04zXpuudvQUAaPh/RYtPCG5AMx68c1vTRAx/uQqjGSOhqxKY1feeH6Cub8Wx3ZtU+xO3mNgEA0AXrEwvcunmBiDzjtWiLQxF5UlO0dsVS8NWcFjYI8sZe4P3t1bSulwHRPlNAGFpl39qnmBVsgYzVu3D7pA7tt9CabatFDPLEo568VHdTB4HEQO8elAD22bxsYE9OKJ7YyrkMKxLW5WMs753DrWrBeKYw0bnB7Z6UAcr4x06M2RkDBGAznvmuIt7WIRM0kZdxwMV2vje5E6LawOPNbg81xNu1zaXaW0vKdeaAGW13JHK6KpQAcCqt7e3STqshJRumec1q6rZ+VKkgIC9xWTqLSyyRyRkbEOCKANnSIRCFkXJGOQetdbpN2k0bRqpyO5rnLS3a4skeJXGBk9q0LUTQJ5kaZUcE0Aak03nM0a7RInSr+nwLexB5j80fBNYFxMI5I5u7HkCtuylELAl1EbjJHrQBYhP2vdGuSiHH1qtfwwXSNbyqCCMYNQ3GsRWM5Fvlmc4496sWiSeZ50mcuelAHi2q2MvgrxxHcQLtsLo7Sp6c11HhjUbnwF8R4dR8vboWqkByB8qk1a+OelS3fh03CqTJEQy7R3rmPCfib/hLPAlxoN3j7dZxgxyPyTjoRQB1v7VnhaK+sLPxPp0YbACzMo6qehr5gHXrivsj4W61Z+N/h5eeHtRcS3lujW8ivyeBwa+TPFWjzaD4gvtOnUq0MrKPcZ4oAyj1ODkUlFFACngmkoooAKKKKACiiigAooooAKKKKAFpKKKACiiigAooooAKKKKACiiigBSMHFSW8ZllCqKirs/hd4am8SeLbCwSPdG8gMnB4UdeaAPpr9mbwpF4f8AC1x4hv41jknXcA38KAdfzrxr4leMf7b8Z6lqavviUmC2U8nHTI/Gve/jt4itvBHw7TStNdYbiVBFGi9l718q/D3T7rxP4xs4VUtEkgkkwOMZ70Ae+fBTwqmiaCdW1CMG/ugWBI5H413JuQysJgd5HUir9xEkdtBFGir5agEHHp6VSMa3BLbe+OKAM+K9is2bzf4jxViC6tyN4baGPc9qS7it5SqsgYjpzVPUNJEkQMbMhIzxQBqpdQhDucfMf0q5ZxxbiyMCB71yCWN1b7RI7FT3PNE13cWZBKnaO+aANLxfbRSxNtG2T1FefeRFChO4+cvAINbGp69LKu1ANxHFYqSlZNsqFifQUAPjzE2eTuPOa1jYILTzTne3ccVDb263DqHDBR046Vqz7fIMSuDtHFAHKySGNfL2cg5zXo3gu7R7IRKRux27159cfI7nJJHPNW/COpytfsucD1FAHq93JHHjfn2AohkSZCVUZweTziuffUopZdm8MR1z2pn9rokuyNgAe4oA2jIUnxz9BQGeGbd/AevNR2sU0imcsWB5/wD1Vcm8sxgSAAZ5NAGD4q1t9Gmg+y6bNOZjgtGM4rYtIw1vHL/FIOV+tW7hhFbhiBIvQVAjZAZAFHpQBi63pW9H8kYJWuKkW+tsr5hQKelenXk6rCzbhuHvXmHiLU0ub3YOfXA6UAU7rYkizu2+UHgmql2Vu50ZG2P2zU86pJGR342giqlrBuYtyGHIFAFnUITPbDzGwcYyPWqemRxJcCN33sTwDV0LLLcnzCSpGNueB9KoQQf8T5Cg24PegD0PQoF8ryGQKGHU1JJaCAyQgFk9cUrXEMVpHtbM/ap91ytv5si4yO9AHLz2skszLJ8qrytUL0XEiskZIC9COa6DUnSD55m+8OhPFcvf6lFYybo2BR+uOc0Ab3he2jlhzOFZ17murhubZ7R0LBGQfxV5ZYa/Lb6h5Vsd/mHoQePault7O8uWMksgUPzgHpQBsXca6lbvE58yMjDAV4d8TfCk3hDUI9a0ZnS3kbEqr0Ga9n0+B7WR4oc5PQmoPHmktrPg+9gmQMyoSpx3oA8d+C+u/wBjfEeCbzgLbUOHy3HP/wCs1qftTaFDY+JbTU7dTi8T5yBxke9eMW1xNY3sciMwkgfcAD0INfTPiONviZ8Gor21hEl5brn3BXr/ACoA+W6KdIjRuyOCGU4IPY02gAooooAKKKKACiiigAopaSgAooooAKKKKAFBIzjvxSUUUAFFFFABRRRQAUtJRQA5VJBI7V9M/s0w6f4a0S+8Ra1lCRhHIOAo9K+dtKQSTwwlNxlYKPxNfcV3o+laD8G4ra6gUILUKeO5H/16APl741+PT4+8UKbRWEEZ8mEc8jPWvZvgt4Mi8J6EL67j3XtwN2SOQK8U+GvhqPV/HKvIP9Hhl34x1wa+qHKh0iGBHEMKB0oAJnbaXY5B5qnDcxfOwbpUeqXh8khGIB6Yrm765kij2RqctyTmgDqonVozKq5yag1q6uE09pLOLzZMcAd8Vxa63eWSEglgRwprSsvFw2x+cmxx6jrQBv8Ah68GpW2y9t3guR1Vqu3OlLLuWQZU1mweKdOGHdAr+oFEPiOEzNIzEAj5c0AUdZ8OwfZJDCNjjnd6VwtrLcrfeVId+Dwfauv13xMLmM29uDvbisKCAxqTKMSf3hQBomOeSIFeFB606MxIDvzlu9RRXQt7cxswdmOAKm3s6DKD8qAM+4tg14wUlkPXNVbCJba7bC43dxWtLkDeidT68VXQ+WCWU7ieMUAV5Zp4ZmJcJuHXpmtHw+omuBvfc2eTWRewyS5eeTCj9BT/AA7dBbtV3DZnIx3zQB6vYzZVYd2Nowai1sGSFYoFYn1FUdPcNgKPm7GtYTKi5k7H5gB0oAZHAWtlR9xbb3NLEpSN/mAOMc1Ja31veEi13Er1OOlUr9JxuKnkUAcr4rnuIIJTDJk+nauPs7S6kQ3nknygcFs963vFX2pEaQqXHfHasPTY/tMDvK4z6A9KAHSCaW5QoAVXqaS7QxXIlUFQOoHen2MixBwilst3qZs3O0gYZexoAdcXUIgDR7tw7YqhZzeZqaybRhTzmtC+VLiFEjYbx1FZuEtNwbl+elAHST3ifa42LfKvQVKmuvM8iISwUcA+1cykkrj5VMme3pXTeGdNxEZZkVQB0NAHPaimoapJIjgKnbd0qo2gOsBdi0u0dq7SRRLcMsfCg4zjinRWxiSRVO4N60AcVpllGHWUoVcHqa6SCdo54jJJuTGCPSoZ7CWRZCoCnJqlb2z3EZjlYh14yeAaAOruL6GHY0WNxHUVYN19sspIpWGx12t9KxVijtbLMvzbfTnirVp9nurMPuKN27ZoA+X/AIiaI+heJ7qHaRDIxkjPYg16n+zPrOoTtqOgxyr9ldCyq38OeuPzrO+PumSLDZXgwUUlWOPXpXJfBLWpNG+IOnMj7Y538px6g0AZfxM0KXw74xv7Kb+/vU+oPNctX0Z+1b4XaOey8QQqPKceU+PXsa+c6ACiiigAooooAKWkooAKKKKACiiigAooooAKKKKACiiigAooooAX60DnijtT4RmQDFAHafCbRv7b8YabZZw7TKwz6A5r6a/aZ1NLLwXDpEU2y5cgqg7gVwX7JugJfa/capMoJtY/LBx0Jpn7VWt2914ghgtZS09oNrbTwpoArfASMWs0hmUCUjJz1Fe1TOkivt4fPH0ryf8AZ2si+i3Oo3J3SM5C7q9RO5oJcKQc8UAQiEMQJduM5wOabe2S3DbI4/lHfFTacVY5f5iP51bLSo29V+U+/SgDn38ORvkyIQKxpvDztebkBKr0ruvMY5JJye1VogoLu5PBI9KAPONXsbiPKxxn5e9ZdoJhcKJWYgds9K9XmjtbmIgRkuegNcxqGj7H8yNR5hPTuKAOeZJn1CPyY1YJ1JrXvSskJCDDgEdOtUoLWezvWkllHPatJtmx5vvcYOB3oAz4raJ49zAeYpyc+tSmbJVADg96z2n3uzbSvPWrAuC+xo8emcd6ANea0kNqjA4zz0qhcWs0UiPKVKf7JrpbKNpIEDNu3LxxUU1uYEJmGA2cE0AcZrDhwVjJQD1PWq3h4KuoquckkdelbNxZW7ymbzFcZ5FZi7DqQIGwKcDHQ0AelWT/ADJtU5xitPVbtNK0G6uZkG5UOCfWuOsL51kRFc/L3zVH4hXhuNM+zyTSBG6hTyaALXwm1K8v7W8urm7UB3JSPGMe1dbdSl42JfcxPUVxHw/mtbTRxFDGRjqX6mumnv8ANufLC8Zz2oAzvGFykGjYY4YjGc1xGmTRw2zHaST0GetaXiG+jnXY43Ec4BrPhMcMAYBfoTQA+0vAZnBj8sjPatS0j8wvIxw2KrWV7ZajL5K8S9M4rdtLFreXJ5XHU0AYyBY45DkFh2rOAjeN5Rkv0w1WNVmCXrhBuJ9TWf8AaFicF4zuJwRmgCvc6jNp8Zbyznrx3qzZeKJWtMsWBI+7UmtFbqGEIox78Vg3iJbuqnK7hyT0oA9B0rUluLUOgAPHatO3ukM65PyHuOa8+s75LCwJLNgjJxSJ4nt2ttwysg5HNAHcavfwW0hVehGeaxodQhnlkiYBPQ1yWtXkl8kMsTMSPSknN3CsMkNuxz1IoA663u5p2a2jJZAeo9K27bT1EahgRxmuc0ICLbNIWRyMkM2K3r3WY44owGXGccd6AOX+MWn3ereGnhsbXzPKAY4HPHpXzlp1xJp2p29wMpJBKGPqMHmvsixumkj+YK0bjGDXzf8AGHwtJouvSXkSj7LctuG3saAPoz4p258Y/BGK6gXdIsKXAzyeBzXxjIpR2VuoODX2d8E9Tj8QfB+Sy4aaKFoiOvavkDxDayWWt3tvOhSRJWBB+tAGdRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSqcEHAOPWkooAKKKKAFpKKUdaAFHKkYzip7VAzgpyw7Gq6jJxXS+CdJl1bxBYWtqm6V5lUj2oA+vf2edDXw98N31KYGOS5BnORjjFfLXxL1htc8cXcsOHWWUqAB1ya+vPirfHwp8MEtrYBf3QhwOMcV82/CDwVNrPicareJmzgk3AE53GgD1X4ZW9ppei2tluMU7oGeM8c13aEtuX2yMVj3ulWzamt7brteEYwB1rSt7jzBl/loAglhY52nacnk1LaOqgqeW6VP5QlyVYFcdRThbRuV2MQw/ioAYCFJRsFj+lMldY+CMY6mnLAyz5dyMetMvIx8zOQFJ4JoAqrIkk7eUMqBnjpWfeTRpI7YyPpir0Nt5NpJLE+8n36Vh3DO2RMwTPT3oAxL79/IxWQ46hTUsHnJaFQOD1B71XuGje4EUByepPrV61RFkUTNx6UAVIIUeFo5l4qtql3HaxQqnABxwK2JhGZP3ajHQkCuX8Ur+4DAsozg4NAHpvhN4rqwhJwTjPHpXL/GfU203TokhO1mxyOv1rU+HB3WMKs54xwPSuN/aKhlKW/l72OePSgDn/DeuR7FjnmBY9Sx610yJHeOWgkQcYBB714FbTS2coW4kPJ6dq7rQ9XzCiRzbMHigDu1ubvT5kVzvXOMntS+LLt7iOEwttZsdKz7LzLlkPmlsgZzzWpJpU3yu4OwdKAIob42FvHkl9wxgDFPGtTTN5aAqpHOTUN3BLDHyu5fpwKoXF/bwhWkAB/u9OKANSC4jVHNyowBnLd64XxN4mMBeK2KmPNP8S+KIGs5ILYqjAdSeTXml7dfaBxnI96AOq8L+JpotfjAxukcZ/z+NfSc4b+yI5WBBYZr5P8ACdjcXniWw8qMnEik47V9a+KXW38Pw5Yq4QAgUAeZX0yHWFCuSe4qO6G66VmcY7qai0LZLqU0065GcAtzWpfRwJmWNAxJHXtQAj7Jo128beapaxEJrYlRgg1uafbrPaEgAEVl6pbSiFztwKAMjS7drtXSUfKO1T6f4cSa625GwN90irHhmDJaRziuwihjiXepAJ/iIoAzoNLt0XyhErBOtaTWsYt1Ea8LUiI6tvQgg8/WtKyNoyFJSFbpyaAMb+ykvVV9xXtgd6kvtFjMKB1+UHrT9WM1kC9vyladoTqViskUqn1XvQBVhh8qBEThB+WK5H422Ed34UYxLukjUHdXZSIfKZAQCe571zniW583w9d25i3kKR60Acx+yj4iSz1i80Sfgz5ZPqOtcR+0PpTab8R75wgWK4xIuBxWN8MdY/4R74hWF1MdiCXY59Aa9t/am8PC+0XTdds0MhUBWZR/CehNAHy7RSng4pKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApaSloAVAS3Fe//ALK2gLqXi7+0JE/dWkeSSP4ia8JtIfOkWIZ3OcD3r67+HumXPw7+FcmpQwbrh4/NbselAEH7Rurvf+INM0O1fzI5GwyKehzXR+GtKj0fR4re2i8s7ct9a+cPCPie61n4nw3V+7SGWb+LtzX07qTOojZM7WXGRQBU+2iOVoyNzMe1WYpY5yFfBC9hXO32l3ImaeGU+61mwXl3Zys0oIXPBzQB6DZNE7FFXAAxnFXI4Y3cgSYAwelcTaeIQkfmMCxPHBqwniAblBVhk9c0AdRLGjyk7/bg4rA8TW97IY0tW/dE8884qBtaCXIQKSD3qvP4h2XJUI3HOetAHSxwrZ6cmcFwv3T3rhtdvC9w3y4HbA5FN1TxDPKRtU7c44NZTXJnU72G48jigBmm2stxdPLuCgdvat3yx5TbRzjFUrKymCh0YAdDVi6WW2eM/eB54/rQA+QNFCGzgdTXK+KEd0V1b5Bzg11fnfaQYwvPesvXNPJgKe/TrQBo/DSbZtG4kEZwO1a/xDs01G3BaMMR096x/BMZijaJQFcDriuoilWRWEy7iM8GgD5n8b6YLP53i2nPFczZ3uwDqCDXtHxVsIjp7yfKCMkce1eFSERvkHjPSgDv9D11t8IQnCnGa+idDsjqOl27na67cV8hWk7ooCNgs3PtX2V8HYC/hG0d+SVzmgDkfilLDoem7hEFZuhIr571XU5pZ3lMhO73/pXtH7UFzLDDawqu2Nm+9nmvm1XcuQ/OR3oAmvXa4YkuQenNWNItpXlSOJN5/OsjJ4HPHSvUvhZZI7rLIuW9x1oA7L4b+HPs0qXk9t5cuMgEHmu58e3sceikux8zbjGavaarJCuemOmOKwfHgT7Duk+bjpmgDivDNmt0CXkxvNdVOFs4xEI94xnJrE8OwN5AlRRx0FdAZZpWPnwjjGKACPA2EEKT2x19qk1O1DW20yDkfSolfzyV2FSp4NZ/iCRygHmFcY9qAMi0jnsrw55i966RdQW+CRRjhTjrXIJey/Oi7ZPc8mrulPKJxuHl/NQB6NaRQrGiyHLDrVm+soGZGVfbIqDT4kFvHucEnk1pTqBDlXBUUAZclizAo7ZjbsT0qnDbzaK8n2Z96N0HpWm+913RtnFV52kEfOaAKWpahFa2oeZwJZDjYOvNRT6bctoNxKsfLqT0Gaq3enJd6lFNISSuOCa6MXcjMsO8eV02igD421MyRatck5SRZSfoQa+t/CN+PHPwSeKdN88cBj5GeVHUflXinxq8ICyv/wC1LFB5cx/eKoxg5r139knVrK88L3mjyY+0RMWI7kHvQB8n30DW15NDJndG5U59jUFd58atAk0D4ganCyBYpJDIhHcHvXB0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABS44BpKcBkAe5oA6z4b6Qda8U6baKDueZc+4z/APrr7D+OOpJ4d+Gf2dFz5qCHgDjj0rw/9lXw6NT8XNqEgwtomRx1b/JrvP2lNSlv9d03w/GC0Mxy209Dn/CgDxf4U+FL/XPFSX9vGYreBw24jrX02+ofZLZYrhN+0YJHasPw1pqeGtGhtbdAMqAX71PNerDG24Bs9d1AGyI47u3SWNwBnJBrJ12xhaA7xx6DvWa2qtE37rPThQeKz57m7mLkSNtz+FACR6coQ+WeB0x61mtNMLnyz0HFEd3dBixbgdhWhDZrdR7+Qe5HrQA3fJCoYnPbNZ087oeeSTWs+kzEgxSMwx0POKlttCaRGMyvv7UAc9vdfnbO3txU+mRw3G51JBHTPrXTWnh8HKysSMdMVWHh5oLpgsrbewHQUAQwRSx4bd8ueB61NcF8MW5WopIbgyeWclR0zVryWii/eAjPYmgClZ5ikLEj5jgA1NMHjkMkhyvvTQIpryIZI/DpVrUV5TyyGAGD9aAKeiXO3UHAGPwrpUhBwyPyTyBXIweZHdGQA7c/lXRaLO89yFwdo5zQBzHxp03d4eRoVzIeuK+Y54zFKyyEg5719h+JYE1NWt5GG1VIIr5s8Q6G8ni97G3BAZto4xQBylmjOVJJIzgfWvuf4I2zJ4HsTJ3jz0r5b1nwHNoZsInJLTsDuFfY3gK0Gn+ErGIDAWMcUAeCftVxP9psjjEQHX3r5ulTNyuD1FfZf7Q3hpte0GKSI/PG2SMCvnzWvh3d2Wkw3scbE4ySOaAPNmtN0oC8DrivePhhYW89lbxwkqRjdn1xXA+EPBt1q93ulyiKec4Fe6+D/D8emQAqGG0c7qANrKwSFZCAigCuQ8TCO7l2xsSnf0roNWkLozpkgHk+tcnqN2SgMceOfm4oAXQIAJhEr4x+Va88MsbMRIGxziqunW7GATRAKx7kUuoyKkG6Rj5jcY7UAV7eaSNj5wHLcEUzWglxGAYyFPHHSrVosU8KicHd6ZpuqZSARxqSOmQKAOUu4vs8gFtGS464BxTbKWZ3P2hSHxgHFdFDYyLGHz8x6k85qpeWjiVWL4A68UAOttbu7CREkw0ZPBNdNa+JbUqizN9/0rhdStwZE3sdnc05YxcSLHbt8q+vagD0xr62Ea+Uyqr9DmmR3KHIYq/cHvXnl3b3m9YrecnA6A0+L+1oAN7HGMDvQB2TFELuzAZ6c9KS1miKkBsntiuMtpL+UuJUYBTnp1FdDo0wcqCpwCMZGKAJPGFimp+G7qJyNwQ7eOfavH/gZ4rTwV4+2XgYW8zGF+2Oepr3S1ijuLwxzDCsMYPpXgHxG0yLwz8RVu1QG2Mwl244oA9O/aw0hdQj0/X7KI+Vt2Ow96+Z6+6PHVvB42+C7y2SjcbcSpgdCBmvhqZDHK6N95Tg/WgBlFFFABRRRQAUUUUAFFFFABRRRQAUUUtACUUUUAFTwrnYR1qCtLRrdrq9tolGcuF/MigD7P8A2Y9DTS/AZv3j2TXJLHPpXmk+p/2x8Z7wXrb1hkIi74wa93gRPDHwoBhIVobPdkeuK+NPDviOSLxi1+xZpnlJIx1570AfVt4BIFVFBI71l3Onb42My57imaPrsN/DESPLfHzZ4rZuGjkt8o43dueKAOSNqqOeef5Vc8yJLUkx4H5ZqxcwKg3uRk1nzz7ozCVyvrjGaAKVyLRIN5OA3FWtLl2W+UwVJyM1Wm0oSR7fmIzxzWrZ6JEqqN5BAzQBc066iDksBvz07VrQyqzfOgUe1Yo0p+sbjAq4FuFUecx28cigDSMbYJA7VnmUx5Eike54rRt5UKqCcUX9kLmMktj6mgA0PShe3QzH8nXNdHrnhiBrFmjTDKpxU/gyOOO3KAZI4ya6qeMNCR2NAHzzNZk3TZGxkPQ1Yt7ZB8rHMprr/F2nLHMxQbSRzjtXDXRmic/xEenNAEosZWkPlfl6mrVkHtHZiOW461WtftAYyLJ36VZkbzWTkZzz9aALCui27tKvLH72K4+Xwwmo63DLGp3B87hXZ3bHyFjypA7Vo6NZRqUmDDKmgCDU/DEN1c6alwDJJEQVz2xXqkKeTYQxKMKEArB04LLexsyZ2+tdHIOg6gUAYPiuyS5019+MAc5rzmCFNT0m5hK4SPIBI4r1LVoDPA4VeCuMVxK6eYdPmWABSc5oA8v8LafGt5PHAwOxzkV6PDd2wsBGygSAdB3rnrCCLT53KxhZC2CQKsXKZm3oceuO9AFPUmDI0ScDPNYUNpvkMakMo54q/cBpZnBfCjvUFrbszuFPyjvigCZXkEXlw84HNUGt3lfEwyrGrcE8kcjgnhe+K1dE09taudi5wD+lAGXFbrbur4yhHXNSXNwjIwhQM3SvUX8EwpYDpvx1FcTe6VHZ3uwgEjuO/tQByCy3DShZAwGfTpVq+eIRKHG0mtae7t/PEL2+B0zjj86nudHS7h3bRjsaAOFv5Lby8Py2PlrGile1nZ4/ukYBrsNQ8NxENhyMfWueuNJSNxuYhQ3agBttNJAu8nDHkmuk0e6jvBtc9Kwj5EcZjf5o/aoTe/2cQ9qg2kjhjQB3iW6PKoWMbcdelPW1WNxMq4VOTWdpeuR39ntaVI3YcjuKsKggtpAk/mB+ozmgC/prJe6iGhfAU8kV4j+0a0I8Q2scTh2CkkivTIbGayZrqJ2CscnB6V4r8Z1Da/FMrblZTzQB9H/s26lHrfwwaxlbe0IaNl9sV8ofEPSf7E8Y6nZYACTNjHpmvdf2Pb8+bq9iW4wJAv6V5x+0dafZfiXe8f6wB/zoA8upKKKACiiigAooooAKKKKACiiigAooooAKKKKACu9+Dul/2t400u3I+UzAn3wRXBV71+ypo4vfGEdy3IhjZwPQ5I/pQB7h+0bqjaJ8NzBbHBl2xcelfJ3ww03+1vGlorKxjD5avoP9rfUglvYWDHAYl8fhXnn7POiRy31xeEDeq8e1AHsup+G7KZkFsxSRBzj2q5BbRWloi7jJJ3JqaNnhmbd0B4+lM3BrjcSu3rigBk8YmIQAcdqr/Yo2nwQAMZzWgqsxZzwB0pkcAjkJZt2fXigCoAjOEAAx1NXrTyw+1wD2FRG1BDvGB+dQxwOULHOQemaANGdfLkVkbC57UpBuImB259qgiVXCrOxA9agmDQytJaSFgBnaRQBJ5TiQZ4I7dKtfO4AGSO1c3a6tqGq35gSNI1Q4LNXVwMIkxwzjuKANbwtO0dyyPwD613AwYeteZ285EwkUEEHmu70e6E9uATkjigDP1/TUu43BA3EcE+teZ3ulNDKQ4Jz0r2G9XKnjNYM9qs7MSgNAHk82+OXYqsCa0I49sS5UbzyCRXR6rozqRJGPbOKxDa3AkUOxI6igCEQSb1BUt7YrT0+Gbdg5AyeKsWVqWQkNyBWlp8LHLOMHpQB0GgIroDjJFaVzIEdR3pukQLHbAqOfWq1+wN9Cm4bs9KALzRF4jyACK5HUYgVmjj4IB4ruAoCAYrktWVUvWI+8e1AHmD71vGEmQ6t3rQRZNpYoCPrU+qwLJebtuGPei2gkQAsenagDAkQC6Yk4OOAaljDR5wgweuBVq+szKcpuDZ9OlTQafcsiqCOaAKdtp7M5ZVBLHoehrvPBmjtbN5rIASentRoWhk7WY/P9OK7awtVt1C9fWgC1tAh6fnXm/i6yQ6iHDBT6V6NNIEiPpXnPiO4WS5JGCc+tAGA1vC0brJGNw/iAqlOtzaOnluDGep9q1WJMBJA2k9c1RnciExbc5/SgClqJjuFUxSfMR8wIrFOki5ch+fStgWnlsMdT1Bq1xbYxgl6AOLvNGkD7I1JUH/OKcdG/dkSocj1rtIomkfe4APWpJAkgKvt454oA8j1Tw/qEDebaMxjB6K1TadeSW5WK7d0c89etegSp5cTpGMg/jVFtIgu1ZnQeaBxkUAN0GZrm1eOTlfU14T8ZLeSHXkJz5RB28V7jYWk1okomX5B2Fc98ZtHtbzwQ17FEBNGd27HORQBxP7M2pXNp8RYbaA/u7iMq4ro/2tdFe18S2eollPnptKjtivM/g/qDab8Q9HmD7AZgpOccGveP2tbNZtA069GMh9pPtigD5TooooAKKKKACiiigAooooAKKKKACilFJQAUUUUAFfVX7HlqAbu6wP8AV7cj/eNfKtfZ37I1qi+Cpbjb85cjPr1oA4f9rGdbzxPbQhvmhj7daZ8Bt9hHL8rYk5BNYXxru3vfihexSnKRsEA9q9K0fRGsPDtrc2oCHYOcUAdqVEhYSHAbuagWyZnITIH94ms+0vXljTzgxxwT2ro7a4hMQ2nIFAD7PTLiaHZkenTNFxpN15RUwHI74rodHngZB84B75OK6NHyMkAr6mgDzS0h2BhINuT/ABUyWLa58vJ+lejXGn2t4CGiX1Jrm9Y0GSD5rbG31oA5qWNVTez4OelU7p/stlNLuK5yBmr0tvdxDDoGUetY2rWd/qQVYwghUjcOmaAK3hHTWlkluy7ncxIzxXYfYHaPdEvzeoqz4bgjS1WPy1Vh2ArpbOFFTBGRQBxqrLGRGIyW9QK6nS1Fvbg4OT2960VtUckrGB71NFZKuWYdaAITcFk6c4qpASjcjg+taU1rlOBj0NVZIJFGeBQBDfRGSBgE/SuT1RUtivmkICcV2RikbG48CuJ8YSxTX0NsDlgeRQBP5KxwB435PX3q/YxhmiQkgnsapWkJZCVOY4xmrvhGX+0b+aV1ISFsL6UAdfGqw2wA4wK5K7lZtfSQ5C9jXUancLFAcemK83vNcC6qI42yQ3NAHqceGiHOQa5fWLdVu2YDLY4re0qYT2kcgOcqKx/F00dnEssnAJ6igDiNSXc7sowRz9KdZRidNzkhs4NaLIjReYq7jJ0pdIgEVx5U45PINADINL3E7Rk5q3Z2HkuS4xW/BF5bDC9f0pb6Nnc7VoAdZAogKmtWM4HzHk1mW25Ys474zRLcMFOTgDvQBU8R6kttCVVzuPauCkBuJXc53N0FbGrXKNdtvbrWEplWWSSMZVckfhQBheKNZh0eDb5bS3RztjXvVPwxrd9f25OoWRtXzld56iqC79Z8SOLmMYiPAPetu9h80PECV2jAIHFAGlMCVWRmBJ6YNVLlWWYM/foKxU/tDTSrykzQe9X11m3uNrTKUYjGKANKKdnOD90djUk1xDa7tuSSOao8PErQyBVPAJrLu7doX3tKGQnueaANRL6KTcE25PtU8HlCEunL+gOMVj21kqTPLCcgjkZqVJHR9nQnmgCx1aQuRg9jWT8Q4o2+Hd8oPyhCafI01xeeXAx2dzWH8TNQvrrwldWOmQiRAP3j/QcmgD5y0Kc22t2EysVKTo2fT5hX2B+0PanVPhBDcxAFl2SZH0r41iJWaM91Yfzr7P8AFrPf/AWNpWyTaL+goA+KyMEikpzjDsD1zTaACiiigAooooAKKKWgBKKKKAClAycCkooAKKKKACvtj9lAeX8Oycgjexr4nr7O/ZblP/CunQdVJwaAPCPjbfMPiTfSKSNspU4+te6+D9asbnwbaQPOHl2KME814B8TLdr/AMfaghOWM5yex5r174Y6JbxQRlkDhVx1OKAOyOnTecjIcRnnC1v20CLb8DoOaz724xOFhXaqjHsalVmC7wxK9xQBpW7IJAobBHviun0W8lkbY7fLj865nTLc3siuBgV2ljZIgXaMEUAaBg2rvi4bHrTCSww/zfWricKAagmjIbeooApSWkMhw6gDvxWde6IjZ+zNj8K2ElBYrgZHtVxApUHAoA4uz0u6tpzgcZ7jrXTWdq2zLjBxWgAOwFLQAirtUAUtLRQAlVrhQGyTxVliAuaxdb1BNPtXnmYbQO5oAk1K9htLN5HYKqjua86syNU1Ge8ZSEzhCRwRXHeMvGzarObW2OIVf5iDXVeHLnfpEOAMKuSe9AFrxZr0ehadtt8tJLwMCut8AWzQaHFNKoWWb52/GvGNb1FfFHjSy0u0zticF8civoGzjWCzhtwMbVA4oAzvErv/AGfKEByRjNeRJYOLtnUtuLck+le23tss0WzO4HqKxE0CFCG2hmHOSKANDwoph02NDzx1NQ+OoVl0dy4+7zmtOwj8vAAwOlVPGA3aFc9xtNAHJQbf7JjeLDYXORVDT7tZdWhBYgZ5qj4R1m3ksJrVpA0ikjB7Viape/YrsNGSGU54oA9wigDIhUZGBUwtx3GayPB+rR6jpUDqw3bcH610NAFX7OOwqG5sw6EEZJ6VoUhAI5oA4S/8ONLcMxzgfhVSWyjs4WRgPTB7V6BcoCnSuH8Rhw52g56AUAeUXFwlj4kZPl2SHrtxXUQ22W8xCrKepqlr+ijUIsqhV053Acg1z+jamLK5NhfSkHP3iePpQB09/GIx8p3YPTrVFoIbhlEsKll7gVowxLIrOjBkFMEe2Utvyo7UAUJ4R5RjUbVXvWetqLw7ZWxt6EHpW64WZScjn071VWARlgw6/rQBzOoaDqBvopLK+2xAjIB61vwxjaIpgGlPBNSmIxEbTkdsVJYr5crM43E8jPagA+yx2wVwoAPU+1VLmzhvNLvbW3Kq7oeSMk5qS8ZzJuJOzptzVPTJ3XVWVsBSPzoA+TdcsZdM1a5tJwQ8TkdOtfX9my3/AMAYwfn/ANFwPwr52+N+nC08VGZVwswJ+uK+g/A8Udz8CFQtwtu3egD47uRi4lHo5H61FU14MXcwH98/zqGgAooooAKKKKACiiigAooooAKKKKACiiigAr7G/Zc3N8O7ntgnv7V8c19h/srvu8EX0Gejf0oA8e1e3F14y1JuS4uGX9a9w8JWrWujR7NuSoPP615ppGlt/wAJ7rEF0AHFwSD1716xYAQWvlq+7A6UAXpoAiYY5duhxU8cMn2UgAsWxVjRys7jzOTxmuqt7JMAhePpQBT0G2kggAkHI5x611VljjNVPJKxg7eBVqxVs4PagDQoI9aKKAK80AwSo5qFGIXa3arj/dNUpDtPPegC3EOMjoakqvbyZj5qVGGcbsmgB9ITgilqnqt7HYWM1xKQBGpNAFTXNZtdLtWluplQYzycV89fFL4gnUw1rYOfJ7kDrXM/EbxdeeItTmZZGW1Q/ImTXFPIZCC2d57nrQBt6Fclr9BOSc9T7V6ImpzSN9ls5AiBcEg9favOdFsnmfe/yqDwxOP89K7jw3YiS5SCE75mIAI5xQBv/CHQZYfF895MpKj+LHevfgnzliOaxPCWiR6bZKpH7xuSSK3yu2gBjLx8vWlA+X5utOUZqQqMcAUAQbeeBxVXWYlm0u4iYEqUI4q6Rg4qOdd0RX+8KAPj+K+k0nxpcRmVlQSFfm/Su01S83WyTkId35VzXxr0GTTPEsl5CPkkbqM8VY8LXUGu+FZLeR1F5GDtHfNAGz4L8Zy6NriwzsDbSH7/AGHNfRmn3iXdrHNC4ZWGRivh/VJpYYjBcgxyRtkN39q9l+B3xCyI9I1GX584jZu/40AfQytnjvTqqo+4qyng4Iqdm9KAHMAwwaxdQsw7MSARnrWuGxnOaimXcn160Acbq9rHBCSi7jjOAO9eb6zpFvfXKmSDEo5yK9m1G2QqSc9KyrTT7Z7jLpn3NAHn+h6NeQybI9zRdRuFbw0OSTO8dOeOK79bGFRhRgVN9jix0oA81k0N9oWNCD60SeHJnhHDbq9MW2jA+6v5UrIoGMDH0oA8jm0K6tRkxsw75rnNQaWB23Ahgehr269ESpulZQOnNeWeMPslzdFLdss2QSKAOOn1FnXaDznoKfZXPzgvw/TPeknsfKZUIyAcg1ZtYkAGPmcDt3oA8v8A2gbMlNNuPUkZx617D4EWC3+Bm6Y7R9nYkn6V5R8ermSTSrSNlA8uQZIr0m5vYtO/Z4SST5S1sB065oA+R79g17Oy9C5I/Oq9PlbfK7epJplABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABX1T+yVqCmDUbFz8xVWA/Cvlavbv2YdVa08cxwEnZNHsx74oA7vxQE0X4tTxuNq3Tbvrmu5lgQZ2fKWHrXC/Hmzng+Iel6kwK2zALurr9LvUljRpAWRgPoDQBbsWubSZHDsy8A4r07QriO5gGeCMV5tcSK8fy7gBgg9K2vDd7tYKZACT0oA9KREAxjIqRIgpBBrJsr7ja4z71qxzK454NAEtGKKKAA1UnXaSeuKt1DOMKfegCnESGwDxU0P3xVaNiJ8EYzV0YVTznvQBITub0ryL4/eJDY6D/Z9tJtlm4J9q9Qv75LS1knk4RBnNfJHxU8RN4h8Qyyx8wREhR9KAORnLeUFXqepzUkdjOux9uVbFUoy7yAgV6D4L8PXerCMYIhPQ0AY0MFxcBLeFmUnsK+g/hP4Nj0+0S6ny8rKDuIqTwt4H0+08uSSBZH45I6V6TaQJBCqRqFUDjFAEwAAAHahlyOtLTWbaKAETvT6iZs4zToyMdRQA+mOoK89KfTX+7QB5L8YPCz6np0lzHuyg3Y9q+YVa60a/L2zshTrg9a+5dYtReWUsLDhgQK+OPiDpU+keILuOVCsbE4JGO9AGfr+oRaraRSkASgfMRWXpd49lqFtPA2xkkB3VUjZFyrHp2pkpG9Cg4BBoA+4PAOpyal4ctZpm3OUBzXTjoK8t+A+oC78LQx7slOD7V6eDg5oAn3cdKikbavTNKCCucioZXODwOlAGfdDfnJOB2qC1RHlAGQQasMu5zuH4UtsoEhIHPSgDTRNox14p1A6CigBQMgmo5mEcTO3QDNSEY6HNVNRDGBlXuKAPN/EWqtcXrR+YyoD2NcreeW0byREnHc1ueI7YRSs3djiuekkKuUToR83FAFG2nJD+eMD86fpkiNKWj6dDz0qhqc5j3QW+HJH/AHzVKXzNH8OXF5cMF+Qn6cUAebfFa+OpeM4NNVg8LsqjB4yTXpnxsmi0f4VafphG0SRqMD6V4V4TeXXPiFpxf5z9oDdM5ANem/tP6zFcyaZYxNzCnKj+tAHgFJRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV23wq1n+wfGGm3jcqJBkexriat2khiljdWwQRQB9rfH60fV/AFvf2SFnjKyBlGTtIrlfA12uoaHbxqw86IDf7muy+GOpp4y+FHkSKHmWEwsOvIHBrxrwXeyeGfE91plwD5jyMgB7c0AetyThQIyucjB9qfaKsLCaM+Xg8r61DLuEyEcq+PzqWMATlXBxmgDrNH1PzmHPzA4zXU2kzvj5hxXCaNsST93gHPNdxo8fmhTQBuQnMYyeakpFUKMDiloAKinBIA7VLUcjDacdRQBUkiO4HPNSMQqjP41HO3ALde1ICCM9qAOO+K98bDwncle64618jyzmSZ1Uckk19HfHSef+zTHG48snkd68G0XR/t10CNwbPPpQBqeEPD76lcRkL8m70r6F8IaGlnDHGkSj6Cub8BaMttbxhh8wx2r1bSLVYUVmoAv2tsqRKMYqyOBihcY46CloARgccHFc5rVxqMExMSlovp0rpCcDms7UruJYGUOCaAOC1vxRfWK/KvJx07mptH8TXdxEJJozuPpxXJePGmnvoEiYLluSK7LwdHGY4lm2uQoHSgDobG/ubvny2QepraRHCDJJNSRoiDCAAelSUAZeo2v2tDFLJNHH/F5blCR6ZHP5EV5d8YfBy6tpxmtUzLGOo5JGPevYLhNyVnzW4kiZH5GOAaAPhTV7BtNmkjlUiQHBBrMgdt2Wzj0r3X4xeEjFPJdRoeuc4xXh0oaFyjcEHFAHun7OmtFbyeyLHaTkCvo9DuH1FfGXwc1b7B4rgUnhmxmvseCUNbo4P3gMYoAmBAGM9KqzuTJwasYJ6VUlGHNADHOQSfSlsGGeuaa3KmnWaAHAFAGluPSn1UadI+XYcURX8MhOyRCR70AWyQOpqG4IK4oEqv3GaoahdGND0z2GaAOZ8S2KzB2wA+K821gLYxSscs+COK7rXtXjVGBb5j29K841K4NzcMvVSc4oAp+GbIqr3VwQxc5wewrM+N7ung4rCxG/sPSttpWt4VXblRxXLfGW62eFIHlXdvOCueaAOT/Z08Pi91651WUjyrOMkZHeuL+K2pDVPG2oTxuXiDbVOfSvXvA2kXXhH4V32sSuYxdRkhTweRxXztPI0szuxyWYmgCOiiigAooooAKKKKACiiigAopaSgAooooAKKKKACpYdo5b8KiqeNN6jk0AfRn7KPij7JrE2iTuPKmBZAeOe4p/x60lvD/juHWIwWiusEezV4l4F1iXRPEtheRuVMcoJPqM19lfFDR7Xxh8O01GBfMnjjEsbKenHrQBznh+5/tbw9DNuBfaCcHoa04o9sCkf6w9S3pXkXwg8TG01E6XePkSk4J7HivZbiPy5AcjawyM8UAXNB2JOFc4LHg16RpGFhU4ryKC8CzDJ2sCMd673TtWxDGd3FAHYs4Ck5FRLdIThmGa52fVPNX5H5x0rLuNW2EEPyKAO7LZBxVO6lZBkE4rI0PXUuwI34J4HNaN63P1oAFk3Lhskj1pEl6qBk1Xh++Oalb5XJQc0AeR/F+TzCIx1PUVxPhKzitroOSRvwMHvXSfEy5cayY5vunNZfgS2/tLWERhuVWBzQB694Ysyyo4UlT39K7OADIGBgVR0uBbe3VIxhQOlVNa1MW3yxNiTFAHQhl6AimPMqg4PIrg7TWbmOctNKWRqvvqcj8BsKe+aANLWdUdIikZAzxmuVurhyoBfczcdetPubl5XYFlIXqSayjcwTXQjjmVnB5A7UAc/4yvo7O7tRtG8sBg812WiTiK3hlC4LKDXlPje68zxha2lw3yZHFehw3UUEEUUbdgefSgD0HT9QExHzAnFXxc4IyeK840XVMTSAkhAetdHHqCtt2nNAHXo4kXIxioJACazIdUihRS7datRX0dwA0bAg+1AHLfEPSP7Q0aZBknH618feLtOa11CRXzgNwD2r7nvlSa3ZD/EMV8nfGLR2t9blO3EbZINAHA+G5Pseq29wpIKMDmvtXwdqK32h28rEHKg8V8RWEYSRS55LcCvrj4XBo/DttuU4K+tAHfebjox/OmqhdyQPl6VDgyEBRip1cRLjr70AQXny8Z/Cmxy+TGSMFqjukaWXK9PWmSRNtxnmgDH16Zp1bDEeozXLLLNHJiGVi35111zas2dw4rm9QtxAXYHa3bAoAfb+I7q0XDuXPQVXufEs95G+B83aucuXklbEqsB24qFS6yeXGpI9aAEvpHdi85bP86yYVeKQv94HpW/dWyR2+9sEntmqSxdPlG33oAjI+0vBAn33IJ9q5Hxzbv4m8f6P4YtxviRg8wUZAA6110l1aaNp95qt3Io8pDsDdz7VW+Adi0w1fxvqwH73d5TOPuoM8j8KAMb9pzWoNJ8P6d4ZsCiLtG9VPRR0FfMddf8AFTxI/ijxpqF9vLQlysYzkBRXIUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFKaAEqSOQpwOlR0UAXbdyvzcEetfYP7OXjKHXPB8uh3rK09shAU87k9a+M1Yqcg16N8FvEL6N4vtWEpSKZhG49jQBueK4j4T+JMzKoC+cdo9ia98Rn1TSLW7jcHKg8fSuC/aL8Ht5MHiS2csp4cADgdjWn8H79pdDWO6kZh1XvigDpYo9xbjDepq9YzFAAzZx+VAjDSsCQBnr7U2TZCVAGR3ANAFtp5hJ5iSEJ71UW4klmIOBnjPrUV/ephUUYHWrGhr9puFDAAA9aAOt8MWTBlZgDg9fWuhvAcYQZ7VV0xhBGFQAitVUQ4JOT3FAFOxUy8vmrnlDOBkVNHGFGAuKACDkigDwv412ItblbtWGTkYpPgjaCcTTsBv3da3fjzbhdAM4UnB7dqz/goPK0TzRxuPNAHrgIERO7BH61yGvzA3QZjz0FdIJlaL3+tcl4gXMue45FAGbd3iW8yI4PzcCrCyyxrvc4jPrxXNXo+0XCtJI2FPAHer/2t7mLY+SqjAoAm1CUTwSx2r7C/8VYegWlvot2cs807nJy2cVMbhkQrjj1qrbRvcXiPkgg9TQBzHimVF8dWjXAUhyMDPeuxu8goRhGK8CuD8SO0/wAR7NWO5UI4x0rtdVlUajAOWCgE4+lAF7SblkVkmTOD1q9NeTWaK8fzRk84rHW7DsqbSq+lXDfJHtUcjvnmgDXtdWtr1NscwEhHKmtvw7csNyEfNz0rzW6to11JbqEsDnlR0xXW6Ne+WySbsDHNAHdtNt+9+deNfHa1jfTxOFBOeor11biG4tE2nJx1rzL4soLjSWiYAKAc0AfPWhwJc6nbxYGS4GK+yfCloLPQ7aJVx8o6fSvmH4W6E2p+L4lA/do24/hX1zaReTBGoAwoAAxQA9SFi+bIPYVAHy3TrUl1IF96bEgKbjnNAChlDDJH0zVkRo6/4VRd1L7erGrFvuQc0AU9Tt8Biorl5IxJdES4Za7S8QyQNu4461y08S72ABBzQBg6hYiRzIvCg8CuanbyrjoBg11epz+VGyt1ridRl/eEYOGPWgCa5driddrZUCpolBSUtgqOrZ6VRs1bBjCsxI4I7Vh+PPEMPh3RJAXBuG4CY/z60AcD4puLzxX4xtfDunu5gMmDt6EZr1340a1F4B+GNrodjsS5mjES7RjjHJrB/Zn8OCd77xXqI3DJEJZeg7kV5H8dfF7+K/Gt0yuWtbVjDEv0PJoA82Y7mJPc5pKKKACiiigAooooAKKWkoAKKKKACiiigAooooAKWkooAVjkkgAA9hSUUUAFT2dzJa3CTRMVZSDxUFFAH3J8NtasviB8LxZX2yS6SHy3U9zjg15f8PZJdD8UX+j3/wC7kDkRqeBjNcz+zP4xt9A8SC0v2CwXHyZY8Ak8V6p+0L4ebT7qy8VaQuHUgTEDPHY0AbTRSB5GZ+T0x0NZVw1xuOwkHPcVF4T8QQa1p0DCVXmRfmUVtTMHYqFUd+aAMtLa5mhDueR7VraPcyWjLuTilto2e48x2AjHbFWpmgVugwfUUAb0OsyqyhI/l9a3dM1Vp5URgCc889K4drto4isfzA8fQ10HhG0dZhLMzFj2PSgDv4ySuT1p1Mj4XFObPUGgDkvihp41DwhfRgAsIyy/UV5f8FNSVNLubFyBJHIRjvXud/CtxaSxOMh1K/pXy+hl8G/Em4t33JbTycEn3oA9qivfKn5OOe9Saqq3kIMWDj0rnr2bc6ujhkPTmqV9qskcQjtXIcigCTVrVEBwcGq9hAQjOzHYB61ShvVWMjUnIkPIGKP7VUxGKMYQnigBszjztqsCBSo5a4Xyz0Has1yxudka4BPVasWrmG6ZlwTtOaAOWtttx42ZyAzr0NdfdWwe4Eu/3rk/Czi88W3Ug6KTwO1dLe3KrcSKAw9hQA0SsFPy4APWnwL9pIKEs30qu93F5RULuGOcetO0vUEgDiNCrt0yKALDu9vIEA3MTWzbFwgCp15rFtFmUvcTEOzHgeldHa3ccVuHYZb0NAGlpd4U+RgcDua5b4pzxposzEjeRgDNa0l+hw2QFPQ9hXm3jS8bxD4kstLs2Mi7wr4PUZoA7X9n7w8IbOTUZAQ0h+UEV7WuO/SsnwnpiaXo9tbqMFEAP1xWlO2wHH6UAU7x134PApYZWxsXketVrwhnXio5byOxjGX5I6GgDTKxqOdu/r1qRWBUc81yI1JnlMrPhT05rZs7wPGrBxz3oA3GXMe32rntWtzC3mKOK3reTeo5zmkvrUXCbW9KAPNdYTzWYA4xXGXhAnO8H5egr0LxFp8lsGkXOPQVx8rxRxSS3BASMEtmgDG1zW4fDejSajejGRhVxjPp1r59vLy+8e+MIIF3E3EoCqOgGa1Pin4wfxTqb2kEm3T7Ynbj+I9K9J/Zi8Cqon8UaiNqR5WDfwPc0Adj8StXt/hl8KYNHsdqXk0XkqAcHJHLV8ezOZJWdyWZjkk16J8c/Fs3inxlcnzQ1pbMY4QDxgd684oASlopKAFHXrikpybdw35255xSUAJRSkEYyDzSUAFFFFABSjk4HU0lFABRRRQAUUUUAFFLSUAFFFFABRRS0AT2F1JZXcc8TEMjA8V9xabKvxE+DSC3nEk0kGN2MHcPb8K+Fa+hP2YfGjWF6+iXU6R2s2dm84w3t9c0AUPh7btDrU9gXZLm1c72XuenNeq3F1JJPAUA+U4bHf3rnvij4WuPCXipfEVhGf7OnOZiBwCTWp4enGpCS/XBhdcKMYzQB0VzdxwwggZc9RWPc3by7WPHfFaMFsr/ACyjk9GPeoZhDCxSVlIHI9aAL+lQtO6bgduQetei6NHGirnt0rz7w9cHfzjrwteg6OwkRc53CgDoYW7+tPLggjHtUSHCAUu7HXFACsex5rw/9oTww91AmsWijzYOTjr1r22UBkYk9sYrOv7KDUdOms5FBRlK4x0FAHzz4M8SR6jYLbXMu24C7Qx68V0dxC3l70GCOh9a838YaDdeD/F0QUYt5Jfkb2zXrEckd1okDqBuKgUAcpd3EruQy5I9TTRI8TfOu4Egc1Z1B4raRlccngn3p1kirGWkG4dqAJp3bMWxccdhUFjlLmcNkswOAaZbz/6aBIfl/hHpSmcpfuxQ7ccYBoAp+CrYR6/evHg5OavanHJNeSsFwN3aqegyRxalPIhwz5yPatYyDLk42k+tAGIbo2zbFYYPUVNYhHLuDljzU93YRzXCvbkB+ppbiJotgQBcnBNAEmmGZN+9iw5xmr0XnlsTDbEerHsK2fDttbzxJnDOvXFc18T9WfTrY29muwscE+lAHMeOvGMGmo1lYtvmP8S9BW98AfC093evrV+jMc5Td1ryzw/osviHxFDbwqZHZ/nPXvzX2J4U0mHRdGt7SFAgVfm4oA3EACge1QTIz5AGOetTqOAAaCMGgDIvUEUJfow6d81xOsyy+YS5z7V6BqkQa2cnnjNeZ6w6+dKYzkqcUAQwTOT5ZOVxWxp14rOsKN071yEkzKmc/Mexq7bzNDty3PsaAPRob/ygoVs+orXju965zXCWNyTgAk+9ajagLWMsWxjv6UAa+uzQNaFZCAx457V86/GvxNDoelSWdsVNzcZXAOSB616F418WQadps97dSgBVJUYxmvkLxZrt14l12S5mJbc22NAOg7cUATeA/D1x4q8VWmnR5zLIC/0719VfGDVrb4f/AA0TR9MYRzSxeTHt69OTVD9nTwAnhvQm8Q6xHsvZk3Lv/gTqPxrxb47+OT4m8TypEQbS2bZGB0OO/wCNAHlM7mSVmbkkkmoqUnNJQAUU4/TFNoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqcKZMIvbpUFTxTFMYGOMZxQBGyMrbSOa0tIupLK5hlt2KyRsJFb3FZzuSxz1qSCQpIrqRuHYigD7o8Cata/E74ZPaXzB7gR+VLzkh+xrzTwMJ9E1zU/DeonbcQu3lZHBX2rhv2d/Gh8OeKkt7mXbZXh2uCeAe1e4fHXw5cMtn4u8PoWurUAzBB9+OgCjO0ts7CQ/MvYGqu9Ls5DAN0waZpepw69pUV5B/rMYlj7g9DmpZrOOFfMJ+vtQBJb3RsJklPzFcdOlekeGNYt7i3WUEAnsTXlQkjCcfNmq8F5NZTn95tVuQMnigD3241KJVDb1OOuD0rC1DxVb27soOSK8nufFVw8nkbt2eOuKdbiW5w0vP16igD0yDxxbSTbJBtXHU10MOoxSWvnxEsAOi8lvyrx28skSy+fG7rmjw14kmsmNtK3yk4AoA9D8XaBZeJIkF2qZQ7gSOfpXIawF0xEtYjhVGBiumt9SRolJYAMPWuT8WSKLhXHzEgYoAwCwnaQyplgM5Pf3qexkIjKup2L0OKRgGiGwfOepA7U0iSOMIGwSf0oAV7YSy+ZCRgdR3pYS8iSAIvmAd6jlMtuA0Tgk9fpUdrcyGR3AAbHOR+tAFdYeJmQhHXqRRpNyCknmNvA7GrmnLFcxXBDgN0xWDChs7ibgsGJGKAN6x1FfOYDqDwKiv598hy2WJ4FZjv5JDQr8z8nvipYIp5nEj8tnp6UAegeCIljONxYn1FUPH/AIbu9cu47ezQ/N95gOlavhAkxqNpBHBOOtehWMCqquwBPqaAOW+H3gGy8L2qyFVkuyMl8c5ruMVHJMij5nGccc1GlyhblgB9aALqZUe5oqJJlJzuyKlBBPFAEU4V4yDyMYNeXeJrGWC9eRPuZPFeoSK2eOhrlfFtsDC74yPUCgDznasjfP0pFRpDuDZIPAFQ3ssUBbDc571nHV/shHIOT60AdbY3rW0ZMicnpmsfxJ4qg0S1e7v5AFx8oPeqwvHu3jO47Qckdq8W+OmuR3epw2NtMWSLlwOmaAOf+IfjW78VX5Cgx2qnCKO9em/s8/CdtZmi1/Wox9ijbdHG38Z9a4/4KfDq58cazG84Mel27BpXxy3sK+lvih4xsPh34VTT9NVUuWj2QxrxtGOtAHJ/tD/EaPRNLPh7R2Czum1yp+6vpXyRe3BuJi7Zz3z3rR8S61daxqMtzdSs8jnLE81i0AFFLSqQAcjOentQA2iiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACnq+FIIzmmUUAOOOvrSg8cD5u5pPel2kruBHXFAF7R7jyrxCzlcHg56V9ofAXxonifw82jalIJLyFNpDfxLjAPvXxCx+YEda7r4aeJ5fDmvWd9DIVVXAkAOMr6UAeveMtPu/hf40muFDSaPfOWHBIXPJFdRZaja6tCJrSQSK/OPSu98X6PY/Ez4fqbcq0jR+ZER2bFfHg1XXvAviCa1mEkbQyFXRhgHHpQB7+yqJsEYAPIqtfWYuLeRgSCo+XI61j+FPGml+JZYYjKsF4RnBIGT/WuznsxC5jkGQw4x3oA5PQLMNOTO+9lPU811jbtyrCu3is+1010lZimB1+tXlZgCmduOM9xQA+43SrtkIYYxXP6ra/Z8yk5C8jHatlsMSRJn2J5qhfSIEYSj5T0zQBb0W/8APiRnk4U4HFXPEEpFmsgQEDvXI6XOqOSp+UHFdFNd/arEKCCQOhNAEliQII5yMEjkUahtMYddoYn8aqxSiSDykOCP1qRRHJHtaTDDjGaAKoIidGbJBHTtiiKKaeWRoxtXHGPSopy8dwoYAqKtpfyAtHCuMqccUAYXhlmj1m6iuGO3ceCelX7qBZ528luB/Os/RN7a1c+aOSetXJm2XUixY56+lACrGbeQCbJXJGfwq/BLGIxtOdx4IpJEjltlWZhn1HaqkCCKWNM/Lng0AeleEP3VkJJjxn8RWzqGux2cGTJgdRk1wzX0ltYBVkJGMVymqapNcSiJ5WxmgDt9S8ZFpCijKHpgVlya1fTr+5cqSeCe1YNlg8E56Zz2rVtH35CgACgDd0/xHfWOPtTh+Rkmu70jX47uFGLqCeuK8j1Ebo8enNUtP1S4s5UVHKrnPWgD6CM4YKQePc1ieILpDbuhxjng1wVt4wkVQhb5sc81TuvEUt5uRmLEnoKAMbxDaJPcOIXCsTnArHg0lzMqy5fnr6Vfld3lcjJdjj6VieOPFsPhXSGiVle/nU7eeR+FAFb4geLLTwrpxtrRlkv5ARgHO2vIPBfhrUPHPiqK1XezTPmWQ/wjvVPT7LVfGHiOK2i8y4vJ3+u0f0r7J+GHgjS/hr4de8vmj+2Mm+4mY8A46D2oA0LS10n4X+D0QGKKOJPmOPmkOOp96+Rvi54ym8Va5LdM/wC7BxEOmBXQfG/4j3HibWnS1kYadC2I1z19zXj00rSsWc0AMJycnrSUUUAFFFKBk8kD60AJRRRQAUUUUAFFFFABRRRQAUqkA8jI9KSigAooooAKKKKACiiigAooooAKKKKAHA8YNORtoIzwwwRUdFAD3AzndnIyaltpmhYYPAOajZMH5h09KRWxnrg0AfTX7PnxFXTpV0q9c/ZZiAuT91j/AErtv2iPhzF4k0R9b0qIfbYF3NtUZdetfH2j6jNYXSTRSlSpBHNfZPwP+KFt4j0yPStTkX7WihcsfvigD45Bn0q9jliLRzITxnBBr6W+FPiMeJ9BU3TI11F8rHPPAq78d/gwt8LjX/DcarMAWlt1H3/ce9fPfhHXLvwfr6yjzY4idssR4/SgD6pilSAsZMY6cnpVC6uIrgMEwO3HGazLe+g17TYL7TJA+9QWReTmqzGVXEHKydTntQBZgUib7zBeuS1LrkarZtI2Txz71UkuFt3VWYZHr1qa/uUubUo64+tAHN2zHB8hiBnBrqbeP/iWsp+8R0rmLaSOC4dNpPPArct7hhtwCVJ70AQBjZgrvw7DgZ6U0Ox+bID+pqzqUURdCwAPcDkVWhtS2QmQByM0AXbYtfgB1GVHBqzYosIlkmP3AeKqaTJ5Nw4b8qs6gQ9lcCDqR1oAxNEkk1DU7mbaVhUlee9a8TRfMDGS3TNc94aDRxXKFzvyRWzpzSY2OuT1JxQAl1BLAFbGUY5xSXEoRU9aj1i/kM6RIMAdSPSq19I4iXABzyTQBNfX8jPHuchT2IqjceYkyzclPSrc9qosftDYwOvsT0qtZsbh/l+4B3oAEv2dwFbancmui0+/hTb5bBzjk1zN3o9w+fszAZ9qzrFb6yuSJw2AetAHpUhiuoSeB9K5bX2jt4sx8sO9aljfCaFVVcc1l67B5m2M53Me1AFXQ7aa4g86VmKEkgCtiKGRgohPsSTRpMP2S22yfLEoyzHoK828b/Elk1J7HQdoijPzSj+lAHoGs6lBoFoZXIeTtznBrwTXbq98V+IEjgDyyO+1FVc4zWx4c03xF8RdXWytGleLcPOkz8qivqnwN8OPDngDTFuJkia8VQXnlxwevFAFD4T/AA80r4e+HzqOo+Wb9490szj7o9BXkvxz+K669G+m6XKy2KnDFeN//wBaofj98UJtZuTpmlyvHp0Zw2OPMNeB3E7StyTtHQUANnmaU8njOcVFSjrRQAUlLQTn0oASiiloASiilJ4AwPrQAlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADiSeppdhIOO3Wmg4pScnmgBB164rovB+vS6HqUNzEzCRGBBB6Vz2BznNIKAPuP4QfE+38T2n2XVJI0uB8uCfvVF8Tvg5ouuXc+txQgOttJviTgO207Tx3Br450bXbrTp0eGQoV/iU4Ne1+A/2gbuwV7DxFE91Zsm0PGRvH50AeWaH4i1jwXqTRhZFwfmhlyB+XavbfCXivTvFUKsrrFfbRuQnHNd5eeFvC3xa0mLUYtNQSFQPMjnCScdjgGvMPEnhDQPhxfrcXPhvX2I5SeK8Vk/l/OgDpJ9Nkaa4mkQ7IV3O4/hBOBVJ4H+2JGzkq3cVS034weHLq1l0/+w73ZOojdprsDjOeoFdZYXmnXCLPbaLFIMZH+nk8flQBj6/o/kWSzRtyOcim6UksunTT4/d2675D3AzitHVfFVuCLaTw0jp/1+tj/wBBqG18QRQ2k8EPhuzSC4XZIrXbnIz/ALtAC3ERkg3jJOcZFJD93aDhumTWlaa2Jo9kejaYMcbTM5/pTJL24ifcug6XtJ/vSH+tAFD7K6/ap4jmO3TzJOeSPamQSEWksjEEYJxSaj43fS5nt7vS9KhhnXYxZJCCPTrXP+Jfis2nSW9rY6Vo11BMdoYwsAM/jQBc8PJJLb3U6odhYke9a8eYdInv5DtWJ0Ur/vHAOatWusX6aPHPBa6IN4DGOO2JAJ/4FVRvEGsS27wrBpKwuQXX7EMHHI43UAUpLqEZPDMfSqb3Mxb/AFZIHtXQwajqLr8raYpAz8liv6c1B/wkmrvciNLmAL6izjxQBXkjlufB2rKRwZICo6EfNXO20txaXZtysgH94jFegWmqavMpQ6mFjYZYLbRDp07Vz2reJtbt7lgmpyCP+8II/wD4mgDQ0mZWABLEkdqv32kiezjnETF3uPKI2n7u3Oa5SPxL4iucm31m4UL1Aij/APia27TVNdfTt8+t3ylfmJ3KoP8A47QBq2+lyWaErFI3YYQ1Wm0S8vHUyQSKp77DkVwHib4pfY4JIbPV9SkvF7ifjP5VneDtR+JPji8EOlajqUMefmmaQhVH9aAO1+IFrqUPgi7TSbS6nvFmSEhImJ2kZJHFcB8N/gr4j8SXwfV4ZdNsScu8owzD2FfRvhHwFJo9kLjxR4g1G+ufvOsl0yoD9M1yHxT+I2haVYTWmir5l4vBdZGG0+uQaAPQNG0fRvh1oa2+jafJJKF5EUe55D715P8AEm48V+LdAvpoNLv4JI7hFgg+6WjIOSefpXz/AKp4y1y5mY/2tfHJP/Lw+B7DmsufW9W8vD6nfNk8/wCkP/jQB0l58PPG17Jvk0O5HJ6lR/WoV+FnjE43aO6A92lQf1rlW1O+dTvvbpvrK3+NRNeXLfeuJj9XNAHaeMPB8nhnwXpcup28cGrTXciuBKrsY9oxwCcCuEAzTnkdzl2Zj7nNNoASil+tFACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUueMYoASiilJycnrQAlFFFABRRRQAUUpBHUUlABRRRQAUUU4KT0BoAQEjoachXkPnocY9aTacmgKaAEIxigGpI1B+/kUgB2HgmgDt/h98Q9V8IXYbT5mSHPzR9VavpXwL8ZND8Vwmz8R28MEpAGJACrV8ZBScY5JqxFcTW6gI5XPpQB9d+OPgb4e8UxSX/hieO1uZPm/dtlG/CvIbjwN4/8CyGRbWe5tEPJiO4Y+nUVzXgv4l654Z+WwvX8vqUk5Ga9x8E/tCWF/CLXxHAI5c43gfKR70Aeeab8TrIHy9bsJI5FGCCpzW7pfiXwxrDTbbgW7Y+UMcGvZILX4e+NLbe1vp0jPx9wBgf51xuvfs++Fr6Z59MvXtdxyFSQYH50Acrb3FtZ5aK9ikU5HytnjtS6H42ih1ZrW9IdcfI2Knv/ANm+7aAvpeuOWHQSHI/SuJ1L4QePdKuNttbfathyro3NAGV498bS3muSwtbLJFGxAzXDgy6i0hEhRA2VTGcV1rfDzx1c3L+ZoV0ZGHLMg/nWjpXw88c6cf3egyFlbPzAYoAf4E0rxpbxNPZ2klxaNyPMJ/Su0S4uraNzqsJhdF3YAo0+9+KWnokUehBYwMAMtYniDRviTrNwxm0dgSPurgA0Aa/hrxFbXj3CyPs2njdxmuht7nR/KLNdRqxJydwFeVWPw18fzzPs0m5Vj3df61I3wc8fyzY/s+ZCx+Y5IH1oA9OfWNHiCxR38YzgcOKgd9MLsXvYCvcl64vS/wBn/wAa3coF08FsmfvGQtXo3h79nWxtU367q0s7Y5VTgUAcdfeKtG0mYi3/ANJlVjhIuc+1VZY/G3jp4rPS9KmsbCQ8ytkDHqTXr0WkfDjwJIZbhrQXC95cM361geM/j5pemW/l+HLVbhsYBHAFAE/hP4EeHdCaO+8S3aXcqjcySHCA1veKPit4U8EWv2PRYoZpgMBIANoPua+XPF/xL8QeJZi15dyKn/PNCQo/CuPmlnP72VmO/JBJoA9J+IHxa13xBfPi5aK36eVHwMV5vdX0107NK5Yt1yarfeJ5pADnjPHcdqAJrZSzrhSSTx6VYkiVGKs4MjHHHQ1DEu8ZQDpjntUu7M/OWxngDp7UAVJU2Y5BB6EVHUs+3zDsUgd8+tRUAFKTmkooAKKKKACiiigAooooAKKKKACiiigAopxJIGewwKbQAUUUUAXJPuH6GpU+4PoKKKAIW+8frSJ0P1oooAF6N9aVvuD6GiigCGbtRb/6yiigB9z/AKtKr0UUAOT7wqyOg+lFFADW++/+8P5VPbdHoooAUdF+lMn+4aKKAIk/hqSf7ooooAZF1H0NRnrRRQAxutPt/wDWL/vCiigD0rwL/wAfC/jXtWh/8ej/AE/xoooA9a8D/wDHmv8AuCus/gNFFAFKXp+NI1FFADm6Cmj7rfSiigDSt/8AVLUzdGoooAx5v9a/0rjPE33bn/doooA+PfiZ/wAh6f6iuPk++PpRRQBWb7zVLP8AcT6GiigCuvWpYejUUUAW9M+5N+H86lH+sb/e/pRRQBny/wCukqGiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial MRI from an eight-year-old male with adrenoleukodystrophy, demonstrating the typical posterior pattern involving occipito-parietal peri-ventricular white matter and posterior corpus callosum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Alan Percy.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42498=[""].join("\n");
var outline_f41_32_42498=null;
var title_f41_32_42499="HEp-2 cells stained homogeneous";
var content_f41_32_42499=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F74351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F74351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Anti-DNA antibodies stain the nuclei of HEp-2 cells in a homogeneous pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 512px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIAAgADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3n4ofEDSvhxoFvq+uW99PbTXS2irZojOHZHYEhmUYwh7+leYf8NV+B/8AoFeJP/AeD/49R+2t/wAks0r/ALDUX/oievKfgN8HvC3jr4f6p4h8TajqtmbK8lhY2ssaRrEkUbliGjY5+du/QDigD1b/AIar8D/9ArxJ/wCA8H/x6j/hqvwP/wBArxJ/4Dwf/Hq4r4XfBz4W/EnTLy80HUfGEItJhDLDdy2ySDK5VsLGw2nnHP8ACeK+X6APtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqKAPtX/hqvwP/wBArxJ/4Dwf/HqP+Gq/A/8A0CvEn/gPB/8AHq+KqUDNAH2p/wANV+B/+gV4k/8AAeD/AOPUf8NV+B/+gV4k/wDAeD/49XxZikNAH2p/w1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1H/DVfgf/AKBXiT/wHg/+PV8VUUAfav8Aw1X4H/6BXiT/AMB4P/j1dh8L/jX4c+I+v3GkaHZavBcwWrXbNeRRqhRXRSAVkY5y47etfn1X0B+xT/yVPVf+wLL/AOj4KAPdfHv7QHhbwT4svvD2q6frc17Z+X5j20MTRnfGrjBaQHow7Dmuf/4aq8Ef9ArxJ/4Dwf8Ax6vAP2o/+S6+J/8At1/9JYq9I8X/AAb+HXhrxGuiOPHWoXv9nvqbfY57EKkCEhiTIE5G3oM0Adv/AMNVeCP+gV4k/wDAeD/49R/w1V4I/wCgV4k/8B4P/j1eN/F34Y+EfDvwq0Pxj4RvdbnTVLuOJE1F4+I2jlb7qopDZQDqR168GvEKYH2n/wANVeCP+gV4k/8AAeD/AOPUf8NVeCP+gV4k/wDAeD/49XxZRQK59p/8NVeCP+gV4k/8B4P/AI9R/wANVeCP+gV4k/8AAeD/AOPV8WUUBc+0/wDhqrwR/wBArxJ/4Dwf/HqP+GqvBH/QK8Sf+A8H/wAer4soosFz7T/4aq8Ef9ArxJ/4Dwf/AB6j/hqrwR/0CvEn/gPB/wDHq+LKKLBc+0/+GqvBH/QK8Sf+A8H/AMeo/wCGqvBH/QK8Sf8AgPB/8er4soosFz7T/wCGqvBH/QK8Sf8AgPB/8eo/4aq8Ef8AQK8Sf+A8H/x6viyiiwXPtP8A4aq8Ef8AQK8Sf+A8H/x6j/hqrwR/0CvEn/gPB/8AHq+LKKLBc+0/+GqvBH/QK8Sf+A8H/wAeo/4aq8Ef9ArxJ/4Dwf8Ax6viyigLn2n/AMNVeCP+gV4k/wDAeD/49R/w1V4I/wCgV4k/8B4P/j1fFlFAXPtP/hqrwR/0CvEn/gPB/wDHqP8AhqrwR/0CvEn/AIDwf/Hq+LKKAufaf/DVXgj/AKBXiT/wHg/+PUf8NVeCP+gV4k/8B4P/AI9XxZRQFz7T/wCGqvBH/QK8Sf8AgPB/8eo/4aq8Ef8AQK8Sf+A8H/x6viyigLn2n/w1V4I/6BXiT/wHg/8Aj1H/AA1V4I/6BXiT/wAB4P8A49XxZRQFz7T/AOGqvBH/AECvEn/gPB/8er0/4X/EDSviPoFxq+h299BbQXTWjLeIiuXVEYkBWYYw47+tfm7X2n+xV/ySzVf+w1L/AOiIKQw/bW/5JZpX/Yai/wDRE9cf8BNB1nxR+zf4n0Pw7cWlrd3+sPBJNcsyqsJht/MxtUkkrkY9zzXYftrf8ks0r/sNRf8AoieviugD7+8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXwBS0lABRRRQAUUUo60AFOVcipIkVg2euOKROD0qWyWxu2msKnKYTIqMrxzQmJMjFJTiuKbVFhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFfQH7FP8AyVPVf+wLL/6Pgr5/r6A/Yp/5Knqv/YFl/wDR8FAHK/tRDPx18T/9u3/pLFX1L8R/h3qPiH4i2fiCHS/DusWEOkvYGz1eV0AlLswkGIZBwD7HryK+W/2of+S7eJv+3b/0lirymmB9V/tDeHL3wl+zj4U0TVNRbUry01WNZLg5wcxXDBRnnCghRnsO3QfKtJS0CCiiigAooopgFFFLQAlFHFHFABRRRQAUUUUAFFFFIAooooAKKKKACiiigAooooAKKKKACiiigAr7T/Yq/wCSWar/ANhqX/0RBXxZX2n+xV/ySzVf+w1L/wCiIKAD9tb/AJJZpX/Yai/9ET18VV9q/trf8ks0r/sNRf8AoieviqkMXvSUUUAFFORSxwOtPMRB560ribSI8VIi/lTliJPSp4UXcM9KmUiZSI0XninmM7quGEADAqxDa71yQOPWsXVS1MnIoCPIximNER1FawhAUYxmka2Un5qhVSeYxZVHFQ7ecCtWe22nOKoSJtfit4TT2NYyK7IR2ptWwcjBqKWMDlTVqXcpS7kNFKRikqiwooooAKKKKACiiigAooooAKKKKACiiigAr6A/Yp/5Knqv/YFl/wDR8FfP9fQH7FP/ACVPVf8AsCy/+j4KAOV/aj/5Lr4m/wC3X/0liryuvVP2o/8Akuvib/t1/wDSWKvK6YgooooAKKKMUwCjFLRimlcAoxTtppdpqlBiuMxRT9p9KTFPlC42kp2KTFTYdxOKKWikAlFFFIAooooAKKKKACiiikAUUUUwCiiigAooooAK+0/2Kv8Aklmq/wDYal/9EQV8WV9p/sVf8ks1X/sNS/8AoiCkwD9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qpDCiilXrQA+PKtkdasgljkio8DaCo5p8WT1rOTuZSd9SeNN+D0q3b2gycmmwxZUEetdNoOnGaTfKMqK4q9ZU4tmLlYp2WlSXOAowvqa3rPQowoDtkitWJFRdqgKO2KnUAc4rxquLnLbQycmzJm0GBj6VnXmhSRqWjO5RXVjkYAp4i3JzyBWMcXUh1FzNHnElvglWBDHisy6tDGxBFeianpqTZKKAfWuXvrZlby3XB9a9XD4pT2NIyucrIm000YPFXbyPaSKpFMetenGV0apg8II4qu8ZGas5JNSCMMpVuB61SlYpSaM/GKVlGBippIiDgc1CQQcVonc0TuNNJTqTFUUJRTttKEJ6CgLjKKcVNJg0BcSilApdtAXG0tSrCSM0piGcClzInmREFJr3/8AYrGPinqn/YFl/wDR8FeFxphcYya98/Y2UL8UdRx1OjTZ/wC/9vUqV3YSld2OM/aj/wCS6+Jv+3X/ANJYq8rr1T9qP/kuvib/ALdf/SWKvK60KCiiimAYpaKcozVJXBsFXNWbe2eQgKpqSytjK4AziussbNI1ACjNejhMG6ruzixOKVJWW5iwaMzY8w9atPoqAYBNdNHbAgHHNOa3JPCmvbjl0Etjx5ZhNvc4u40llB281nS2zI2GBBr0E2Tc/LVC/wBMWReF+auatlul4nRRzHW0jhXTBNRkc1sXtk0LHcOKznTBrxqtFxdmetTqqauivikIqQrTK52jVMbRSmkqGigoozRSAKKKKACiiigAooooAKKKKACiiigA7V9p/sVf8ks1X/sNS/8AoiCvi0V9p/sV/wDJLdV/7DMv/oiCh7AJ+2t/ySzSv+w1F/6Inr4tABGe9faX7a3/ACSzSv8AsNRf+iJ6+KwakYGgdaSlFAFqJeOvWrS27jGR8vrVKI8iryF9uOcVhO6MJbmpp0AkZBz1xXe21uttarsz0ritC/4+IwRwWrvs/IBjIrwcfJ8yRzzZVU5yakRjkVIIcHmhUwxxXC5JkDiSD6CpYpSMjORUMmSMd6ZG23PPNRa6AsSNhDkVm3tnHcKSRhvWtFPmGTUcmOQRThJxegLQ4PULRQzAjB9aypIQiksp9q6rWY/nJA4NYF0crjrg172HqOSRtF6GNJw3Sm7mPFTzLlsYqFl2813p3NEISQKbJH8oO7Jpw96eeRgCqvYd7FJlwaTFW2j46URwFlNVzovnKykirFvG7BmToO1EVuXbGDntW9HZpb2Jd1+bFZ1aqjoTKaOedRuwT9aHjBOF5HrROD5jEVGpINaIa2JPJIOKmSFDHuZsH0qOOX5vnGae+CMg1LuJ3AcHHapvKj8oMOWqAcEEjip48sMDpUyJZMiooDYINe5/segf8LT1DH/QGm/9H29eGovIBPFe7/sh7f8AhaV9t/6As/8A6Pt6mD99BD4jgv2o/wDkuvib/t1/9JYq8rr1T9qP/kuvib/t1/8ASWKvK66zcKO1FLTAUVLCuSB61EOtWrUAuPrW9KN2RN2R02jWYEIY8ZragRd2B1qtpwC26cdq17O2LtuxgV9bhaNopRR8via15NslgUgCrflnstKIdrACr0SBhg17FOl0PJqVOpREZBGaq3UIVjxxW7HbruqveWoduBWk8O3EiFdcxyGoWiTxnIrk722MTsMHFeg3kIQEEVy2swjBZa+czDDK1+p9BgMQ726HLOuDUJGKuTrzxVZh1r52cbHvQlcipKcRSGsGjUSkpaKhoYlGKKWkMSloxSGnYQYpaKSkMKKWigAoooqkhCivtP8AYt/5Jdqv/YZl/wDREFfFor7S/Yt/5Jdqv/YZl/8AREFEl7oluN/bW/5JZpX/AGGov/RE9fFVfav7a3/JLNK/7DUX/oieviqsygpydabSigC4oVgCoxjrVu2Ut34rOjYjgHitO1mCrjjNc9RNIwkjZ0ohJ48nvXfwqHjUqcjFebWjEyKQe9dzod0ZIdpOWFeHj4P4kc80aDZAwaRCd1SNgn5qExkdK8y5ncjmAUZqoxOfar9wm4cVUaIgVcHoNE0DfLjNNnHByarjchzu4pXm3Cny63QGHqp461gSplvlroNQUu2FUmqC6dM5yFr1aM1GOpomYs8RJzVSaI8V1J0mdkOU4qjdadJFyYyfwrpp4iO1ylI554iooj4PTmr0keGORUQi5PHFdSndFXGyZKAkAe4psUiqcMCRSyggYNQmmldD3NLTJ4Y5C0gBx0qfU9SS4i2KOM1jDgcU0EniodGLlzMVr6j3AboMUx4Rg4pfmzTsccmtdiiBYflzRsOMdhVkkBQFpMAjmjmY7lbJ6Gpo5dqY70FMimiP2puzAsRSbuD0r3j9j4qfinqAXtos3/o+3rwEAqcdMV7z+xu274p6j7aLN/6Pt6UV7yYQXvHF/tR/8l18Tf8Abr/6SxV5XXqn7Uf/ACXXxN/26/8ApLFXlddJsFLSUtMBRVy1+8PrVRasQnDCumk7MznqjvNHIeBOeAK3rd9mfSuL0K72nYT9K6mKUkDNfYYGspQTR8pjaLjNpl4z5fNXbeQYDGsocn5a0IFOwA16dKTuebVirFxpSACBTo5QwO6oFR9p9KruxjNdLqOOrOdQT0RHqMe4muV1iLEbV0lxchlxnmub1h9ykA14+PcXFtHrYFSUkmcrcL8xqm4PpWnLCzHgVA1s/pXytSm29EfTQqJIziKYRVySBh2qu646iuacGjpjJMipKcaSsWrFiUUEUVNgF7UlFFPcAopcUYpWC4lFLijFFguJS0UUwFFfaP7Fv/JLtV/7DMv/AKIgr4tr7S/Ys/5Jbqv/AGGZf/REFKWwIT9tb/klmlf9hqL/ANET18VV9q/trf8AJLNK/wCw1F/6Inr4qrMoKUCgU5aBDhx0qxE3IquKehINQ1ciSNSCZlwR+VbOm6jJDICG5rnI5dvSrcUnORXHVpKSs0YtHpVlqEVyi7mUPjuatqw3Z4NecW92y4wa2LLV5VIGcivHq4FrWJk4HZ7s81FMCR8ozVTTL4XTDIwK2gqYyDzXnzTpuzM3oZBhducHFCwBc5FX/MUFh1qrJIS2COKpSbGmQtBuICqKuW0CRgKygmiFWCZzU6DK7sZNTOb2BsnWFMDgAGoLi0ilUqyio5JnBqeNmZQTWVpR1uScpr2hKIjNCuCOSK5Z12krjkV6lP8AMhVuhrgtdtBBcsVOFPNevgcS5e5I1hLoznJxkmqzqRV2ZMHrVSQEmvZgzVEQzT4hzSBSTVq2tyx75q5SSQ2QlDkY709bdj0BrorHRGlUMc4+lbtrokKIPMHPpXDUx0IaEOaRwgtGJ+6aX7M4b7px9K9CNnAgzsHFI8VuRgIPyrD+0L9Bc5548RTtSRKMnIrubzR7edCUG01zV/pklsxKjKetdFLFQqadRqdzJlAYZA5717h+xsNvxT1L/sCzf+j4K8R27Sc17n+x6c/FTUP+wLN/6Pt67ab1SNYbnD/tR/8AJdfE3/br/wCksVeV16p+1H/yXXxN/wBuv/pLFXlddRsApaSgUwHCpUODUQpynmtoOzJepo2szRsCpwRXV6ZqKyhVcgGuJRuOtW4ZypBBr08LinSehwYnDKqtT0eCQHGDWjDIOua8/s9VkjABORWza6uHwDxX0OHzCmzwK+AmjrnugEIBrLnlZycdKhjuVdQc02W5VT1H0rsqV+dbnJCjyvREUme55rMu8McdauT3AYniqjjOWFedVaeiO+kmtWVkhUHLCpTEhHAFAyRzTdzDjFcySR0NtlWe2U9hWZdWQ5KitwncOagkAwc1hVoxkb0qsos5SRCuciozWrqMIByKzGGDXjVafK7Hr058yuR0YpcUoGaw5TQQUoXNSJHk1ftbFpcYBrWnRcnoZzqKOrM8R807yie1dPZ6JuA31eGkQoPu5r0IZbUkrs4p5hTi7I4ryW9DTWjI7V2xsrfbytVZtMhkX5QQaJZdJLRhHMIvdHIlaQite901oclckVmspB561w1KMoOzR2QqxmrohxX2j+xZ/wAkt1X/ALDUv/oiCvjAivs/9iz/AJJdqv8A2Gpf/REFc9RaGyE/bW/5JZpX/Yai/wDRE9fFgFfaf7av/JLNK/7DUX/oievivNYlC0oFNqRDgHikxMegA605vamjPoanRfkJrN6GbIkzmrcPHJNRJipI+vPIqJO5DZOjfvBg8Vftm+Y4qhEBvIq5A2GAxXPUWhLO48PQKFRm4BreYKrkLwtYWhSboE5xgVqSu+BzXzddN1Hc53uSCJS+RT5YkX2NVhMySAZqWe43KMgZrK0riHKuFx2qaJsZzVDzWZgKs5IIz6UpR7gwn2jOBRbS44zSOuR3qJU2sSOtNJNWAtzMNhz6VyPiEBgT6V0U8pKnmuZ1pxyOtdWDjadyo7nLXAxVYjJq5dAHpVeNMtX0EXobJjooyxXA5NdVoGkCR/McYUVR0WwFxMu4cZ5rtDGtvAFi6V5uMxLXuR3IlLoK/lxR7YwBioy+4cmoHLE5bgUm4AcHNeaokWHyYwRmqbId3WnSEscU+JWJrVLlQAHKjHY0yWNZYSrcj0qZoyVxjmkWMgYxSulqgOM1WyaGQ4+6elevfse/8lU1EH/oDTf+j7euI1S08y1Y7eRXefsirt+K+oDGP+JNP/6Pt69vA1vabm9J3ZwX7Uf/ACXXxN/26/8ApLFXldeqftR/8l18Tf8Abr/6SxV5XXrI6QpaSjtQAopwptLVpiZIpxUqNiq+aeDW0ZESRcRzkc1pWBJPtWPGxrSsZCBXZQl7xy14+6dDHMFAwaSSTe3BqirkrUiMVwTXre0b0PLdOzuaEYBXJpdvBFQRTgLg0jy5PymtuZWMeV3HkbTxTZFxyKcHO35uaUgNzU6MexArAHBpsm0rSSrVdpcZFYylbRm0Y31RSvgCDWPIOTWrdtkGstzzXlYjWR6lDREWKljTNIq5q7ZQGRgoFYwhzOxtOfKrlnTbBriQADiuxsbGK3iUYG4Dmm6bZJbW4ZR82KtoGbkivpsHhFRSbWp83i8U6rsnoOjUfhSmAEcdDUkcY7mnSOFwAK9FRVtTgcnfQyri3IbgcUzyii5IrWWIv15FE0HyNxWLw99Uaqv0ZhyxK6Nurm9TsxG5Zelde9seSRVC9tQ6EFc152Jw/tI6o9DDYjklucQ64NfZf7Fv/JLtW/7DUv8A6Igr49u49rEYxivsL9i//kl+rf8AYal/9EQV8ziI8p9DSlcb+2t/ySzSv+w1F/6Inr4qr7V/bW/5JZpX/Yai/wDRE9fFgUmuU1EFOHHFKiE/hSGkK5aVlEXvSKcnFV1NSxtUNWM3ElPy8Cpo2XgHNVGc5pVfpUuN0TympGFwSDzUts+W54xWZG545qdZeQaxlAho7jw9cja0bH6VvGQMADnFef2N40bKy9K7LT7yO6gB6MOorxMXQcZcxlJdS/IBt3DqKgEpZsMDTnm6YqNX+fLVyJaakk+cNlRVmKTcPpUDupUYoiZVBzUNXQiaacA8GoWlLHIqCaQZyKqzXYjU1Uad9gsTXkoVeormtQuA8hyOlS316ZGbB4rIkkLE16eHocurNIxsRyncSabEo3D601wakgHzDNd2yKOs0FFWPNbTg7Se1Y+isDCNp5rWOduCa8Kv8bMnuVnG4ECocFWwasjgmk2A9aE7ARAc5qSI7Wp4UY46U5IwTz0qXICSJd/XpSHAJHpT2O1MCohwCe9QtRDbkg27gntXY/snDHxa1H30af8A9H29cJqMoS3b1xXefsnkH4r3xH/QGn/9H29etlitM2o/Eed/tR/8l18Tf9uv/pLFXldeqftR/wDJdfE3/br/AOksVeV19AjrCiiigBRRQKKaBi05aaDRWiZJMpxV20kw1Z6mpY32kGt6crO5nOF1Y345MDAqwvK1lQThgPWr6SjZjFepTqJo82pTaJfMxxUiOMCqm/mp1YYrSMtTKUSwH3U8SbR1qsrc0kjVpz2VyOTUdNJnpVOQ8USSYBzVKebNc1Wr3OmnT7DLl8jAqm3WnO2c0w158pXZ3wjyokQdK3tDiDPmsKLqK6LQT8xFdeDSdRXOXFtqm7HVW6E4HtU5UA4ptqOKZK+1zk19UrRjc+Xd3KxZQbcU+RBkHFVYph3qwswJ9q0jJNESi0ySEhW9qnJDA1WhIappGCRkjk1tF6GMlqUrwqr4rNuCMHFTzMXck1RuWwpNedWne56FGFrHKaqoWdsV9cfsYf8AJMNW/wCw1L/6Igr5E1F98xNfXf7GH/JMdW/7DUv/AKIgr4/G6vTufVYb4VcZ+2t/ySzSv+w1F/6Inr4ujYA819o/tq/8ks0r/sNRf+iJ6+KxXAdTJVyc7aNhNELFWBFXfKIVWI4NZylymcnYoFCp5FOA7Vak29MVHGoOdwo5hcxCRiheaeI2J46UhjIGadx3QDipo2JNRxjtU8a54FRJktlqFiAK07S6e3kUoxHtWSilTzV2EbmBwa5akU1qZM6y21COVRvO01cjbzGG1gRWfo2miZPMfPsK2fsBiA214tV04ysjJ2BQw+8eKrzXKRk/NVowOvUHFV7mx3JkA81lFxvqIzLi/wBzEA4FZt1cF+hq5cWu1iMVnzQEDpXoUlBbFqxXcse9QMOakIYZpnQ11rQoaRkcUKNpqxDtPUU6YKBwOaXN0A2dBuCpKk9a3pVJAINcXZz+W4I6V1dncLPGCOcCvNxVNxlzIiSJ4lJPNPI7d6AMjg0qqQMmuRskcEwcU7jHWlz8pNQznZHuzyalagK8u0HnNU5rggHnFRPJ3NUruYdM10U6V2NIq6hOZCRu4r1f9kz/AJKne/8AYFn/APR9vXj1wy9j+Nev/slHPxUvh6aLP/6Pt69jCRtJG1Ne8jz79qP/AJLr4m/7df8A0liryuvVP2o/+S6+Jv8At1/9JYq8rr1kdIUUUUALRRSCgYtLSUVSJHCng1HTlrSLEyxG5GMVehnyMZrNQZNaNlbmVuelddFtuyOaqopXZbjbcMDmp0RvSpY7YIBirKRHHSvThSfU86dVdCk7eX1qu84PStV7PzFzis+4stvFKpCaWg6c4PcoTSZHWqjnnNWpYGUniqzqR1rz6l76nfTt0IT1NHpSkUgrE2JENbOjzeXNWKtWbaTawrejPkkmYVoc8Wj0GJy0e5T2pgDM3NZumXgeMLntWop3dK+np1FUimj5ucHTk0wI2HrzTkJxmoypzzSo2DirvqQ1oWonIHWlMuOp4qshyCemKp3E5yeaqVXlRMaXMye7nUD5eK57Ubw4YA1PeXQCnJ5rAuZdzHmvHxmJ6I9bCYbqyGVs5ya+w/2MP+SYat/2Gpf/AERBXxs7cV9kfsXf8kv1b/sNS/8AoiCvAxDuj26SsN/bW/5JZpX/AGGov/RE9fFdfan7a3/JLNK/7DUX/oieviquQ2JEbaRVzzSyDk8VRFSxsVNRJXM5K5aGO4qMfex2NAl3OABipkTgnrWe25GwbDsyBnFRsh25q3CPlxmk8kljgcVHPYm5WijyasBdp96lhQIvK1MiDHK1MpibII0J6mtGw5kCkd6hSEnkCrNqjJMpx3rCpK6Ez0LTY0WFQvYVoRgPwRz61iWE37sHPatKKfgV81Vg7s52WJkC8YqEupBBWkkJJ6nFNCkjgVCWmoivPZRyqWOFNZk+nYU4INbkoO3BNV0jLt14ranVlHqUnY47ULCSMFgOKzHQivQ7i3V4mXbxXKavp5icso4r0sNiuf3WaKVzGVtnTrTJX3Up4Y5qCVvmOK9CK1KHJIQeelalhe+Q45OKw9x9KekmD1pzpqSswaPRLS6hlhBU84qdnO3jpXBWt68WNrHj3rUTW5PLwwyK8upgpJ+6RynStJsHNZ13d9s8CseXV2dcAYqjNcs5JJNVTwjTvIOU1Jr0YIFU3l31REnPNSGUAcV1qko7FJCysMYJr2T9kRs/FXUP+wLP/wCj7evEpZMivaf2P/8Akqmof9gab/0fb110I2kjSn8Rw37Uf/JdfE3/AG6/+ksVeV16p+1H/wAl18Tf9uv/AKSxV5XXoI6AoopaBhQKKKBBRRSirSELTlFCjNSqh9K1jEluwsa88V0WlRjyxnvWJGhBrd07iNfavRwcbS1ODFyvE0UQFsVfWAKoqgrfNVpJG4r26bijxqibL0caBMEVTu7dGJI4q1CcpSXCfu8iumUVKOxzxk4y3MKe0znFZV1ZN94Ct5wxbFKYwVOcV5lShGfQ9GnXlA42RMHBqMrit7UbPgsorFkUgkHivJrUnTdmerSqqauiOno2DTGpM1imbWuadndNCwI6V02n36SKDnk1xSMRU8Nw0Z+ViK7sNi3SfkcWIwqqrzO780EZzxTFkAya5mDVnVcNz+NSNq3HQ/nXpfXoPW5531Ka0N2W5CDg1j3l5tJxWbPfs54JH41TklLnJNcdfG82iOujg+XVk1zcFzzmqjtSM3vUbNXmzm3qz0YQSEY5r7N/Yt/5Jdq3/Yal/wDREFfF5r7Q/Yt/5Jdqv/Yal/8AREFclV3RvFWG/trf8ks0r/sNRf8AoieviqvtX9tb/klmlf8AYai/9ET18VVgWKKljNRCnocUmJonCAMKswvg1XU5XnrViCPeCe4rGW2piyZVyT2q1GwVueRioYU3d+lSiL5hzXPJrqQyWMbjjrWlFb+bEqhMe9N020LsGYYFbsMIQAACuKtWSdkQ2UINPBGD0q2tlGOi4NXYxxjFSBc8dzXFKtJkXI7UgJt9O9WgWTBzxULw7RkHGKWOUONp7VjLXVCLSTlvpVyGXIGMVlqMPjHFWk6cVjOKEy4WJY5Apyxkc1WSQZ5q0r5A5GKxkmhWI5OuKr3cEVxAVb71XJwoXcKpMPmyeKqD6oEcFq1ubW7YY4zWbKQ3PSum8XIMq4xmuSZsMRnivo8LL2kFI3jqh/y9M00HYT3FQFz605SSvTNdXKXYkD45zUscuVwKqZGMUithqHG4WLhbnrS7jVPcc9eKejnccnilyCsWlLMOKUNioYrjYeBmiSbeScYqeV3Cw6RuM17b+x0274qaj7aNN/6Pt68KZ8jBr3P9jf8A5KnqX/YFm/8AR9vW1JWZdNanF/tR/wDJdfE3/br/AOksVeV16p+1H/yXXxN/26/+ksVeV11I2ClpKO1MBaKKKpAxRUiLmmqua0LK2MjgD8a3pU3J6GU5qKuxlvbs/QGtW10xnxkVpWNmiIOBWxaxIuMgV7mGwCduY8fEY5r4TJi0hVAJU1Zhs1jyNtba7W4AFSNZ7gTXqxwUV8KPMljJP4mYn2YjkDilDY4xWiybTtNU7iLacr0pSp8iuhxqc246GbHFWDIGGDWeo5qXfgjJojUaWoSgm9B7Q5yQKqTZXjFaEcm9cA0yeJSufSiULq6CM7OzM0bXUq+KwdUt/LckdCa3Jhg8VQ1MBrck9RXm4mClB36HoYeTjJW6nON1ppNPfrURPNeI2eyhwOKUN61H3pc0uYqxKH96PMPrUOaM0cwuUlL03dzUe6jNHMNRHZpDSZpM1LY0ha+z/wBiz/kl2q/9hqX/ANEQV8X19ofsWf8AJLtV/wCwzL/6IgrKpsUhP21v+SWaV/2Gov8A0RPXxVX2r+2t/wAks0r/ALDUX/oieviqsShaUU2lB5oAtRHK1PFuA+U8VUibBq9b45zWM9DCWhZt32qQe9XLKMyyAE8VSAx24rb0aMNliM1xVpcsWzKTNq2UIoKt0FWS7EAgVFGqgYxipVwmc9O1eRLVmTJYC2+r0cO45rPhmCtnHFWZLvAAU1jNNvQQtzEd2Aap7Np4ODT2nLdTUqL5i5NNXitRhE4fgnBqYkAcGqLoQSVqrJeNE+G5FNU+bYLGwp9TSpNhqzob+NuCetTmWLoGH51LptaNAXxcl8qTxUUkoCkE8VRa7ijU5YVlX+p5UpGeveqp4dyeiBIg165SY7VPC1y1z1OKu3MjEHJqjN93Jr3MPT5FY2irFbJBqaOTB68VWZ6A4zXY43NLFpgDzkGomPpUe/mn9cUrWFYN/rTt2aay5puDmjQB4NKGNMCkmpoo85pOyAQZNe7/ALHAI+Keo5/6As3/AKPt68YtLUyjAXLGveP2TrM2fxQug3VtFuP/AEfbVEKq51HqEH71jzr9qP8A5Lr4m/7df/SWKvK69U/aj/5Lr4m/7df/AEliryuuw3CiijimAtKKSnKKuImTwRlmArptOtgoXGM1i6bHukHFdNaoFxXs4GkviZ5eNq9EWkUjpVyFSccVHAnfPFWVbDACvepwseJUlcu21ucggVoTQsEGKjtHURZJ5qVpSwyTXqwjFRPLnKTkZkkRJIIOfWqsy8EMK3UVZBVG/gGDjrWNWj7t0bU62tmc/L8jYFRsxNM1JmhfnpVIXYJ614tSooysz14U3KN0XPPKHANKbzK4zWe8qnnNRGdVzzWLrtdTZUE+hdlmFZWpTDYVBps94AODWZcTbyc964q+ITVkdlDD2d2RO3NRk0pNMbrXmSZ6SQuaM0lFRcYZopKKVwFzS02ii4xRTgM0KK09OgSTcXGeK2pU3N2RnUmoK5mgZr7P/YuGPhfq3/YZl/8AREFfIX2XDk7cCvsP9jhdnw21hR21mT/0nt6mvTcI3fcKdRSdkV/21v8Aklmlf9hqL/0RPXxVX6VeMv8AkY/An/Yak/8ATdeV1VchsflXSiv1TooA/K5Tz1q7bSqCMso/Gv1EoqZR5iXG5+YrXCOceYgA/wBoVvaPeWiRDfdQIf8AakA/rX6OUVz1MKpx5bmbop9T8/BqGnbc/b7XI7ecv+NRyalYnlb22/7+r/jX6D0VzLLI/wAzF7Bdz894tSsifmvbb/v6v+NOk1GxJ4vrX/v6v+NfoNRT/s2P8wvYLufnxBe2s0qxxXMMjnoqyAk/hWzCAsfNfRH7Uwz4O8Pj/qNJ/wCktzXzzJgx4HWvMx1FUZqCZlUjyOxG+Cvy1zursUkIroI8gEntXK6zcb7hvQUsLG8yYkIm6c4NP+0HGd/61kvLgnmo2mPY16fsbl2NiWYMBg81RuZQDw3NU/OyOtRO5J5q4UrMpImZ2fjOfeoHJOQaaWPalLYQ1ulYdiu6+lR9DU7HA9zUOMnNao0QoPrUofPvUNPTpQwZIpJqZFBzziokB7VOqEjNZyZDCNCGq5BFvYKo5J61FDyQAK6bS7QRxqzAEnmuWvV5FqQ5FrSbEW8YZwC5r2P9msEfFWbIx/xJbn/0fbV5hZ4DAHp716x+zuVPxUfbj/kC3P8A6Pta4MJUcsVG/n+TFSd5o8c/aj/5Lr4m/wC3X/0liryqv0p8G/8AIx+O/wDsNR/+m6zrqq+hOw/Kylr9UqKdwPyuzTlI9RX6n0VSnYVj8x9LmiQ/PIi/VgK6GC8syPmu7dfrIP8AGv0Xoruo5jKkrKNzjrYJVXds/PNdRsguPtlt/wB/V/xqSHU7Hd815bD/ALar/jX6EUV1LO6i+wjmeUwf2mfBCappoQY1Czz/ANd1/wAaQavp5POoWn/f5f8AGvviitv9Yan8i+8x/sOn/Oz4g02WC5gMltPFNGDtLRuGAPpkVHdEENjrXZ/FeRV+KPjAHr9qt/8A0jt68+nm5P1r6ijifbYaFRq3Mj52rh/ZYiUE9mYevKMZNcrK2Dwa6HxDcBmC1zMzV83j5r2jsfRYGL9mrg0pB6monlJ70xzmoWNeXKbPSjBDnbPeoyaaxpKxlI2SAmkoorJu5QUUUlIBaDQKKYBSgUU5RVREx6jnFamno6ncM49KrWsOSCRxWrCAoGK78PT1ucdeppYkYFhnFfWX7IAx8PNZ/wCwzJ/6T29fLAClMDrX1T+yGMfD7Wwf+g1J/wCk9vVZjG1NPz/zM8FK82vI9I8Zf8jH4E/7DUn/AKbrytrxDqtvoWhahq16wW2soHuJCTjhVJx9eMVi+Mv+Rj8Cf9hqT/03Xlc98c9M1bxPoml+EtFSeIa1dhLy+W3MsVrbxjzGZ+g5IUBSRu5FeMemZvwX8VeKL3WLrR/HdwsuoXen2+t2G2FI9lvJ8rxEKByjbRzk88mr2tfGfRNN1jV9Lg0TxNql/pUxjuotOsPP2KFB8wkNgJzjJIOQeMc1zGseEPHHhvxX4X8Wah4mn8WGwuxZTWtrokdvIlrN8sjfuiS4U7WwRx1yOc9n8MNPvbLxR8Qpby0uLeK61nzYHljZFmTyUG5CR8wyCMigDnPib8V3sdC8B6x4Si1W7sNZ1OEyPaWSymW3BIe2w3SVycKBgnY2CMc7tv41uNX8V+BxGuu6FBqf28SaTqOmRpJP5UakGRmfdEATuXaDuzg4Fec2Gha/Y/AP4fSjQtTnv9B16PU7rTlgYXRiS4nJCxnBJw6kD0Oa7eW9vPFXxB+GuvQaBrunWcI1RZ01GzMUlvmJFUyAEhNxB25PPagD1ivEbH/hYXi7xZ4zTRPHi6NZ6TqTWlvaPo8FwGGxWGXOGA5x3NdlY/CLwPYeKh4ktNE8vWhcNdC4+1zn96xJLbS+3qTxjFcHoninUPA/jLx5HceCfGOpjUNWa5tp9O0xpIXXy1UfOSO46gGgDc0nxv4jh0fxxoniZbSDxZ4f06S8hu7Rcw3UZjcxzKrA4IKgEHjPbqKr/C3xvr154Y1Ow8U3Ym8Qx6UmtWd15KRi4tZoQ6sFVQpMbkoePSorDQfEer6f8QPF3iDSn0/UdX0h7DT9JjbzZY4UifG/aOXdjkAdOlV/FPhbV0+E3g3W9FsLk+JtC0mGGSyEZEtxA8CpPblcZ3DqBjIZeBk0AdJp/ji8sfgDa+L9Vl+06mdKWfdsVfNuHGEG1QBy5UYA7074Oa94huJtc8OeOLpLrxFpTwytMsaRiSCaMMpCqAPlYOpIHYZrhW8NeJfEHgX4YeD7SO90VoLdNRv7+408yJavAv7qJ0fCli5zsY/w5wRxWxZ+FvGfhP4paB4i1fX5/FcOoK2j3z2+kJbm2iILxO4iJyokHLEDaD15oAsftSDPg/w+P+oyv/pLc189NtCj1r6F/ajOPCHh/P8A0GV/9Jbmvm2+uViHJFeDmcXKuku36s5K/wARHf3KwIcHrXHalIGdjnk81oXd21xLg/dFYd+w3sBnIrXCUeTcmKK0j5qFpMUkjHBqH616cYm8UTLJmnNJxVdTTsE0+UGhxfFHmZ60wg01qpJFJIlLhh0pqHnBFRrTgeaLBaw9xzxT1XFIvI96kzgVLJfYenHIPOamUl2qCME9uKsqMYrKRDNLSbcS3KKeneuujhUYAOMVzmgodxNdNGpcgqeleRi5NysYzY5B82O9erfs5Kq/FN9v/QFuc/8Af+2rymR9j8DmvUv2bH3/ABSkJ6/2Nc/+j7apwN/rEX6/kyqXxo958G/8jH47/wCw1H/6brOuqrlfBv8AyMfjv/sNR/8Apus66qvoztCuC+Omu6p4b+GOq6poF39j1KKS3SKfy1k2b540PysCDwx6iu9rzj9oexvdR+EmsW2mWV1f3ZltWW3tYmlkcLcRscKvJwAT+FAGDrsPxQ8C6dP4gm8V2Xi/TrFDPeWE2mR2UhhXljG0efmAyef7vfoek+IXjKaL4c2OpeFJsanr7W1tpDsgb95cEFWKnI+VCzYOR8vNcv4l8ceIvHGi3fhzwr4E8TadcalE9rNf69aizgtY3GGfqxc7d3Axzjr0qvr3gjxBqnivwtoHhzU7nQ9O8H6Uhg1abThcJPcMoiCqrkIxEakkgnaWxjvQB23wm8Q6lrPhm+tvEEyy+INGvZ9OvpAip5jo2VkCgAAMhU8DHWvItL8T/Ee1+Etp8Rrzx7YXMJRpW0i90qCJJdsjL5YlTDFjt4AArs/BPh3xV4N+KV7/AG3qc/iKz8SWRkn1CHTVt0huYAAgcRkquYyQGONxAHJFZfwN+DXhaPwV4f1jxH4WZPEqhnmF8ZgyuJW2loWbaOAv8PvQBf8AGGo+Nbj4i+CbXRfFh0jTPEsMsv2M6ZDObXyYFkYb2G5t2SP4dvv0r2qvFfibrd7b/GbwVc2/hXxRqFnon2r7Rc2WnNLE/wBohVF2ODg7T97OMe9e1UAFFFFAHyJ8YWA+K/i7J/5eLf8A9I7evPL+RY1J3V2vxxnEXxb8WgnH7+3P/knBXlGp6huBRTX2FDExp4OC8j5irh5TxU35lLU7jzZic1lSP1p88mTVZ25rxK1TmbZ7VKnyqwjGo2NKTTCa5ZM6UgJzSUUGsmUFJRRSAKKKKQBS0lLTAUdaliGWAqIVatgDIPStoK7sRN2RpW6YUVaVSCKhhGQMVdCgKM9a9anHTQ8ypLUfGCBX1d+yJ/yT/W/+w1J/6T29fKcTbsivqz9kQY+H+t/9hqT/ANJ7esMx/gr1/RmmC/iP0/yPR/GX/Ix+BP8AsNSf+m68rqq5rxppuq3k/h+80OGxnudL1Brtoby5eBJEa2nhIDrHIQQZgfu9j0qL7d44/wChe8N/+D6f/wCQ68U9Q6qiuV+3eN/+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDoA6qiuV+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDoA6qiuV+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDoA6qiuV+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDoA6qiuV+3eOP+he8N/wDg+n/+Q6Pt3jj/AKF7w3/4Pp//AJDoA87/AGtZfJ8B6G46jWU/9Jrivkq5vN0h8019e/GLwb44+I/huz0oWPhvTfs96t55v9rTzbsRyJtx9lXH+sznPbpzXj8n7MnjiTrqPhv/AMCp/wD4zXLWoc8+byMakHJ3R4o90m75TVO9ZXlJU5Fe4H9l3xx/0E/Df/gTP/8AGaT/AIZc8cf9BPw1/wCBM/8A8Zpxo8ruJU2jwRsYqI9a9+P7LHjg5/4mnhv/AMCZ/wD4zQP2WPG4H/IT8Nf+BM//AMZrZJotRaPBEC55qcBQhPevdP8Ahljxv/0E/Df/AIEz/wDxml/4Za8cf9BTw3/4Ez//ABmk4tg4tngLtk1H1Ne/n9lfxuf+Yp4b/wDAmf8A+M0f8MreN/8AoKeG/wDwJn/+M1SRSVjwEUor33/hlfxv/wBBTw3/AOBM/wD8ZpR+yv43zzqfhv8A8CZ//jNFgseDxHmn9WxXu6/steN1P/IT8Nf+BM//AMZp3/DLfjf/AKCXhr/wJn/+M1LiyHF3PDITjjtU+Bu4Ne3p+y/44Qcal4a/8CZ//jNOX9mHxuDn+0fDZ/7ep/8A4zWbpyJ5GeX+HQSCBXTwLhTXc6d+zp44smJF54af/t8nH/tCtdPgZ45UY83w0f8At+n/APkevKxODrTleMfyM5UpPoeWSwNkGvUf2bEK/FKQnvotz/6PtqmHwR8cAff8NH638/8A8j12nwf+GXiPwn41k1fXJdINqdPltFSzuJJX3vJC2SGiQAYjPfuKrB4WvTrRlONkr9V2HTpyUrtHf+Df+Rj8d/8AYaj/APTdZ11VcVFZ+KtI8QeIrjStN0S+stTvUvI3udUlt5ExawQlSq28g6wk53dCOBVv7d44/wChe8N/+D6f/wCQ69s6jqqK5X7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOgDqqK5X7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOgDqqK5X7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOgDqqK5X7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOgDqqK5X7d44/6F7w3/wCD6f8A+Q6Pt3jj/oXvDf8A4Pp//kOgD5A/aRuTF8aPFMYOAXtj/wCSkNeUSSbiRmvpv4m/Ajxx448cap4iE3hux+2mI/Z/t08uzZEkf3vIXOdmeg61yp/Za8cf9BTw3/4Ez/8AxmuyOIXKot7HP7H3mzwZ2zUZNe+H9lnxx/0FPDf/AIEz/wDxmk/4ZX8cf9BTw1/4Ez//ABmodVM1UbHgJNJXv3/DK3jj/oKeG/8AwJn/APjNH/DK3jf/AKCnhv8A8CZ//jNZuaY7HgNFe/f8MreOP+gp4b/8CZ//AIzSf8MreN/+gp4a/wDAif8A+M0uZBY8Bor37/hlbxx/0FPDf/gRP/8AGaP+GVvHH/QU8N/+BE//AMZpXQWPAaK9+/4ZW8cf9BTw3/4ET/8Axmj/AIZW8cf9BTw3/wCBE/8A8Zouh2PAaWvff+GVvHH/AEFPDf8A4Ez/APxml/4ZW8cf9BTw3/4Ez/8AxmnzIVjwJat2f+sr3L/hlfxx/wBBTw3/AOBM/wD8ZqWH9lzxvG4P9peGzj/p5n/+M1rTqRT1JnFtaHj8BwwxV7aWGRXr6fs1eOF/5fvDZ/7e5/8A4xU6fs5eOEH/AB++Gz/2+T//ABivTp4uilZy/M86eGqt3SPHIoyK+rP2Rv8AkQNb/wCw1J/6TW9ecH9nTxzjAvPDQ/7fJ/8A4xXt3wH8D6r4C8K6hp2uTWMtzc6g12ps5HdAhiiQAllU5zGe3cVhjsTSq01GDu7muEoVKc3Ka6GT+094w13wT4C0/UfDF99hvZdTjt3k8mOXMZilYjDqR1RecZ4r5j/4aA+JuefFGP8Atwtf/jVfQP7ZY3fDPSAf+gzF/wCiJ6474LeI7vwd+zT411vS0Vr211N/J3LuCs8VsgYjvjdu/CvIvrY7+tjzEfH/AOJh/wCZpH/gDa//ABqpV+PPxOOD/wAJOcH/AKcLX/41X2b4Q0/WYI7a91LxLcarDcWqM8E1tAqpKcHdE8SIdnJGG3Hpzwc/nfZpvt48j+EVFSTgrkyuj0yL44fE2Qf8jO//AIAWv/xqtGz+LvxRuSMeJZQp7/YLX/41XGeHNGM7h5FOyu1htIoBhAOK8bE5m6b5YbmMqrWiNaH4l/Eg/wCs8WTj6WFp/wDGqe3xK+IgOB4suf8AwBtP/jNYM5xnj8qh3k54ri/tDEPXmI9pLub8nxN+Iy/d8W3GfextP/jNV2+KHxOGdviqU/8Abhaf/GqxJGKkZHNNZyRwuDWkcfX7h7WRoTfFr4ppnHiaQj/rwtf/AI1VOb4zfFSPr4kk/HT7X/41VZzlc4qN0SZTlQRXRHMqi3KVVg/x2+KC/wDMzNn/AK8LX/41UJ+PfxPH/MzH/wAALX/41VSfRYJX4Xbn0rLu/DLjcYgWUV2U8xhLRuxaqm7/AML++J//AEMx/wDAC1/+NUn/AAv/AOJ3/QzH/wAALX/41XEXOlvCSGQj6iqE1vt4IrsjWUti1M9F/wCGgPid/wBDN/5IWv8A8ao/4aA+J3/Qz/8Akha//Gq8yMWKaYzWnMVzHp//AA0D8Tv+hm/8kLX/AONUn/DQXxO/6Gb/AMkLX/41Xl+w+lGyncdz1D/hoH4nf9DMf/AC1/8AjVH/AA0F8Tv+hm/8kLX/AON15h5ZNKkJc4Ao5guenD9oH4n/APQzf+SFr/8AGqX/AIaA+J//AEM//kha/wDxqvL9hBoK4ouK56j/AMNAfE3/AKGb/wAkLX/41R/w0B8Tf+hnP/gBa/8AxqvLcE9qOlFwuerJ8fPia3/Mzn/wAtf/AI1St8e/iaOnic/+AFr/APGq8rVsUvmZ61N2K7PTX/aA+JynH/CTf+SFr/8AGqb/AMNBfE7/AKGf/wAkLX/41XmEhzzUdUmUj1T/AIaC+J3/AEM3/kha/wDxqvXv2YPij4x8bePr/TfE+sfbrKLTJLhI/ssMWJBLEoOUQHozDGcc18mfWvf/ANir/kqeqf8AYGl/9HwUxmr8evjF478K/FjXdG0HXfsum23keVD9kgk27oI3b5mQk5ZieT3rz/8A4aC+J3/Qz/8Akha//G6X9qP/AJLp4n/7dv8A0lir6j8Sat4iv/jnH4T0zxFdaRpreHzqA+z21vIfP85kBJljYlcYyoI6cEVQHy3/AMNBfE7/AKGb/wAkLX/41S/8NA/E7/oZv/JC1/8AjVei/GzxZfeMv2c9D1LVo4Rex+IfssskIxHMY4rhfMUdgfT1z9K+aFBJ4qoq4mz1L/hoH4nf9DN/5IWv/wAaqRfj58UG6eJT/wCAFr/8arzi2s8gFhV1IFUYxXXTwt9Wc88Qlojvh8ePiif+ZmP/AIAWv/xqj/hfHxR/6GY/+AFr/wDGq4PaFOMCjYD2rb6pAz+sM7k/Hv4og/8AIyn/AMALX/41TW+PvxQXr4lP/gvtf/jVcP5Y9KY8SnjFQ8IiliDuT+0B8T/+hmP/AIAWv/xqk/4aB+J3/Qzf+SFr/wDGq4JrZSOgqB7MY4rKWFa2NFXiz0T/AIaC+J3/AEM3/kha/wDxqk/4aC+J3/Qzf+SFr/8AGq8zktnXtUJUjqKwlTcd0aqSex6l/wANBfE7/oZv/JC1/wDjVH/DQXxO/wChm/8AJC1/+NV5YRSVFhnqn/DQXxO/6Gb/AMkLX/41R/w0F8Tv+hm/8kLX/wCNV5XRSsB6p/w0F8Tv+hm/8kLX/wCNUf8ADQXxO/6Gb/yQtf8A41XldFAHqn/DQXxO/wChm/8AJC1/+NUf8NBfE7/oZv8AyQtf/jVeV0UAeqf8NBfE7/oZv/JC1/8AjVH/AA0F8Tv+hm/8kLX/AONV5XRQB6p/w0F8Tv8AoZv/ACQtf/jVH/DQXxO/6Gb/AMkLX/41XldFAHqn/DQXxO/6Gb/yQtf/AI1R/wANBfE7/oZv/JC1/wDjVeV0UAeqf8NBfE7/AKGb/wAkLX/41R/w0F8Tv+hm/wDJC1/+NV5XRQB6p/w0F8Tv+hm/8kLX/wCNV9P/ALL/AIx13xv4B1DUvE999uvYtTkt0k8mOLEYiiYDCKB1ZjnGea+DK+0/2Kv+SWar/wBhqX/0RBQBN+2T/wAk00jP/QZj/wDSeevLfgr8VfC/g3wJq/hzxVpOpajHf3kkzpbwxSRPE8MSbW3yKc5Ru3pzXqX7ZR2/DTSD/wBRqL/0nnr5BVCRknArCpLllcluzPp7w38bvhp4dnE2k6B4tV1i+zx+fMLgQx5B2RiS5YRrkDhcDgegr5t0qMnyUcYwADUEaqrZNXbZwsgYdK5q1RyViJSuej6cFigUKAAAKuZ3fMKzrGcSWyFOhUVahcjgnOe1fKVIu7bOV7krhdnTk1VnjweDV6ZR5QJ4NUnO73xUwYkRKox8wyRVdiWkOBgVbycYxS28JZiX6Gtea2rGVUgMoxTvsuxcZFX2CIPlHIqjKSX6mnGbkO4wQtu9RVgtsUoRx602F9vB5qQHe/IyKTbe4ijcWkNxEysBk9/SuH1ixa3uWUjPpXpMsQZfkGBXKeLECCM4+bua7cDXany9y4S1OPaMMpAAqIQg/eIFWAfmOe9RzRkEnPFe6m9jcpsMHipY1QxljjPpTSw9BTMHGRWm4xBgUsWQ5AOKjJzT0BDA1TAa6kZOc0isB25p82WJPAqu3WqWo0OdsnNR55pe1J3qkikLSZoJpCaYxTTDSlqTvQCCvfv2K/8Akqeqf9gWX/0fBXgFe/8A7Ff/ACVPVP8AsCy/+j4KYzlf2ov+S6+J/wDt2/8ASWKvVfEPxr+E3iDW/wC19T8P+LjqRtfsJnt5zbloMljGRHcqCpLHIPXvXlX7UX/JdfE3/br/AOksVeV1aVxXPePjZ8V/CHi74daV4Y8H6RqOmRWN8lwkc0EUcSxrHKpA2SMc5kB6c8knPXxawiDPk9qpDtWlpp4NdWHiubUxrNqOhogADAqRI91MHLCrsCbhXrwjzOx5c5WRVaGmhCDirjDBpu0Zq3T7EqoQNGAPeoGUirpTJpPJy3NJwvsNTtuUghJ4ppUg81oMgQcCosZ61Dp2KVS5SKDvUE0Kt2rTdFI4qu0VZTpGsKhiTwmM57VARWvcplGGKymGCa82vT5Xod9KfMhlFLikrnNQooNFIAooooAKKKKACiiikAUUUUAFFFFABX2n+xV/ySzVf+w1L/6Igr4sr7T/AGKv+SWar/2Gpf8A0RBQBL+2Z/yTLSP+w1F/6Inr4+WU7QOa+wv2yhn4aaQP+ozF/wCk89fHgjPGBXPVtfUiW5PG2QM9KsxMDkCqAOPap4ZADXPKJJ1fh/UvKbypWwvbNdNHONyspH1rzpZBwQcVrWOrMm1XOQK8rEYTmfNEylC53guBKu0n8aquCjcDrWVaanHIQFIyfetm2dXUZxXmSpulujK1hpRgwPY1YJMajIzmpUQHjrTsAkZ7Vi53FcqhznG3rTChLEEcVf2p1qBxzx+NCl2C5X8oE9OBTVBWX7pxVkIACSw+lRPcIoIJAx3NWm3sA6aUIMYwO5rhPEV+JrplByq8Vq69q4WKRLchnxxzxmk8W+C3s/C2neKdDvm1fQLlVS5n2BJLK5wN0UqAnaMn5TnHIGTlS3r5fhH/ABGbU4dTiJTluBTHVimSce1Ndir9aZLIW9q9dI1IwRkg1GWI4B4oPWkNapFDe9LuI6E001MkRdSQeR2qnZbiIGJPOaaaeVINBXAzimmUmR5pDTjQwXau0kkj5vaqGMJpppxpKYxMUtFFAwr379iv/kqeqf8AYFl/9HwV4DXv37Ff/JU9U/7Asv8A6PgoA5X9qH/kuvib/t1/9JYa8sFeqftQ/wDJdfE3/br/AOksVeV1qtiWKKtWkmyQZPFVKcpxWtOXK7kyV1Y6SIqwBHetC2ZQMVzVpdmPAPStWCcMowa9ihXi9jy69FouzH5sikTmo9+4YzUkRCk88V0J3Zz2siRdvemFxSlhgioggPeqb7CS7jnYEVGw4zTnTA4qJiQeKzk+5cV2AnA5pCRtzSZ5+amSuoXrxWbZaRUu2AQmsZ+tej/D/wAKab46i1TSo9Taz8VgLJpcExVbe7AB3xFuokPBHOOPrjgdTsbrTNQuLLULeW2u7dzHLDKu1kYdQRXk16ilKx6dGHLEqUGg0GuVm6E70UtJSGFFGKKBBRRRQAUUUUAFFFFIAooooAK+0/2Kv+SWar/2Gpf/AERBXxZX2n+xV/ySzVf+w1L/AOiIKAJ/2x/+SbaP/wBhmP8A9J7ivkReATX2H+1xD5/gHRIv72sp/wCk1wa+R7u0kgyGUgetcVeaU+Uzm9SjKoYjaKYqHNTgbevWmsfmzUpiAEjg08MQetN3BRkjNMDcdaVrgX4JipyGxWra6vLEAA+faub34p4kHrWU6EZ7icUzu7XxEowHHPtV5fEFrgbgR615wlwQKe10xFccsuptmfs0ehz+IbMIdjc1Rk1+LscfjXEC4Pemmc+tEcugh+zR2EviBQOOax7/AFiWfPOB7VimUmmM+RgmuinhIQd7FKCRO9wS2TzXQ+APHN74N1aWWKGO90q8TydQ02fmG7iPBUg8BgCcN29wSDyZNMPWuyC5XdFLTY9A+JPgq2sLGDxX4Qla+8G6g37t+slhIetvN1IIJwCevHsT501dn8OPHF14Nv7hHgTUdCv18rUdMm5juY+nQ9HA6H8OlXfiX4Fh0aC28R+FpzqPg3Umza3Q5a2Y/wDLCYdVcdMnrj1zW1k9UVvqjzzFSCMGNmJ5HajbSkY4qbiuQheelTIGHAFPUAKDjnvSsSxHFJu4iuQS2adINw46CrCxjFMK9eKOYZSYYNMINWniNRtGRWikUmQEUhqRhTCKsYw0tKRxSUygr379iv8A5Knqn/YFl/8AR8FeAV7/APsV/wDJVNV/7A0v/o+CgDl/2oBn46eJ/wDt1/8ASWGvK8V61+03CzfG/wATuBwDbD/yVhrylgQa6ow91Mz5tbEVKKcRTTStYY7NSxzMh4JqClziqUmhNXNGG+ZeDVyK+Vjyaww1KHIrohiJRMJYeMjpFuEb+IU4zr/eFc4JT6ml858da3WL8jF4RdzoGuVPVhUL3Kg5BFYnmt/eNNMh9TUyxbZSwqRqzXg9aoT3TPxniq5bNNPNc9SvKRvCjGJJFNJBPHNBI8c0bB0dG2srA5BBHQg17Xby2/xx0VLS7ktrX4k6fFiCZsIusxKPuMeglUDg9/pnb4fUltcTWlzFcWsskNxE4kjkjYqyMDkEEcgg965XrqbIdfWlxYXk9pewSW91A5jlikUqyMDggg9DUFe44tvjlooO63tfiZp8OMcRprUKjr6CZQPxHt9zxO6t5rS5lt7qKSG4icpJHIpVkYHBBB5BB7VO4yGilooASloApcUWC43FFOxRinYLjaKXFJSsAUUUUgCiiikAV9p/sVf8ks1X/sNS/wDoiCviyvtP9ir/AJJZqv8A2Gpf/REFAGr+1Z/yJOg/9hlP/Sa4r5nvIVmhIPJxX0x+1YM+CtAH/UaT/wBJrivm8JxivEzF2qp+X6swq/EchdwGKTBqqM5rptYtv3e8CuckXB6VpRqc8bhF3I5BuNQuMGpweaUxhxx1roTsUVSaDmpZFCHpzUTcn0qlqA3dgU7fTCKKqwEmTmkyaQg4zSqD3pAFOxzQRipQpYCk2BGEz3odBjipwuOAKVYmY4C5qeYCssLFS2OK7L4ceNZ/CNzc2l5arqfhvUR5epaXLykydN6/3ZB2Pt9COeW0mYfKpx6VLaWAe+gW+aaG1ZgJZYYhK8a9yELLu+mRSjVSe4JnYeKPhfPDrWjS+Ebg6t4a16dYtMvlBOxmOPKm/uuvOc4yFPQggZvxl8EjwB48u9IhMklk0aXFrJJ1eNhzn6OHH4V9Ufs/aZ4K0nSLmHwh4hn1Wa4KzXMNzJsdHHG4QEAp6Zwc4HJwK579r7wr/aPhGw8RwJmfSpvKmIHWGUgZP0cJ/wB9NXU4pxui2tD5F3bkxipI1yOaEjwOKtW8BfHFcspJENldYiTxVqGyeTHH6V0mg6E95MqImc16poHgG0RVe9UYxyK8jG5vSwvxPUxnVUTw46WwGSKqzaeRzivpq48KaN5JSK2Qcda4XxN4Rihid4UAA5AFceG4gp1ZW1REcQmeHz2hU9KpyQlTXX6lYmNyCp4rHmhXkFa+jpYjmVzoUjDK8U0irssIBquY661JM0TISK99/YsH/F09U/7Asv8A6PgrwkRYFe8/sXjHxU1T/sDTf+j4KpO5SZB8fbcTfGLxZuGf3tuP/JSCvHtQs/JkPHFe0/HRWPxi8VkdPOt//SSCvN7+1EkbA9a+kp4dVMNB9bHiyruniJLpc411xTMVbuotjEehqqRXlzjZnqQldXIzSU4im1i9DQKKKKm4xc0ZpKKdwFzSUUUrgFFFFABR60uKMUWAlsbu4sLyC7sp5Le6gcSRSxsVZGByCCOhr2m5t7b446K17Zi3tviVYQ/6RbKBGmsRKP8AWL2EoHUd8emNviW0+le5/s+f8KstdSsbzxTqWo2niKCQSRNdSGC0Rwcgq6HP/fZA9qUlbUEzJ1L4R3Nh8BI/GNxbzR6qt8XmhcEFLQnyxlezbwD9G9q8gr9PNXsbDxP4bvLCZ0uNO1G2eFnjYMGR1IypHHfINfmr4h0i50DXtR0m+XF1Y3D28nHBKsRkexxke1KOo2Z2KUDNKozU0cWa1jC5DlYiCZ7U7yj6VrWenvMwCqTmt+38KytEHc44rvo4CpWV4o4q2Op0viZxBjPpTCpFdfe+H2iLbecVz95atExVhyKyr4KdL4ka0cVCr8LM4ikqRlxTCK4ZRsdSYlFFFQMK+0/2Kv8Aklmq/wDYal/9EQV8WV9p/sVf8ks1X/sNS/8AoiCkwNj9qYZ8HeHwf+gyv/pLc185ZHbivoz9qj/kTNA/7DK/+ktzXzj0X614OZ/xV6fqzCruV9TwbZvXFcfc5VjXU6pIoj2g9a5y4XfRhPdRMTPLEGpkJIGKjlQg80J9a73qjQfMv97rULpkZUYqZvmHrimE9u1JaAV2z3oUA9akYDn1pgFaXAePmOO1OAyQDToUzjJp8gIIFS3rYAIHAxTgAGA7UKufWtXTrHcQ8g49DWM5qCuxNkVnYPKdzDC1t22noiAhQasBMEbQAKtIu1QB3rzateUjJyGw26YHAxT2gRRkDmkD7RtI5p6PvyDXM3LckgEeyZJk3RyxndHIjFXQ+qsOQfcV2kPxO8Rr4fvtD1uRNe0i8t2tpI7w7Z1VlIyswGcjOcuGOQORXJKvzYz1pJ4xjP8AKtqWJqUn7rLjNxOJjtpFCrMMSAcitSwgG9c9KmvoQs24jrS2vWuudVzjcbZ6X4KWCEqwA3cV6Cbj90MHrXkfhy6MbgZr0O3uS0CD2r4zMqD9rzM5KkdS5JcMpbnis7ULhZYtrDNOnkwDjkmqqgs3zCuenBLUlI8/8V6cAd6rgGuIu7bjIGMV6z4pgJtmIXpXm93EGVucGvq8uruUFc6qctDlp46qOuM1q3MZUmsu44yBX0FN3Nyu744Fe7/sXHPxU1TP/QGl/wDR8FeBt1Ne9fsWf8lU1X/sDS/+j4K6oo0ijQ+NQB+LfizOP+Pi3/8ASO3rgLlBg13XxtYj4v8Aisf9N7f/ANI4K4Gd8A19rg5L6rD0PmMUn9Zn6nI6rGFnbtWU4xWvqrbpyayHrwsRbndj3MPflVyM02nNTK45HUgoooqBhRRRSAKKWjFNK4BTlUseKVEycVo2tsANzda2p0nIznUUUVorUt1q3HaKOoqygAPFSZwa7oUIo451pMiFouPu017OPGCBVwSCmPkHpxWzpxtsZKpK5q+EfF3ibwXMJfDOs3Nmhbc1vu3wv9Y2yp+uM+9Z/wAQvE1z4z8Sy65qFnb2t9PGi3Jt8hJXUbd4Uk7cqFBGTyM96YE3LzVS7iynHauaphYr3om9PEPZmUietaenQCRwDxVIDmtCxfa4NKhFc2pVaT5dDvNBsY1AwAT610DptXHauf8AD9znA9q6XZuXNfc4JRdJcqPisY5Kp7xmXMIZGyBXIa9pwILqOa7e5UZxWRqcK+Ua58dh1Ug0zfB13Tkmjy65hKk+1VWGK2tSiCyNgd6yZV5NfEV6fK2j7OjPmVyA0lONNriaOgK+0/2Kv+SWar/2Gpf/AERBXxZX2n+xV/ySzVf+w1L/AOiIKlga37VZ2+C9AP8A1GU/9JrmvmaabAPNfS37WBx4H0I/9RlP/Sa4r5buZQTg14+OhzVV6fqzGqveKt1IXc5NVZCMVJMRniq8jZ4pQiJEE2DUHQ1M4JqEjmuiJSHL7UpAxQBxSqMngUwImTimMp61bxngCn/ZmI+6aOe24XKsR5BNWCVJ6UNbMvO0iliQ5ORUtp6ibL+l2vnzgY4FdPHbLjHpWf4fgURsxHNbcCjdzXk4mq3Ky6GUnqRJERgHpU5iU8AYPapmxVeZiOnSuS7kySvKjK3FMDFeO9PMhPGKaUYnvWq8xiIrFhg1PISgA702OFgM0kpI470m7sDP1Dnr1qpE+GxUuoykSYPJqpGec11wj7pRvWFwY3BHau+0e98+BFzzivMoGrqvDVyRMqFsCvMx1BSjfsZTV0dzGmSO9adtaCTG5ar2KKVUkg1rpcQwxElhkV8xWm9kczZheI7ES2zoAAMV4/q0It53Q9ia9f8AEGqRrbMQQDivG9duBPO7n1r3clU7NS2N6Nzmr3gmsWf7xrTvZM5ArKlbLGvsqCsjsiV2717z+xb/AMlT1T/sDS/+j4K8GkHPFe8/sW/8lU1T/sCy/wDo+CuyJoix8cXCfF3xYe/n2/8A6RwV5hf3mxWAr0H9oCUR/GHxWM4/e25/8lIK8ivJiznmvpaeI5MNBLseNKhzYiTfcgnfexJqm/WpXaoGPNeZUlfU9KEbDGptONNrBmyEpaMU4LxS5QuNxRipAnHSl2Z4xVKAuYjxT1Wn7CKmgj3OB71cYakynZE9nb8bj1NaEaY4pUhICgdKvR2+5c16lKjZWR5lWtfVlQQ7uaSSMgVo+XsWq8pDDGOa3lTSRjGo2ymBUh5qUR8ZxQVwKhQsW5JjATt6cVBOQVNWCSBiq0/+rNTPRFQ3M4j5iamgbBqE9acprhi7M7Gro63w/d7Hwa7KC6ZoxjpivMbCYpIOa73RnMsK5ORivqMqxDkuQ+bzPDqL5zRIDcmorqANDk1ejjXaelVbyZEBBIr2ZxSjeR5EJNytE8412ApMxxxmufmHJrrfEkyOSBXJz9TXw2PjGNR2PtMDJygrlRqbT260yvIkemhK+0/2Kv8Aklmq/wDYal/9EQV8WV9p/sVf8ks1X/sNS/8AoiCsmUXv2um2/D/RD6azH/6TXFfKUj7q+qv2wDj4d6Kf+o1H/wCk9xXya0gxx0rz8VG80/IymtRZGFVWYk052yajPrmoirEiMxxTV5PNNc0J1q7aDJTyelT28TO2B3pkK/MK2bO32qDjrWNSpyoluw+005BgtzWiIVUY2jFJGwCgVOPnUelebOcm9TO5BJCjjG0VTk08M2VGDWmRyMDimgHdSjUa2C5BpoaElD0Na6gryvNZ7rsYMKuWchHPUVnV973hMnG70pJAG4IxVwuPKyAM1TkJJ5wDXPF3JREY8DApFf25FODHBoVNzZq/UZIx4GOKhkTc2anZMsBVxNOeSEkCoc1HcV7HKXsW+ZjUCwH1rpZdEuMkquRUQ0qZPvIQfXFdUcTG1kyuYx0BXtVy1uDEQVODV3+zmI6Gq01myZ4NL2kJ6CudDp/iOSJArsT+NW5PEoVTuySenNcPKGjPeqktwyj5ieKx+oUpu9hezTOg1rWZLk8thfY1yOoXWSRTbu8LDrWTcS5Jwea9TC4VU1ZGsY2IriTNUZDyakkY1Ax5r1YRsaoYT6173+xb/wAlT1T/ALA0v/o+CvAzXvn7Fv8AyVPVP+wLL/6PgrZGiMT9pOYp8a/FCg8b7Y/+SsNeVO5PWvTf2mjj44+J/rbf+ksNeVs3vXoxm+RIwcPebFc5qMmgmkqG7miQlKBRSqM0kNiquauW1m8p4HFFpB5jAYrpLK3RVHpiu3DYb2juzixGI9mtDPg0tdoL81ZXTYfStNQNpWlEeFzXqRwsF0PMliZt7mLNpa4+Q81WFm8MgJXiuiC88ipWhDp0qXg4y1joUsXJaMx1BIHFWEkKjirJtvSnC3U9q1jSkjOVWLK/mb+DTHj5yKneIA8Uz2NDi9mCfYhDYGCKUFWB4pZVyOKaiEA8VGt7F6WuRyLmqV2uFrSVGY8Cqt5CxP3TWNWF1c1pys7GQVoxirht29DSeQfQ1x+yZ1+0RFE+05roNL1p7dQpxisJoWHamMStbUq06DvEyq0oVlaR2/8AwkR24BFZeo6uXBw+Sa5ppSBioJJj61vVzOpNWbMKWW04u6RYu7lpCcnNZ0rZalkkyetQs2a8irUcmerTp8qGscmmmlNJXI2boQ19p/sVf8ks1X/sNS/+iIK+LK+0/wBir/klmq/9hqX/ANEQVmxln9sP/knOjf8AYZj/APSe4r5HLV9cfthvs+HOjN6a1H/6T3FfILyZOa5K6vIia1HuSOtQls0Fs02s0iQPNPTqKbinJ1psC9aKGdQfWuiiwqYxXO2ZG9frXRxDcBXn4nczmSR8irEeNnWoYyA2M09jxx1rilqQWGAC8Y5qDlWzmpUVpIuSOKhaIgnnpUrsA+UhiKEcxt8vSmbsHGKkI70/IC5DKCvByamKbhkd6ylkaNsjpV6C4XgE9axnBrVCaLixJt5602X5cbaaJOpzxQrBm5rKzEX9LgEzZYVuqm1Nq1l6TPCoKk/NWvAC7+1cFeT5tTORLboOM1eWGKRMOoNQhNuB3qeJGHJrhnK+pDZCdKhdgFFNuvDaFMgCte2UE+9bEMe5VBFYSxVSm9GS5NHj2t6R9nZuOK4fU02ORXvXi3Slezd1ABArxDX4RHKwHY19LlGL9utTppS5jmLljyBVGVuc1euRyaz5OtfUUzpIJDUJ61IxqMmulFoaa98/Yr/5Knqn/YGl/wDR8FeBk175+xX/AMlU1T/sCy/+j4KtFI5n9p4kfHPxOPe2/wDSWGvLDXqX7T5/4vp4n+tt/wCksNeV5rqi/dRLWotJRS4pgKOlSRjmmAVNEORVxREmbWkQ7ssRWyicgCs7SBmLityBQCC3SvoMJTXIjwsVN87H21uT1qwbfJAFTIVABHShH3S4FepGnFKx5kqkm7lWWHYeFp42+X71PMrZOaqyjaDk0pLleg4vmIweakYDqoqFeTT92KyT0NGitcjn5etVYwWbmtCXBGRVNvlPFYVFrc3py0sOMeF5qNSG+X1pDLkYzRER5i81DavoWk7amlY2w4J5q6tmjPkqKit2AUYrWtEDcntXp0KUZKx5tarJO5VGlwyD7g/KqlzoYXlAMV0SY7dKZMM11SwlOS1RzRxVSL0Zx8+lNtOFrGu7B485HFeirCpU8ZrL1GxDI2Frz8Rl0XG8Tvw+YNSszzi4QoTVSTpW3qsHlysCKxZRXy9eHJKx9JQnzJMrtTDTn60w1wzOxCE0UUnasmykFfaf7FX/ACSzVf8AsNS/+iIK+LK+0/2Kv+SWar/2Gpf/AERBUsCb9sr/AJJppH/YZj/9J56+PAxNfYf7ZXPw00j/ALDMf/pPPXyBFHkZFc9XciW4gBNTRRlu1W7e1M2AorVtbERkA9a4qlZRM3IyI7ZwQ2zPHenCxm28LXSpAoPTipvJA5FcrxbJ5mcrFG8LjepBzW9bPmJcdTVqW1WQfOo+tU0QwSEc4qJVVVXmJu5OqkEk9aduII9KchLDIFMZT1BrH1JLCy4XiguxOR3qsn3wKlY4PpUuNmBMBjBapWClcg1U83jBpUfn5alxYFry1KZHWqk6EA881bEvy1FJ81KLaYGcmpTQkxMQR708ahJ64qhqabJd4zVVZjjFdioxkrpFWudJYX7JIGzkZrrtM1uIY3HmvNoJiOK0YZ8L15rkxGEjU3JlC56wmowykFcH8asR3iucDFeWW+oSR9GI/GtK01iRCCTmvJqZa1sZOmep2UmSD61uRNkLg1wuh6tFcquWANdZbzxrHuLgY5614WKoyjKzRhJCeJ226ZKWP8JrwDxAwMz/AFNeneNPECyxtBE2VHUg15Fq9x5kjc19FkWGnTjeXU6KEbGHdHk1ny9auXLg5qi5z0r7CmtDrRA5qKntTDXSjRDWr379iv8A5Knqn/YFl/8AR8FeAV7/APsV/wDJU9U/7Asv/o+CqKOX/ag/5Lr4n/7df/SWGvLQK9S/afGfjr4m/wC3X/0lhrzqythOTuOABXXSg5WSMpzUdWUwOacFNWjbfPgdKtxWowK3jRkzKVZIzlQ+lSRqcitdLRSOlKLRccjmuiOGkjB4mJNozYBFbG8nAFY1rGYJMitiIjANephm1HlPMxFnLmRYSQhQGNWYJVHPeqg5HApAxBrujNxOOUEzQebfmoH/AHnaiIcZNSo4BxitbuW5lbl2Et7fPtSNb4cilWQh+D0qRZN7bjTSi1YTck7lGdNmQBWTdytC/PK1uXbqScdaxdTTdEfauLFKybidmGd2uYpNdrTBeHdxWc5wcU3divIdeR6qoROq06/BADEV0drex+TjcM15skxU5BNXLe/dD1NehhsydPRnDiMvU9Uek290gXkjNOecFutcFHqzZFa1nqayPyea9SnmUZ6HmVMulDU62GQbTUF0+YzVGG5yvFNurxI4juxmu2VdcpxxoPmOS145nb6Vzs3U4rX1a5EszEdKxZn9K+Mxk1KbaPr8JFxgkVm60w09qjNeZM9BAaSg0ViUFfaf7FX/ACSzVf8AsNS/+iIK+LK+0/2Kv+SWar/2Gpf/AERBSYFj9sXn4b6N/wBhqP8A9J7ivky3hMrhUFfW37YC7vh3oqjvrUf/AKT3FfMdjbiEDI+bvXn4ypyMzqOxasbcQIBjLVYSPMvIxmprTBPzU64A3ApXiSm3LUwI3kEb4xmrC7XXcAM+lVmXdyetKm5T1qWroQ+UseMVWliJXJXkVczlOD81BRsHJzQpWAzY5NhwelWSUZPlxmsu/ZomyOOaLW5D4Bauh07rmQ7GjEuWp/lmTIx0pkTqrDFW4nGCetYybQiv5QwQetKmFGMU5jySaRPmGRRfuA4At0FOVG5yMVNEcrTn4GGIrNy6BcwdaVfLznmufZsHitvWm7ZrCf616uGXuGkdieOXpzVyG49TWSGxUkcnzcmtZU0x2N1JARnP4VPHcY4rHWbaODxUqzd81zSpE2Oht750I8typHpWh/wkN0IihnbHpmuQF1jvUMt6cHnJrB4OM3qhctzcvtTLq2WyTXMXc5ZiTTJrotnLVTkmz3rvoYdQ2LUbCSuCaquadI1Qua7oxLSGGmmlJpM1qWNr379ir/kqeqf9gaX/ANHwV4BXv/7Ff/JU9U/7Asv/AKPgplHM/tPf8l08T/W1/wDSWGuA04sjdOO9ei/tLR7/AI6+J/ra/wDpLDXC2yBABivTwkG7M48TNJWJXRSAQuKmhjBGcVKsI2ZoT7u3pXrRhZ3Z5jndWRKkakfL1oCgZ3CmRsUPtVg7XHNbJXMW2iswG7gVZgfbjmo2GDwKjlJjGRSXu6jtzaGpEQ49KSQYesyC87Buatxylzkmt41YyWhjKk4vU0o/uinovXIptu6hBupbiQDGyuxWSucjvewwR4l56UshCDio2mJwD1oyGODU3WyKs+pVkc7jVe5AaM/StB0AGdufesy9bAOK5aq5U7nTSfM9Dm5zh2HvUG6pLhsu31quTzXz83qe9BaEm6gP71CSaUGs+YvlLKymrEVyYzkGs7dSh6uNVoh00zo7fWpExnmoL3VHnJOcD0rD83FIZTitpY2o1ytmKwcFLmSLE824k5qpI2aaXz3phNcU6lzshDlAmmmlzSVg2aCUUUVAwr7T/Yq/5JZqv/Yal/8AREFfFlfaf7FX/JLNV/7DUv8A6IgpAaf7WKB/A2gqeh1pP/Sa4r5pWPGSK+l/2r/+RI0H/sNJ/wCk1xXzYgO7IHFeLmL/AHi9DCruLEMsBmnz/LwpqMOEbinudwB7V5z3MhIwzj3ppLZIIqSJsHGKmRF+Y9aTlYCAZGCD+FTK5I5HSmMw59aFkKg+lJ6gYustkE+9YyyEHIOK1tYI2E571hM3NepQV4GsdjYtL4j5X/OtKOcsMo2RXKq5zVy2nKDIbHtSqUE9UJxOnQlhzUsKEc1kW2pKRhhg+tXlu0KgbhXDOnJaWItYuMxQcHrRLIBFkn8aoy30aD5jnHpWXdX7Thgp2r6UQoSkFrkWqziWQ7e1ZZ6U6RiW5qSMqPvDivUhHkjY02Ke7NKHApZgASV6VXOetbJXKLYm4pfPIqnuNJmjkQFp5zioWlNMY8ZqFm5qowQEjSZqNmqNm701m4rRRHYUtUTHNBNJWiVi0gppNLnFIaYxK9//AGK/+Sp6p/2BZf8A0fBXgNe/fsV/8lT1T/sCy/8Ao+CmMyP2jVz8cPFBx/Fbf+ksNefpxgV6H+0X/wAlu8Uf79t/6Sw1wKplRXuYWP7tHl4h++yaJmxTyc0kYBGKUdea9BXscT3I95HXpTvNYnipmjBFHlBRnvRysXMgilxwwqO7ZdlI5AaoLpwUonO0Whxh7yZmtIVkODirltqG0BX596y5W+c0wOa82NaUHdHoSoqa1OviugU+U5qRbgt1rlIbp4zweK07a+Vj8xxXoUsYpaNnDUwjjqjYLfMDmnPNgcVSE6k5zTGnB71v7Wxz+yuXftTMpHQVl6jNtjPNMku1jz81ZN5dGVvauTEYn3bX1OuhhnzXtoQSNkmoSc0jNmmk15DketGIuaM03NITUcxVh26jNMzRmp5h2HbqQmm0UnILATSE0UhrNsaFpDR2opDCiiikAV9p/sVf8ks1X/sNS/8AoiCviyvtP9ir/klmq/8AYal/9EQUgNX9q0Z8E6D/ANhpP/Sa4r5vRfkOK+kP2rm2+CNBP/UaT/0muK+cYH3YArw8z/iL0/zMKvxEDRkPUqxkLnHFTuyjhuTTBIWkA7V53M2ZCZUdRzUW45xmnytluaaw2mmgHGPKZPWq85IXANS+d1rM1C8ESED75q6cHJ2GtTK1GXdIRngVnN0zUk0hZiSarlq9iEbKxqlYXOKBIVNRF6ZvrTlGXo5uvY1MZWA5Y1mCTnrUiyFjjNS6YWLglOcMajecrkColILYJqKU/MaFBXCxIZyTzU0LLJ1NUCaI32sCKtwutALsvynjoaZhWXmkkmL4x0pikEHJ5qUnYBrAbjtqJjhqsAKOD19ahZck4q0wGknFRNUxI21A9aRGhp5phpckUhqy0JSE0tNzTGJS0UUxhXv37FX/ACVPVP8AsDS/+j4K8Br379iv/kqmq/8AYFl/9HwUAZn7RH/JcPFH+/bf+ksNcK3QYru/2iP+S3+KP9+2/wDSSGuGhIK8jivoMHrSSPHxXxtiRAgmp1APWmeYqDNO3Kwz3rtjZHJK7CVtuADTS5emsjEZpoOOvWk27jSVhpBHWqN3JhTV2aTA5NY15Lk4FcteaijqoRcmV3bnmoyc0jGmE15rkeiokm6nLIRUOaQt6VPMPlLa3Lr0JpWunx941TzxSFqftX3J9muxM0pY8moy3vTM0mazcy1GwuaQ0maM1HMygoopKkYpoozSUXAKKKTNJsdgNLScUVIBRRRQAUUUUgCvtP8AYq/5JZqv/Yal/wDREFfFlfaf7FX/ACSzVf8AsNS/+iIKAN/9prR9S1/wv4c0zQ7Q3eoz60vlQCRELbbW5Y/M5CjABPJ7V4pbfCf4hRD5vCdwT7X1p/8AHq+ofGX/ACMfgT/sNSf+m68rqq562GhWd5ilBS3PjaT4UfEFmyPClyP+360/+PUq/Cr4hD/mU7nP/X9af/Hq+yKKx/s+j2J9lE+NH+E/xDJ48KXP/gbaf/HqP+FT/ELqfClzn/r9tP8A49X2XRR9Qo9g9lE+L5PhJ8RSDs8KT59760/+PVmXPwU+JUzFv+EXkz739r/8dr7jorSGFpw2GqaR8JN8C/iUenhd/wDwPtf/AI7UZ+BHxMz/AMiu3/gfa/8Ax2vvGitVTih8qPg0/Ab4l/8AQrt/4H2v/wAdph+AnxM7eGG/8D7X/wCO1960U+RByo/Ovxl8M/GHgrTYdR8TaObGzmmFukhuYZcyFWYDCOx6I3OMcVyANfY/7Z//ACTHSf8AsNRf+iJ6+NTwamSsTJakgY07cCMHrUOTTge+ahoTRKqBs5NI0e0ZpgPFKWOKVmICTT1XjIqHJpyuRTaAlbqM4pjY55NLIw4K/lUJbNJIaBiOxNMbpQOTSvjHFaIZEc02nHrSHrVFIYaKftz2o8o+lO47jKKV1xSUxhXvv7FX/JU9U/7Asv8A6PgrwKvfv2K/+Sp6p/2BZf8A0fBQBsfF74c+LvF3xd8Wah4b0Zr6yjuLeB5BcwR4cWduxXDup6MvOMc1zZ+C/wAR9uB4Wl/8DrT/AOO19a+Df+Rj8d/9hqP/ANN1nXVV1U8XUpx5YmE8PCbuz4dHwU+JHfwtL/4HWn/x2pB8F/iMAB/wi0v/AIHWn/x2vt6irWOqol4Smz4kHwa+I4XH/CKy/wDgdaf/AB2om+CvxHPTwtL/AOB1p/8AHa+4KKbx9Z9RLB0kfC1x8EPiXIPl8LuPrf2v/wAdqk3wE+Jp/wCZYb/wPtf/AI7X3tRWMsTObuzWNGMdj4GPwB+Jp/5lg/8Agfa//HaQ/AD4nf8AQsH/AMD7X/47X31RUe0kXyo+BP8AhQHxO/6Fg/8Agfa//HaT/hn/AOJ3/Qs/+T9r/wDHa+/KKXOx2PzE8UaBqnhbXbrRtetvsupW23zYfMV9u5Q6/MpIPysDwe9ZVeqftQ/8l18Tf9uv/pLFXleapNtCCikNFABRRRSbAKKKM0rjCkzRmlpAJ3oNFFABRRRQAUUUUgCiiigAr7T/AGKv+SWar/2Gpf8A0RBXxZX2n+xV/wAks1X/ALDUv/oiCgD1Xxl/yMfgT/sNSf8ApuvKsfETxEnhPwTrOtvy9pbs0S4zvlPyxr+LlR+NV/GX/Ix+BP8AsNSf+m68qj8UPBk3joaHpVy8A8Ox3n2nVIjI6STqiny412joWOSdykYGM0hnC/CHR7r4b+NovDWozPIniLS49R3yEnOoRDFyqnvkMG/CtB/GHxI1vxH4q03wfpXhk2+i3pgW51GSUeaNisIwiNkvzncSq4wPelvvgdoOiXuj6x8O9Pt9L1zT7+K4MlxeXDpLCMiSI7i+Nyk8gduoBNdj4G8M3ug674vvbyW3eLWNS+2QCJmLKnlquHyBg5U9M/WgDyL4i+KNf8aeBvhV4g0O30q2a81+3Jhu2kYJeq7pGMr/AMssrLu/i+7jvXYzSaynxG+GkfjOx0KbXpBquLnTmuBHAoiTHlhmAJZTht6t/s461Tg+Fmv23we8L+H7W/0yPxH4f1JdUt5W3vbPIs0rqrHaGxiTn5eo/GuitvDXivU/E/gjXfE8uhLeaP8AbxeJpxlEbCZFWPyw4JONvzZI9s0AWrH4u+B7/wAVDw3aa35mtG4a1Fv9knH71SQV3FNvUHnOK858M/DLwn458b/Ea78S6Y11dwa00MMyXMsRjXykPAVgCcnPINfQVeNp4V+J2heJ/FN14SuPB39nazfG8B1E3LTR5UL0RQvbOOaAMu0N/wCGofiX4GuNSutU0uz0J7/TpruTfNBHJFIrRM3VgCBj0H6UPhhLJ4P8Mp4aunP9l+IPDw1jSnYn5ZzbKbmAcdcnzAOwJru9F+HN/Z+HfFsmrasmreLPEVpJBPfSR+VEn7tkjjRQCVRd3Pr1x2pvif4cXesfCXQ9Ahuba38R6NaWws7wEmNJ4owjc7c7GAYHjoQSOMUAc9Y65Pon7MOg/wBn86rqGnwabYKOrTzfIuPcZLf8BrR+Dem/8IH4q17wAZXe0SCDVtOZ+rRsojm/KRc4/wBqoR8JLnV9E8C+HvFbWV14e0KzcXttBPKpubrZsQggKdigsc5BycYxVq1+DWkeFfF3h7Xfh9ZwaZLa3DJqEc11O4uLZ0KsBuL/ADKcEDgE9SMCgDnf2z/+SYaT/wBhqL/0RPXxpX2b+2Wu74Z6QP8AqNRf+k89fGxGCc1nN6kS3GdqUDuRUkabmA9adJkfKOgrO/Qm5GcAe9N3UMCaAoxTAUN6imk5oxSkYU+tADM9qAMmgdBmiqGNPU0uBihqYTximAHgmkzSUYplFm1Cs3zVNcKqDiqSuUPFDSlupqHFt3JtqRu2TTaU80VqaBXv37Ff/JU9U/7Asv8A6PgrwGvfv2K/+Sp6p/2BZf8A0fBQB9U+Df8AkY/Hf/Yaj/8ATdZ11Vcr4N/5GPx3/wBhqP8A9N1nXVUwCvLv2mUWX4Ma3G4yjS2ikeoN1FXqNcX8YfC+oeMvh7qWh6PLaxX1w8DxvdMyxjZMjncVBPRT0FAHC+L/AIP6B4Q8O6j4i+HzXnh3W9Lt5LyOSG7lkjm8tSxSVJGYMpAYduvOelXvH2vTeL/hv4Q0q3HkX3jb7MjomcxW7Istww9ggK/8Co1Lwp8T/GNudJ8Za14a0zQJ/lvE0GOZp7mM9Y9033AcYyOxOc9KveIvhLpvivxbbv4mtLa48KaXpqWWl6fFcSxtHJuBd227cfKqKBuOQORmgB/wXd9JsPEfgu5ZjL4bvXit93VrOXMkB/Isv/Aa+bPCo+H5+GunDw8uqt8VyCIP7NN0JRN5jbCT/qtu3bnH+NfSPhn4U2Xgnx5b6p4Jgt7HRbmxltNStJLiZ2Z8ho5E3bsnIIIJAAORk10Pwi8MXvg34daNoGpy28t5ZI6yPbszRndIzDBYA9GHYUAeY/EDwNo+q/GH4ZyeINPE+oarDdf2mwmkUSyW9sjJ91gF2tk/LjPfNe/V5T498L+PdV+Jfh/X9Al8Lrp2ieb9mS9a4Er+dGEl3hQQcAfLgj3zXq1ABRRRQB8BftRf8l18Tf8Abr/6SxV5XXqn7UX/ACXXxP8A9uv/AKSw15XWi2JYUUUUMYUlLSd6kBaSlpKBhRxRRQIKKKKACiiigAooooAKKKKQBX2n+xV/ySzVf+w1L/6Igr4sr7T/AGKv+SWar/2Gpf8A0RBQB6r4y/5GPwJ/2GpP/TdeV1VYvifQBry6cy6jfabc6fdfa4LizERdXMUkRBEqOpBWV/4fSs//AIRfV/8Aoe/En/fjTv8A5FpDOqorlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaAOqorlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaAOqorlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaAOqorlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaAOqorlf8AhF9X/wCh78Sf9+NO/wDkWj/hF9X/AOh78Sf9+NO/+RaAPL/2y/8Akmekdv8Aicxf+k89fHKx7m56V97+M/hRF400yHT/ABL4t8SXtnDMLhI9tlHiQKyg5S2B6OwxnHNceP2XvBo6ax4k/wC/9v8A/GaznFt6EtXPjzYFPGcU08ivsb/hl/wd/wBBjxJ/3/t//jNJ/wAMu+Df+gv4k/7/ANv/APGaj2cieVnxxtyfehkIOK+x/wDhl3wb/wBBfxJ/3/t//jNH/DL3g3Of7X8SZ/672/8A8Zp+zkHIz46EBHJ6UNHxx0r7HP7MPg8jB1jxJj/rvb//ABmmH9lzwYf+Yv4l/wC/8H/xml7OXUfKz4zdcGkGO9fZh/Za8Fn/AJi3iT/wIg/+M0n/AAyz4K/6C3iT/wACIP8A4zV8jDlZ8aS4PSo+K+zv+GWPBX/QW8Sf+BEH/wAZo/4ZX8E/9BXxJ/4EQf8Axmmoj5T4w60lfaH/AAyv4J/6C3iT/wACIP8A4zSf8MreCf8AoK+JP/AiD/4zTsOx8XE0yvtQ/sq+CD/zFfEn/gRB/wDGaP8AhlXwR/0FfEn/AIEQf/GadhnxZRX2n/wyr4I/6CviT/wIg/8AjNH/AAyr4I/6CviT/wACIP8A4zQB8WV79+xX/wAlT1T/ALAsv/o+CvVf+GVfBH/QV8Sf+BEH/wAZrr/hf8FfDnw41+41fQ73V57ma1a0ZbyWNkCM6MSAsanOUHf1oA6Xwb/yMfjv/sNR/wDpus66quVuPCNx/a+qX+m+J9b0z+0ZluJ4LZLR4/MWKOLI82B2GViTjdjOaP8AhF9X/wCh78Sf9+NO/wDkWmB1VFcr/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLQB1VFcr/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLQB1VFcr/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLQB1VFcr/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLQB1VFcr/wAIvq//AEPfiT/vxp3/AMi0f8Ivq/8A0PfiT/vxp3/yLQB8WftQ/wDJdfE3/bt/6Sw15ZX3P4o/Z28OeKddutZ17XvEl1qVzt82bzLZN21Qi/KsAA+VQOB2rK/4ZW8Ef9BXxJ/4EQf/ABmrUrCsfFtFfaX/AAyt4I/6CviX/wACIP8A4zR/wyt4I/6CviT/AMCIP/jNHMgsfFlBr7T/AOGVfBH/AEFfEn/gRB/8Zo/4ZV8Ef9BXxJ/4EQf/ABmldAfFdLX2n/wyr4I/6CviT/wIg/8AjNH/AAyr4I/6CviT/wACIP8A4zSuM+K6K+1P+GVfBH/QV8Sf+BEH/wAZpP8AhlXwR/0FfEn/AIEQf/GaLgfFlFfaf/DKvgj/AKCviT/wIg/+M0f8Mq+CP+gr4k/8CIP/AIzRcVj4sor7T/4ZV8Ef9BXxJ/4EQf8Axmj/AIZV8Ef9BXxJ/wCBEH/xmgLHxZRX2n/wyr4I/wCgr4k/8CIP/jNH/DKvgj/oK+JP/AiD/wCM0XCx8WUV9p/8Mq+CP+gr4k/8CIP/AIzR/wAMq+CP+gr4k/8AAiD/AOM0BY+LK+0/2Kv+SWar/wBhqX/0RBR/wyr4I/6CviT/AMCIP/jNen/C/wCH+lfDjQLjSNDuL6e2numu2a8dGcOyIpAKqoxhB29aQz//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Human serum containing anti-DNA antibodies stain the nuclei of HEp-2 cells in a homogeneous pattern (A and C). DAPI staining in panels B and D indicates the location of nuclei. In dividing cells (indicated by white arrow in C and D), staining is associated with the separating chromosomes. The anti-DNA antibody reference serum was obtained from the Centers for Disease Control repository of ANA standards.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42499=[""].join("\n");
var outline_f41_32_42499=null;
var title_f41_32_42500="Heart conduction WPW PI";
var content_f41_32_42500=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53316&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patients with WPW syndrome have an extra electrical pathway between the atria and the ventricles, known as an accessory pathway. The abnormal pathway directly connects the atria and ventricles and bypasses the AV node, which is the slowest conducting part of the heart's electrical system. As a result, the normal sinus impulse can travel down the normal pathway through the AV node, as well as the more rapidly conducting accessory pathway. This allows the impulse traveling through the accessory pathway to reach the ventricle earlier, causing what is termed \"preexcitation.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42500=[""].join("\n");
var outline_f41_32_42500=null;
var title_f41_32_42501="Screening for diabetic retinopathy";
var content_f41_32_42501=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Screening for diabetic retinopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     David K McCulloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42501/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/32/42501/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retinopathy is a major cause of morbidity in patients with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/1\">",
"     1",
"    </a>",
"    ]. The vast majority of patients who develop diabetic retinopathy have no symptoms until the very late stages (by which time it may be too late for effective treatment). Because the rate of progression may be rapid, and therapy can be beneficial for both symptom amelioration and reduction in the rate of disease progression, it is important to screen patients with diabetes regularly for the development of retinal disease.",
"   </p>",
"   <p>",
"    Issues related to screening for diabetic retinopathy will be reviewed here. The pathogenesis, clinical findings, natural history, and treatment of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link\">",
"     \"Classification and clinical features of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE FOR SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for diabetic retinopathy (DR) is important because the majority of patients who develop DR have no symptoms until macular edema (ME)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proliferative diabetic retinopathy (PDR) are already present. In addition, the efficacy of laser photocoagulation in preventing visual loss from PDR and ME is well established in randomized trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Panretinal photocoagulation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link&amp;anchor=H22#H22\">",
"     \"Prevention and treatment of diabetic retinopathy\", section on 'Focal laser photocoagulation'",
"    </a>",
"    .) However, laser therapy is more beneficial in preventing visual loss than reversing diminished visual acuity. Thus, early detection through screening programs and appropriate referral for therapy is important to preserve vision in individuals with diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     METHOD OF SCREENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ophthalmoscopy is a reasonable screening method when performed by well-trained personnel on dilated fundi. The accuracy of ophthalmoscopy is substantially lower when performed by primary care physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/2\">",
"     2",
"    </a>",
"    ]. As an alternative, seven-field stereoscopic fundus photography is another acceptable method, but also requires both a trained photographer and a trained reader. Fundal photography compares favorably with ophthalmoscopy (performed by an experienced ophthalmologist, optometrist, and ophthalmic technician) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/3\">",
"     3",
"    </a>",
"    ]. In one study of 1949 patients participating in the Wisconsin Epidemiology Study of Diabetic Retinopathy, there was almost complete agreement between the three observers in 86 percent of cases.",
"   </p>",
"   <p>",
"    The availability of digital stereoscopic retinal imaging allows remote interpretation by an ophthalmologist, which may improve retinopathy screening in areas with a shortage of eye care specialists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/4\">",
"     4",
"    </a>",
"    ]. The examination takes 15 to 20 minutes and does not require dilation of the eyes. When compared to dilated fundoscopic examination or the gold standard seven-field stereoscopic fundus photography for retinopathy screening, digital imaging (three fields) has good sensitivity and specificity for detecting diabetic retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. As an example, in one study comparing digital imaging with dilated fundoscopic examination, there was concordance in 86 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/5\">",
"     5",
"    </a>",
"    ]. The majority of discordant diagnoses (35 of 46 eyes) were related to a greater frequency of finding mild to moderate NPDR with digital images compared with dilated fundoscopic exam. Although there were few cases of macular edema (six eyes), there was 100 percent concordance between the two modalities. Most fundus photography is currently being changed from film-based methods to digital cameras.",
"   </p>",
"   <p>",
"    For the initial screening examination, we prefer evaluation by an ophthalmologist or optometrist who is experienced with diagnosing and treating diabetic retinopathy. In certain settings (eg, when previous exams have been normal or when there is a shortage of eye care specialists), subsequent examinations can be done with retinal photographs if there is a trained photographer and reader. A comprehensive exam is required for follow-up of abnormalities detected on retinal photographs. These recommendations are consistent with ADA guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SCREENING INITIATION AND FREQUENCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     When should screening begin?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 diabetes is typically a disease with insidious onset and some patients already have retinopathy at the time of diagnosis of hyperglycemia (",
"    <a class=\"graphic graphic_figure graphicRef58736 \" href=\"mobipreview.htm?2/16/2318\">",
"     figure 1",
"    </a>",
"    ). Thus, in patients with type 2 diabetes, we suggest an initial comprehensive examination by an ophthalmologist or optometrist shortly after the diagnosis of diabetes is made (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, it is unusual for patients with type 1 diabetes (under age 30) to develop retinopathy that requires specific ophthalmologic therapy earlier than five years after the onset of diabetes (",
"    <a class=\"graphic graphic_figure graphicRef70042 \" href=\"mobipreview.htm?24/45/25309\">",
"     figure 2",
"    </a>",
"    ). As an example, in 1613 patients with type 1 diabetes of less than five years duration who were screened for enrollment in the Diabetes Control and Complications Trial (DCCT), 874 had evidence of diabetic retinopathy either by fundus photography or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/11\">",
"     11",
"    </a>",
"    ]. However, none had proliferative retinopathy requiring laser treatment and only six (0.4 percent) had preproliferative retinopathy. Thus, in patients with type 1 diabetes, we suggest an initial comprehensive examination by an ophthalmologist or optometrist within five years after diagnosis (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Children and adolescents",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with type 1 diabetes, it is unusual to develop retinopathy prior to age 10 years. Initial screening in children and adolescents is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=see_link&amp;anchor=H26#H26\">",
"     \"Complications and screening in children and adolescents with type 1 diabetes mellitus\", section on 'Retinopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=see_link&amp;anchor=H14#H14\">",
"     \"Comorbidities and complications of type 2 diabetes mellitus in children and adolescents\", section on 'Retinopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Frequency of examinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few data on the frequency of follow-up examinations after the initial screening examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. In the Wisconsin Epidemiology Study of Diabetic Retinopathy (WESDR), patients with type 2 diabetes and no retinopathy on baseline examination (standard stereoscopic color fundus photographs) did not progress to proliferative retinopathy over four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/12\">",
"     12",
"    </a>",
"    ]. However, patients with a longer duration of diabetes, retinopathy on baseline examination, gross proteinuria, or poor glycemic control were at greater risk of developing proliferative retinopathy.",
"   </p>",
"   <p>",
"    Similarly, a cohort study from the United Kingdom found that the incidence of sight-threatening DR (moderate preproliferative retinopathy or worse, or clinically significant macular edema) in patients with type 2 diabetes with no retinopathy on initial screening was 0.3 percent (95% CI 0.1-0.5) in the first year and 1.8 percent (95% CI 1.2-2.5) in the fifth year, suggesting that screening every three or four years may be adequate in those with normal initial examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/13\">",
"     13",
"    </a>",
"    ]. Yearly or more frequent screening was required for those with background or preproliferative retinopathy on initial screening.",
"   </p>",
"   <p>",
"    A cost-utility analysis of screening intervals for retinopathy in patients with type 2 diabetes showed that the cost benefit of various screening intervals depended upon the presence of risk factors for progression of retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/15\">",
"     15",
"    </a>",
"    ]. As expected, annual screening was most beneficial and cost-effective in those in the high-risk group (poorly controlled blood sugar, younger age), whereas for some low-risk groups (good glycemic control, no retinopathy on previous exam, older age), screening every three years provided similar benefit as annual screening and was more cost effective.",
"   </p>",
"   <p>",
"    Based upon these studies, some healthcare organizations and auditing groups (such as the National Committee on Quality Assurance) have suggested that those individuals documented to have no diabetic retinopathy may be screened every two years.",
"   </p>",
"   <p>",
"    However, it is not clear if the results of the above studies are applicable to all patients with diabetes. As an example, it should be noted that the WESDR study subjects were white patients of northern-European extraction, and some studies suggest racial and ethnic variation in diabetic retinopathy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    .) In the Veterans Affairs Diabetes Trial (VADT), the prevalence of moderate to severe diabetic retinopathy was higher for Hispanics (36 percent) and African Americans (29 percent) than for non-Hispanic whites (22 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/16\">",
"     16",
"    </a>",
"    ]. Furthermore, it is not clear that the standards used in the WESDR study for evaluation of the photographs can be adopted nationwide. Finally, there is greater potential to lose patients to follow-up with less frequent screening intervals.",
"   </p>",
"   <p>",
"    For these reasons, we suggest yearly follow-up examinations initially, with more frequent follow-up in patients who have abnormal findings or if retinopathy is progressing (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Less frequent examinations (every two to three years) may be considered with the advice of an eye care professional in the setting of a normal examination. These recommendations are consistent with ADA guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of pregnancy on the natural history of diabetic retinopathy has been addressed in several studies; progression has been observed in 16 to 85 percent of patients, and the rate of progression may be accelerated. This topic is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link&amp;anchor=H12#H12\">",
"     \"Classification and clinical features of diabetic retinopathy\", section on 'Worsening during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because pregnancy may exacerbate underlying DR, women with diabetes who are planning pregnancy should have a comprehensive eye examination and be counseled on the risk of development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of diabetic retinopathy (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with diabetes who become pregnant should have a comprehensive eye examination in the first trimester and close follow-up throughout pregnancy and for one year postpartum. This guideline does not apply to women who develop gestational diabetes, as these women are not at increased risk for diabetic retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SCREENING IMPACT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two studies have addressed the value of screening for diabetic retinopathy in both type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. They concluded that, in patients with type 1 diabetes, annual screening (ophthalmoscopy with dilated pupils) for those without retinopathy and follow-up every six months for those with retinopathy followed by appropriate treatment would result in a saving of 70,000 to 80,000 person-years of sight and 60 to 80 million dollars annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/18\">",
"     18",
"    </a>",
"    ]. Comparable numbers for type 2 diabetes were over 94,000 person-years of sight and over 250 million dollars per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42501/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/34/11810?source=see_link\">",
"       \"Patient information: Diabetic retinopathy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with diabetes, we recommend screening for diabetic retinopathy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Screening must be performed by those with expertise and can be accomplished with dilated fundus examination or retinal photography. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Method of screening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with type 1 diabetes, we suggest initiating screening three to five years after diagnosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In patients with type 2 diabetes, we suggest initiating screening soon after the time of diagnosis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening initiation and frequency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients found to have no abnormalities on the initial screening examination, we suggest annual follow-up examinations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Some experts suggest less frequent examinations (every two to three years) in low risk patients with normal examinations. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Screening initiation and frequency'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Follow-up in patients with retinal abnormalities depends upon the type and severity of the abnormalities. Patients with macular edema, severe nonproliferative retinopathy, or proliferative retinopathy should be closely followed by an ophthalmologist experienced in the management of diabetic retinopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"       \"Prevention and treatment of diabetic retinopathy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with diabetes who are planning pregnancy should be counseled on the risk of development",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progression of diabetic retinopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=see_link&amp;anchor=H12#H12\">",
"       \"Classification and clinical features of diabetic retinopathy\", section on 'Worsening during pregnancy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In pregnant women with preexisting diabetes who would not otherwise be due for screening, we suggest that such screening be performed during the first trimester (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). More frequent retinal evaluations are required during pregnancy and for one year postpartum (",
"      <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"       table 1",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      This guideline does not apply to women who develop gestational diabetes, as these women are not at increased risk for diabetic retinopathy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/1\">",
"      Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/2\">",
"      O'Hare JP, Hopper A, Madhaven C, et al. Adding retinal photography to screening for diabetic retinopathy: a prospective study in primary care. BMJ 1996; 312:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/3\">",
"      Moss SE, Klein R, Kessler SD, Richie KA. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985; 92:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/4\">",
"      Taylor CR, Merin LM, Salunga AM, et al. Improving diabetic retinopathy screening ratios using telemedicine-based digital retinal imaging technology: the Vine Hill study. Diabetes Care 2007; 30:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/5\">",
"      Ahmed J, Ward TP, Bursell SE, et al. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care 2006; 29:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/6\">",
"      Vujosevic S, Benetti E, Massignan F, et al. Screening for diabetic retinopathy: 1 and 3 nonmydriatic 45-degree digital fundus photographs vs 7 standard early treatment diabetic retinopathy study fields. Am J Ophthalmol 2009; 148:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/7\">",
"      Bragge P, Gruen RL, Chau M, et al. Screening for presence or absence of diabetic retinopathy: a meta-analysis. Arch Ophthalmol 2011; 129:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/8\">",
"      American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/9\">",
"      Fong DS, Aiello L, Gardner TW, et al. Retinopathy in diabetes. Diabetes Care 2004; 27 Suppl 1:S84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/10\">",
"      American College of Physicians, American Diabetes Association, American Academy of Ophthalmology. Screening guidelines for diabetic retinopathy. Clinical Guideline. Ophthalmology 1992; 99:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/11\">",
"      Malone JI, Morrison AD, Pavan PR, et al. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years' duration screened for the diabetes control and complications trial. Diabetes Care 2001; 24:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/12\">",
"      Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994; 112:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/13\">",
"      Younis N, Broadbent DM, Vora JP, et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 2003; 361:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/14\">",
"      Thomas RL, Dunstan F, Luzio SD, et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. BMJ 2012; 344:e874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/15\">",
"      Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000; 283:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/16\">",
"      Emanuele N, Sacks J, Klein R, et al. Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial. Diabetes Care 2005; 28:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/17\">",
"      Klein R. Screening interval for retinopathy in type 2 diabetes. Lancet 2003; 361:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/18\">",
"      Javitt JC, Canner JK, Frank RG, et al. Detecting and treating retinopathy in patients with type I diabetes mellitus. A health policy model. Ophthalmology 1990; 97:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42501/abstract/19\">",
"      Javitt JC, Aiello LP, Chiang Y, et al. Preventive eye care in people with diabetes is cost-saving to the federal government. Implications for health-care reform. Diabetes Care 1994; 17:909.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1755 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42501=[""].join("\n");
var outline_f41_32_42501=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE FOR SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      METHOD OF SCREENING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SCREENING INITIATION AND FREQUENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      When should screening begin?",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Frequency of examinations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SCREENING IMPACT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1755\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1755|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/16/2318\" title=\"figure 1\">",
"      Retinopathy onset in NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/45/25309\" title=\"figure 2\">",
"      Retinopathy and duration of DM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1755|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/18/17707\" title=\"table 1\">",
"      ADA opthalmologic exam schedule",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/11/36023?source=related_link\">",
"      Classification and clinical features of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34249?source=related_link\">",
"      Comorbidities and complications of type 2 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/29/40410?source=related_link\">",
"      Complications and screening in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=related_link\">",
"      Pathogenesis of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/34/11810?source=related_link\">",
"      Patient information: Diabetic retinopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_32_42502="Optic disc Frisen grade 2";
var content_f41_32_42502=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59423%7ENEURO%2F72175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59423%7ENEURO%2F72175&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade II showing the halo of disc edema is circumferential.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Optic disc Fris&eacute;n Grade III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fris&eacute;n Grade 3 showing obscuration of a major vessel as it leaves the optic disc (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Wall, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42502=[""].join("\n");
var outline_f41_32_42502=null;
var title_f41_32_42503="Treatment of acute pulmonary embolism";
var content_f41_32_42503=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute pulmonary embolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42503/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42503/contributors\">",
"     Victor F Tapson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42503/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42503/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42503/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42503/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/32/42503/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute pulmonary embolism (PE) is common and often fatal, with a mortality rate of approximately 30 percent without treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Most deaths are due to recurrent PE within the first few hours of the initial event [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Therapy with anticoagulants decreases the mortality rate to 3 to 8 percent, making it imperative that effective therapy be instituted as quickly as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical severity of acute PE can be highly variable, ranging from asymptomatic to severe hypoxemia, right ventricular failure, shock, and death. As a result, therapy varies from patient to patient and requires considerable clinical judgment. Common questions asked by clinicians when a patient presents with PE include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Which anticoagulant should I administer? How much? How long?",
"     </li>",
"     <li>",
"      Should I administer thrombolytic therapy?",
"     </li>",
"     <li>",
"      Should an inferior vena caval filter be placed?",
"     </li>",
"     <li>",
"      Is embolectomy indicated?",
"     </li>",
"     <li>",
"      Can the patient be treated as an outpatient?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of patients with acute PE is reviewed here. More detailed discussions regarding anticoagulation and thrombolysis in acute PE are presented separately. The epidemiology, prognosis, pathophysiology, risk factors, symptoms, signs, and diagnosis of acute PE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link\">",
"     \"Overview of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with suspected acute PE, the initial focus is on stabilizing the patient. This may require respiratory support, hemodynamic support,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    empiric anticoagulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Respiratory support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental oxygen should be administered if hypoxemia exists. Severe hypoxemia or respiratory failure should prompt consideration of intubation and mechanical ventilation. Of note, patients with coexistent RV failure are prone to hypotension following intubation. The initiation of mechanical ventilation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of mechanical ventilation\", section on 'Initiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hemodynamic support",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic support should be instituted when a patient presents with acute PE and hypotension. Hypotension may be roughly defined as a systolic blood pressure &lt;90 mmHg or a drop in systolic blood pressure of &ge;40 mmHg from baseline, but the precise thresholds that warrant hemodynamic support depend to some degree upon the patient&rsquo;s baseline blood pressure and whether there is clinical evidence of hypoperfusion (eg, change in mental status, diminished urine output).",
"   </p>",
"   <p>",
"    Intravenous fluid administration is first-line therapy. It may improve hemodynamic performance, as illustrated by a series of 13 patients with acute PE and a cardiac index &lt;2.5",
"    <span class=\"nowrap\">",
"     L/min/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/10\">",
"     10",
"    </a>",
"    ]. Administration of 500 mL of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    significantly increased the cardiac index from a mean of 1.6 to 2.0",
"    <span class=\"nowrap\">",
"     L/min/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"   </p>",
"   <p>",
"    Intravenous fluid (usually normal saline) should be administered cautiously because increased right ventricular (RV) wall stress can decrease the ratio of RV oxygen supply to demand. This may result in ischemia, deterioration of RV function, and worsening RV failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/11-15\">",
"     11-15",
"    </a>",
"    ]. Clinicians should be wary of administering more than 500 to 1000 mL of normal saline during the initial resuscitation period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/12\">",
"     12",
"    </a>",
"    ]. If the patient's blood pressure and hemodynamic status do not improve with intravenous fluids, then intravenous vasopressor therapy should promptly follow.",
"   </p>",
"   <p>",
"    There are no randomized trials that definitively determine the optimal vasopressor for patients with shock due to acute PE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       Norepinephrine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       dopamine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      may be effective [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/13,14,16\">",
"       13,14,16",
"      </a>",
"      ]. Norepinephrine is the least likely to cause tachycardia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       Dobutamine",
"      </a>",
"      increases myocardial contractility and causes vasodilation (ie, decreases afterload), which is ideal for cardiogenic shock. However, the effects of vasodilation can exceed those of increased myocardial contractility and worsen the hypotension, particularly at low doses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Using a combination of dobutamine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      initially may increase myocardial contractility, while minimizing vasodilation and the risk of hypotension. As the dose of dobutamine is increased, the effects of the increased myocardial contractility may exceed those of the vasodilation, allowing the norepinephrine to be weaned off and the dobutamine to be used alone.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/31/23029?source=see_link\">",
"       Isoproterenol",
"      </a>",
"      , amrinone, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/18/3366?source=see_link\">",
"       milrinone",
"      </a>",
"      have been investigated in animal models, but are not indicated for hypotension due to acute PE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/19,20\">",
"       19,20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physiologic properties and practical issues regarding the use of vasopressors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link\">",
"     \"Use of vasopressors and inotropes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Empiric anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;PE-directed therapy should be considered during the resuscitative period (",
"    <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"mobipreview.htm?2/31/2544\">",
"     algorithm 1",
"    </a>",
"    ). Empiric anticoagulation is indicated when there is no excess risk for bleeding and there is a high clinical suspicion of acute PE, a moderate clinical suspicion for acute PE and the diagnostic evaluation is expected to take longer than four hours, or a low clinical suspicion for acute PE and the diagnostic evaluation is expected to take longer than 24 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/9\">",
"     9",
"    </a>",
"    ]. Stratification of clinical suspicion and the initiation of empiric anticoagulant therapy for suspected acute PE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link&amp;anchor=H2#H2\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Initiation of anticoagulant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once it has been determined that empiric anticoagulant therapy is indicated, it should be initiated as soon as possible because its efficacy may be related to achieving therapeutic levels of anticoagulation within the initial 24 hours. A pooled analysis of three anticoagulation trials demonstrated that the risk of recurrent PE was 25 percent if the activated partial thromboplastin time (aPTT) was not therapeutic within the first 24 hours after initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the approach for patients with no excess risk for bleeding, empiric anticoagulant therapy should be considered on a case-by-case basis if there is a moderate or high risk of bleeding, or if there are conditions in the differential diagnosis that are contraindications to anticoagulation (eg, pericardial tamponade, aortic dissection). If anticoagulant therapy is judged to be contraindicated, the diagnostic evaluation must be expedited so that therapies that do not require anticoagulation (eg, inferior vena caval filter, embolectomy) can be initiated if acute PE is confirmed. Stratification of the risk of bleeding as low, moderate, or high is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link&amp;anchor=H2#H2\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Initiation of anticoagulant therapy'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POST-RESUSCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation should be performed as quickly as possible once the patient has been stabilized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=see_link\">",
"     \"Diagnosis of acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients in whom the diagnostic evaluation EXCLUDES an acute PE, anticoagulant therapy should be discontinued if it was initiated empirically during the resuscitative period. Alternative causes of the patient&rsquo;s symptoms and signs should be sought.",
"   </p>",
"   <p>",
"    For patients in whom the diagnostic evaluation CONFIRMS an acute PE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anticoagulant therapy should be initiated or continued if it was begun empirically. Placement of an inferior vena caval filter is an appropriate alternative to anticoagulant therapy for patients who have failed anticoagulant therapy, developed complications of anticoagulation, or have an unacceptable bleeding risk. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link\">",
"       \"Anticoagulation in acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"       \"Placement of inferior vena cava filters and their complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      It should be determined whether the clinical presentation is severe enough to warrant thrombolysis. Embolectomy is appropriate for patients whose presentation is severe enough to warrant thrombolysis, but in whom thrombolysis is either contraindicated or unsuccessful. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link\">",
"       \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H13\">",
"       'Embolectomy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is depicted in an algorithm for the management of suspected acute PE (",
"    <a class=\"graphic graphic_algorithm graphicRef57249 \" href=\"mobipreview.htm?2/31/2544\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anticoagulant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy is considered primary therapy for acute PE. It is discussed in detail separately, including indications for empiric therapy, assessment of the risk for bleeding, anticoagulant agents, dosing, monitoring, outcomes, and duration of therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic therapy is generally considered for patients with severe clinical manifestations. Thrombolytic therapy for acute PE is reviewed in detail separately, including the indications, contraindications, agents, administration, and outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link\">",
"     \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     IVC filters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inferior vena caval (IVC) filters provide a screen in the inferior vena cava, allowing blood to pass through while large emboli from the pelvis or lower extremities are blocked or fragmented before reaching the lung. Placement of an IVC filter is generally considered in patients who have contraindications to anticoagulation, failed anticoagulation, or developed a complication due to anticoagulation. In addition, IVC filter placement is often considered when the hemodynamic or respiratory compromise is severe enough that another PE may be lethal. IVC filter indications, types, outcomes, and complications are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Embolectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolectomy (ie, removal of the emboli) can be performed using catheters or surgically. It should be considered when a patient's presentation is severe enough to warrant thrombolysis (eg, persistent hypotension due to acute PE), but thrombolytic therapy either fails or is contraindicated. Whether surgical or catheter embolectomy is chosen depends upon the availability of resources and expertise of the institution, since a direct comparison has never been performed and data regarding the effectiveness of each therapy are limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Catheter embolectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rheolytic embolectomy, rotational embolectomy, suction embolectomy, thrombus fragmentation, and ultrasound plus low-dose thrombolytic therapy are techniques that have been utilized to reduce the embolic burden in patients with acute PE. Case series using these techniques are small and none of the techniques has been compared with other forms of therapy in randomized trials. Larger studies are needed to determine which, if any, catheter technique is most effective compared to alternative treatment modalities.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rheolytic embolectomy &ndash; Using a rheolytic embolectomy catheter (ie, the AngioJet embolectomy system), embolectomy is accomplished by injecting pressurized saline through the catheter's distal tip, which macerates the emboli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/22\">",
"       22",
"      </a>",
"      ]. The saline and fragments of clot are then sucked back into an exhaust lumen of the catheter for disposal. The major disadvantage of this system is that a large venous sheath or a venous cut-down is required to insert the large catheter, which increases the risk of bleeding at the insertion site. In a case series of 12 patients with acute PE who underwent rheolytic embolectomy with or without catheter-directed thrombolysis, technical success was achieved in all 12 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/23\">",
"       23",
"      </a>",
"      ]. Ten patients survived (83 percent) and were discharged from the hospital, but two patients died (17 percent) due to cardiac arrest within 24 hours of the procedure.",
"     </li>",
"     <li>",
"      Rotational embolectomy &ndash; Rotational catheter fragmentation of emboli has been performed using conventional cardiac catheters that do not require venotomy at the insertion site [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. Newer catheters also exist that use a rotating device to fragment the thrombus, while continuously aspirating the fragments. A case series of 20 patients treated with rotational embolectomy reported that approximately one-third of the procedures achieved recanalization, but mortality was high (20 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/25\">",
"       25",
"      </a>",
"      ]. In a more recent case series, 18 patients with acute PE complicated by shock underwent catheter-directed rotational embolectomy, most with continuous aspiration of thrombotic fragments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/26\">",
"       26",
"      </a>",
"      ]. Clinical success was achieved in 16 cases (89 percent), defined as improvement in oxygenation and blood pressure without a major complication. One patient died from refractory shock.",
"     </li>",
"     <li>",
"      Suction embolectomy &ndash; Suction embolectomy involves suctioning thrombus through a large-lumen catheter by manually applying negative pressure with an aspiration syringe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. This technique requires an aspiration sheath with a detachable hemostatic valve; it cannot be performed with a conventional vascular access sheath because the fragments of thrombus get trapped within the sheath due to the hemostatic valve.",
"     </li>",
"     <li>",
"      Thrombus fragmentation &ndash; Mechanical disruption of the thrombus (to reduce pulmonary vascular resistance by breaking the thrombus into small fragments) can be achieved by manually rotating a standard pigtail catheter or peripheral balloon angioplasty catheter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ultrasound plus low-dose thrombolytic therapy &ndash; Catheter-directed ultrasound combined with low-dose thrombolytic therapy has been studied and may offer benefit. This was suggested by a case report in which a patient presented with shock due to massive bilateral pulmonary emboli [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/29\">",
"       29",
"      </a>",
"      ]. The patient was given a partial dose of standard systemic thrombolytic therapy and then managed with catheter-directed ultrasound plus a continuous infusion of low-dose thrombolytic therapy. The pulmonary emboli resolved in less than 24 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Surgical embolectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical embolectomy is typically limited to large medical centers because an experienced surgeon and cardiopulmonary bypass are required. Although the usual indication for surgical embolectomy is systemic hypotension due to acute PE in a patient in whom thrombolysis is contraindicated, surgery has also been prompted by echocardiographic evidence of an embolus trapped within a patent foramen ovale, the right atrium, or the right ventricle [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical embolectomy has been compared to repeat thrombolysis in patients who failed initial thrombolysis. In a small observational cohort study, patients who underwent surgical embolectomy had fewer recurrent PE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, there were fewer deaths and fewer major bleeding complications among the surgical embolectomy group, although these differences did not achieve statistical significance. Surgical embolectomy has not been compared to catheter embolectomy or primary thrombolytic therapy.",
"   </p>",
"   <p>",
"    Transesophageal echocardiography (TEE) should be performed before or during pulmonary embolectomy to look for extrapulmonary thrombi (ie, thrombi in the right atrium, right ventricle, or vena cava). In a series of 50 patients with PE, intraoperative TEE detected extrapulmonary thrombi in 13 patients (26 percent), which altered the surgical management of five patients (10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiac arrest predicts mortality during surgical embolectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. In one study of 36 patients with profound hypotension due to acute PE (but without cardiac arrest) who underwent surgical embolectomy, 35 patients survived (97 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, operative mortality among patients with acute PE who were resuscitated from a cardiac arrest, then underwent surgical embolectomy was approximately 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Mortality after cardiac arrest due to acute PE is high in the nonsurgical setting as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10692090\">",
"    <span class=\"h1\">",
"     INPATIENT OR OUTPATIENT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all patients who have symptomatic acute PE need to be admitted to the hospital for initial therapy. Patients who do not require supplemental oxygen and have a normal pulse, normal blood pressure, and no recent history of bleeding, may reasonably be considered for outpatient management if they do not have serious comorbid conditions (eg, ischemic heart disease, liver or renal failure, thrombocytopenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/9,38\">",
"     9,38",
"    </a>",
"    ]. Additional considerations include the amount of support from family and friends, access to a telephone, and the ability to return to the hospital quickly if there is clinical deterioration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is supported by several observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] and a randomized trial that showed no significant differences in outcomes when patients treated as outpatients were compared with patients treated as inpatients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/42\">",
"     42",
"    </a>",
"    ]. In the trial, 344 patients with symptomatic acute PE and a low risk of death were randomly assigned to receive either inpatient or outpatient therapy with low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    followed by oral anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/42\">",
"     42",
"    </a>",
"    ]. Within 90 days, recurrent venous thromboembolism occurred in one outpatient (0.6 percent) and no inpatients, death occurred in one outpatient and one inpatient, and major bleeding occurred in three outpatients (1.8 percent) and no inpatients. The mean length of stay was 0.5 days for outpatients and 3.9 days for inpatients. The trial defined a low risk of death as falling within pulmonary embolism severity index (PESI) class I or II. The PESI is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of acute pulmonary embolism\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In stable patients being considered for outpatient therapy or early discharge, it is logical that an important risk factor for poor outcome would be residual clot burden in the legs. In fact, in patients with a first episode of acute symptomatic",
"    <sup>",
"    </sup>",
"    PE, the presence of concomitant deep vein thrombosis (DVT) has been shown to be an independent predictor",
"    <sup>",
"    </sup>",
"    of death in the ensuing three months after diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42503/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, when outpatient therapy of acute PE is considered, the clinician may wish to evaluate the legs prior to discharge (ie, assessment",
"    <sup>",
"    </sup>",
"    of the thrombotic burden may assist with risk stratification",
"    <sup>",
"    </sup>",
"    of these patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/32/24067?source=see_link\">",
"       \"Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2517?source=see_link\">",
"       \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient presents with suspected acute pulmonary embolism (PE), initial care should focus on stabilizing the patient. Patients with significant hypoxemia or hemodynamic compromise should be admitted to the intensive care unit. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supplemental oxygen should be administered if hypoxemia exists. Severe hypoxemia or respiratory failure should prompt intubation and mechanical ventilation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Respiratory support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the patient presents with systemic hypotension, prompt hemodynamic support should be instituted. Intravenous fluid administration may be beneficial; however, clinicians should be wary of administering more than 500 to 1000 mL during the initial resuscitation period. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemodynamic support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose hypotension does not resolve with intravenous fluids, we recommend prompt vasopressor therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). We suggest using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/28/16838?source=see_link\">",
"       norepinephrine",
"      </a>",
"      as the initial agent (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/20/42310?source=see_link\">",
"       Dopamine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , or a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      plus norepinephrine may also be effective. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Hemodynamic support'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision about whether or not to initiate empiric anticoagulant therapy during resuscitation and the diagnostic evaluation depends upon both the degree of clinical suspicion for acute PE and the risk for bleeding. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Empiric anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the diagnostic evaluation EXCLUDES acute PE, anticoagulant therapy is discontinued if it was initiated empirically during the resuscitative period and alternative causes of the patient&rsquo;s symptoms and signs are sought. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Post-resuscitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When the diagnostic evaluation CONFIRMS acute PE, anticoagulant therapy is initiated (or continued if it was begun empirically) and it is determined whether the clinical presentation is severe enough to warrant thrombolysis. Anticoagulant and thrombolytic therapy for acute PE are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link\">",
"       \"Anticoagulation in acute pulmonary embolism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=see_link\">",
"       \"Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An inferior vena cava filter is an appropriate alternative for patients with confirmed acute PE who have a high risk for bleeding, complications of anticoagulation, recurrent PE despite therapeutic anticoagulation, or hemodynamic or respiratory compromise that is severe enough that another PE may be lethal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"       \"Placement of inferior vena cava filters and their complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with acute PE in whom thrombolysis is indicated, but who fail thrombolysis or have contraindications to thrombolysis, we suggest catheter or surgical embolectomy if the necessary resources and expertise are available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The decision of whether to pursue one of these approaches should be based upon local expertise. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Embolectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Outpatient management is reasonable for selected patients with acute PE who do not require supplemental oxygen and have a normal pulse, normal blood pressure, and no recent history of bleeding, assuming that they do not have serious comorbid conditions (eg, ischemic heart disease, liver or renal failure, thrombocytopenia). Additional considerations include the amount of support from family and friends, access to a telephone, and the ability to return to the hospital quickly if there is clinical deterioration. (See",
"      <a class=\"local\" href=\"#H10692090\">",
"       'Inpatient or outpatient therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/1\">",
"      Horlander KT, Mannino DM, Leeper KV. Pulmonary embolism mortality in the United States, 1979-1998: an analysis using multiple-cause mortality data. Arch Intern Med 2003; 163:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/2\">",
"      Dismuke SE, Wagner EH. Pulmonary embolism as a cause of death. The changing mortality in hospitalized patients. JAMA 1986; 255:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/3\">",
"      Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975; 17:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/4\">",
"      Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/5\">",
"      Carson JL, Kelley MA, Duff A, et al. The clinical course of pulmonary embolism. N Engl J Med 1992; 326:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/6\">",
"      DONALDSON GA, WILLIAMS C, SCANNELL JG, SHAW RS. A reappraisal of the application of the Trendelenburg operation to massive fatal embolism. Report of a successful pulmonary-artery thrombectomy using a cardiopulmonary bypass. N Engl J Med 1963; 268:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/7\">",
"      Tapson VF. Acute pulmonary embolism. N Engl J Med 2008; 358:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/8\">",
"      Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/9\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/10\">",
"      Mercat A, Diehl JL, Meyer G, et al. Hemodynamic effects of fluid loading in acute massive pulmonary embolism. Crit Care Med 1999; 27:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/11\">",
"      Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/12\">",
"      Kucher N, Goldhaber SZ. Management of massive pulmonary embolism. Circulation 2005; 112:e28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/13\">",
"      Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology 1984; 60:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/14\">",
"      Mathru M, Venus B, Smith RA, et al. Treatment of low cardiac output complicating acute pulmonary hypertension in normovolemic goats. Crit Care Med 1986; 14:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/15\">",
"      Molloy WD, Lee KY, Girling L, et al. Treatment of shock in a canine model of pulmonary embolism. Am Rev Respir Dis 1984; 130:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/16\">",
"      Boulain T, Lanotte R, Legras A, Perrotin D. Efficacy of epinephrine therapy in shock complicating pulmonary embolism. Chest 1993; 104:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/17\">",
"      Jardin F, Genevray B, Brun-Ney D, Margairaz A. Dobutamine: a hemodynamic evaluation in pulmonary embolism shock. Crit Care Med 1985; 13:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/18\">",
"      Vasu MA, O'Keefe DD, Kapellakis GZ, et al. Myocardial oxygen consumption: effects of epinephrine, isoproterenol, dopamine, norepinephrine, and dobutamine. Am J Physiol 1978; 235:H237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/19\">",
"      Tanaka H, Tajimi K, Matsumoto A, Kobayashi K. Vasodilatory effects of milrinone on pulmonary vasculature in dogs with pulmonary hypertension due to pulmonary embolism: a comparison with those of dopamine and dobutamine. Clin Exp Pharmacol Physiol 1990; 17:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/20\">",
"      Wolfe MW, Saad RM, Spence TH. Hemodynamic effects of amrinone in a canine model of massive pulmonary embolism. Chest 1992; 102:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/21\">",
"      Hull RD, Raskob GE, Brant RF, et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997; 157:2562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/22\">",
"      Koning R, Cribier A, Gerber L, et al. A new treatment for severe pulmonary embolism: percutaneous rheolytic thrombectomy. Circulation 1997; 96:2498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/23\">",
"      Kuo WT, van den Bosch MA, Hofmann LV, et al. Catheter-directed embolectomy, fragmentation, and thrombolysis for the treatment of massive pulmonary embolism after failure of systemic thrombolysis. Chest 2008; 134:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/24\">",
"      Brady AJ, Crake T, Oakley CM. Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolus. Lancet 1991; 338:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/25\">",
"      Schmitz-Rode T, Janssens U, Duda SH, et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol 2000; 36:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/26\">",
"      Eid-Lidt G, Gaspar J, Sandoval J, et al. Combined clot fragmentation and aspiration in patients with acute pulmonary embolism. Chest 2008; 134:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/27\">",
"      Engelberger RP, Kucher N. Catheter-based reperfusion treatment of pulmonary embolism. Circulation 2011; 124:2139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/28\">",
"      Cuculi F, Kobza R, Bergner M, Erne P. Usefulness of aspiration of pulmonary emboli and prolonged local thrombolysis to treat pulmonary embolism. Am J Cardiol 2012; 110:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/29\">",
"      Stambo GW, Montague B. Bilateral EKOS EndoWave catheter thrombolysis of acute bilateral pulmonary embolism in a hemodynamically unstable patient. South Med J 2010; 103:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/30\">",
"      Bloomfield P, Boon NA, de Bono DP. Indications for pulmonary embolectomy. Lancet 1988; 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/31\">",
"      Meneveau N, S&eacute;ronde MF, Blonde MC, et al. Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 2006; 129:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/32\">",
"      Rosenberger P, Shernan SK, Mihaljevic T, Eltzschig HK. Transesophageal echocardiography for detecting extrapulmonary thrombi during pulmonary embolectomy. Ann Thorac Surg 2004; 78:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/33\">",
"      Yalamanchili K, Fleisher AG, Lehrman SG, et al. Open pulmonary embolectomy for treatment of major pulmonary embolism. Ann Thorac Surg 2004; 77:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/34\">",
"      Aklog L, Williams CS, Byrne JG, Goldhaber SZ. Acute pulmonary embolectomy: a contemporary approach. Circulation 2002; 105:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/35\">",
"      Clarke DB, Abrams LD. Pulmonary embolectomy: a 25 year experience. J Thorac Cardiovasc Surg 1986; 92:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/36\">",
"      Dauphine C, Omari B. Pulmonary embolectomy for acute massive pulmonary embolism. Ann Thorac Surg 2005; 79:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/37\">",
"      Clarke DB. Pulmonary embolectomy re-evaluated. Ann R Coll Surg Engl 1981; 63:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/38\">",
"      Baglin T. Fifty per cent of patients with pulmonary embolism can be treated as outpatients. J Thromb Haemost 2010; 8:2404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/39\">",
"      Kovacs MJ, Hawel JD, Rekman JF, Lazo-Langner A. Ambulatory management of pulmonary embolism: a pragmatic evaluation. J Thromb Haemost 2010; 8:2406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/40\">",
"      Erkens PM, Gandara E, Wells P, et al. Safety of outpatient treatment in acute pulmonary embolism. J Thromb Haemost 2010; 8:2412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/41\">",
"      Zondag W, Mos IC, Creemers-Schild D, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/42\">",
"      Aujesky D, Roy PM, Verschuren F, et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet 2011; 378:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42503/abstract/43\">",
"      Jim&eacute;nez D, Aujesky D, D&iacute;az G, et al. Prognostic significance of deep vein thrombosis in patients presenting with acute symptomatic pulmonary embolism. Am J Respir Crit Care Med 2010; 181:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8265 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-113.53.254.124-B894B13FA1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42503=[""].join("\n");
var outline_f41_32_42503=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Respiratory support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hemodynamic support",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Empiric anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POST-RESUSCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anticoagulant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IVC filters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Embolectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Catheter embolectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Surgical embolectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10692090\">",
"      INPATIENT OR OUTPATIENT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8265\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8265|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?2/31/2544\" title=\"algorithm 1\">",
"      PE treatment algorithm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/57/6042?source=related_link\">",
"      Diagnosis of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/1/28697?source=related_link\">",
"      Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/1/13336?source=related_link\">",
"      Overview of mechanical ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/32/24067?source=related_link\">",
"      Patient information: Pulmonary embolism (blood clot in the lungs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_32_42504="Calcium carbonate: Drug information";
var content_f41_32_42504=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium carbonate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/17/13589?source=see_link\">",
"    see \"Calcium carbonate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/38/18024?source=see_link\">",
"    see \"Calcium carbonate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F144392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alcalak [OTC];",
"     </li>",
"     <li>",
"      Alka-Mints&reg; [OTC];",
"     </li>",
"     <li>",
"      Cal-Gest&reg; [OTC];",
"     </li>",
"     <li>",
"      Cal-Mint [OTC];",
"     </li>",
"     <li>",
"      Calci-Chew&reg; [OTC];",
"     </li>",
"     <li>",
"      Calci-Mix&reg; [OTC];",
"     </li>",
"     <li>",
"      Caltrate&reg; 600 [OTC];",
"     </li>",
"     <li>",
"      Children's Pepto [OTC];",
"     </li>",
"     <li>",
"      Chooz&reg; [OTC];",
"     </li>",
"     <li>",
"      Florical&reg; [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Children's [OTC];",
"     </li>",
"     <li>",
"      Maalox&reg; Regular Strength [OTC];",
"     </li>",
"     <li>",
"      Nephro-Calci&reg; [OTC];",
"     </li>",
"     <li>",
"      Nutralox&reg; [OTC];",
"     </li>",
"     <li>",
"      Oysco 500 [OTC];",
"     </li>",
"     <li>",
"      Oystercal&trade; 500 [OTC];",
"     </li>",
"     <li>",
"      Rolaids&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Super Calcium 600 [OTC];",
"     </li>",
"     <li>",
"      Titralac&trade; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; E-X [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Extra Strength Sugar Free [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Quickpak [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Smoothies&trade; [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; Ultra [OTC];",
"     </li>",
"     <li>",
"      Tums&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F144393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cal&reg;;",
"     </li>",
"     <li>",
"      Calcite-500;",
"     </li>",
"     <li>",
"      Caltrate&reg;;",
"     </li>",
"     <li>",
"      Caltrate&reg; Select;",
"     </li>",
"     <li>",
"      Os-Cal&reg;;",
"     </li>",
"     <li>",
"      Tums Extra Strength;",
"     </li>",
"     <li>",
"      Tums Smoothies;",
"     </li>",
"     <li>",
"      Tums&reg; Chews Extra Strength;",
"     </li>",
"     <li>",
"      Tums&reg; Regular Strength;",
"     </li>",
"     <li>",
"      Tums&reg; Ultra Strength",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F144430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antacid;",
"     </li>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Calcium Salt;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F144397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is in terms of",
"     <b>",
"      elemental",
"     </b>",
"     calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults, Females/Males: RDA:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     19-50 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;51 years, females: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-70 years, males: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Female: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia (dose depends on clinical condition and serum calcium level): Oral:",
"     </b>",
"     Dose expressed in mg of",
"     <b>",
"      elemental calcium",
"     </b>",
"     : 1-2 g or more/day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary supplementation:",
"     </b>",
"     Oral: 500 mg to 2 g divided 2-4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antacid:",
"     </b>",
"     Oral: Dosage based on acid-neutralizing capacity of specific product; generally, 1-2 tablets or 5-10 mL every 2 hours; maximum: 7000 mg calcium carbonate per 24 hours; specific product labeling should be consulted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis:",
"     </b>",
"     Oral: Adults &gt;51 years: 1200 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F144415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/38/18024?source=see_link\">",
"      see \"Calcium carbonate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosage is in terms of",
"     <b>",
"      elemental",
"     </b>",
"     calcium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: Adequate intake: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: Adequate intake: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: RDA: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: RDA: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: RDA: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Pregnancy/Lactating: RDA: Requirements are the same as in nonpregnant or nonlactating females",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypocalcemia (dose depends on clinical condition and serum calcium level):",
"     </b>",
"     Oral: Dose expressed in mg of",
"     <b>",
"      elemental calcium",
"     </b>",
"     Children: 45-65 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Antacid:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-5 years (24-47 lb): Elemental calcium 161 mg as needed; maximum: 483 mg per 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-11 years (48-95 lb): Elemental calcium 322 mg as needed; maximum: 966 mg per 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F144398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake for Calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males &le;70 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males &gt;70 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      All other indications:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F144399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute: Dosage adjustments may be necessary depending on the serum calcium levels.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calci-Mix&reg;: 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Florical&reg;: 364 mg [equivalent to elemental calcium 145 mg; contains fluoride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gum, chewing, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chooz&reg;: 500 mg (12s) [sugar free; contains phenylalanine 1.4 mg/tablet; mint flavor; equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:  (480 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Quickpak: 1000 mg/packet (24s) [contains sodium &lt;5 mg/packet; berry fusion flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 1250 mg/5 mL (5 mL, 473 mL, 500 mL) [equivalent to elemental calcium 500 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 648 mg [equivalent to elemental calcium 260 mg], 650 mg [equivalent to elemental calcium 260 mg], 1250 mg [equivalent to elemental calcium 500 mg], 1500 mg [equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Caltrate&reg; 600: 1500 mg [scored; equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Florical&reg;: 364 mg [equivalent to elemental calcium 145 mg; contains fluoride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nephro-Calci&reg;: 1500 mg [equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oysco 500: 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oystercal&trade; 500: 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Super Calcium 600: 1500 mg [gluten free, sugar free; equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Super Calcium 600: 1500 mg [sugar free; equivalent to elemental calcium 600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral: 420 mg [equivalent to elemental calcium 168 mg], 500 mg [equivalent to elemental calcium 200 mg], 600 mg [DSC] [equivalent to elemental calcium 222 mg], 650 mg [equivalent to elemental calcium 260 mg], 750 mg [equivalent to elemental calcium 300 mg], 1250 mg [equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alcalak: 420 mg [aluminum free; mint flavor; equivalent to elemental calcium 168 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alka-Mints&reg;: 850 mg [spearmint flavor; equivalent to elemental calcium 340 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Gest&reg;: 500 mg [equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cal-Mint: 650 mg [aluminum free, dye free, gluten free, sugar free; mint flavor; equivalent to elemental calcium 260 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calci-Chew&reg;: 1250 mg [cherry flavor; equivalent to elemental calcium 500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children's Pepto: 400 mg [bubblegum flavor; equivalent to elemental calcium 161 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children's Pepto: 400 mg [watermelon flavor; equivalent to elemental calcium 161 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Children's: 400 mg [contains phenylalanine 0.3 mg/tablet; wildberry flavor; equivalent to elemental calcium 160 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maalox&reg; Regular Strength: 600 mg [contains phenylalanine 0.5 mg/tablet; wildberry flavor; equivalent to elemental calcium 240 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nutralox&reg;: 420 mg [sugar free; mint flavor; equivalent to elemental calcium 168 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Titralac&trade;: 420 mg [sugar free; contains sodium 1.1 mg/tablet; spearmint flavor; equivalent to elemental calcium 168 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg;: 500 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg;: 500 mg [contains tartrazine; peppermint flavor; equivalent to elemental calcium 200 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [tropical fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [wintergreen flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; assorted berries flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; cool relief mint flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; fresh blend flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; E-X: 750 mg [contains tartrazine; tropical fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Extra Strength Sugar Free: 750 mg [sugar free; contains phenylalanine &lt;1 mg/tablet; orange cream flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Smoothies&trade;: 750 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Smoothies&trade;: 750 mg [contains tartrazine; peppermint flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Smoothies&trade;: 750 mg [contains tartrazine; tropical assorted fruits flavor; equivalent to elemental calcium 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; assorted berries flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; assorted fruit flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; peppermint flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; spearmint flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tums&reg; Ultra: 1000 mg [contains tartrazine; tropical assorted fruits flavor; equivalent to elemental calcium 400 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, softchew, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rolaids&reg; Extra Strength: 1177 mg [contains coconut oil, soya lecithin; vanilla cr&egrave;me flavor; equivalent to elemental calcium 471 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rolaids&reg; Extra Strength: 1177 mg [contains coconut oil, soya lecithin; wild cherry flavor; equivalent to elemental calcium 471 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F144378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As an antacid; treatment and prevention of calcium deficiency or hyperphosphatemia (eg, osteoporosis, osteomalacia, mild/moderate renal insufficiency, hypoparathyroidism, postmenopausal osteoporosis, rickets); has been used to bind phosphate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calcium carbonate may be confused with calcitriol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Florical&reg; may be confused with Fiorinal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Mylanta&reg; may be confused with Mynatal&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nephro-Calci&reg; may be confused with Nephrocaps&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remegel [Hungary, Great Britain, and Ireland] may be confused with Renagel brand name for sevelamer [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Remegel: Brand name for calcium carbonate [Hungary, Great Britain, and Ireland], but also the brand name for aluminum hydroxide and magnesium carbonate [Netherlands]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F144428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Well tolerated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypophosphatemia, hypercalcemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation, laxative effect, acid rebound, nausea, vomiting, anorexia, abdominal pain, xerostomia, flatulence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Milk-alkali syndrome with very high, chronic dosing and/or renal failure (headache, nausea, irritability, and weakness or alkalosis, hypercalcemia, renal impairment)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F144381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypercalcemia, renal calculi, hypophosphatemia; patients with suspected digoxin toxicity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F144366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: Constipation, bloating, and gas are common with calcium supplements (especially carbonate salt).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Achlorhydria: Calcium absorption is impaired in achlorhydria; administration is followed by increased gastric acid secretion within 2 hours of administration especially with high doses. Common in the elderly, use an alternate salt (eg, citrate) and administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoparathyroid disease: Hypercalcemia and hypercalciuria are most likely to occur in hypoparathyroid patients receiving high doses of vitamin D.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kidney stones (calcium-containing): Use caution when administering calcium supplements to patients with a history of kidney stones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Minerals/other oral drugs: Calcium administration interferes with absorption of some minerals and drugs; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vitamin D: It is recommended to concomitantly administer vitamin D for optimal calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Taking calcium (&le;500 mg) with food improves absorption.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Antacids may decrease the serum concentration of ACE Inhibitors.  Management: Separate fosinopril administration from antacids by at least 2 hours. US and Canadian recommendations for use of other ACE- inhibitors with antacids may vary. Consult appropriate labeling. Monitor for decreased therapeutic effects of ACE-inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Enalaprilat; Ramipril.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Antacids may decrease the absorption of Allopurinol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Antacids may decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antacids may decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): Antacids may decrease the serum concentration of Anticonvulsants (Hydantoin).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antacids may decrease the absorption of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Antacids may decrease the absorption of Atazanavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisacodyl: Antacids may diminish the therapeutic effect of Bisacodyl. Antacids may cause the delayed-release bisacodyl tablets to release drug prior to reaching the large intestine.  Gastric irritation and/or cramps may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Antacids may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Antacids may decrease the serum concentration of Bosutinib.  Management: Administer antacids more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the cation exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of CPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Antacids may decrease the serum concentration of Cefditoren.  Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefpodoxime: Antacids may decrease the serum concentration of Cefpodoxime.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefuroxime: Antacids may decrease the serum concentration of Cefuroxime.  Management:  Consider administering antacids and cefuroxime at least 2 hours apart.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chloroquine: Antacids may decrease the serum concentration of Chloroquine.  Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Oral): Antacids may decrease the bioavailability of Corticosteroids (Oral).  Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Antacids may decrease the serum concentration of Dabigatran Etexilate.  Management: Dabigatran etexilate Canadian product labeling recommends avoiding concomitant use with antacids for 24 hours after surgery. In other situations, administer dabigatran etexilate 2 hours prior to antacids. Monitor clinical response to dabigatran therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Antacids may decrease the absorption of Dasatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Antacids may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Antacids may decrease the serum concentration of Delavirdine.  Management: Separate doses of delavirdine and antacids by at least 1 hour. Monitor for decreased delavirdine therapeutic effects with this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Antacids may increase the absorption of Dexmethylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Antacids may decrease the serum concentration of Elvitegravir.  Management: Separate administration of antacids and the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product by at least 2 hours in order to minimize the risk for an interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antacids may decrease the serum concentration of Erlotinib.  Management: Separate the administration of erlotinib and any antacid by several hours in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gabapentin: Antacids may decrease the serum concentration of Gabapentin.  Management: Administer gabapentin at least 2 hours after antacid administration.  Monitor patients closely for evidence of reduced response to gabapentin therapy when both of these drugs are being used.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Antacids may decrease the serum concentration of HMG-CoA Reductase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Antacids may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Antacids may decrease the absorption of Isoniazid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Antacids may decrease the serum concentration of Itraconazole.  Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Antacids may decrease the serum concentration of Ketoconazole (Systemic).  Management: Administer oral ketoconazole at least 2 hours prior to use of any antacid product.  Monitor patients closely for signs of inadequate clinical response to ketoconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Antacids may diminish the therapeutic effect of Mesalamine. Antacid-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Avoid concurrent administration of antacids with sustained-release mesalamine products.  Separating antacid and mesalamine administration, and/or using lower antacid doses may be adequate means of avoiding this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: Antacids may diminish the therapeutic effect of Methenamine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antacids may increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Antacids may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, antacids may decrease the absorption of orally administered iron.  Management: Separate dosing of oral iron-containing multivitamin preparations and antacids by as much time as possible in order to minimize impact on therapeutic efficacy of the iron preparation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Antacids may decrease the absorption of Mycophenolate.  Management: Separate doses of mycophenolate and antacids by at least 2 hours. Monitor for reduced effects of mycophenolate if taken concomitant with antacids.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Antacids may decrease the serum concentration of Nilotinib.  Management: Separate the administration of nilotinib and any antacid by several hours whenever possible in order to minimize the risk of a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Antacids may decrease the serum concentration of PenicillAMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Antacids may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Antacids may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Antacids may decrease the absorption of Protease Inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Darunavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antacids may decrease the excretion of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Antacids may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of quinolones.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Antacids may decrease the serum concentration of Rilpivirine.  Management: Administer antacids at least 2 hours before or 4 hours after rilpivirine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Antacids may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. The combined use of these two agents may result in metabolic alkalosis and/or loss of efficacy of the exchange resin.  Management: To minimize this interaction, consider: a)separating doses by 2 or more hours; b)rectal administration of the exchange resin; or c)alternatives to antacids. Monitor for metabolic alkalosis and attenuation of SPS effects. Avoid magnesium hydroxide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Antacids may decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Antacids may decrease the absorption of Trientine.  Management: Separate trientine dosing from other oral drugs (eg, antacids) by at least 1 hour. Monitor for decreased therapeutic effects of trientine if an antacid is initiated/dose increased, or increased effects if an antacid is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Antacids may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F144389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase risk of osteoporosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food may increase calcium absorption. Calcium may decrease iron absorption. Bran, foods high in oxalates, or whole grain cereals may decrease calcium absorption.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F144384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM, 2011). Calcium-based antacids are considered low risk during pregnancy; excessive use should be avoided (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13333809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Calcium is excreted in breast milk. The amount of calcium in breast milk is homeostatically regulated and not altered by maternal calcium intake. Calcium requirements are the same in lactating and nonlactating females (IOM 2011). Calcium-based antacids are probably compatible with breast-feeding (Mahadevan, 2006).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F144385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a dietary supplement, should be given with meals to increase absorption. May decrease iron absorption, so should be administered 1-2 hours before or after iron supplementation. Limit intake of bran, foods high in oxalates, or whole grain cereals which may decrease calcium absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Calci-Mix Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg (100): $13.71",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Florical Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     145.6-8.3 mg (100): $10.91",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Calci-Chew Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg (100): $11.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Calcium Carbonate Antacid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (100): $1.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Childrens Mylanta Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (24): $3.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Childrens Soothe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (24): $5.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Maalox Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (32): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Maalox Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (150): $4.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Os-Cal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg (60): $6.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Rolaids Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1177 mg (6): $0.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Titralac Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     420 mg (100): $4.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums Calcium for Life Bone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (90): $5.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums E-X 750 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (96): $4.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums Freshers Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (25): $2.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums Kids Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (36): $3.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (12): $0.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums Smoothies Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     750 mg (12): $1.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Tums Ultra 1000 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1000 mg (160): $7.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Calcium Carbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg/5 mL (473 mL): $11.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cal-Carb Forte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg (100): $7.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calcium Carbonate Antacid Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     648 mg (1000): $15.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calcium Carbonate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $3.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1250 mg (100): $9.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 mg (60): $1.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calcium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (60): $4.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Caltrate 600 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1500 mg (150): $12.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Florical Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     145.6-8.3 mg (100): $10.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (High Potency Calcium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (60): $4.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Oystercal Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (60): $3.50",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F144377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum calcium: 8.5-10.5 mg/dL. Monitor plasma calcium levels if using calcium salts as electrolyte supplements for deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     In low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corrected total calcium = total serum calcium + 0.8 (4.0 - measured serum albumin)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F144386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Additiva Calcium (PL);",
"     </li>",
"     <li>",
"      Andrews TUMS Antacid (AU);",
"     </li>",
"     <li>",
"      Apo-Cal (HK, MY);",
"     </li>",
"     <li>",
"      Bica (AR);",
"     </li>",
"     <li>",
"      Biolectra (AT);",
"     </li>",
"     <li>",
"      Bo-Ne-Ca (TH);",
"     </li>",
"     <li>",
"      Bonacal (SG);",
"     </li>",
"     <li>",
"      Cal-Sup (AU);",
"     </li>",
"     <li>",
"      Calbone (PH);",
"     </li>",
"     <li>",
"      Calcanate (TH);",
"     </li>",
"     <li>",
"      Calcefor (CN, PE);",
"     </li>",
"     <li>",
"      Calci Aid (PH);",
"     </li>",
"     <li>",
"      Calcichew (FI, GB, IE, LU);",
"     </li>",
"     <li>",
"      Calcifar (PL);",
"     </li>",
"     <li>",
"      Calcigamma (DE);",
"     </li>",
"     <li>",
"      Calcigran Sine (EE);",
"     </li>",
"     <li>",
"      Calcilos (DE);",
"     </li>",
"     <li>",
"      Calcimate (PH);",
"     </li>",
"     <li>",
"      Calcimax (PY);",
"     </li>",
"     <li>",
"      Calcioral (PT);",
"     </li>",
"     <li>",
"      Calcit (BE, FR, IT, NL);",
"     </li>",
"     <li>",
"      Calcium (BG, PL);",
"     </li>",
"     <li>",
"      Calcium 20 Madariaga (ES);",
"     </li>",
"     <li>",
"      Calcium Carbonate (FR);",
"     </li>",
"     <li>",
"      Calcium Dago (DE);",
"     </li>",
"     <li>",
"      Calcium effervescens (PL);",
"     </li>",
"     <li>",
"      Calcium Genericon (AT);",
"     </li>",
"     <li>",
"      Calcium Klopfer (AT);",
"     </li>",
"     <li>",
"      Calcium-Carbonat Salmon Pharma (CH);",
"     </li>",
"     <li>",
"      Calcium-Phosphatbinder Bichsel (CH);",
"     </li>",
"     <li>",
"      Calcium-Sandoz Forte (BG);",
"     </li>",
"     <li>",
"      Calciumcarbonat Fresenius (CH);",
"     </li>",
"     <li>",
"      Calciumcarbonat-Dial (AT);",
"     </li>",
"     <li>",
"      Calcuren (FI);",
"     </li>",
"     <li>",
"      Calnat (ID);",
"     </li>",
"     <li>",
"      Calos (ID);",
"     </li>",
"     <li>",
"      Calperos (CH, PL);",
"     </li>",
"     <li>",
"      Calsan (CH, MX, PH);",
"     </li>",
"     <li>",
"      Calsuba (ZA);",
"     </li>",
"     <li>",
"      Calsum (TH);",
"     </li>",
"     <li>",
"      Calsum Forte (TH);",
"     </li>",
"     <li>",
"      Caltab (TH);",
"     </li>",
"     <li>",
"      Caltess (PL);",
"     </li>",
"     <li>",
"      Caltrate (AE, AU, BB, BH, BM, BS, BZ, CO, CY, EG, GY, IL, IQ, IR, JM, JO, KW, LB, LY, MX, MY, OM, PL, PR, QA, SA, SR, SY, TT, YE);",
"     </li>",
"     <li>",
"      Caltrate 600 (CO, CR, DO, EC, GT, HN, NI, PA, PE, SV, VE);",
"     </li>",
"     <li>",
"      Caltr&oacute;n (MX);",
"     </li>",
"     <li>",
"      Cantacid (KP);",
"     </li>",
"     <li>",
"      Caosina (ES);",
"     </li>",
"     <li>",
"      Capool (TW);",
"     </li>",
"     <li>",
"      Carbocal (ES);",
"     </li>",
"     <li>",
"      CC-Nefro 500 (DE);",
"     </li>",
"     <li>",
"      Chooz Antacid Gum 500 (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Cimascal (ES);",
"     </li>",
"     <li>",
"      Cipcal (IN);",
"     </li>",
"     <li>",
"      Densical (ES);",
"     </li>",
"     <li>",
"      Dreisacarb (AT);",
"     </li>",
"     <li>",
"      Edee (KP);",
"     </li>",
"     <li>",
"      Fixateur phospho-calcique Bichsel (CH);",
"     </li>",
"     <li>",
"      Fixical (FR);",
"     </li>",
"     <li>",
"      Fortical (ES);",
"     </li>",
"     <li>",
"      FructiCal (PL);",
"     </li>",
"     <li>",
"      Gastrocid (PH);",
"     </li>",
"     <li>",
"      Iroviton Calcium (AT);",
"     </li>",
"     <li>",
"      Kal-Zarevet (IL);",
"     </li>",
"     <li>",
"      Kalcidon (SE);",
"     </li>",
"     <li>",
"      Kalcij-karbonat (HR);",
"     </li>",
"     <li>",
"      Kalcijev karbonat (HR);",
"     </li>",
"     <li>",
"      Kalcitena (SE);",
"     </li>",
"     <li>",
"      Kalzonorm (AT);",
"     </li>",
"     <li>",
"      Mastical (ES);",
"     </li>",
"     <li>",
"      Maxi-calc (CH);",
"     </li>",
"     <li>",
"      Maxi-Kalz (CZ);",
"     </li>",
"     <li>",
"      Mubonet (MX);",
"     </li>",
"     <li>",
"      N-Zarevet (IL);",
"     </li>",
"     <li>",
"      Natecal (ES);",
"     </li>",
"     <li>",
"      Noacid (UY);",
"     </li>",
"     <li>",
"      Orocal (FR);",
"     </li>",
"     <li>",
"      Oscal (NZ);",
"     </li>",
"     <li>",
"      Osteocal 500 (FR, ID);",
"     </li>",
"     <li>",
"      Osteomin (MX);",
"     </li>",
"     <li>",
"      Pluscal (AR);",
"     </li>",
"     <li>",
"      Plusssz balance calcium (PL);",
"     </li>",
"     <li>",
"      Tetesept Calcium (AT);",
"     </li>",
"     <li>",
"      Titralac (NO);",
"     </li>",
"     <li>",
"      Tums (IL, MX);",
"     </li>",
"     <li>",
"      Tums EX Sugar Free (IL);",
"     </li>",
"     <li>",
"      Tums Smoothies EX Peppermint (IL);",
"     </li>",
"     <li>",
"      Tums Ultra Assorted Berries (IL);",
"     </li>",
"     <li>",
"      Tums Ultra Spearmint (IL);",
"     </li>",
"     <li>",
"      Tzarevet X (IL);",
"     </li>",
"     <li>",
"      Vicalvit (PL);",
"     </li>",
"     <li>",
"      Vitacalcin (PL);",
"     </li>",
"     <li>",
"      Weifa-Kalsium (NO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F144365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As dietary supplement, used to prevent or treat negative calcium balance; in osteoporosis, it helps to prevent or decrease the rate of bone loss. The calcium in calcium salts moderates nerve and muscle performance and allows normal cardiac function. Also used to treat hyperphosphatemia in patients with advanced renal insufficiency by combining with dietary phosphate to form insoluble calcium phosphate, which is excreted in feces. Calcium salts as antacids neutralize gastric acidity resulting in increased gastric and duodenal bulb pH; they additionally inhibit proteolytic activity of peptic if the pH is increased &gt;4 and increase lower esophageal sphincter tone.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F144380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Requires vitamin D; minimal unless chronic, high doses are given; calcium is absorbed in soluble, ionized form; solubility of calcium is increased in an acid environment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces (as unabsorbed calcium); urine (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bauwens SF, Drinka PJ, and Boh LE, &ldquo;Pathogenesis and Management of Primary Osteoporosis,&rdquo;",
"      <i>",
"       Clin Pharm",
"      </i>",
"      , 1986, 5:639-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/32/42504/abstract-text/3527528/pubmed\" id=\"3527528\" target=\"_blank\">",
"        3527528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heaney RP, Recker RR, and Saville PD, &ldquo;Menopausal Changes in Calcium Balance Performance,&rdquo;",
"      <i>",
"       J Lab Clin Med",
"      </i>",
"      , 1978, 92(6):953-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/32/42504/abstract-text/739173/pubmed\" id=\"739173\" target=\"_blank\">",
"        739173",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Washington, DC: The National Academies Press, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U and Kane S, \"American Gastroenterological Association Institute Medical Position Statement on the Use of Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(1):278-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/32/42504/abstract-text/16831610/pubmed\" id=\"16831610\" target=\"_blank\">",
"        16831610",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/32/42504/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NIH Consensus Conference, &ldquo;Optimal Calcium Intake,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1994, 272(24):1942-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/32/42504/abstract-text/7990248/pubmed\" id=\"7990248\" target=\"_blank\">",
"        7990248",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Recker RR, &ldquo;Calcium Absorption and Achlorhydria,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1985, 313(2):70-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/32/42504/abstract-text/4000241/pubmed\" id=\"4000241\" target=\"_blank\">",
"        4000241",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9185 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42504=[""].join("\n");
var outline_f41_32_42504=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144392\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144393\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144430\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144397\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144415\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144398\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144399\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144376\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144362\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144378\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144437\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144428\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144381\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144366\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298933\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144371\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144389\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144384\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333809\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144385\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524390\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144377\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144386\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144365\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144380\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9185|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?13/17/13589?source=related_link\">",
"      Calcium carbonate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?17/38/18024?source=related_link\">",
"      Calcium carbonate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_32_42505="Peripheral nerve innervation";
var content_f41_32_42505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 577px\">",
"   <div class=\"ttl\">",
"    Pattern of innervation of skin by peripheral nerves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 557px; height: 553px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42505=[""].join("\n");
var outline_f41_32_42505=null;
var title_f41_32_42506="Antithrombotic therapy to prevent embolization in atrial fibrillation";
var content_f41_32_42506=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antithrombotic therapy to prevent embolization in atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Daniel E Singer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Gregory YH Lip, MD, FRCPE, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/32/42506/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/32/42506/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolization of atrial thrombi can occur with any form (ie, paroxysmal, persistent, or permanent) of atrial fibrillation (AF). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=see_link\">",
"     \"Paroxysmal atrial fibrillation\"",
"    </a>",
"    .) Ischemic stroke is the most frequent clinical manifestation of embolization associated with AF. It can occur at any point during the clinical course of AF. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=see_link\">",
"     \"Stroke in patients with atrial fibrillation\"",
"    </a>",
"    .) Systemic and pulmonary thromboembolism also occur, but are less commonly recognized.",
"   </p>",
"   <p>",
"    As a result, chronic antithrombotic therapy with either oral anticoagulation (ie, a vitamin K antagonist, direct thrombin inhibitor, or factor Xa inhibitor) or antiplatelet therapy is considered for most of these patients. Both therapies are effective in preventing clinical systemic embolization, although anticoagulant therapy is far more effective and preferred in all but the lowest-risk patients. As antithrombotic therapy is associated with an increased risk of bleeding, its use must take both benefit and risk into account.",
"   </p>",
"   <p>",
"    Antithrombotic therapy for the prevention of embolic events in patients with AF will be reviewed here. The role of anticoagulation in relation to restoration of sinus",
"    <span class=\"nowrap\">",
"     rhythm/cardioversion",
"    </span>",
"    and the treatment of patients with AF who have suffered a stroke are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=see_link\">",
"     \"Stroke in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENTS WITH VALVULAR HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major clinical trials of antithrombotic therapy and subsequent meta-analyses have excluded patients with prosthetic heart valves, those with mitral stenosis, and those with decompensated valvular heart disease who were likely to require valve replacement in the near future [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/1-10\">",
"     1-10",
"    </a>",
"    ]. Thus, the newer anticoagulants should not be prescribed for these patients. Anticoagulation in these patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=see_link\">",
"     \"Antithrombotic therapy in patients with prosthetic heart valves\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link&amp;anchor=H10#H10\">",
"     \"Medical management and indications for intervention in mitral stenosis\", section on 'Prevention of thromboembolism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients with valvular lesions (without heart failure) such as mitral valve prolapse, non-rheumatic mitral regurgitation, or aortic valve lesions have been enrolled in the clinical trials of the newer anticoagulants. These trials also likely included a few patients (with or without heart failure) with severe valvular lesions who were not scheduled to undergo valve replacement. Until further evidence is available, we believe these newer drugs can be considered for these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621955964\">",
"    <span class=\"h1\">",
"     MECHANISM OF THROMBOEMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanisms leading to an increased risk of thrombus, embolism, and stroke in AF are multiple and closely interact with each other. Blood stasis, especially in the left atrial appendage (LAA), and activation of the hemostatic system are thought to play primary roles in patients with nonvalvular AF. Coexistent aortic atherosclerosis may also play a role. These topics are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43528?source=see_link\">",
"     \"Mechanisms of thrombogenesis in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31528?source=see_link\">",
"     \"Echocardiographic evaluation of the atria and appendages\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION TO GUIDE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have evaluated risk factors for embolization in nonvalvular AF, and multivariate risk models have been constructed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/11\">",
"     11",
"    </a>",
"    ]. Historically, the CHADS2 risk score is the most popular and has been best validated in different patient populations (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/38/1633?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The main advantage of the CHADS2 score compared to other risk models is its simplicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. A detailed discussion of risk stratification is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of our authors and reviewers support the use of the more detailed CHA2DS2-VASc model, which emphasizes the importance of age over 74 years and includes vascular disease, age 65 to 74 years, and female sex as risk factors and improves risk stratification among patients with CHADS2 scores of 0 and 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/14\">",
"     14",
"    </a>",
"    ]. Use of the CHA2DS2-VASc model will lead a recommendation for antithrombotic therapy in a higher percent of at risk individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link&amp;anchor=H692407161#H692407161\">",
"     \"Risk of embolization in atrial fibrillation\", section on 'CHA2DS2-VASc score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite limitations of all current models, including CHADS2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/15\">",
"     15",
"    </a>",
"    ], we recommend risk stratification in all patients as part of the process of choosing therapy. Consideration needs to be made for patient factors, such as stroke risk versus bleeding complication, as well as patient compliance and comorbidities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ANTITHROMBOTIC PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned directly above, we suggest using the CHADS2 or CHA2DS2-VASc (for those with CHADS2 of 0 or 1) score for evaluating risk of stroke and arterial embolization. Antithrombotic prevention is recommended when the benefits outweigh the risks.",
"   </p>",
"   <p>",
"    Many antithrombotic (anticoagulant and antiplatelet) strategies to decrease the risk of clinical embolic events in AF have been evaluated in randomized trials, which are discussed below. These trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/1-7\">",
"     1-7",
"    </a>",
"    ] and meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/8-10\">",
"     8-10",
"    </a>",
"    ] have demonstrated that among patients with AF at",
"    <strong>",
"     moderate to high risk",
"    </strong>",
"    of thromboembolic events,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , compared to placebo, significantly reduces the incidence of clinical stroke at an acceptable risk of bleeding. The evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is better than placebo is less robust. The vitamin K antagonist warfarin is approximately three times as effective as aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit to risk ratio from oral anticoagulation in patients at",
"    <strong>",
"     low risk,",
"    </strong>",
"    such",
"    <strong>",
"    </strong>",
"    as those with a CHADS2 score of 0 or a CHA2DS2-VASc score of 1, has not been well studied. If the use of antithrombotic therapy carried no risk or cost, virtually all patients with AF would receive such preventative therapy. Our authors and reviewers have differing approaches to patients with just one of the following risk factors in the CHA2DS2-VASc scheme: age 65 to 74 years, female sex, or atherosclerotic cardiovascular disease.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is made difficult by the need for monitoring using the International Normalized Ratio (INR). The newer oral anticoagulants",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    have comparable or superior efficacy and safety to warfarin in randomized trials do not require laboratory test monitoring, and have fewer",
"    <span class=\"nowrap\">",
"     food/pharmaceutical",
"    </span>",
"    interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H147982501\">",
"     'Studies of anticoagulant monotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621956305\">",
"    <span class=\"h2\">",
"     Prevention approach by CHADS2 score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term antithrombotic therapy, usually with anticoagulant therapy, is recommended for",
"    <strong>",
"     most",
"    </strong>",
"    patients with permanent AF who have CHADS-2 risk factors for stroke. While all current risk stratification schemes, which include the individual risk factors, provide only modest capacity to predict stroke risk, the CHADS2 score (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ) is simple and well validated. As a result, our recommendations for antithrombotic therapy depend on the CHADS2 scheme [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    We suggest the following approach to antithrombotic therapy, which is based on evidence provided by the many studies of antithrombotic therapy discussed below (see",
"    <a class=\"local\" href=\"#H147982501\">",
"     'Studies of anticoagulant monotherapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H16\">",
"     'Alternatives to anticoagulant monotherapy'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a CHADS2 score of 0 who receive no antithrombotic therapy are at low risk of stroke (rate of 0.5 to 1.7 percent per year), and a benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      has not been conclusively shown in these patients. Thus, we suggest no antithrombotic therapy, as the risks likely outweigh the benefits.",
"      <br/>",
"      <br/>",
"      Patients with a CHADS2 score of 1 are at intermediate risk of stroke (2.0 percent per year, or perhaps somewhat less) and should be treated with oral anticoagulant therapy or aspirin (75 to 325 mg daily). Based on the studies discussed below, which show that anticoagulant is more effective than aspirin, we prefer anticoagulant therapy to aspirin in most CHADS2 patients with a score of 1.",
"      <br/>",
"      <br/>",
"      The choice between anticoagulation and aspirin will depend upon many factors, including the clinician's assessment of risk, the ability to provide high-quality monitoring of the intensity of oral anticoagulation (if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      is chosen as the anticoagulant), the patient's risk of bleeding with oral anticoagulation, and patient preference (including issues related to cost, convenience of monitoring, and dose frequency). Patient preference is an important issue, since the absolute reduction in stroke risk is likely to be small, but stroke remains a feared outcome. Better patient education can improve understanding of the benefits and risks of anticoagulant therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The role of dual antiplatelet therapy with aspirin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      remains unclear in patients with a CHADS2 score of 1 who do not wish to take anticoagulant therapy, for reasons such as the inconvenience of INR monitoring or cost of the newer agents. Dual antiplatelet therapy and oral anticoagulation have similar bleeding risks, as shown in the ACTIVE W trial. Such an approach may be reasonable for patients who require dual antiplatelet therapy for other reasons, such as those with coronary stent placement or acute coronary syndrome. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Aspirin plus clopidogrel'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      As antiplatelet therapy is inferior to anticoagulant therapy with regard to efficacy, patients should be fully informed of this fact before a decision is made to choose antiplatelet therapy. If the reason for not choosing anticoagulant therapy is concern about bleeding, aspirin plus clopidogrel is not beneficial, as the combination produces a similar risk of bleeding to that seen with warfarin.",
"     </li>",
"     <li>",
"      Patients with a CHADS2 score of 2 or higher are at relatively high risk of stroke (at least 4 percent per year). Thus, oral anticoagulant therapy is strongly recommended for most patients with a CHADS2 score of 2 or higher [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The RE-LY, ROCKET-AF, and ARISTOTLE trials (",
"      <a class=\"graphic graphic_table graphicRef80932 \" href=\"mobipreview.htm?34/12/35021\">",
"       table 2",
"      </a>",
"      ), compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      , respectively, came to similar conclusions regarding the efficacy and safety of these newer antithrombotic agents compared to warfarin in non-valvular AF. We prefer dabigatran, rivaroxaban, or apixaban to warfarin in most cases in which oral anticoagulant therapy is chosen.",
"      <br/>",
"      <br/>",
"      Among these newer agents, we currently prefer dabigatran and rivaroxaban for reasons of cost and availability and pending reviews of non-public (not published) data by the United States Food and Drug Administration and the European Medicines Agency. Recommendations may need to change should these agencies detect adverse outcomes not currently reported.",
"      <br/>",
"      <br/>",
"      The following are situations in which it is reasonable to prefer warfarin instead of these newer anticoagulants:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients already on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      who are comfortable with periodic INR measurement and whose INR has been relatively easy to control.",
"     </li>",
"     <li>",
"      Patients who are not likely to comply with the twice daily dosing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      <span class=\"nowrap\">",
"       (when/if",
"      </span>",
"      approved,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      is once daily).",
"     </li>",
"     <li>",
"      Patients for whom the use of any of these other anticoagulants will lead to an unacceptable increase in cost.",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease, whose creatinine clearance is less than 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39721?source=see_link&amp;anchor=H9066197#H9066197\">",
"       \"Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease\", section on 'Benefits and risks of oral antithrombotic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H621956777\">",
"    <span class=\"h2\">",
"     Prevention approach by CHA2DS2-VASc score",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of our authors and reviewers, who support the use of the CHA2DS2-VASc score (",
"    <a class=\"graphic graphic_table graphicRef83272 \" href=\"mobipreview.htm?30/23/31101\">",
"     table 3",
"    </a>",
"    ), consider it reasonable to choose antithrombotic therapy for patients with none of the CHADS2 but one of the following CHA2DS2-VASc risk factors: age 65 to 74 years, female sex, and evidence of atherosclerotic cardiovascular disease. Benefit from therapy in such patients has not been established in randomized trials.",
"   </p>",
"   <p>",
"    These authors and reviewers agree with the 2012 focused update of the European Society of Cardiology guidelines for the management of AF, which makes the following recommendations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CHA2DS2-VASc score is strongly preferred to the CHADS2 score.",
"     </li>",
"     <li>",
"      For patients with a CHA2DS2-VASc score of &ge;2, a strong recommendation for oral anticoagulant therapy is made.",
"     </li>",
"     <li>",
"      For patients with a CHA2DS2-VASc score of 1 (but a CHADS2 score of 0), a weak recommendation for oral anticoagulant therapy is made.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      is not recommended. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk stratification to guide therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"       \"Risk of embolization in atrial fibrillation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with a CHA2DS2-VASc score of 0, no antithrombotic therapy is recommended.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    have not been studied in this lower risk population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1127350851\">",
"    <span class=\"h2\">",
"     Patients with chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;While not included in the CHADS2 or CHA2DS2-VASc risk prediction models, chronic kidney disease is a powerful predictor of thromboembolic risk in patients with AF. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39721?source=see_link\">",
"     \"Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147982501\">",
"    <span class=\"h2\">",
"     Studies of anticoagulant monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In large randomized trials of patients at intermediate and high risk for clinical thromboembolism,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    has been compared to placebo and to the newer oral anticoagulants (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ). Warfarin significantly lowers the risk of stroke and systemic embolism compared to placebo.",
"   </p>",
"   <p>",
"    Compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , anticoagulation with each of the newer agents leads to similar or lower rates both of ischemic stroke and major bleeding. Three 2012 meta-analyses have pooled the results from the RE-LY (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ), ARISTOTLE (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ), and ROCKET AF (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ) trials and reached similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. These newer oral anticoagulants (compared to warfarin) are associated with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction of",
"      <span class=\"nowrap\">",
"       stroke/systemic",
"      </span>",
"      embolism (odds ratio [OR] 0.85, 95% CI 0.74-0.99; absolute risk reduction, 0.7 percent) and major bleeding (OR 0.86, 95% CI 0.75-0.99; absolute risk reduction 0.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A significant reduction in all-cause mortality (relative risk [RR] 0.88, 95% CI 0.82-0.96) and hemorrhagic stroke (RR 0.48, 95% CI 0.36-0.62) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These meta-analyses support the broad concept that newer oral anticoagulants (direct thrombin and factor Xa inhibitors) are reasonable alternatives to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in many cases. They do not directly compare the relative advantages and disadvantages of each agent nor do they demonstrate that the different agents are equivalent in terms of safety and efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Warfarin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    was studied in numerous trials, including SPAF-I, SPAF-II, and SPAF-III trials, and AFASAK, BAATAF, SPINAF, and CAFA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Together, these trials randomly assigned more than 4000 patients with nonvalvular or nonrheumatic AF to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , warfarin, or placebo, and demonstrated that anticoagulation with adjusted-dose warfarin [equivalent to INR 2-3] significantly reduced clinical stroke risk in patients with AF when compared with aspirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/2-4\">",
"     2-4",
"    </a>",
"    ] or placebo (",
"    <a class=\"graphic graphic_figure graphicRef79839 \" href=\"mobipreview.htm?38/8/39053\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/1,2,4-6\">",
"     1,2,4-6",
"    </a>",
"    ]. Overall, adjusted-dose warfarin reduces the risk of stroke by two-thirds compared to no antithrombotic therapy, with the expected degree of absolute benefit dependent on baseline risk (",
"    <a class=\"graphic graphic_table graphicRef66736 \" href=\"mobipreview.htm?17/44/18124\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/7,8,26\">",
"     7,8,26",
"    </a>",
"    ]. The relative risk reduction compared to aspirin was about 50 percent. Warfarin was effective in both men and women and in all age groups, including those over the age of 75 years (",
"    <a class=\"graphic graphic_figure graphicRef73006 \" href=\"mobipreview.htm?32/18/33069\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/7,27-29\">",
"     7,27-29",
"    </a>",
"    ]. In addition, mortality was significantly reduced by warfarin compared to no antithrombotic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    provides benefit in patients who have already had a stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=see_link\">",
"     \"Stroke in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These trials were conducted more than 15 years ago, and the following concerns have been raised about whether the findings can be applied to current practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While more studies continue to support the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , lower absolute levels of stroke risk have been observed, resulting in a smaller absolute benefit of anticoagulant therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/13,31\">",
"       13,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The real-world benefit may be lower than that demonstrated in clinical trials, since the patients are less likely to have a therapeutic INR. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Underutilization and discontinuation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    More contemporary data regarding the risk of stroke or systemic embolism in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    from over 20,000 AF patients are available from the RE-LY, ARISTOTLE, and ROCKET AF trials in which a target INR of 2.0 to 3.0 was universally used for patients with AF randomized to warfarin. In these trials the incidence was 1.7, 1.6, and 2.2 percent per year, respectively. A 2012 meta-analysis of eight randomized trials (published between 2003 and 2011), which included nearly 56,000 individuals treated with warfarin, found that the annual incidence of stroke or systemic embolism was 1.66 percent (95% CI 1.41-1.91) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H524842274\">",
"     'Direct thrombin and factor Xa inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     Bleeding risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major safety concern with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (and all oral anticoagulants) is the risk of major bleeding. Major bleeding includes bleeding that requires hospitalization, transfusion, surgery, or involves particularly sensitive anatomic locations. Intracranial bleeding is the most serious bleeding complication with warfarin, since the likelihood of mortality or subsequent major disability is substantially higher than bleeding at other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overanticoagulation (as defined as a supratherapeutic INR), prior stroke, and increasing patient age are three of the most important predictors of major bleeding, which includes intracranial hemorrhage (ICH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21,30,34,35\">",
"     21,30,34,35",
"    </a>",
"    ]. In an attempt to estimate the probability of major bleeding in patients on chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, a number of risk models have been developed (",
"    <a class=\"graphic graphic_table graphicRef59051 \" href=\"mobipreview.htm?32/58/33707\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75259 \" href=\"mobipreview.htm?38/14/39148\">",
"     table 6",
"    </a>",
"    ). The risk factors and risk models are discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=see_link\">",
"     \"Risk of intracerebral hemorrhage in patients treated with warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The increased risk of major bleeding (with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) is particularly relevant to older adults in whom varying combinations of frailty, poor mobility, poor compliance, the use of concomitant medications that can result in drug interactions, and frequent falls are common. Issues related to anticoagulation in older adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link\">",
"     \"Anticoagulation in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of major bleeding appears to be significantly higher with adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . In the individual patient meta-analysis of six prevention trials cited above, the absolute rate increase of major bleeding with warfarin compared with aspirin was 0.9 events per 100 patient-years (2.2 versus 1.3 events per 100 patient-years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/9\">",
"     9",
"    </a>",
"    ]. The risk of ICH is extremely high at an INR above 5.0 (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"mobipreview.htm?42/18/43296\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    also require",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for another indication, such as intracoronary stent placement or acute coronary syndrome. The combination of warfarin and aspirin increases the risk of bleeding. In the study of Medicare recipients discussed above, the rate of major bleeding was 2.8 percent in those treated with warfarin plus aspirin. Combination therapy was associated with a threefold increase in the risk of ICH (0.9 versus 0.3 percent, odds ratio 2.95). In another meta-analysis, combination therapy was associated with a significant increase in the risk of ICH (relative risk 2.4, 95% CI 1.2-4.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4339005\">",
"     'Aspirin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The rates of major bleeding in patients taking the newer oral anticoagulants (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) are presented below and are similar to or less than the rate in patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef80932 \" href=\"mobipreview.htm?34/12/35021\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4338483\">",
"     'Dabigatran'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H358919860\">",
"     'Rivaroxaban'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H147982962\">",
"     'Apixaban'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The management of anticoagulant therapy in patients who are bleeding is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14130832#H14130832\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dosing and safety issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Net clinical benefit",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to use antithrombotic therapy to prevent clinical embolization in patients with nonvalvular AF is based upon an assessment of the absolute benefits and risks of such therapy. For most patients, the benefit will outweigh the (bleeding) risks and thus a formal assessment of bleeding risk using one of the available risk models is not necessary (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H28#H28\">",
"     \"Therapeutic use of warfarin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Combining ischemic events with major bleeding together to yield net clinical benefit attempts to balance benefits and risks. The ATRIA study evaluated the net clinical benefit (NCB) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in 13,559 patients with nonvalvular AF who were identified in an outpatient database in 1996 and 1997 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/30\">",
"     30",
"    </a>",
"    ]. NCB was defined as the difference between annualized rate of thromboembolic events prevented by warfarin, minus the annualized rate of ICH induced by warfarin, multiplied by a weighting factor. In the model, ICH was weighted as 1.5 times the impact of ischemic stroke. A strength of this analysis is that extracranial bleeds, which have less long-term impact compared with strokes, were excluded.",
"   </p>",
"   <p>",
"    Outcomes were evaluated in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and no-warfarin groups (approximately 50 percent of the latter were on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) over a median follow-up of six years. The NCB became statistically significant at a CHADS2 score of 2 (1 event prevented per 100 patient-years) and progressively increased at higher CHADS2 scores (2.2 events prevented per 100 patient-years at a CHADS2 score of 4 to 6). This relationship reflects the much greater reduction in embolic risk compared to increase in ICH risk with higher CHADS2 scores.",
"   </p>",
"   <p>",
"    The ATRIA study supports the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy in patients with a CHADS2 score of 2 or higher. The NCB with warfarin in patients with a CHADS2 score of 1 was small, and the confidence intervals around the NCB included the possibility of harm.",
"   </p>",
"   <p>",
"    A larger analysis, which evaluated the net clinical benefit in 132,372 patients in the Danish National Patient Registry whose risk of stroke or embolization was assessed using the CHADS2 score, came to similar conclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Of note, this study also evaluated net clinical benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    using the CHA2DS2-VASc score, which includes age 65 to 74, female sex, and atherosclerotic cardiovascular disease as risk factors (in addition to those in the CHADS2 model). (See",
"    <a class=\"local\" href=\"#H621956777\">",
"     'Prevention approach by CHA2DS2-VASc score'",
"    </a>",
"    above.) In patients with a CHA2DS2-VASc score of 1 (n = 86,370), there was a trend toward net clinical benefit of warfarin, particularly in patients at lower risk of bleeding.",
"   </p>",
"   <p>",
"    Thus, for patients with CHADS2 scores of 0 or &gt;1, formal assessment of bleeding risk is not necessary. Patients with a CHADS2 score of 1 who are at high risk of bleeding, particularly ICH (",
"    <a class=\"graphic graphic_table graphicRef59051 \" href=\"mobipreview.htm?32/58/33707\">",
"     table 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef75259 \" href=\"mobipreview.htm?38/14/39148\">",
"     table 6",
"    </a>",
"    ), may reasonably choose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    instead of an anticoagulant. While most patients with risk factors for bleeding have a CHADS2 score greater than 1, some risk factors for bleeding such as history of gastrointestinal bleeding, abnormal renal or hepatic function, drugs or alcohol, or high risk for falls are not included in the CHADS2 model. These are the patients for whom a decision to choose aspirin rather than anticoagulant may be reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Initiation of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of whether to start",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    alone or in combination with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or low-molecular-weight heparin (ie, bridging) is based upon an assessment of the risk of a thrombus developing within the next several days versus the risk of bleeding complications.",
"   </p>",
"   <p>",
"    In most patients with nonvalvular AF, the risk of stroke during the several days typically required to reach a therapeutic INR or therapeutic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    is very low. Thus, it is reasonable to administer these agents as an outpatient without bridging. For patients deemed to be at high risk of thromboembolism (eg,",
"    <strong>",
"     remote",
"    </strong>",
"    cerebrovascular",
"    <span class=\"nowrap\">",
"     event/TIA",
"    </span>",
"    or intracardiac thrombus, bioprosthetic valve, or mitral stenosis) and low risk of ICH, initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bridging regimen is reasonable. This approach is in general agreement with the 2012 ACCP guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/40\">",
"     40",
"    </a>",
"    ]. However, there are few data from randomized trials addressing such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/41\">",
"     41",
"    </a>",
"    ], and expert opinion is divided as to the benefit of heparin bridging in certain situations.",
"   </p>",
"   <p>",
"    Patients with nonvalvular AF who present with",
"    <strong>",
"     acute",
"    </strong>",
"    stroke have a relatively high risk of recurrent embolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive ischemia (approximately 5 percent during the first two weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Although early use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    reduces the rate of recurrent embolism",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progressive ischemia in some trials, this is balanced by an increased incidence of transformation to hemorrhagic stroke, especially in patients with large strokes. The conclusion from these data is that there is no overall benefit to early heparin therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], and we generally do not recommend heparin bridging in patients with acute stroke. Though unproven, it may be reasonable if&nbsp;the stroke is small",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    there is residual left atrial appendage thrombus identified on transesophageal echocardiogram (TEE; if performed). This issue is discussed elsewhere.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H6#H6\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Parenteral anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other issues surrounding the initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H22#H22\">",
"     \"Therapeutic use of warfarin\", section on 'Loading doses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     INR monitoring and goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;An INR between 2.0 and 3.0 is recommended for most patients with nonvalvular AF who receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/40,44\">",
"     40,44",
"    </a>",
"    ]. This is based upon the increased risk of stroke observed with INR values significantly below 2.0 (four- to sixfold at an INR of 1.3 compared with an INR of 2.0 or above) and the increased risk of bleeding associated with higher intensities of anticoagulation (",
"    <a class=\"graphic graphic_figure graphicRef65373 \" href=\"mobipreview.htm?42/18/43296\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H21#H21\">",
"     \"Therapeutic use of warfarin\", section on 'Warfarin administration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The severity of stroke and the mortality rate in patients with nonvalvular AF are also increased when the INR is below 2.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Bleeding risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Advanced age (over 74 years) is an independent risk factor for bleeding during anticoagulation, and some experts argue that a lower INR target (1.8 to 2.5) is a reasonable compromise between toxicity and efficacy for patients over 74 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21\">",
"     21",
"    </a>",
"    ] since patients with an INR of 1.8 are afforded considerable protection from stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/30,50,51\">",
"     30,50,51",
"    </a>",
"    ]. However, the BAFTA trial, in which the mean age of participants was 81 years, found that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.0 to 3.0) was superior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for stroke prevention, with no difference in major bleeding between the two treatment arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/29\">",
"     29",
"    </a>",
"    ]. The benefits of warfarin were independent of age (75 to 79, 80 to 84, or over 84 years). Furthermore, aiming for an INR range of 1.8 to 2.5 will likely lead to a substantial number of INRs below 1.8, which carries an attendant increased risk of stroke but does not significantly reduce the risk of intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/30\">",
"     30",
"    </a>",
"    ]. Therefore, aiming for an INR of 2.0 to 3.0 provides the best target range for guarding against the sequelae of under- and over-anticoagulation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=see_link\">",
"     \"Anticoagulation in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some have suggested that target INR values higher than 2.0 to 3.0 be used for patients at particularly high risk, such as those with prior thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21,48\">",
"     21,48",
"    </a>",
"    ] or TEE documented atrial thrombi or prior to cardioversion. Evidence from the ATRIA study makes it clear that the there is no benefit in targeting INR levels higher than the standard range of INR 2.0 to 3.0 (",
"    <a class=\"graphic graphic_figure graphicRef78252 \" href=\"mobipreview.htm?41/27/42430\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=see_link\">",
"     \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance of the INR between 2.0 and 3.0 is often not achieved, and the failure to maintain a therapeutic INR is associated with worse outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SPAF-III trial, only 61 percent of INR values were between 2.0 and 3.0, and 25 percent were less than 2.0, despite the use of a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      nomogram and nursing assistance with INR monitoring and warfarin dose adjusting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar findings were noted in a systematic review of four studies in which the INR was less than 2.0 on 26 percent of measurements [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/53\">",
"       53",
"      </a>",
"      ]. An INR at this level was associated with a fivefold increase in ischemic events compared to values in the therapeutic range.",
"     </li>",
"     <li>",
"      In a retrospective analysis of the SPORTIF III and V trials, patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      therapy were categorized as having poor, moderate, or good control of anticoagulation (therapeutic INRs less than 60 percent, 60 to 75 percent, or greater than 75 percent of the time, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/54\">",
"       54",
"      </a>",
"      ]. Patients with poor control had, when compared to those with moderate or good control, significantly higher annual rates of mortality (4.2 versus 1.8 and 1.7 percent), and major bleeding (3.9 versus 2.0 and 1.6 percent). In addition, patients with poor control had a significantly higher annual rate of stroke or systemic embolization than those with good control (2.1 versus 1.1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The importance of time in therapeutic range (TTR) was further emphasized in a secondary analysis from the ACTIVE-W trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    versus vitamin K antagonists (VKA) for patients with non-valvular AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/55\">",
"     55",
"    </a>",
"    ]. A wide variation in TTR achieved across participating centers and countries was observed, and the relative benefit of vitamin K antagonists was strongly associated with average TTR. For example, in the analysis by participating country, an average TTR of 50 percent was needed to demonstrate any benefit of anticoagulant therapy versus clopidogrel plus aspirin. This benefit increased with higher levels of average TTR, while at lower TTR levels anticoagulant therapy was the inferior therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our authors and reviewers believe that the benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is greatest when the TTR is at least 60 percent and that the higher the TTR the greater the anticipated benefit. For patients whose TTR is less than this goal, physicians should review with the patient possible causes of poor INR control, such as inconsistent adherence, dietary changes, or interference from concomitant medications.&nbsp;If poor INR control cannot be remedied, consideration should be given to switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    . Though reasonable, the benefit from such a practice in this population has not been validated.",
"   </p>",
"   <p>",
"    The frequency of INR monitoring soon after initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy is determined by how quickly the patient can get to the INR target consistently. The initial three months of adjusted-dose warfarin are a particularly high-risk period for bleeding; as a result, especially close anticoagulation monitoring is warranted during this period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After stabilization at a therapeutic level of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , the INR should generally be monitored at least monthly, and more frequently if there has been a change in medication or diet as these may alter the effect of warfarin. The method of follow-up will vary from patient to patient and practice to practice. Less frequent (every three months) monitoring may be reasonable for patients who have been maintained on a stable dose of warfarin with therapeutic INR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=see_link&amp;anchor=H31520063#H31520063\">",
"     \"Therapeutic use of warfarin\", section on 'Laboratory monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several algorithms have been developed to help manage",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dosing. We provide one such tested approach (",
"    <a class=\"graphic graphic_table graphicRef87435 \" href=\"mobipreview.htm?19/31/19964\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h4\">",
"     Temporary cessation of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients on long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy may occasionally require cessation of warfarin anticoagulation to prevent bleeding in the periprocedural or peri-surgical period or to avoid teratogenesis during pregnancy. Less often, reversal of anticoagulation may be required for emergent surgery or other urgent indications. These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=see_link&amp;anchor=H18#H18\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Surgery/invasive procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of the management of anticoagulant therapy in the patient undergoing percutaneous coronary intervention is found elsewhere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H32#H32\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Patients who require warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h4\">",
"     Underutilization and discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the compelling evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    reduces the risk of stroke in most patients with AF, such therapy continues to be underutilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/10,61-67\">",
"     10,61-67",
"    </a>",
"    ]. In a study of over 3600 patients with AF or atrial flutter in a community database (2000 to 2007), antithrombotic treatment was given in accordance with guideline recommendations in only 53 percent of patients, with 31 percent classified as undertreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/68\">",
"     68",
"    </a>",
"    ]. Patients were less likely to be treated if they had paroxysmal AF or atrial flutter. The lack of warfarin use in those with paroxysmal AF may be related to the misconception regarding thromboembolic risk and rhythm. &nbsp;",
"   </p>",
"   <p>",
"    Even when anticoagulation is appropriately initiated, it is often discontinued, or the target international normalized ratio (INR) is not achieved. Discontinuation rates between 26 and 34 percent at one year have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/64,69\">",
"     64,69",
"    </a>",
"    ]. The risks of termination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, even in patients in whom sinus rhythm has been restored, were highlighted in the AFFIRM and RACE trials. Seventy to eighty percent of ischemic strokes occurred either after discontinuation of warfarin or when the INR was subtherapeutic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h4\">",
"     Thromboembolism in anticoagulated patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolic events occur despite adequate anticoagulation in patients with AF. Predictors of these events include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\", section on 'Atrial fibrillation and cardioembolic stroke'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TEE evidence of dense spontaneous echo contrast and low left atrial appendage ejection velocity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The INR is often subtherapeutic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/53\">",
"       53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31528?source=see_link\">",
"       \"Echocardiographic evaluation of the atria and appendages\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H14\">",
"       'Underutilization and discontinuation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Elevated D-dimer levels. In a single center, prospective, observational study of 269 patients, D-dimer levels were elevated (at least 0.5",
"      <span class=\"nowrap\">",
"       mcg/mL)",
"      </span>",
"      in 23 percent and elevated levels were significantly associated with a higher rate of thromboembolism (hazard ratio 15. 8, 95% CI 3.33 to 75.5) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/71\">",
"       71",
"      </a>",
"      ], similar for von Willebrand factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/72\">",
"       72",
"      </a>",
"      ]. However, we do not recommend D-dimer or von Willebrand factor testing, as it has not been shown that changing the antithrombotic regimen alters outcome in this setting.",
"     </li>",
"     <li>",
"      While most ischemic stroke in AF patients is due to embolism of left atrial appendage thrombi, other stroke mechanisms should be considered. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/249?source=see_link&amp;anchor=H21816470#H21816470\">",
"       \"Pathophysiology of ischemic stroke\", section on 'Stroke subtypes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TEE evidence of complex aortic plaque [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/70\">",
"       70",
"      </a>",
"      ]. TEE detected thrombi can be related to clinical risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/73\">",
"       73",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524842274\">",
"    <span class=\"h3\">",
"     Direct thrombin and factor Xa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    , an oral direct thrombin inhibitor, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    , both oral factor Xa inhibitors, have been compared to adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (INR of 2.0 to 3.0) in large randomized trials of patients at intermediate to high risk of stroke.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    use was allowed in the trials.",
"   </p>",
"   <p>",
"    These trials, discussed below, demonstrate equal or better efficacy and safety of these newer anticoagulants compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Advantages to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    (compared to warfarin) include no requirement for international normalized ratio monitoring and less susceptibility to dietary and drug interactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/74\">",
"     74",
"    </a>",
"    ]. Disadvantages include twice-daily dosing (dabigatran, apixaban), higher pharmaceutical cost, lack of an",
"    <span class=\"nowrap\">",
"     antidote/reversing",
"    </span>",
"    agent, the potential need for dose adjustment in patients with chronic kidney disease, and lack of long-term safety and &ldquo;real world&rdquo; data.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    <strong>",
"     should not be used",
"    </strong>",
"    for the prevention of embolization in AF patients with prosthetic heart valves, those with mitral stenosis (particularly of rheumatic origin), or those with mitral regurgitation or aortic valve disease associated with heart failure that might require valve replacement in the near future. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Patients with valvular heart disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Further information on the use of these agents, including drug interactions (",
"    <a class=\"graphic graphic_table graphicRef61344 \" href=\"mobipreview.htm?24/0/24590\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef73141 \" href=\"mobipreview.htm?12/29/12766\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87789 \" href=\"mobipreview.htm?7/56/8078\">",
"     table 10",
"    </a>",
"    ), dosing in patients with chronic renal disease, and the need to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    with food, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4338483\">",
"    <span class=\"h4\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RE-LY trial (",
"    <a class=\"graphic graphic_table graphicRef80932 \" href=\"mobipreview.htm?34/12/35021\">",
"     table 2",
"    </a>",
"    ) evaluated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    (at two doses) compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In RE-LY, 18,113 patients with nonvalvular AF and intermediate risk for thromboembolism (mean CHADS2 score of 2.1) (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ) were randomly assigned to receive oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    at one of two doses (110 or 150 mg) twice daily, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (INR 2.0-3.0). Exclusion criteria included important valvular heart disease, conditions associated with a high risk of bleeding (eg, recent or planned surgery, bleeding diathesis, or gastrointestinal hemorrhage within the past year), active liver disease, pregnant women or those who might become pregnant during the study, or a creatinine clearance of less than 30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    After a median follow-up of two years, the following findings were noted (the event rates and their associated risk ratios, with the exception of hemorrhagic stroke, reflect those reported in an updated analysis of RE-LY [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/75\">",
"     75",
"    </a>",
"    ], except as noted):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rate of the primary efficacy outcome of stroke (including hemorrhagic stroke) or systemic embolism was 1.53, 1.11, and 1.69 percent per year in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      110 mg, dabigatran 150 mg, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      groups, respectively. The differences in rates were driven principally by reductions in ischemic stroke. Dabigatran 110 mg met the criteria for non-inferiority compared to adjusted dose warfarin (relative risk 0.90, 95% CI 0.74-1.10), while dabigatran 150 mg was significantly more effective than warfarin (relative risk [RR] 0.65, 95% CI 0.52-0.81) or dabigatran 110 mg (RR 0.73, 95% CI 0.58-0.91).",
"     </li>",
"     <li>",
"      The rate of major bleeding (defined as a reduction in the hemoglobin concentration of at least 2.0 g per deciliter, transfusion of at least two units of blood, or symptomatic bleeding in a critical area or organ [including hemorrhagic stroke]) was 2.9, 3.3, and 3.6 percent per year in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      110 mg, dabigatran 150 mg, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      groups, respectively. The risk of major bleeding was significantly less with dabigatran 110 mg than warfarin, and dabigatran 150 mg was of equal safety to warfarin (RR 0.80, 95% CI 0.70-0.93 and 0.93, 95% CI 0.81-1.07, respectively).",
"      <br/>",
"      <br/>",
"      The rates of hemorrhagic stroke were significantly lower in the dabigatran 110 and 150 mg groups compared to warfarin (0.12, 0.10, and 0.38 percent per year, respectively; RR 0.31, 95% CI 0.17-0.56 and 0.26, 95% CI 0.14-0.49, respectively).",
"     </li>",
"     <li>",
"      The benefit from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      at both doses was similar in patients with and without prior",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was a trend toward a higher rate of bleeding with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg in patients over 74 years (5.10 versus 4.37 percent per year; p = 0.07) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/77\">",
"       77",
"      </a>",
"      ]. This finding was evident for extracranial but not ICH.",
"     </li>",
"     <li>",
"      In a post hoc evaluation of RE-LY, the rate of myocardial infarction was found to be non-significantly increased for both the 150 and 110 mg doses compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (0.81 and 0.82 versus 0.64; RR 1.27, 95% CI 0.94-1.71 and 1.29, 95% CI 0.96-1.75, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/78\">",
"       78",
"      </a>",
"      ]. There was no significant difference in the annual rates of a composite of myocardial infarction, unstable angina, cardiac arrest, and cardiac death were 3.33, 3.16, and 3.41 percent per year, respectively. The relative effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      compared to warfarin on these events were consistent in patients with and without documented coronary artery disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The finding of a higher rate of myocardial infarction in RE-LY was explored in a 2012 meta-analysis of 7 trials (30,514 individuals) which compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , or placebo for stroke prophylaxis in AF, short term prophylaxis of deep venous thrombosis, treatment of deep venous thrombosis or treatment of acute coronary syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/79\">",
"     79",
"    </a>",
"    ]. Dabigatran was associated with a significantly increased risk of myocardial infarction, cardiac death or unstable angina compared to the control group (odds ratio 1.27, 95% CI 1.00-1.61) and these results did not change after exclusion of three short-term trials. However, the absolute risk difference was very small (0.27 percent). RE-LY comprised 57 percent of the cohort and 74 percent of the events. As the magnitude of the increase in risk of myocardial infarction is small and as the benefit for the prevention of a clinically more important end point (ischemic stroke) is larger with dabigatran, the findings of this meta-analysis do not change our recommendations for the use of dabigatran in AF.",
"   </p>",
"   <p>",
"    We prefer the 150 mg twice daily dose for patients not at high risk of bleeding. For those patients at high risk of bleeding (such as those above age 75 years) or those patients who are particularly concerned about bleeding complications while on anticoagulant therapy, the 110 mg twice daily dose is reasonable (but not available in the United States). A 75 mg twice daily dose is available in the USA and is approved for patients with creatinine clearances of 15 to 30",
"    <span class=\"nowrap\">",
"     ml/min",
"    </span>",
"    based on pharmacokinetic modeling. However, we do not recommend the 75 mg twice daily dose as it has not been tested in clinical trials.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    is not approved for those with a creatinine clearance of less than 15",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    Many practitioners have been concerned about a potential for a higher rate of serious bleeding with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , based on post-marketing reports of patients taking dabigatran. In a statement issued by the United States Food and Drug Administration in November, 2012, the rate of bleeding with dabigatran did not appear to be higher than that with warfarin in patients who were using either drug for the first time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/80\">",
"     80",
"    </a>",
"    ]. This statement was based on an assessment of insurance claims and an administrative data set.",
"   </p>",
"   <p>",
"    A subgroup analysis of RE-LY including patients taking antiplatelet therapy is discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Patients on long-term antiplatelet therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17731647\">",
"    <span class=\"h5\">",
"     Drug stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the potential for product breakdown from moisture and loss of potency,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    capsules should only be dispensed and stored in the original bottle (with desiccant) or blister package. Patients should not store or place this agent in any other container, such as pill boxes or pill organizers. Once the bottle is opened, the pills inside must be used within four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    who require invasive procedures or surgery is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14#H14\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H358919860\">",
"    <span class=\"h4\">",
"     Rivaroxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    has been approved for use in the United States, Canada, and the European Union for the prevention of thromboembolism in nonvalvular AF as well as for prophylaxis of venous thromboembolism in some postoperative orthopedic patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H23#H23\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the ROCKET AF trial (",
"    <a class=\"graphic graphic_table graphicRef80932 \" href=\"mobipreview.htm?34/12/35021\">",
"     table 2",
"    </a>",
"    ), 14,264 AF patients at intermediate to high risk of stroke (mean CHADS2 score of 3.5) (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ) were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    (20 mg daily or 15 mg daily in patients with a creatinine clearance of 30-49",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.0-3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to the rate of the primary efficacy end point (composite of stroke and systemic embolism),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    was noninferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (1.7 versus 2.2 percent per year; hazard ratio [HR] 0.79, 95% CI 0.66-0.96) in the per-protocol as-treated analysis. In the intention to treat analysis, the rate of primary end point was 2.1 and 2.4 percent per year respectively (HR 0.99, 95% CI 0.74-1.03). There was no significant difference between rivaroxaban and warfarin in the primary safety end point of major and non-major clinically relevant bleeding (14.9 versus 14.5 percent per year, respectively). In addition, the rates of ICH and fatal bleeding, each a component of the safety outcome, occurred significantly less often in the rivaroxaban group (0.5 versus 0.7 and 0.2 versus 0.5 events per 100 patient-years, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H147982962\">",
"    <span class=\"h4\">",
"     Apixaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;In December of 2012,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    was approved by the United States Food and Drug Administration to reduce the risk of stroke and systemic embolization in patients with nonvalvular AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/82\">",
"     82",
"    </a>",
"    ]. The drug was also approved by the European Medicines Agency in November of 2012 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/83\">",
"     83",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H21#H21\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Apixaban'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the ARISTOTLE trial (",
"    <a class=\"graphic graphic_table graphicRef80932 \" href=\"mobipreview.htm?34/12/35021\">",
"     table 2",
"    </a>",
"    ), 18,201 AF patients with intermediate risk of clinical thromboembolism stroke (mean CHADS2 score of 2.1) (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ) were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    (5 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR 2.0-3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/84\">",
"     84",
"    </a>",
"    ]. The primary composite end point of stroke and systemic embolism was significantly reduced in the apixaban group (1.3 versus 1.6 percent per year; hazard ratio 0.79, 95% CI 0.66-0.95), meeting criteria for non-inferiority (and superiority in a similar prespecified secondary end point). The rate of major bleeding, the primary safety end point, was significantly lower in the apixaban group (2.1 versus 3.1 percent per year), including a significant reduction in the rate of hemorrhagic stroke (0.24 versus 0.47 percent per year). In addition ARISTOTLE is the first study to show a significant reduction in the rate of all-cause death compared to warfarin (3.5 versus 3.9 percent per year). Patients with a creatinine greater than 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or a calculated eGFR of less than 25",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    were excluded from the ARISTOTLE trial.",
"   </p>",
"   <p>",
"    A subgroup analysis of ARISTOTLE was performed in the 3436 patients with prior stroke or transient ischemic attack (TIA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/85\">",
"     85",
"    </a>",
"    ]. There was no significant difference in the rate of the primary outcome between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    groups (2.46 versus 3.24 percent per year; hazard ratio 0.76, 95% CI 0.56-1.03). The failure to achieve statistical significance in this subgroup is likely due to the fewer patients in this analysis. Of interest, the absolute reduction in the primary end point with apixaban versus warfarin was greater in patients with compared to those without prior stroke or TIA (0.77 compared to 0.22 per 100 patient-years, respectively). Most of the difference in outcome between the apixaban and warfarin groups was attributable to a reduction in intracranial bleeding with apixaban.",
"   </p>",
"   <p>",
"    A second subgroup analysis of ARISTOTLE evaluated outcomes according to the CHADS2 and CHA2DS2-Vasc (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef83272 \" href=\"mobipreview.htm?30/23/31101\">",
"     table 3",
"    </a>",
"    ) embolic risk or the HAS-BLED bleeding scores (",
"    <a class=\"graphic graphic_table graphicRef75259 \" href=\"mobipreview.htm?38/14/39148\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/86\">",
"     86",
"    </a>",
"    ]. There was no evidence of a differential effect by risk of stroke or bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524842440\">",
"    <span class=\"h4\">",
"     Reversal of anticoagulant effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important concern, about the use of oral direct thrombin and factor Xa inhibitors, is that no antidote has been shown, in studies of patients taking these drugs, to cause immediate reversal of their anticoagulant effect. In one promising study in 12 healthy subjects, the infusion of prothrombin complex concentrate (a four-factor product not available in the United States) led immediate and complete reversal of the anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ; this effect was not seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/87\">",
"     87",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H14130832#H14130832\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Dosing and safety issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433859596\">",
"    <span class=\"h4\">",
"     Transition from newer oral anticoagulants to warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients may need to be switched from a newer anticoagulant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for reasons such as cost, availability, or intolerance.",
"    <strong>",
"    </strong>",
"    The US Food and Drug Administration has required the manufacturers of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    to include information about transitioning patients to warfarin. As these newer agents have a relatively short period of clinical efficacy compared to warfarin, there is a concern that patients might not be adequately anticoagulated unless there is a period of drug overlap. This concern was supported by the observation of an increased risk of stroke in the ARISTOTLE and ROCKET AF trials when patients were transitioned from these newer agents to warfarin at the end of the trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there are no data to inform us as to the optimal method of transition, we believe that consideration should be given to co-administration of&nbsp;each of these newer anticoagulants with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for at least two (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ), and perhaps three (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , assuming normal renal function) days prior to stopping these newer agents. In some cases, consideration can also be given to starting a parenteral anticoagulant and warfarin at the time the next dose of a newer agent would have been taken.",
"   </p>",
"   <p>",
"    Practitioners should also be aware that the newer agents can alter the international normalized ratio (INR), causing uncertainty as to when the patient is properly anticoagulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Licensing information available from the European Medicines Agency&nbsp;includes the following text regarding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    : After two days of co-administration of apixaban with warfarin therapy, obtain an INR prior to the next scheduled dose of apixaban. Continue co-administration of apixaban and warfarin therapy until the INR is &ge;2.0 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H433859457\">",
"    <span class=\"h4\">",
"     Temporary discontinuation of newer oral anticoagulants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Temporary discontinuation of any of the newer oral anticoagulants (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ) for bleeding or planned surgery or invasive procedure results in an increased risk of thromboembolism after the period of effective anticoagulation has ended. The optimal approach to such patients is unclear and likely depends on issues such as baseline thromboembolic risk, duration of anticoagulant, and risk of bleeding. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link&amp;anchor=H4559912#H4559912\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Rivaroxaban and apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link&amp;anchor=H4559905#H4559905\">",
"     \"Management of anticoagulation before and after elective surgery\", section on 'Dabigatran'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1803752\">",
"    <span class=\"h3\">",
"     Summary of anticoagulant monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation with each of the newer agents (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    ) leads to similar or lower rates both of ischemic stroke and major bleeding compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . Important additional advantages of these newer agents include convenience (no requirement for routine testing of the international normalized ratio), a small reduction in the risk of intracranial hemorrhage, and less susceptibility to dietary and drug interactions. Disadvantages include lack of an antidote and the potential that, with time, unidentified side effects will become evident, such as a potentially higher rate of myocardial infarction with dabigatran and twice daily regimen (dabigatran and apixaban). Should experience in real world populations mirror the net clinical benefit found in randomized trials, our confidence in the superiority of these drugs will increase. (See",
"    <a class=\"local\" href=\"#H4338483\">",
"     'Dabigatran'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We believe that anticoagulation, when indicated, is reasonable with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or a newer agent. We believe the evidence suggests that the three newer agents have similar efficacy and safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alternatives to anticoagulant monotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the randomized trials of oral factor Xa and direct thrombin inhibitors (discussed above), alternatives to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    with antiplatelet therapy were studied, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , low-dose warfarin plus aspirin, and aspirin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    . Warfarin is superior to these alternatives in patients at high risk of stroke, while aspirin therapy is considered a reasonable option in patients at low thromboembolic risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4339005\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    has been compared to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or placebo and been shown to be less effective than the former and not clearly superior to the latter. Thus, the evidence to support the use of aspirin for the prevention of thromboembolic events in patients with AF is very weak.",
"   </p>",
"   <p>",
"    Randomized trials have shown that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is consistently and substantially less effective than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in all AF patients with a CHADS2 score above 0 (",
"    <a class=\"graphic graphic_table graphicRef66736 \" href=\"mobipreview.htm?17/44/18124\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/3,8,9\">",
"     3,8,9",
"    </a>",
"    ]. The magnitude of the difference was illustrated in an individual patient meta-analysis of six prevention trials (AFASAK 1, EAFT, PATAF, SPAF-II, AFASAK 2, SPAF-III) in patients with nonvalvular AF (76 percent primary prevention) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients treated with warfarin were significantly less likely to experience an ischemic stroke (2.0 versus 4.3 per 100 patient-years, hazard ratio 0.55, 95% CI 0.45-0.71); the benefit was similar in patients with chronic and paroxysmal AF. It was concluded that treating 100 patients with warfarin rather than aspirin for one year would prevent 2.3 ischemic strokes.",
"   </p>",
"   <p>",
"    The issue of whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    could be a reasonable choice in very low risk patients (CHADS2 = 0) has not been well addressed. The individual trials that compared aspirin to placebo enrolled very few such patients. Two meta-analyses performed in 2006 and 2007 found that the risk of stroke was reduced by about 20 percent, but that the confidence intervals included the potential for harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/8,10\">",
"     8,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, for patients with no identified clinical risk factors for stroke, defined as a CHADS2 score of 0,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is of uncertain benefit (or anticoagulant). This is consistent with the 2012 European Society of Cardiology guidelines for the management of AF, which concluded that the available evidence does not support the use of aspirin in most patients who are defined as a CHA2DS2-VASc of 0 or 1, as the risk of bleeding may exceed the small benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/22\">",
"     22",
"    </a>",
"    ]. That document does recommend oral anticoagulant therapy for patients with a CHA2DS2-VASc score of 1.",
"   </p>",
"   <p>",
"    For those patients with CHADS2 score of 0 and a CHA2DS2-VASc score of 0, and who are willing to accept the risks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy in exchange for a likely small decrease in the risk of stroke, aspirin may be a reasonable choice. With regard to efficacy, there is no solid evidence favoring one dose of aspirin over another, although several trials have used 325 mg daily. No significant difference in bleeding risk has been found between doses of aspirin above 162 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    compared to 75 to 162",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    While some of our authors and reviewers are comfortable with an aspirin dose within the 75 to 325 mg daily range, most prefer a dose of 75 or 81 mg daily. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H6#H6\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for secondary prevention of cardiovascular disease in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    for AF is discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Patients on long-term antiplatelet therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Aspirin plus clopidogrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two large randomized trials have investigated the safety and efficacy of dual antiplatelet therapy in patients with AF. ACTIVE W compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and ACTIVE A compared clopidogrel plus aspirin to aspirin alone in patients who were not candidates for anticoagulation with a vitamin K antagonist. All of the patients in the two trials had AF and one or more risk factors for stroke (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ). The primary end point in both trials was a composite outcome (the first occurrence of stroke, systemic [non-central nervous system] embolization, MI, or vascular death).",
"   </p>",
"   <p>",
"    The ACTIVE W trial included 6706 patients who were randomly assigned to combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or to oral anticoagulation with a vitamin K antagonist (target INR 2.0 to 3.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/90\">",
"     90",
"    </a>",
"    ]. The trial was stopped at an interim analysis after a median follow-up of 1.3 years because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation significantly lowered the annual rate of the primary end point compared to combined antiplatelet therapy (3.9 versus 5.6 percent, relative risk 0.69, 95% CI 0.57-0.85). Although the overall rate of bleeding was significantly increased in the dual antiplatelet group (15.4 versus 13.2 percent per year), there was no significant difference in major bleeding (2.4 versus 2.2 percent per year). There were numerically more myocardial infarction events in dual antiplatelet therapy treated patients, compared to warfarin. Thus, in AF patients who are candidates for oral anticoagulation, dual antiplatelet therapy should NOT be considered an alternative.",
"   </p>",
"   <p>",
"    The ACTIVE A trial included 7554 patients with AF who were not candidates for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation and were randomly assigned to combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or to aspirin alone at the same dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/91\">",
"     91",
"    </a>",
"    ]. The reasons that patients were not considered candidates for anticoagulation included the physician's judgment that such treatment was inappropriate (50 percent), a specific risk for bleeding (23 percent), and strong patient preference (26 percent). Patients were excluded from participation in ACTIVE A if they had documented peptic ulcer disease in the previous six months, significant thrombocytopenia, prior ICH, or ongoing alcohol abuse. The primary end point, as in ACTIVE W, was the first occurrence of stroke, systemic (non-central nervous system) embolization, myocardial infarction, or vascular death.",
"   </p>",
"   <p>",
"    After a median follow-up period of 3.6 years, patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    had a significantly lower annual rate of the primary combined end point (6.8 versus 7.8 percent, relative risk [RR] 0.89, 95% CI 0.81-0.98), which was primarily driven by a reduction in stroke (2.4 versus 3.3 percent, RR 0.72, 95% CI 0.62-0.83). On the other hand, dual antiplatelet therapy had a significantly increased incidence of major bleeding (2.0 versus 1.3 percent per year, RR 1.57, 95% CI 1.29-1.92).",
"   </p>",
"   <p>",
"    The net clinical benefit of adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (compared to aspirin monotherapy) was assessed in an analysis of data from the two ACTIVE trials, using methodology similar to that discussed above (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Net clinical benefit'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/92\">",
"     92",
"    </a>",
"    ]. There was a small non-significant benefit, defined as ischemic stroke equivalents prevented, to combination therapy (0.57 events per 100 patient-years of treatment; 95% CI -0.12-1.24).",
"   </p>",
"   <p>",
"    Dual antiplatelet therapy may be a reasonable alternative to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone in the occasional high-risk patient with AF who CANNOT be treated with anticoagulation. With the availability of newer oral anticoagulants, this situation should be extremely uncommon. It should be kept in mind that as dual antiplatelet therapy and oral anticoagulation have similar bleeding risks, a patient who would not be a candidate for oral anticoagulation because of bleeding risk is also not a candidate for dual antiplatelet therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H411109061\">",
"    <span class=\"h3\">",
"     Aspirin plus low-dose warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , low-dose warfarin (1.25",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or target INR between 1.2 and 1.5) in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (300 to 325",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    should",
"    <strong>",
"     not",
"    </strong>",
"    be used to reduce stroke risk in patients with non-valvular AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/26,52,93\">",
"     26,52,93",
"    </a>",
"    ]. In the SPAF-III trial of 1044 patients with AF who were at high risk for embolism, low-dose warfarin plus aspirin had a much higher rate of morbidity and mortality than full",
"    <span class=\"nowrap\">",
"     anticoagulation/adjusted-dose",
"    </span>",
"    warfarin (",
"    <a class=\"graphic graphic_figure graphicRef72790 \" href=\"mobipreview.htm?36/37/37469\">",
"     figure 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62833 \" href=\"mobipreview.htm?17/40/18062\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H411109157\">",
"    <span class=\"h3\">",
"     Aspirin plus full dose warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antithrombotic strategies listed directly above address concerns about the INR monitoring, dietary and medication interactions, and the risk of major bleeding. The issue of whether combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus full dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    might have greater efficacy than warfarin alone has not been well studied. In a post-hoc analysis of the SPORTIF trials, which included a high percentage of patients with cardiovascular disease or at high risk, combination therapy with warfarin (or ximelagatran) plus aspirin, in comparison to anticoagulant alone, did not reduce the rate of stroke or systemic embolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, patients may require",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (or other antiplatelet agent) for reasons such as the primary or secondary prevention of coronary artery disease, treatment of acute coronary syndrome, or after placement of an intracoronary stent. This issue is discussed below. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Patients on long-term antiplatelet therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Nonpharmacologic alternatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventional techniques to prevent thrombus formation in the left atrial appendage have been attempted. The data evaluating the efficacy of these procedures are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21686?source=see_link\">",
"     \"Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonpharmacologic strategies to prevent recurrent AF might reduce the risk of embolic stroke. Approaches that may be considered include the surgical atrial",
"    <span class=\"nowrap\">",
"     isolation/maze",
"    </span>",
"    procedure in patients undergoing cardiac surgery for some other reason and pulmonary vein isolation by radiofrequency catheter ablation. However, there are only limited data confirming a reduction in embolic risk with these procedures, and their use should be considered only in selected patients and only by experienced operators. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40938?source=see_link\">",
"     \"Radiofrequency catheter ablation to prevent recurrent atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5367?source=see_link\">",
"     \"The role of pacemakers in the prevention of atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=see_link\">",
"     \"Surgical approaches to prevent recurrent atrial fibrillation\"",
"    </a>",
"    .) The previously mentioned AFFIRM and RACE data, suggesting thromboembolic risk was unrelated to maintenance of sinus rhythm, would suggest that these non-pharmacologic strategies will not obviate the need for anticoagulation in at-risk patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Specific patient groups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H524844231\">",
"    <span class=\"h3\">",
"     Patients with acute stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the prevention of secondary embolism in AF patients with an acute stroke and for the antithrombotic management of patients with an acute embolic stroke are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=see_link\">",
"     \"Stroke in patients with atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H652183\">",
"    <span class=\"h3\">",
"     Patients with prior stroke or TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among all known predictors of stroke in patients with AF, prior stroke or transient ischemic attack (TIA) is the strongest independent predictor. In patients not treated with anticoagulant therapy, the annual rate is between 6 and 10 percent per year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/95\">",
"     95",
"    </a>",
"    ]. Outcomes comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in this subgroup of patients are presented above. (See",
"    <a class=\"local\" href=\"#H147982962\">",
"     'Apixaban'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Patients treated with rhythm control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients treated with pharmacologic rhythm control have rates of thromboembolic events similar to those with rate control, as was shown in the RACE and AFFIRM trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=see_link&amp;anchor=H8#H8\">",
"     \"Rhythm control versus rate control in atrial fibrillation\", section on 'Comparative studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This observation likely occurs for two reasons: recurrent episodes of AF are common and asymptomatic in up to 90 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/96,97\">",
"     96,97",
"    </a>",
"    ], and some patients have other reasons for thromboembolic risk, such as aortic plaque or left ventricular systolic dysfunction for which anticoagulation may be protective from clinical thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these findings, most patients with AF, regardless of whether a rate-control or rhythm-control strategy is chosen, should receive antithrombotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Patients with hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of anticoagulant therapy is less well defined in patients in whom the underlying disease associated with AF can be corrected, as in hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=see_link&amp;anchor=H6#H6\">",
"     \"Cardiovascular effects of hyperthyroidism\", section on 'Atrial fibrillation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    guidelines recommended",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation (INR 2.0 to 3.0) in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21\">",
"     21",
"    </a>",
"    ]. This recommendation was made even without firm evidence that AF in hyperthyroidism is associated with increased thromboembolic risk. Once the patient is euthyroid, the recommendations for antithrombotic prophylaxis if AF persists are similar to those in patients without hyperthyroidism (see",
"    <a class=\"local\" href=\"#H621956305\">",
"     'Prevention approach by CHADS2 score'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Lower-than-expected",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    doses are usually required, since hyperthyroidism is associated with increased clearance of vitamin K-dependent clotting factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H485506357\">",
"    <span class=\"h3\">",
"     Patients undergoing cardiac surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patient at risk of AF after cardiac surgery is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=see_link\">",
"     \"Atrial fibrillation and flutter after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Patients on long-term antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combined therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and an anticoagulant may be reasonable in selected patients with coronary artery disease, especially those with acute coronary syndromes or those who have received coronary stents, for whom the potential benefits may outweigh the increased risk of hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/99-101\">",
"     99-101",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link&amp;anchor=H2#H2\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\", section on 'TOAT versus other therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=see_link\">",
"     \"Chronic anticoagulation after acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H32#H32\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Patients who require warfarin'",
"    </a>",
"    .) The issue of whether aspirin is necessary for secondary prevention of cardiovascular disease in patients treated with anticoagulant for AF is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H611366894#H611366894\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Anticoagulated patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, neither",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is as effective as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in preventing stroke. However, the combination of antiplatelet with anticoagulant increases the risk of bleeding compared to either alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/102\">",
"     102",
"    </a>",
"    ]. Thus, for patients with indications for both therapies, any potential benefit must take into account an increased risk of bleeding with concomitant antiplatelet and anticoagulant therapy.",
"   </p>",
"   <p>",
"    The impact of antiplatelet therapy on bleeding (and efficacy) outcomes in patients taking either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    was evaluated in a post hoc, subgroup analysis of the RE-LY trial (see",
"    <a class=\"local\" href=\"#H4338483\">",
"     'Dabigatran'",
"    </a>",
"    above) in which about 40 percent of patients were taking concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    at some point during the study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/103\">",
"     103",
"    </a>",
"    ]. Very few patients were taking two antiplatelet agents and individuals taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    were not enrolled. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      110 mg twice daily to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for the prevention of ischemic events, antiplatelet therapy did not significantly change the relative risk (dabigatran non-inferior to warfarin). With regard to the outcome of major bleeding, the relative risk did not change significantly, but the crude rates of bleeding were higher in those receiving antiplatelet therapy (2.22 versus 2.81 and 3.84 versus 4.81 percent, comparing dabigatran 110 mg to warfarin in the no antiplatelet and antiplatelet groups, respectively).",
"     </li>",
"     <li>",
"      In the comparison of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      150 mg twice daily to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      for safety end point of ischemic events, there was a non-significant decrease in the relative superiority of dabigatran compared to warfarin with the use of antiplatelet therapy (hazard ratios [HR] 0.52, 95% CI 0.38-0.72 and 0.80, 95% CI 0.59-1.08, comparing dabigatran to warfarin in the no antiplatelet and antiplatelet groups, respectively). With regard to the outcome of major bleeding, the relative risk did not change significantly, but the crude rates of bleeding were higher in those receiving antiplatelet therapy (2.65 versus 2.81 for dabigatran 150 mg twice daily and 4.41 versus 4.81 percent for warfarin (INR 2.0-3.0), comparing the no antiplatelet and antiplatelet groups, respectively).",
"     </li>",
"     <li>",
"      Concomitant use of a single antiplatelet agent significantly increased the risk of major bleeding (hazard ratio 1.60) while dual antiplatelet therapy increased this risk to a greater extent (HR 2.31).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This subgroup analysis from RE-LY raises the possibility that in AF patients treated with both oral anticoagulant and antiplatelet therapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    might be preferred to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    to reduce the absolute risk of major bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304772709\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the use of antithrombotic agents in patients with AF are available from the American College of Cardiology",
"    <span class=\"nowrap\">",
"     Foundation/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/Heart",
"    </span>",
"    Rhythm Society, the European Society of Cardiology, and the American College of Chest Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21,22,40,104,105\">",
"     21,22,40,104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We agree with relevant recommendations made in these guidelines with the following exceptions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European Society of Cardiology updated its AF guideline in 2012 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/22\">",
"       22",
"      </a>",
"      ]. In this document, the CHA2DS2-VASc score is preferred to the CHADS2 score for risk assessment. This guideline makes a weak recommendation for oral anticoagulant therapy for those with a CHA2DS2-VASc score of 1 (and a CHADS2 score of 0. (See",
"      <a class=\"local\" href=\"#H621956305\">",
"       'Prevention approach by CHADS2 score'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American College of Cardiology",
"      <span class=\"nowrap\">",
"       Foundation/American",
"      </span>",
"      Heart",
"      <span class=\"nowrap\">",
"       Association/Heart",
"      </span>",
"      Rhythm Society (2006 and 2011) and the American College of Chest Physicians (2012) guidelines do not make recommendations for either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      as they were written prior to publication of the ARISTOTLE and ROCKET AF randomized trials. (See",
"      <a class=\"local\" href=\"#H524842274\">",
"       'Direct thrombin and factor Xa inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A scientific advisory (Oral antithrombotic agents for the prevention of stroke in nonvalvular AF) from the American Heart",
"      <span class=\"nowrap\">",
"       Association/American",
"      </span>",
"      Stroke Association was published in 2012 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/32/42506/abstract/106\">",
"       106",
"      </a>",
"      ]. It emphasized caution with the use of the newer agents in patients with chronic kidney disease and in those older than 80 years, as well as when used in combination with an antiplatelet agent. The document also noted that the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      75 mg twice daily may be considered, but its safety and efficacy have not been established.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=see_link\">",
"       \"Patient information: Atrial fibrillation (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=see_link\">",
"       \"Patient information: Medicines for atrial fibrillation (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=see_link\">",
"       \"Patient information: Latest medicines to prevent blood clots (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=see_link\">",
"       \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=see_link\">",
"       \"Patient information: Warfarin (Coumadin) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H485506384\">",
"    <span class=\"h2\">",
"     Indications for and choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombotic therapy with anticoagulant therapy is effective in reducing the risk of systemic embolization in patients with nonvalvular atrial fibrillation (AF). Anticoagulation, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    reduces this risk by almost 70 percent, and should be considered for most of these patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    reduces the risk by a much smaller amount.",
"    <br/>",
"    <br/>",
"    Aspirin has been compared to either warfarin or placebo and been shown to be less effective than the former and not clearly superior to the latter. Combination antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    plus aspirin is superior to aspirin and inferior to warfarin in terms of efficacy, but is associated with a higher rate of bleeding than aspirin alone (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Alternatives to anticoagulant monotherapy'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Risk (of arterial embolization) stratification should be performed in all patients as part of the process of choosing therapy. Some of our experts prefer the CHADS2 score (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 1",
"    </a>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/38/1633?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), while others prefer the CHA2DS2-VASc score (",
"    <a class=\"graphic graphic_table graphicRef83272 \" href=\"mobipreview.htm?30/23/31101\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Risk stratification to guide therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The use of antithrombotic therapy is also associated with an increased risk of major bleeding. Prior to recommending its use, patients should be informed of this risk. However, most patients do not need a formal assessment of bleeding, as the benefit from therapy will outweigh the risks in most patients. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Net clinical benefit'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our recommendations for antithrombotic therapy in patients with nonvalvular AF are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients with CHADS2 and CHA2DS2-VASc scores of 0, we suggest no antithrombotic therapy rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4339005\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients with a CHADS2 score of 0 but who have one risk factor included in the CHA2DS2-VASc model (age 65 to 74 years, atherosclerotic cardiovascular disease, or female sex), our authors and reviewers have differing approaches, with some recommending no antithrombotic therapy and some recommending oral anticoagulant therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For patients with a CHADS2 score greater than 0, we recommend chronic antithrombotic therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H621956777\">",
"       'Prevention approach by CHA2DS2-VASc score'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a CHADS2 score of 1, we suggest anticoagulant therapy in preference to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). In deciding between the two, it is particularly important to be sure patients are well informed about the benefits and risks of therapy, and that patient preferences are part of the decision. For patients at high risk of major bleeding (",
"      <a class=\"graphic graphic_table graphicRef59051 \" href=\"mobipreview.htm?32/58/33707\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75259 \" href=\"mobipreview.htm?38/14/39148\">",
"       table 6",
"      </a>",
"      ), aspirin is a reasonable choice. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bleeding risk'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Net clinical benefit'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with CHADS2 score of 2 or greater, we recommend anticoagulant rather than antiplatelet therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For the uncommon patient who cannot take anticoagulant therapy for reasons other than bleeding risk, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 to 100 mg daily plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      75 mg daily, rather than aspirin alone (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Alternatives to anticoagulant monotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with AF for whom anticoagulant therapy is chosen, we suggest an oral direct thrombin inhibitor or a factor Xa inhibitor rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1803752\">",
"       'Summary of anticoagulant monotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       Dabigatran",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      should not be used in patients with impaired renal function (eGFR less than 30 mL per min), those with prosthetic heart valves, those with mitral stenosis, or those with other valvular lesions associated with moderate to severe heart failure that might lead to valve replacement in the near future.",
"      <br/>",
"      <br/>",
"      Warfarin is a reasonable choice in the following circumstances:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients already on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      who are comfortable with periodic international normalized ratio (INR) measurement and whose INR has been relatively easy to control.",
"     </li>",
"     <li>",
"      Patients who are not likely to comply with the twice daily dosing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      (or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       apixaban",
"      </a>",
"      ), and for whom once-a-day",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       rivaroxaban",
"      </a>",
"      is not available.",
"     </li>",
"     <li>",
"      Patients for whom the cost of medication is an important concern.",
"     </li>",
"     <li>",
"      Patients with chronic kidney disease, whose estimated glomerular filtration rate is less than 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39721?source=see_link&amp;anchor=H9066197#H9066197\">",
"       \"Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease\", section on 'Benefits and risks of oral antithrombotic therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4535204\">",
"    <span class=\"h2\">",
"     Dosing issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of the newer anticoagulants",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     rivaroxaban",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"     apixaban",
"    </a>",
"    should take into account potential drug interactions (",
"    <a class=\"graphic graphic_table graphicRef73141 \" href=\"mobipreview.htm?12/29/12766\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61344 \" href=\"mobipreview.htm?24/0/24590\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef87789 \" href=\"mobipreview.htm?7/56/8078\">",
"     table 10",
"    </a>",
"    ) and the presence of chronic renal disease. Additional information on anticoagulant dosing is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients prescribed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,&nbsp;we recommend a target INR between 2.0 and 3.0, as opposed to values below or above this range (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The efficacy and safety of warfarin therapy decreases the more time the patient spends outside this INR range. For patients whose time in therapeutic range cannot be increased above 60 percent, consideration should be given to using another anticoagulant. Patients whose time in therapeutic range is persistently below 50 percent may be getting little to no benefit from warfarin therapy. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'INR monitoring and goal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients prescribed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      , we suggest the 150 mg twice daily dose, as opposed to the 110 mg dose, for most patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Where available, the 110 mg twice daily dose may be preferred in those who are particularly concerned about the risk of bleeding or in those assessed to be at increased risk of bleeding, such as patients older than 75 years. (See",
"      <a class=\"local\" href=\"#H4338483\">",
"       'Dabigatran'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Bleeding risk'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the United States, the 110 mg capsule is not available, and a 75 mg capsule has been marketed. We suggest not using the 75 mg twice daily dose (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4338483\">",
"       'Dabigatran'",
"      </a>",
"      above.) The use of dabigatran in patients with a creatinine clearance less than 30",
"      <span class=\"nowrap\">",
"       mL/min/1.73m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39721?source=see_link&amp;anchor=H9066239#H9066239\">",
"       \"Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease\", section on 'Summary and recommendations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"       Rivaroxaban",
"      </a>",
"      should be prescribed at a dose of 20 mg daily for those with a creatinine clearance of at least 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      or 15 mg daily in patients with a creatinine clearance of 30 to 49",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/62/39911?source=see_link\">",
"       Apixaban",
"      </a>",
"      should be prescribed at a dose of 5 mg twice daily. This anticoagulant may be particularly advantageous for those not considered a suitable candidate for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      . The recommended dose for patients with two or more of the following risk factors is 2.5 mg twice daily: age &ge;80 years, weight &le;60 kg, or serum creatinine &ge;1.5",
"      <span class=\"nowrap\">",
"       ml/dL.",
"      </span>",
"     </li>",
"     <li>",
"      For the rare patient in whom",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      is chosen as antithrombotic monotherapy, doses that have shown benefit range between 75 and 325 mg daily. Most, but not all, of our authors and reviewers prefer dosing at the lower end of the range. (See",
"      <a class=\"local\" href=\"#H4339005\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12718815\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Robert Hart, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/1\">",
"      The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med 1990; 323:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/2\">",
"      Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/3\">",
"      Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/4\">",
"      Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989; 1:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/5\">",
"      Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/6\">",
"      Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/7\">",
"      Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/8\">",
"      Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/9\">",
"      van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/10\">",
"      Cooper NJ, Sutton AJ, Lu G, Khunti K. Mixed comparison of stroke prevention treatments in individuals with nonrheumatic atrial fibrillation. Arch Intern Med 2006; 166:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/11\">",
"      Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/12\">",
"      Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285:2864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/13\">",
"      Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/14\">",
"      Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012; 33:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/15\">",
"      Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/16\">",
"      Ogilvie IM, Welner SA, Cowell W, Lip GY. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/17\">",
"      Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/18\">",
"      Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/19\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/20\">",
"      Man-Son-Hing M, Laupacis A, O'Connor AM, et al. A patient decision aid regarding antithrombotic therapy for stroke prevention in atrial fibrillation: a randomized controlled trial. JAMA 1999; 282:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/21\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/22\">",
"      Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33:2719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/23\">",
"      Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation 2012; 126:2381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/24\">",
"      Adam SS, McDuffie JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med 2012; 157:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/25\">",
"      Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials. Stroke 2012; 43:3298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/26\">",
"      McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003; 139:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/27\">",
"      Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. JAMA 1999; 281:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/28\">",
"      van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/29\">",
"      Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/30\">",
"      Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/31\">",
"      Hart RG, Pearce LA. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009; 40:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/32\">",
"      Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. Arch Intern Med 2012; 172:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/33\">",
"      Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/34\">",
"      Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009; 54:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/35\">",
"      Hughes M, Lip GY, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007; 100:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/36\">",
"      Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/37\">",
"      Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999; 9:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/38\">",
"      Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/39\">",
"      Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/40\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/41\">",
"      Murray RD, Shah A, Jasper SE, et al. Transesophageal echocardiography guided enoxaparin antithrombotic strategy for cardioversion of atrial fibrillation: the ACUTE II pilot study. Am Heart J 2000; 139:E1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/42\">",
"      Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/43\">",
"      Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/44\">",
"      Fuster V, Ryd&eacute;n LE, Asinger RW, et al. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology. Circulation 2001; 104:2118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/45\">",
"      Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/46\">",
"      Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996; 335:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/47\">",
"      Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/48\">",
"      Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med 1995; 333:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/49\">",
"      Singer DE, Chang Y, Fang MC, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/50\">",
"      Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2008; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/51\">",
"      Od&eacute;n A, Fahl&eacute;n M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/52\">",
"      Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/53\">",
"      Reynolds MW, Fahrbach K, Hauch O, et al. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and metaanalysis. Chest 2004; 126:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/54\">",
"      White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/55\">",
"      Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/56\">",
"      Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/57\">",
"      Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/58\">",
"      Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/59\">",
"      Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/60\">",
"      Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/61\">",
"      Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007; 167:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/62\">",
"      Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/63\">",
"      Gage BF, Boechler M, Doggette AL, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation. Stroke 2000; 31:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/64\">",
"      Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 2006; 97:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/65\">",
"      Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/66\">",
"      Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/67\">",
"      Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/68\">",
"      Gorin L, Fauchier L, Nonin E, et al. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 2011; 140:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/69\">",
"      Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010; 3:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/70\">",
"      Bernhardt P, Schmidt H, Hammerstingl C, et al. Patients with atrial fibrillation and dense spontaneous echo contrast at high risk a prospective and serial follow-up over 12 months with transesophageal echocardiography and cerebral magnetic resonance imaging. J Am Coll Cardiol 2005; 45:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/71\">",
"      Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/72\">",
"      Rold&aacute;n V, Mar&iacute;n F, Mui&ntilde;a B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/73\">",
"      Tang RB, Dong JZ, Liu XP, et al. Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation? Thromb Haemost 2011; 105:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/74\">",
"      Gage BF. Can we rely on RE-LY? N Engl J Med 2009; 361:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/75\">",
"      Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/76\">",
"      Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation 2010; 122:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/77\">",
"      Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/78\">",
"      Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/79\">",
"      Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172:397.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm?source=govdelivery (Accessed on November 02, 2012).",
"    </li>",
"    <li>",
"     Pradaxa (dabigatran etexilate) US prescribing information file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ba74e3cd-b06f-4145-b284-5fd6b84ff3c9 (Accessed on November 16, 2011).",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333634.htm.",
"    </li>",
"    <li>",
"     file://news.bms.com/press-release/financial-news/eliquisapixaban-approved-europe-prevention-stroke-and-systemic-embolism&amp;t=634890181706594412.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/84\">",
"      Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/85\">",
"      Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol 2012; 11:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/86\">",
"      Lopes RD, Al-Khatib SM, Wallentin L, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. Lancet 2012; 380:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/87\">",
"      Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/88\">",
"      Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013; 61:651.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/90\">",
"      ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/91\">",
"      ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/92\">",
"      Connolly SJ, Eikelboom JW, Ng J, et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/93\">",
"      Gull&oslash;v AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998; 158:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/94\">",
"      Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/95\">",
"      Hart RG, Eikelboom JW. Reducing the risk of recurrent stroke in patients with AF. Lancet Neurol 2012; 11:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/96\">",
"      Israel CW, Gr&ouml;nefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/97\">",
"      Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 1994; 89:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/98\">",
"      Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/99\">",
"      Lip GY. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008; 336:614.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson, J, Adams, C, Antman, E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/101\">",
"      Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/102\">",
"      Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/103\">",
"      Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/104\">",
"      European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/105\">",
"      Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/32/42506/abstract/106\">",
"      Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2012; 43:3442.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1031 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42506=[""].join("\n");
var outline_f41_32_42506=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENTS WITH VALVULAR HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H621955964\">",
"      MECHANISM OF THROMBOEMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RISK STRATIFICATION TO GUIDE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ANTITHROMBOTIC PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621956305\">",
"      Prevention approach by CHADS2 score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H621956777\">",
"      Prevention approach by CHA2DS2-VASc score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1127350851\">",
"      Patients with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H147982501\">",
"      Studies of anticoagulant monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bleeding risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Net clinical benefit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INR monitoring and goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Temporary cessation of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Underutilization and discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Thromboembolism in anticoagulated patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H524842274\">",
"      - Direct thrombin and factor Xa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4338483\">",
"      Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H17731647\">",
"      - Drug stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H358919860\">",
"      Rivaroxaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H147982962\">",
"      Apixaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H524842440\">",
"      Reversal of anticoagulant effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H433859596\">",
"      Transition from newer oral anticoagulants to warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H433859457\">",
"      Temporary discontinuation of newer oral anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1803752\">",
"      - Summary of anticoagulant monotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alternatives to anticoagulant monotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4339005\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Aspirin plus clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H411109061\">",
"      - Aspirin plus low-dose warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H411109157\">",
"      - Aspirin plus full dose warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Nonpharmacologic alternatives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Specific patient groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H524844231\">",
"      - Patients with acute stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H652183\">",
"      - Patients with prior stroke or TIA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Patients treated with rhythm control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Patients with hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H485506357\">",
"      - Patients undergoing cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Patients on long-term antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304772709\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H485506384\">",
"      Indications for and choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4535204\">",
"      Dosing issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12718815\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1031\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1031|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/8/39053\" title=\"figure 1\">",
"      Warfarin in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/18/33069\" title=\"figure 2\">",
"      Anticoag AF age risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/18/43296\" title=\"figure 3\">",
"      Events in AF according to INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/27/42430\" title=\"figure 4\">",
"      Optimal INR oral anticoag",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/37/37469\" title=\"figure 5\">",
"      Low dose warfarin high risk AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/40/18062\" title=\"figure 6\">",
"      Event rates in SPAF III",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1031|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 1\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/12/35021\" title=\"table 2\">",
"      Anticoagulant trials AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/23/31101\" title=\"table 3\">",
"      CHA2DS2-VASc score and stroke risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/44/18124\" title=\"table 4\">",
"      Warfarin and aspirin in AF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/58/33707\" title=\"table 5\">",
"      Bleeding risk index warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/14/39148\" title=\"table 6\">",
"      HAS-BLED risk score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/31/19964\" title=\"table 7\">",
"      Warfarin maintenance dose adjustment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/0/24590\" title=\"table 8\">",
"      Dabigatran drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/29/12766\" title=\"table 9\">",
"      Rivaroxaban drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/56/8078\" title=\"table 10\">",
"      Apixaban drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/38/1633?source=related_link\" title=\"calculator 1\">",
"      Calculator: Atrial fibrillation CHADS(2) score for stroke risk",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/14/1258?source=related_link\">",
"      Anticoagulation in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/11/18618?source=related_link\">",
"      Antithrombotic therapy in patients with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/59/28602?source=related_link\">",
"      Atrial fibrillation and flutter after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31528?source=related_link\">",
"      Echocardiographic evaluation of the atria and appendages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39721?source=related_link\">",
"      Management of thromboembolic risk in patients with atrial fibrillation and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43528?source=related_link\">",
"      Mechanisms of thrombogenesis in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21686?source=related_link\">",
"      Nonpharmacologic therapy to prevent embolization in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/41/31384?source=related_link\">",
"      Paroxysmal atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/15/249?source=related_link\">",
"      Pathophysiology of ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/11/14515?source=related_link\">",
"      Patient information: Latest medicines to prevent blood clots (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/36/17986?source=related_link\">",
"      Patient information: Medicines for atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/15/21747?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?2/44/2755?source=related_link\">",
"      Patient information: Warfarin (Coumadin) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/62/40938?source=related_link\">",
"      Radiofrequency catheter ablation to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/43/5817?source=related_link\">",
"      Rhythm control versus rate control in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/12/27849?source=related_link\">",
"      Risk of intracerebral hemorrhage in patients treated with warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/29/39383?source=related_link\">",
"      Stroke in patients with atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/45/37591?source=related_link\">",
"      Surgical approaches to prevent recurrent atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/15/5367?source=related_link\">",
"      The role of pacemakers in the prevention of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_32_42507="Iron overload syndromes";
var content_f41_32_42507=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of excess iron accumulation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mechanism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Increased gastrointestinal iron absorption",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"7\">",
"        From a normal diet",
"       </td>",
"       <td>",
"        Hereditary hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ineffective erythropoiesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sideroblastic anemias - hereditary or acquired",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Severe thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Porphyria cutanea tarda",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syndrome of liver iron overload with normal transferrin saturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic liver disease (eg, hepatitis B or C, steatohepatitis, prior portacaval shunt)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        From an iron loaded diet",
"       </td>",
"       <td>",
"        African iron loading",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Multiple red cell transfusions or prolonged parenteral iron infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Children",
"       </td>",
"       <td>",
"        Severe beta thalassemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diamond-Blackfan anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital dyserythropoietic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Adults",
"       </td>",
"       <td>",
"        Sickle cell anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelodysplastic syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Refractory aplastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Long-term hemodialysis patients",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42507=[""].join("\n");
var outline_f41_32_42507=null;
var title_f41_32_42508="Anticholinergic risk scale";
var content_f41_32_42508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F57410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F57410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anticholinergic risk scale*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        3 points",
"       </td>",
"       <td class=\"subtitle1\">",
"        2 points",
"       </td>",
"       <td class=\"subtitle1\">",
"        1 Point",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amitriptyline",
"       </td>",
"       <td>",
"        Amantadine",
"       </td>",
"       <td>",
"        Carbidopa-levodopa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atropine",
"       </td>",
"       <td>",
"        Baclofen",
"       </td>",
"       <td>",
"        Entacapone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benztropine",
"       </td>",
"       <td>",
"        Cetirizine",
"       </td>",
"       <td>",
"        Haloperidol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carisoprodol",
"       </td>",
"       <td>",
"        Cimetidine",
"       </td>",
"       <td>",
"        Methocarbamol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpheniramine",
"       </td>",
"       <td>",
"        Clozapine",
"       </td>",
"       <td>",
"        Metoclopramide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorpromazine",
"       </td>",
"       <td>",
"        Cyclobenzaprine",
"       </td>",
"       <td>",
"        Mirtazapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyproheptadine",
"       </td>",
"       <td>",
"        Desipramine",
"       </td>",
"       <td>",
"        Paroxetine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dicyclomine",
"       </td>",
"       <td>",
"        Loperamide",
"       </td>",
"       <td>",
"        Pramipexole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diphenhydramine",
"       </td>",
"       <td>",
"        Loratadine",
"       </td>",
"       <td>",
"        Quetiapine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluphenazine",
"       </td>",
"       <td>",
"        Nortriptyline",
"       </td>",
"       <td>",
"        Ranitidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxyzine",
"       </td>",
"       <td>",
"        Olanzapine",
"       </td>",
"       <td>",
"        Risperidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyoscyamine",
"       </td>",
"       <td>",
"        Prochlorperazine",
"       </td>",
"       <td>",
"        Selegiline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Imipramine",
"       </td>",
"       <td>",
"        Pseudoephedrine-triprolidine (combination)",
"       </td>",
"       <td>",
"        Trazodone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meclizine",
"       </td>",
"       <td>",
"        Tolterodine",
"       </td>",
"       <td>",
"        Ziprasidone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxybutynin",
"       </td>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"7\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perphenazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Promethazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thioridazine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiothixene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tizanidine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trifluoperazine",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: This is not a complete list of all medications&nbsp;that can&nbsp;cause&nbsp;anticholinergic effects.",
"    <br>",
"     Class IA antiarrhythmics, which are not listed, have significant dose related anticholinergic effects (disopyramide &gt; procainamide and quinidine) according to the US licensed prescribing information.&nbsp;Point values for these medications&nbsp;were not available in the original publication of this scoring tool.&nbsp;",
"     <div class=\"footnotes\">",
"      * To calculate the Anticholinergic Risk Scale score for a patient, identify medications the patient is taking and add the total points for each medication.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168:508. Copyright &copy; 2008 American Medical Association. All rights reserved.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42508=[""].join("\n");
var outline_f41_32_42508=null;
var title_f41_32_42509="Causes of FUO in children";
var content_f41_32_42509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F69379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F69379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of fever of unknown origin in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Infectious disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Bacterial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bacterial endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Bartonella henselae",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Leptospirosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Liver abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Mastoiditis (chronic)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Osteomyelitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pelvic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Perinephric abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pyelonephritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Salmonellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sinusitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Subdiaphragmatic abscess",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tuberculosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Tularemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Viral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Adenovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Arboviruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cytomegalovirus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Hepatitis viruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Enteroviruses",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Epstein-Barr virus (infectious mononucleosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Chlamydial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lymphogranuloma venereum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psittacosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Rickettsial",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Q fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Rocky Mountain spotted fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Fungal",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Blastomycosis (nonpulmonary)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Histoplasmosis (disseminated)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Parasitic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Malaria",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Toxoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Visceral larva migrans",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Unclassified",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Collagen vascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Juvenile idiopathic arthritis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polyarteritis nodosa",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Malignancies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hodgkin disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Leukemia/lymphoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neuroblastoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Miscellaneous",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Central diabetes insipidus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ectodermal dysplasia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Factitious fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Familial dysautonomia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Granulomatous colitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hemophagocytic lymphohistiocytosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infantile cortical hyperostosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kawasaki disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kikuchi-Fujimoto disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nephrogenic diabetes insipidus",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pancreatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Periodic fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Serum sickness",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thyrotoxicosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ulcerative colitis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original table modified for this publication. Lorin MI, Feigin RD. Fever without localizing signs and fever of unknown origin. In: Textbook of Pediatric Infectious Disease, 4th ed, Feigin RD, Cherry JD (Eds), WB Saunders, Philadelphia 1998. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42509=[""].join("\n");
var outline_f41_32_42509=null;
var title_f41_32_42510="Fick shunt calculation";
var content_f41_32_42510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78106&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Calculation of systemic flow, pulmonary flow, and shunt fraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 277px; background-image: url(data:image/gif;base64,R0lGODlh/QEVAdUAAP///4CAgEBAQMDAwPDw8DAwMODg4AAz/9DQ0KCgoAAAAGBgYCAgIFBQULCwsHBwcJCQkEBm/4CZ/xAQEMDN/6Cz/xBA//Dz/1Bz/7DA/3CN/2CA/zBZ/5Cm/yBN/+Dm/9DZ/wAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD9ARUBAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1dbX2Nna29zd3t/g4eLj5OXm5+jp6uvs7e7v8PHy8/T1qAQJAQmWCAT2/3MQMEgwIEABf48EDBDyAAHAh28a7BOyAAICCEIuIphoAOOABg0CGABAYIGAAEISOAA5kkhJAQ8IGDA5cYADkwtfLpA5McFI/5UgCQQQgBFAAAcwARhgsAClTwAfGyw0inQBxKtgFCAEgBRASAIT+k3wF+CBgQIGCBRYuBbAA5QwCUCwSqTAPgcCBxCQaFSAAYFeMeIdIECIQgBxIawlwGCkAgeB1UJYqHCpAcsAFOzji7WzFgVECJMsYJfivsYQHhgeIDBAAJOIF4oegqAA7cJQGxhFmRnAggYORs4+fHj4QtBQCx+ODYF3AIzIXXuefqXxkLkMx2ZksHL36gFrB7COnTw07vLlpfcGkGDBBPG4icuOf1yI6OUK1UuPzpu6/ygB6EYSAws5UICBQwhAIFe4LRZWRuTNJgRYI8mk3XPe9TbVW7WNRv/ZfKut9wBGAkAWW4eIOcTffyxCMZQABwIg0EgL0JWAbQwVsMCCtcEIF4hEGCiAXwbqSBZvoBk0pD8NFNDkh+gdpgCMO3FVgHILGVQAkkKoR80HEkhQgRMSRABCGhpEsMQFG0SgQZpaUEDBERpswEQFZiKR5ge9LDARSUJYdwdy6lRwgAccHMDBBUtQcIAEVDgKqRQVTJrEBgdogOcBWhzAaREfPMoEBRLwecQFHqi5y1JEMADjn3YQik6oHjDawQF2XpBmBJYKEYEHQ4DQJgYVgCDBnKSe2UEEbn6AKa8AXFAmBhkAAGYGbYKQgZtCVCoEBW1ucOa3Hjz6QQSfZoD/QQQdCCFBu2DOmUGppJo6hKdGSHCAqZVuqwGbedYLgJjLbsAoAIbOScQHcjY8bovY3KqBEBccYAEAHlgggQbADlHxpKFyIMEGGISKAQAY7IupBhJwQEGiqQLAgcaJguDoAeha4EG5Y6ILgKMiQ9utBTiD4HMGB2CgQaYoH3CBoSfPPPABCt/7KREenOzroeVagC6w+s7pKQfl2ikE00To66mnqkJ8jb6W4muBBRuUSoSjCoNwqAYdMIquyU1jcOzPourNK6bHiuqzpAD4nLKp9jb+qeNOy3yxoeomWrGdAhOBLxFIV7s14ZD6HDYAOEebuq9tx1GQa7DHLvvstNdu//vtuOeu++689+7778AHT/tUmUAthN4cAAACBl3bi/cQ2xKdvKGJVstmogdkwLijvIYpp+KcMu6zz0eQP/7knIa6tKGYin7E50NscPEQi4M/tdiqrt546wgz6//EZ3id8AZIwAIa8IAITCDwiJeJREkgA9VrXAUogK6HhapdP9uA9uYWLaLNbwMdoMDSQpi0as1tgh2YoP3Ex6lbbYBUvTJfCx+FNK0l6mLoqtytqna2R4VJdQAcHQvvh7r8tY1uRYBhmMTktmywyVMWEF3KDjUmrKnqA9jjwLhW5i4PAjBnypuiB7S3QvsNrGvuk9zoAKABomHgYLc6WRyFwDwjrP8NX7eKXP1Kx6nTrW51jqpiE8sxtwyk8QiYS0KiIvcHCwgyCTHTwq8GeY4KuJEJEbDAw4hguEF8QGtKkBYPrYCpUVLylNJIyxAM8JytOMEhRkCAa1qySloy4TxDyAfxHKAPV6qGCsS7zBEQ8EsoPCApwrQPEhpChGMWMwG/lOVRklCQP/EyAa5MAgH0MiFuGkEuIplQPkwETVQWggAOWNCAHAABXC6BmO4UAnDSSUsETKA/TJCVURYAHtk8YADHHIIDiikFQnnJPFI4j5f0mSAGGmZCB7GSA26CzyH0sylQ+WdAmTAABThHAQ41DATS6Q8ITOYk8gypOfvASnXeJFD/rrSIEGSaS9gkoQCwVAtGiQCUBgiFKELQJ1rYQ9D1+KZCQ3nAPgyQDwEkAAEsKYJBUfJTpUJlS051SQD8IRRXKrQ/yIlKOE8SlAR1aSLLAdRHBFAlq55Fqk0gTESHxBqOQIAxFDGRfXBjgHiu1A/LUU9aZTSWABlBQkUYwE4JIABpFiExi7GOPsOKywEwAKIMcUphLKsXBmwVO0TwqGtQ+hb2bLYxjIHlTJVTFLN26SSuAc1Z0tIWlEJAQIgRAo6MYhfVImAk2FmOrCwbV6JAIAHtHIABJjBTfuLmoK9JUDb/2ofA8maw7CHNdBFLBAMYiEb7OGiE6GPUoO51CGqZ/0oCJqId0RgHPUMAqXgw2t7NPreiC9CRERTKT/GAJjUhEq5rcdmeAjxILk3Cknkh6tAEDAlWhFHLQQ7Dl8bMxksC2UoAVEpdPSynOYZR7YQ8egTuFkE6ExgSAwZChOKQV5/MzQ1E/xTR9biXvNydqo3t26WKOgCk+x3CQjMknwXn9shFcDAACnBX0UhFCDFWC6yUIBrpuBgBhcFyl4oiEBFvuMOAWE6HwGKEA8UosedhpVJaklUhV9TFIdIncNyCESmvki5LLhCPxwvXHueZQejBaXcJJCjXZqg3XfnzYbrzUCRjs7mZ8YeSAdwdOzsBsctxFXv9IeguF2EBtgRzHv+wPIEC/PIBpJnyAlTj6SGgOsUO6ahSrmTqE78ZSFIqQo8EQJYUD0mWeq0NSPYM59C6WUZOasBmU7wll8ToRl499oJRvSPKXKmxruXnTF1lJPa4CjaMhZFDAuBrbC8B01OBwGVTQppfKmhIuFGLqJuxW0CxB89TQEh7quBXlwQq1C0WQl8HoY95LwOdPHUVr62QAIVP9wlDKmqrXrXMIbka3324kcE3zvGOe/zjIA+5yEdO8pKb/OQoT7nKV87ylrv85TCPucxnTvOa2/zmOM+5znfO8577/OdAD7rQh070ohud5slM+kj6HQV8PAfgAm9lRp7edG9u8+FfYHoVVEr/TEj0gwzMRK/VvVkEcLbE6XrFAgFEzIT1ViPRIJEnZBg6hS0NQN1HYAw7cQOcBGjnCR39KIe9QHckmPgIfj18HAq/BPWEXQyDDXyXgLzfkTKgpCetaBW6/gTxQoPMS8aRdh7D1gmZhDdPnUxfqmTR8/hjJgJogENeCoDLt3jwJYaRP+gqI2Wb6Jgleq3sjWIf2QzA7VANvmkXoM+1Vkk86w2AZ/U8fKYWhPiwHz53o1IgE03UAVOxyfJ5k3wTHaX0LjFJW4cEmcD7pCc/uYh4lF2lIYnkKdxPyUoaAHWlmKT6TVUUUaFOezVXCrERAndX67YAaad4SXB+MYETSoFN/1tFElv1ErwBeyglUOEHGUgBgEMhgCAxFbwhHr23gXeWVReRESPVgbkREhVyevoXVYbQWAhQIwiAIprhFfvQFqWlIBtWWok2IRPwTwjxFzJyWYJFPBSSZLKDZiaFXJWBFoxVIAPSEbqBAHPnZ+SmVLNVhSshE/r0WwCAHV24XmvhXT61FNs0ASHRG0gIGIhlGZbBGOJxeYlWImFoALJFhVKyGbDSAIIxe1fIh6zxXkDIGsBlFTWiF5XRGJiRGBi3Sg4hhwTCGJdBhW3RelGYXMvVXBeGT9EVGrITajvIEnJYGO2EGBjhgyjRFjuVEgIiEXt4eZyFiXQoWX4WFnJRBP+XyBdfERZ5GByayBYL8YMxAVqF8BzHhVwgth6u0RqvoWAAcE+xVQSsJAATYCMmkSTXRTyxSBviMY5oJmFV2E6jhRIApY3H11sLJh3qgY5DESAmok8IdiUZMhsN0BTSBx/xlRLdCF9l6BwYIRCCVnuXcVlz1hvyiFIrMgS/ERz2cUzvsWMBNhX3WBhL+IwYUmxH0B4CABrGAWDk0XrmSGGnYQChSBu2113jKB7Z9JAiiRv5ZRXSaBIoIl4TkJBewY8EMpIECY0owQBGSARaJmMSNhGQeFkkeYCeNY18ZghRcRn7OBX80U/i4RDC9ZJJQCAPAGoMeV2wVCMf+YQIZWX/BdFfymUgWulPniWUGfIa49hXVlkETLZNGlmC8TEZMCkhoPGVjiGQ+sEb+NhcI1KSSaKWgXloAPkebEkelHWRutVkebkagxmVRgCYGkIfS3iWP5IcWnaUGJKEbAcVpdhn6jGTQvBjshEeh3hftgZiRDGOeGmZzoESK4Jgf4ces/EAfzcXh7mEWDkeHlkIDIAjBbBuQgkWsNSWIgUh4jghjRF8fIhsJBFjZDlML+lQ6GZZCCFLqpFeX9cV2oFR6uGdGVFaBDBZklaZV9UlAiITfokYkFGdiIUi2PYA+vlLjGF76imSLakifmZRmVUWHhJp1pleiNmeRuFurIEj2FZs/xWYIPWpmrGRaJt4Xg0VKG2mHZ3GAKWpFNsZkwOqmkthWWnxIDICFv5QWoNmHYZFEipJH/jpEOWpjrrFQBciGGYmnbaHoXqhos7pgH+wjxRxHivSI822HHtBGrilFA3AbZAhEDCBHKhWGh0Fb1N2brh0GDcCIw6gFrG3FkIiaOoWeyjhJV96IOEWAPrUcGzlnoiRVagGIzP6j1T6ABYqZKThFLZhaas2IRGHHGu6hYypJLwmpk/CW6rRJIu6HHAKG2fRWIehJd9YHoBhlK6ip1FyjDqSoQL5Ycp5I7WGGAqndUcgk8mhFpABbUrqpyCheUaaI3b6Xpa6bWjqFe1WBP9FshMz4ht0Eag5Um3I5iOY+XOCcoTKGQgmxQ2FhhCFdnQ1xZLiRggTmg37NgTctqXS2q3e+q2dkExSgAAweYJN4HbfhJNZwGGoinhZIK50oFwW1X8d8WUJGAAhugQPphTNoVK8hK8rWkurGY1osHZcsE2sYbAEyq+9hAZfxwTOVIO4hwTqga5S0HBgCaJYZ2tHUBGA9lgT+1hIoE/YZQSMlwQMZbFoQKRTYh8kZgQ3An6zqlTpFLIiyxAEcWauJhUOdnfFJGhsZRMl+4Ca1wTIwXnjegQzwWJ/1x0GQhAx6gQnmwTL8Xi3tAdDMXwOhlJLYZ7FBxXHRxD0t3snoZL/CwF7PbF//RchHgUrwJd23oGBSsEUrjF9q0S3/tdmqwS1xDd+QVUVcxuOOuEPpEcXJXi2AQgVbRsaeqZ8QoYUv5R6WcJW/pB8zkG5UHETlWq3qaptNbJV/bFVO6mtXla0ShBPh2ls6MUqc1uG+OZKSBF8zke29zcSTDWB1/e2iqsPt/tTFchUIYgE/TYbfmIa1UhLrjS4bsF+u/t+KRF/k7G1KNG1TiEcI9glgGtod3BbMtJ+TIJNTFYf3nGGZIgdjSgUQ6kXfCGJVHu2ICVikIGJRCAdrigZ7SivEKV6vwhhboibXLGGyHGK4Kt6QyCIXKEigAiXtwiJ7zu/+Hp5/7cbWpBhwIkohIXBixhhwX3xF5d1I/hrslBlACExlJVIIPXmooYxZfkQO0G2Sl+ZTbEnkbrlEADmuLoGwftQvozIT1VYHgPQv1xRiO8rGuZpFQsMdcOLG4w2FuCRBAaMF0GMi0NMXonITRJhv7GRi46RwI2GBzfyVFEHhIjJhbyRkXGJr7jxEccKskZmURTJQNH4lLBRnCFylGrcev+4kAHsZ9gVkS2xIivyXgw1SxNAwKp7H1NhjW5ae0WpyN5oXiw7p6/jur5BELikpvFErlx5s91kwyRxW8dZUqoBtBy2XARsxp15Y27MjhYZY9XYqaQofa4xZRIyFt3hgH48kf+sHJnksRzZ+Jb4cXdB+ZBIhgcA5VlLARlo+Y5pSpiUecazgcgCycblZSXO6WbDOaTxVGyINZ8CBpcl2x4VCch+JshGIB2sVJj/WB5bSY66uZ5cmZrTDFdVRlWXB8HLyhnQBrNmGXBolgQYZRkL2FpGkM6FcZf1HCKqbM2QeV6EYqGDZbbhwXYS4ifF+4lJIM42QcoW2ctnyx3eEcyXSczt6gbjqRA4glHKd6MZohWm1aC7SBYkAiThdHttDNMK6mbMCSHFUW+GYSI7ilDm9Z/MTJ+JlVlwydKCnE2zVCGTxRAz/ZwyAhU5ClRTLc9NnBJsJyvqoX5SbU+SVmO6tp3/LUzV+1QErcUZfWofgjIeAufUCKpkBuoVrbpnBqqgLu1k7acb71XW/7yaBoYQG4gPoVGg4dkWLj1mtdWaFAEXJnKAECqgh1bSbVCmDpFfuSokZegqb1ix31YYk+pYvbp7QEJ52SFo9ngli3psr1qS+ypQ+DjaQt0b4capcKnZfLokcHmmb2irpdpjk1oaoUUlpD0hTeIkulprTYrc8jyn+zC6qjugCKAAZ2cSvxZU1yZx+lrATppNO2KsKUHdsD0k/LdKtLYPkQraV0Kun40eitoWBvFPWQZvsUZefk0bBlZMTIFemG3VXXJtBPDeWVJrjrrYFKHaKKHZlbrWcNnF/+6grHswtVkAVXJA2eNg4eJApQeZBxKOBeAnBynGreYAfOBa4iZ+4lrATA971P5MtUkm4kmw4ij+D4dhtdpbzSbLsU+QAKY94/MwgAvhEx+euX3rYMy3mrEHS0auT6+hrhDQEmBslFdisz5+Dl+42Akwi/sAGnvI5WuIhwB8Yj5lT25BVbspI7w2tFXODk0JJTvJuqChxz1Ztx9Rjzr+iPfmEhFK5WtODp1Zqc/BJQI2mzD5zdKGkhsOFQpXavna5+gApOSxFILyl1SVJPFpAETtwNfJ1kyHXQTh6OpAbQbek//YplZKa2lhf0wupdoKtzbdYqYL6tTFurLecsVb6/+4nuu6vuu83uu+/uvAHuzCPuzEXuzGfuzInuzKvuzM3uzO/uzQHu2G4HQw3ggyLu2uIBBQK9aNULWNju2owBm+YRFcZhF29YLhJLfsobZlZxIxgbb2obk5oX488bzrHhTBSxXIhLf4d736Pong/gkujeReIbpiQRZmUYx/hoxygXGlgRf7u8GA8cTkSsXJGFmOMcF3Fb5ZvJRbzIMBPwrDVRhJabyo4aA3qWD3uVt2rBvynMuIiGviK83MMcwDGvKgUGig5ZvfyR0u/43ZfKwSEs3uSaju4Y8eDcuRKdK32eA4/wkxaocStVsKomc5utNTXZxNaCEy3dJmzSF/auD/5kxnRn0ike30T+8JLxIjv5qdGjesPEJrn8ldQkIkpFEl8oyoTOIkYv9ixG0lCnaraJ/2qnDr9hatdNDhhG8LtF57FIcHiv8NYMJETrAtj7QEcPIGyxMBeBJEVnABFLBJQ1AnTJD5dBIBjLT4ZGAoiKIoBxNKXgMF5OMGGZM4/BMp+jMEodIrSOAtSIAqt6/6YUArtoIrCHMsEWAwRaAvpkIwQkP5TEQ+YlImxYIBbyQEy0It7lIBBcMoFLAu7LL9xjIvfFIpr8/6kLI66hL+1/IzdtMBkOL7Q8A9+bIv20/9y3P93nItaQIEEsCwcqAMkSDKcvlBPqFRKXIQsF6x/1ntltv1fsFh8ZhcNp/R28GU3Xa/4fF456AZXg4WQOSw0RwwoDgikPI0MA46AA4IFwn5hg4OOCwOPDj6AP4ODzIWJz0yJTYk+CoWKw+KFC08nv4sCBkBMgA3ASw4ADYS8QIhnyhmoTwCIycrLzMhhRkrTyPtnvgkJYXk3qrStrm7vb/Bw9HWsMvNz9ElDq4/9w6GMKHWCwnxZBtngWfVj2ZzAXw5AjjrQgcMmIRMupOrlqInw2YhugCA0q4DF3JFqHWqArshwhohqeUpEiF+ApnNq8UuQkh0L2HGlDmTZk2bN3Hm1MmmiDEQCoEBK8QO4r2S7o6enFVUoEBKHegkDP/JC9PEh/gevUNa5E8RXlajgISyQQ89AEqzAhAmZC2SllA0tJQLbWddu3fx5tW7l+8ThBkweeJDgY4xJMUKcaDAi1UdXmkFogWAKIM6RUwtUfgjFUkzw2YFRq0VCA+gT7omWwCr1pIECafwSEtqBOW7tm2HWNgApaNr10f6Bhc+nHhx4zEv8MpDkk+oCKt3qY5koZK0CtT/QN5HmyAiC9KYFmE0b9iQUCSvHtVUCYNVRIre594drNosOk7MSk7Jdh5ruscBDFDAAQnsi7oMBNNKig/qUA9APFy56Sf82vDApZgiiFAnAgxAggAIAugQGwMIiIKABAJIAAoCEJDjgRb/nzAgAAhKBACBGUUcIoAazUGgRhanEMCcBAQQEsghfJQiARWRIFJIJBsocYApeYRCRhqHMABEGLOh0kNyspyxxhshEPEBJgvM6TrThJJCnVPKOy4qnCp74wIJgJOJlzxxGkCAAJAQAAIHGKiyDQIIBRMJCCAYYIEHPCzgSTgEUJQABhyA4MkGHEhggh8LeKnSIfycQgFzAiCn1CFGjcKKKCYVAEYFrGCASw8x1XSIMxOFg9YAbB0CAgXIuTTTTTv9FAACCjA0zWehjVavAP4c4tIhFnDgCQe0BYDbGIFVFAoHGkCigQcmzRJFARJAoIEGOmx1CAcWGKLQJ1pdktR3/0MEIAAHBHiAgAXkZVXVJwfgt0MFiIT0CQhghPiJVEmNdQ0DCKY4gAUI5hLheoc41VsBHFCVW5DvReLVN0QG2N6N50W5ynwBldbmm3G2aeVVV7aWgSlTxldclRuAcYEEVqXi50t3hKDegleWl4AJRGwWAAMKILGANRgG4F0DEGAACgEWsILgq7Nmlus1GoDgCQQ+DaDciVVl4IqfAdgagLL9jRLuQHcFU+QEGiB8iMKjVpRdX4cwHIFmJ9CxZqmpRiLUnDHPXPM3dn6yZyQZKODWQIcm9QFIE6g36YoNBqBUqCcHk++rQYbA4VFFXlnkQBsdQFfbWxd5dQASKMBquv9J3XrKrR+X3N/YWY0eCVofCJZqA8ROvMl0bSzS4ekDqL7FB9zm9PnWsa1Z+s3Zbz/zlRHw3G0oJA2y9OkBKFKAAib43vUnR/U6RYGIVUYDGQAe0C3t5a5mu0NfqRbIuicQgFauOhjpeAYo7eVvfQAgFpisQEAC5g9GxXOWqaaEhNAJgAH1GqGssHXADrqPhjUsUM+UJToonO50UpBXv+r2hOGtKoBCKljzphZDfCHBZXnjmvM8OLYLNlFvIiMf/RxQgG6p7IIGm1qJHqBBQCVRegvIkQOvxgAGdAiJkSPe8RiHhOYtK3JtVOLYbJhHPR6HhQx4UvEK4L83LqsAaOr/3gQCGbI1BEBSOqQC94i4BgHu0HgqGoAC9Ic0/z2gAAvAGwNDJkUJctKTXNvfAqr0KBsFi4sSzN8aiteAagFrf1v8o/rQ6LUDcrKQIZNUwOK4q/l5TVu8tCQmi8QkR+2Rmc10pl4WcKsarREm08xROSjGhhodjQ2TgqPNBHDNZ46TnOU8hyEB4MdewkSd6MQGI7n3hAUYT5Dbc6O3vgktVZqTn/305z8BGlCBDpSgBTXoQRGaUIUulKENdehDIRpRiU6UohW16EUxmlGNbpSjHfXoR0EaUpGOlKQlNelJUZpSla6UpS116UthGlOZzpSmNbXpTXGaU53ulKc99elP/4EaVKEOlahFNepRkZpUpS6VqU116lOhGtWZGkBEVM1SvGYypQGc8GpiytKWykGArVprrHh5UTnOKlSrliMB9TTr6GSSVmycCEdT+FC/rgZWKCTJXfEUUBPfdTht5fIcv2LlBHP1JF7hTQ6XrFkAiJWXglHqfiMlLOdqpq+55lOylUUH7N5QgFRBQGw+HNS9Fiuus9qKqwAio/GGoCwFAAxkA6sW8RDQKH+RzVAtI5nJ6GWvKn0uG/srUZHWYNvMFqlmACMZ8TpkABVJtwo2kmW3EtYAxqqLWtNlUgLitUiACYxg5CCSGa+2rvmh67n+ktGNVMajMjWuRQArmuvo1f+q7F7sux1y7hb31YA1fMtb3DIZ8chWs74qkLYrIhgqEVgkbTkWvP3Fbe9kCWHmGiCF+20cueAFhRTti7fWrZZtUSndxnUoASAmALXmt+AAb3deArgvgvmmYugi+LYF2/CL/1SlpNWIvdq61t4ATFzwUjhaskIAxxAwx64VzokIBBQLUxXGkUFhcIWbG+KgFyh0oggLUPAToxKgqTXoTctjLVzYOKSiIrpuAg0IUdoqhTWtKWoArLVVJF/pQRV9LWzEi1KfXbc0ahqZmpi8syQvh635UY1cHCoUtcAmNuxRdY2RhLOOs7TGTV8KaIgCILeiZIBT6ZkAuBu0Idvmrfr/LkvUxEIAoLE8AAR0yGl7W8BWrbDpTedPYL1+QqR3DYBeT8BH5XObA24NwDUE7ENbuxRV8TwAVuuNiakuFOE4dCpAu1nOiuLYVvkGMw/1r6zeojWHPae+/KEzz7aO1owgsCRGNVByYTObEckxgSugkXrW4/T5At24eN5aq+LyE7OaVSl/b0xIMsKyASag20CXalWassKfgJdwCVoB109E+KkEXMBxo2sCJidevbgpR7GlTpe10kYoRzijSGJc44t6rNvC5khRi818UfQ4tQAFSiQsgFMiGgDLTV5ya0GgAfVbWQh/vnHuTepDVRcSAx4wVqY7oENSj+TRQX47RTWg/2zhKrq4pd1VLIsc4fe8Z5gEMAGQPT3vU4r39mDlcmhll6psJwcDB6A8XSf8gyl8wgdVNiNAvbCEnCXzFcwspFdVKvFa3TWmziej+s2ZZ7+ekozCPPJUxR13UDxVqzgv7Sy2qPVIYPbdDZZyQWn1xfy++upbJ/p0/X4I9RPWo9zWqlNtTKsLg2KTFtDy2QdaeKwnRwFoBMHHYv58c15i8bNvJKorK3UtN7u0mX/6DbKqd1tV/v8Mhj1tbV5RusPfFH42fYnLr3Gcrb20Qqf4SiuKnmdqYIT2yEFQkITLrESN2ChUyMiEpIDhtCrzhMYAkSTx0seqKIiYEAz+Em1MqP+Iz55EdJBIb2rP/oDnWiIpfAhJ8IBF3hSutOTGWlAvlObIySBwazjQgXJwfHjIZ1BrjMQtZVpE6UhlV6wAUtTGg0rkBKft8EqESPzFYazgB7UOj0JmCoXk+hwvjKAwC1+pz0SwBOtvbjhEyzoQCjVwb66s/hzGfBLmbYpljVywCXOoRSQw8AhQWtgOWyYFlB5nf97QWqquAObm/p7gD3elknzJe7BhdUZlEEVrbyTFzrBmfyzJj84maYqnlhCok7iNVCaAEA8HEVHQ5OxvYIxnwqSNWWysimJEAU5oAtCEk/bnBgmQkSrRa1BR2xoJnXgRUIqHkJhkn1otYAankQb/6/n85ZcIABarbpESqeqmMeESgBMrTlJuRIOMB3qG59caRxt9MZHgSQBKxBpTEQRH5RO1KBTnSbUaiUS8R2TUcQ3mycYKEQkyMcr051YMQLtAURr1BpAcRgF+SZD+T6rgYHj6guaghZqWJdRoyAD8akAuiyFtyCH5QiLTBCJXaX/gSnMeQIYKJCM1MiVVciVZsiURKkmiQK5gQrMcDIbcQCbR4UiGgwBuLCZoklS8JEtupQrQhEzEKVpw8g2SEqJgEqOWErQY0A2IS9K2rA0m6w0mCwHcCi9aJX5mgrgMC0YaQFlcZ2tmh1M8pbUI5CrdgC2JAyVlAi7tZ1dG8p/+/4VssoRg3ClEQgS8XEdh8ofqQmzDqIBWLOldxOVVlCuN2s5uFOW/AvNrXIccHqvBsGd21MXEZLDF3kVKBkBf7KtFUOwJr0tHLLOFakYcpQBjbKxFpAvG8pK5otJlLpNJzgRtRKmx8gsBGmxZMkbhbgsyayaFqAtQZOwvtUtRXnNxdMwvR+UuyStfyCa61GtXJExHZKRTvipGCOa+ipPJjpMvtTOvJujBwOg6KczxMiu3PlM2L5MYyw4xTRMvy2nKVGRpqOzx/sQigXHPiO1DYO7XeETVdE3YPPJ82GxHsO8zeVDm4uw/e83+BM1rEoBZeg7+mO1DxgZSqM5f+oczLf+NJ59t17JtQgvHQlVlK8FmlRJtq6hJbzAzlAxN2RJobt5v3cQpC4QxnODm1aqszdKxXQpFxUBpAOrszuixP5tQaXzkz6zPROGl0MAN0frMRf3r3TzoT+CmRFyQH1uk0IwUE22N1XBHS5WlSw9nRN3t2gi0G2U018gNRV/JQBfGR8mJgbzyL6PylUJuVOZsKkUm54bpeSbubLyPHzMuASVJ8/htF/fxkdIp7Azl/VaG7Wxu7HjtT5DOUenuIl9OAODOYOYILMMnWHRIWW40faKg4RZvYhr1Cu2G4uTObnju8Jyn4zQ17dBH9aRO6VAuAaOtdfiu5fqQmw70U0NVRtH/LumW7j6vCVNNp+84lQBbxeLsJuEqRVCndZwQD2G4Z3cqRXv+VAan9XNITvEQEATBZfQW9eRklP4ssOvIEn2Wb3LabwqjrwpMT9s41cemoCSdL5IyiMscT9WKxBa9JuCWziQl5wqE8VVTBV3lL/TgiVNLr/nWDwRJ7kl9FVv9zmD0z+XChlx2CL2SdRf31flAh2ShoPwGIGSnVWRGZWLh9ZWIDwmfCZTOdFD7sFJGMAvRdHqe8HJsUnIw0EY2LtKualler12BR9Xe9coADP68UGi8pVyuDg05TAnJcAFBqb1oh77wRVugNpK+yMr2lEbnpVyAh2U5ZgpYdXQk1AqO//bWLqdsehAAlIVvVqVrbeRnITVvomwHozBm1ZYF0Y8JZTFQaCx/yPZkaTEEvRZfGpccwugOq6hEnlZmIU1V20viiPYIb9Wd8giUsqiTeot04BFv5qwfJ8Ycv1HEjLOR9jGZ+DEYs/BSlDFq8SldSuUQFfKXWqRncDFrznEKmZFTs8hzmKRyZG53AS2W7CxtHUlvo7FIdOiSMumdINZGaNcS9TETe4m09FFd3bGYRJHPSrEX75H6XM83W5Edt+oSF7f/oiBsoHdSGAl1kteBilHEoJEgqVFg/OgBOBdbLhFQljfQhpF3qcWhrCmg3NImmAVKPooj9yLmcEKDjaqdBP9qgmmCWbqlZC7YU/ECe3QChV1yhVm4hV34hWE4hmV4hmm4hm34hnE4h3V4h3m4h334h4E4iIV4iIm4iI34iJE4iZV4iZm4iZ34iaE4iqV4iqm4iq34irE4i7V4i7m4i71Yhm/TW67QrkBEROhqatlga7Pkfq5kTOoKgUj3i3t4DhFIwIikdASFUDS3UW5LKiMrfwjLWHSFmNKSkNRSjnE4nGTUWiLsuY4sW4TIhFXmbDDmVOYLt4IrnWbGvMgVkXW41QKl6Zjo3QZ2kuHACoommk5lASZNFyknR5TWk3e4uqZOu6xmWD8W4VZpUotEdv1ESE5FSutl/WJUkoXqA1z/4z944jmQoDcoJA5KAQSiAAQiQJlhIjkiQDbOoQIiQJrh4AIw4DNeipahoGxCNk9nBHTq0lUKkXNTjvLuCHCWqgiUgQOgIwos5A4wIQKeQQ5wAwr+GRtO4gl4QQOs+Q2AgQIk4Jnd4Cc8wqUwZlHMBUUUdw3ycJXWmZ0fbwaRBALd6G21MKkYxAMmgg52oyMoIAI2ACyEARoYAyBCwQkyAANUmk+mQUNmuqaFQQPi4hpeYwh++jU6QKUv4AP4YAPoggJCYaE74gM64AMogKYjwCEKoiU6QKnXYQkWGgBAYAOyeSKQOQN6GgnI4p6HAKqZgAK8OaSOx5NMUYDfKJHy/8ePehmzNjq2btERtdd2XYdhi4oOpAEP9OCo/8AwyAIJKsEq/qADekICMOCh76A/Gvuxm4GfVaEplgIU+gAEQoEDZGNNupkPKkGhScEU3IGnLQC0O8IIPiAXJOAfKrufWQM9oEAd6uNCPApFNEeRlUodiOIdgCEeBkI2JAEJfJsOOOCnpUAYgAO5f7otVgKzjcIezoI2pkEr+MAqCuIg1uEn5sMJgIEf6MAT/kAJVKI/FgGyW2qdcGaflKonhuAndCEotKII1joUvJkyzoIatLkzrHu/JUEDboM8sEK6q9um6RsJniIqAjq8jeAk+GHAiUK9AYCb5SKbZXmk/iIw3P+BMEyDIlBjCGqBAypDITpAwOE7ChjEIU6cAnpCwnHBMZaiwH2bTxI8EjxAM+bhQADDHTIABPjhJzBAqfUAxrn6spfbN5I5w0UqOSTBApjDEhhhIn5CmTMgFABhIq5cEtpjCvKZFrC8PWD8Or5jxo/iA0LhM268wiWBD4QABBBhFjKgEjrgJCqgs6XZyNWBoUdKHPz8zzvZp3gcKQhaOqLApDOAz6egCGh7jzBiPk4K0CX9G4pqTX5BQYaAsafgAqhhrRHaAjw9jy6AEsyayU391FE91VV91Vm91V2d1dvqaqZknYlSjt7YDcTK8ZDkmmp9XlKkRHgyo1+dhZmFS///hBHNzCxrBi3nlQ36LHyOpxSpQNldJ+zQBUmMedhbcsQQTovUZ0duE2tysw1WRctSRyLDPZZ3RzW1PYYjbWVsJVgKLVXp6ChX9UlYmZiuiPGEaACfrt1lWH//BC97jZvoPUZ5zJCefZ6isY6I1latZRQ5COBhWH9/zYwL5V5STm8XNg46r4RKEVQ7ZOPdiFnojeIrPvLKmT7bdm5AuiHTpeiuqOWN0Ur8GuVZUjWJCwEUwIyxt0X2enHcYMjuCYl+3kP/UUfiGOdV0iJzpoKZ3oVL8mZEOOqt/uqxPuu1fuu5vuu9/uvBPuzFfuzJvuzN/uzRPu3Vfu3Zvu3d/u3hIT7u5X7u6b7u7f7u8T7v9X7v+b7v/f7vAT/wBX/wlSoIAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42510=[""].join("\n");
var outline_f41_32_42510=null;
var title_f41_32_42511="Electroanatomic mapping WPW";
var content_f41_32_42511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F68542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F68542&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electroanatomic mapping of accessory pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAQoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6popCQBkkAD1pA6k4DDPpmgB1FJkc8jigkAEkgD3oAWijI9aAQehoAKKO9FABRRRQAUUUUAFFFIzBVLMQFAySe1AC0VinxZ4d+wpe/wBv6T9jeJp1n+2R+WY1cIzht2NodlUnoCQOpraoAKKKKACiiigAoooyKACiiigAoooJAxnvQAUUZpAQTgEZoAWiijIoAKKKKACiiigBrelIfqaceaPoKYhMZ6HijBwc/wA6dRSCwlNKtjrzT6KB2G4I9fwNIT39afTDnIwf0pisIDu55x7UvHGSc0c55PPUgUKQRnPWgQdzjr3oBHOM/jQDjqfTmheuQeKAEP8AFzj3A6Vy/wATb2e08Daktiive3gj0+3V22jzbiRYVJ4PQyA9O1dUTwfQVyHi8HUPFvg/SgqNGLmXVJw2c+Xbx7VI7f62aE/hQCPNb2HT9LtvBOrSjdo/9v6ro88flr5DW13PPGN4x/q8xx9eOcnNdv8ADe+l0fULzwBq87S3ukQiXT5ZMbrvTSQsTkjA3of3bcDJUHnNcnr9jPqP7NpuBCbh1U6ptVh88JuDK5XcDgGFmK8HGRWv4rhv9b8H+HPG2jRr/wAJToafaRFJD9/K+XdQMMgjo/Q5ynGc1L3uhpJ2seieI9ZtfDmg3ur363D2lnH5s3kRGRwg6ttHJAHJ9ACazPBnjPRfGUF3NoMtxKtsyCTzreSE4dA6MA4GVZSCD3Bz0IrT8O61ZeItAtNW02TzbS6j3oWGCDyCrDsQQQR6g1oREeUoUqABjA6CqWuqFdNaDuDzjj6UA9hx6GjJx7jqBSnj2oAaAMe+fWjHb9aM/Px1HT0pR82OSKYADx3z6CgEZGO449KXPbPJoPHekA0kd85x6UoUHnnmggEZGOnp1pw4AA6UDQhUHrmgIMY7U6ilcLCAY9aQqMd/WnUUDsJgY/wo5zSmuX8bJ4se1mHhOTTk/wBDnIMwPnC5Cgw7M/JsJyG3dAQRQB1FFeQ67qPxps7/AFd9I0Twtf2f2gGzR7ht4iIUYGSmcYJbdg5Y4yABXr1GvUAoNFB6UAFFGKKACiiigApOp4NLSfSgBmDgZx+FLnAGT1PehTlc/oaMYz0yfWmSBHHXA7UgJOSCMH2pxHTApB37epoARSefyrjYwsnj7XtZkmZY9I0yOxRXwI42fM8revKi374wtdoeuK848K3q3Hwy8QeI0Kp/ajahqQlZScxgskLYP/TGOL06dqN2PqjY8FaRbzfCjRNIkZ2tZtGhtWLcsVaEA/oa5/4M6l9l8KXq6hIY0iC6iyspzCJlJmQgdcXEdyOB/Wu98N24sfD+mWaoyLb2sUWG6jagGD+X6V89/EHStTtNQ1O002d0Nzqlxpk0EcoX7XFMf7RhzkgKytJdKDwCBgnBwZekb9iHJxp8yV7dDY02WDQ5dSttEnuNPtLi9kna388x+UzNgj5cYA27Rxwqr1wSex8IeLLq3uobPVphNBIwRZpDh48gnJJO4qPlznkbxkivNPCFnqen6MqapcbZmdhBuIcxgqoCk5J5wDtz1B4ycLk+B9A1rTdVuJNT8xbcIY2RJCSzEnGB2YYZumQCfU1mpStGy33ORV5+67PX8PU+rh1wOlKfWs/w/LJPolhPKQZJIEZyO52jPrWg3StTtWquIemT25pF4GARilIyfw6UxRtU4IUD0NMB5wTz2obOOuKXr1ApMndwPrQMavOAMce9OpGyF9/ejBAAyKBC5yOMUDIHzYz7UYGfc0YPp0oGLwOKQ8c5GaU89BmkOcYFIBRn9aWk59qBQB8K/FvWryL4meJoYbuZFTUZUXy3PHIyP8+mPevuuvz/APjHEU+K/ivj5f7RkYjp15/X/Oa/QCvZzOlGFGi4rdf5HRXxVTEO05XUdgoooNeMYBRRRQAUmKUUUAJijIzjNGfekxnnHvQIQ/TvQpBzjGR+lJt5yPpg/wCfelUccjBNMkO/THNIuBnApx9cUgHfPHrQM574gatJongrWL+3jL3SW7LbIP45n+SNfxdlH41kfEdf+Ef+D2t2lkzbrfSGs7c8AligiQemSSB9au+OAt7e+G9GK71vNTjmlB7R24Nxux3HmRxL/wACqv8AGCF7jwFd20ab2uLqyg25wTvu4VIHvg8UBfld+x2MUaRRoicIg2jnPHTrXjPxoa4ttQ1NorGaVI9Ng1yGRJlXL2Nz+/UA9GMM684PAPB6V7T1Ncf43t4013wrfyxCWH7ZJp1zkAgw3ELLg57GVIRj/wDVSew1brseb31vFtE0cmN4zGyY2yBlJDKSOACcA5xz3ANMl26eGmkBiMG5iZl+YBADu6E9gRgZypyFOMx2Ft/YngGa91W5DWeiyyadfzQoVkiNvKYUk28k5Xy3GORnsCa7TT/AWovYSSSX402+EK/Ymg+f7LIp3qSvAYBsllJIYMwz3Ks7WZhyu+x3HhoW6+H9NFpOlxb/AGeNo5o/uyKVBDD2Oc/jWoeSK82+GeuW9oy6FIFtopmmaytt4YWssbEXNiCOvlN8ycAGJ12giMmvSc0Rd0bLsNwCckc+tKDgD9AaBz2o79KoAX1xyetL9KBnHv70HgGkMQ+/IoH/ANbil6EYFJ07cUwF7mkOe1L1pBk9RikAZ7YApG6H/OadSY4zjn60xBw1OpvOOB+tOpDR8s/FLwNHqPxE1m6ZgUuLgMHwx8oiNMk888jGOe2Md/qavCvHt00XjPU4lCEB1Zec9UUEY+p/z291rqxGYQxcY04fY0f4L9Dxcqr1KtevGbvZ6fewoozTfx4rlPbHUfhSZyODS0AIeKU00qCwJxx0pQMY5oEKKSj+VLQA0gZzSAdeMg9KU9aQH5Rj9aYhefeg8nIBz/OhgexwaTtQByCxvffFeWZpN1rpOkIkcYAI825lYu3rkJbp+Dn1qf4ip5ujafAAT5usadwBk/LdxOcemApOfQGovh5Jb6jDrmu2zxyx6pqcxSVG3KyQ4tlwemD5JP8AwLPel8dmd77wdBAW8ubW4/OVV3EokE8n4DciEn296T1Qn1v5/wCR1v8A+uuS+K4uU8AapeafFHLeacI9TijcZDtbyLPjp1PlkfU11g4HJps0KTQSQyqGjkUoynuDwRTKW54h8YXtbXwx8SLa2cGHV9Jt9YhC9JXDCGVl7cKlsSQf4xxzz7iPmjBHOQK+efiZJJ/wz9aaw1uVvNKsp9BvVeXlQWFtJjH3v9IghI9ga+g7ck28f+6OD9PpQtgb0Xz/AEPOviBocsOrRXenzizTUZkC3AQEWmpqAttcnj7rj/R5B/EHjXoWrs/C+tRa7pKXSosVyjtBd24cOba4Q4kiYjqVbIz3GCOCKn13SrPXdHvNM1OIS2dzGY5F6EehU9mBwQRyCARyK850PVLvQdXe81Vyxjli0jXXYLEGm+VbbUAv92RWVG54yo6RNUS0d/6/r/gid9z1YdBmkA570uRyM0hNWMQ52ggE/jS85A7UY5pc5PBoATuBil7UUnANIAPtQe5HWjPHej6HNMA/OgjPTijPvQSMcdqADGB8oyaXHFB4HNLSA8E+I6hPGerkgnc0ZAdv+mY5wRyB+WPQcH3uvNfF/h2e+1++vEIRW8vaGbGdq4HPOBkZr0qvFyyop4jEJPaX6yPKy7DTo1q0pLSTuvvf+Yx8E8/SmPn5cEA47intgv6kUzqQMHjgE17iPTYmTnllJ6jjmlidjuBBXBxz9KEDAnPelCgZ44oEOIDAq2CD1BoHXPH+FA69MUfh1pDFBOce1AwMD0pAMdvfk0nUjucdqB3FJ3DuB+RFL39aaGyBSqeOmKAFz2yKxvGGtR+HvC2qaq4Y/ZLd5EVE3M74+VQO5LEAD1NbG7kjB4rkPiGk18PD2kQrE32/WLczeYSNsUBNy3T18hV9Pno2C9tTc8NaYNH8M6VpTPvNnaRW7Nx8xVApJ+pH61meJZv+Kr8H2+5txu7icqF4IW1lUkntzIPzrpc9e/61yust5nxI8Lwg8JY39yU6Hg26A+mP3hGPUj0NDuC0Os54ORxRjI96QEDrxSryOnWgDxX4jpHa/Dr4s6Y0CmKNjexLgtkTxo5Yg9CJRKcj0z1zXrPh++h1Pw/pd/akmC6tYp48kH5WQEdPqK8n+Ory21r4vhKAw6p4Xd0YEcNaTncMY7rdr/3yeldt8LvJs9Iv9DghWGPSb2SKFVGFaCT9/Eyj02ShfqjDtRqinsn5v9Gdnzjg5ri/HttDYXEOuXYhk0mWP+zNahnY+XJZyEqJCCdo8t3ySePLeXviu1IBHTNMnhjngkhnjWWGRSjo4BVlIwQQeoNLcRzHgi+mt3u/DOqXMk+qaSF2zTEbrq1bPlTe5wCjH+/Gx6EZ6o8YzXlVvaXmnMljbrLLr/hHElmqy5bUdJkbHlkD7z7I9g3Y/fQRsSFbn0jSdStdY0u11HTZlns7uJZ4JQCA6MMqcHkcHoeamPYSLnOaDnPtSA5A9R1pc57VYC8+tIc9jRnpzmjqcmgA59RQePpS5/Ok79PegA/H8qCeuMUfUUhIz0NAXFB45xmlHIpu0ZHGcdPanMwVSzEBQMkntSY0ee6/4yhsdbv7RvLBgdVJPORgdACeQT/TrXodeF+Lvhn4i1vxNqt5YT6W1rPcsy+ZMdyggcMAnBH1z078j3SvHy3BSw9evUltOV197/zPZzSlhadKi8PJNta+Tst/ncjbhjk8Ug5Y80r/AHu1IOo5zx64r2jxGIflx0A9e1Pz05znvTcY5b0peQBwP8KAF+n4U1Q25mL5UgYXHA/rTu+Ox680DpgdqQCD5RgkD2pQDkenpQo+lA6j6UAIMFVz1pc44OPelIB54oAGPY0DsGeeorj3MmofFSKHCG00jSjMRtz+/uZCqnPqEgk49JPpXYDnqBXJ+BQl3qHibWEcSJe6i0MLh9y+VbosO1e2BIkx+rGgGjrMgE81w8j3c3xrs4ygaxs/D07bwv3JJrmIYJ/2hBwP9lq7fgelc5YpG/xF1iUDLR6XZR5B6ZluSR/L86H5BqdGvQDt70DJ5A5peDjODR0HGB6UBY8j/adWW2+GV3qlvGjG1WS3m3HBEM8bQnH/AG0aI/hXRaXNJp3j3Tiwi+xa3okaqy5yJ7YlsY6ANHOe/wDyy+mWfHazjvvg94tilHC2DzcDPMeHH6qKm8QTJF4R8N61FMdthcWVyJI8FWikxDITwcr5cztx6Ck9hylovn+h24bk0vOTyNvbikGORTqARy/ji0nhjtPEGmRyyahpLGRoohua5tWI8+Hb/ESq7lHH7yNO2c5+gXtto2tQQW1xFJ4c8QZutKkTlEncGWSIH+7IuZU68+aOBsFds5IHFefPpSpc6p4Nnnkt7K8RtS0e5iG1rdhIHdFxxmKUxyKDgbXC4IQ0muqEz0AHA7BaXisDwdq8+r6Wf7RSKLV7OQ2moRRZ2JcIBnbnnawKuuedjrmt/qecVQCAnPSlyPUUfh1oIBBBAx6GgBAQT2pW4pAdw3KQc96XqccYoAPfikI7mlIppB//AF0AKeOePzrnvHHg/TPGekTadq73iwyRPF+4uXjGG2nLIDscgqCNwOO2K6IDj2pR0GaTGjyLTvgRo+nWT22n+JfFVlGy7G+xXqWwkARUXescaq5XBIYjJLHOa9eoooGMYEnoMfWkKZIOBmnHOT8uaFz3FMmw3advRc+lKFIPGBTjzkdKBnuaLhYTB44FBUHqKU0dqB2EAwOTScb84NKAfU/nQRlhnNAhaO9V4byCW8uLWOTNxbhWkQggqGztPPUHB5HcEdjVmknfYpprcyfFWu2Xhjw5qGs6pMsVpZxGV3cnk9APqSQAB3IrO8D29rong3R9PZ7WJ7e1T7R5cq7fNZd8jZB5LMWYnvnPemfFWwj1T4Z+KrOaKCQSaZcbBMu5VcRsUbocFWAYHqCARzXxB4+0BvDGvzaS7GWKGKOW3n8vyhNE6BkcDp0O0nJG5W7A11YPC/WZ8nNY1p04TTu7Nf1+B98nV9ODsrahZqyruIM65AzjJ56Z4rj9F8T6O/j7xS8uqackcSWdmsjXKLudUkkZRk5OBKOenJHUGvgqVo2BYRrk9wMCq7BB0VScdwK9b+wZNaVPw/4JhOUY7H6PyeLvDMTBX8Q6Mrs2xQb6IEtzwPm68Hj2psnjHwzGP3niPRVydoLX8QyfT71fnDtHHyLn0xTgoOTsU9yMdqP7An/z8/D/AIJHtF2Puj4p+L9B1PwjfaHpupWGoPqcL20v2W6SU28bKQZMKTzkgDOOcntg8v4Y1y6n0mDwdq6LP4fntV0blcSxoyeUjFhgE4xn3zg5BA+avBV1/ZGrLeR2yyjayHp90j8s4yef17ekXfiiTRILfWdI0v7Y9tLHIUulYoFBJLHBznhR+GcHBLfNZtkmawxcPqr5oaaqySd9bq//AA/yPbwGYZVHCyhibKpra+rd9rdF2/M+qPh9qM2qeDNIubsSi9EAhuhMMOJ4/wB3KDyeQ6MOtdCeleLfs/8AxH0zxTqHiDS7ZJraZ5m1eK3lO7y1mIM6BgMELOzEHjKyrwCGA9oyOfat5QlTk4SVmjyI7DW5J44Fc/400u41DSPO01IzrVg/2zTmckATKDhCQR8rqWjbn7rmt09OQeacegGO9BJ51dataWtzpvj3TI5BpV9ElnrKthTBGpOyaVezwSb43HUK7Z/1Yx6MPXA5riI7aHQfF9zp90VfQPEm94opipjjvcfvYQuMYmTdJjP3o5T1erHghpNGuLjwneO7Np6CTT5ZGybiyJwnPdoj+6bqcCNj/rBUbMbudcPw9OtOB65FIOnembz5pQI/3d27jb16fWqbESEZ9KMfSkHIweaQ89sE96AFPB5HFHTqOvvSn2qInEoXBxjOfWmgJMEjHTmn0z88Z6U8dKkpBRRRQMYW/eYz+FM3HI+9+Jpzj5weCRyBTQuB0I9apWM2KDxnJ/HvS565z9B1oyOMY9qQc4wM+vtQA4HnHP40nGSOc+1KOeQCPrR/F07UhiA4IHr0pc4YDkmq9peW15GZLS4gnjVmUtFIHAZeCMjuD1qDVYL2WGJtMult7lGDjegeOUYOUcdQDnquCCB1GQRvS6KirtK9ilq8q6d4i0u9eVY4LsHT5c/xOfmiOfYh1A9ZPz3RwM5Jrmri6fX9EvLEwPY63Gnmi1lYZSVGzG6tjDxl1Uhh26gHIGxouox6totpqFuAFuYVkCg52kjlT7g8fhWMJLnaXX9NH+h0VYNRTe60/Vf15D9Xtxe6VeWp24ngeM7xlfmUjkelfOHxx8Hvrfwg8J+LLSKQ32maZbrdhuGa1eNSSw5OUfB9gznnAx7B4J1fxlea15HifSLe0shbFvNiQj96ChAzvPGHYdBypqz8LXi1H4YaFFPBvh+wi1kjkwwcJmM5B7HaeD2OK1wmKalGrFNNd9CcRRdCoqcmnp0d+x+fDFckFR2x/ke/+e9RkgHgDkf5/wA//qrrPij4QuvA3jS/0K4dpYYCHtZnB/ewMPkbkDJAG0443Kw6AVyqly+QxLHjjJOf/wBf6/nX6DRqKrTVSOzOB3i9REBwduDj8TVqzhMoxGDuzxjGf8+2f6GordMFmOCBxzn09v8APH59NpNl5kY3KxJyAu7OP58nJ/PI64rXY569ZU4mh4asC8sTFWDM2MZyA3O3nsc9/fsc59P0yyjNoIHRRHtCOjgMHG0cEkcc/wBOoIAyfC+liOEGN188DMbqhZoyQRux67v6DccZrshGI4QiY25IBzx7+2Oe/HB6c1yV6lj4jH4t1qtkeSeItO1HwH4ht/EPhm7kiVZTLHJGMGBsnKkH7yEEAg9QcHnOPqb4OfFHT/iLoh/1dprtuoN5Yhvw8yPPLIePdScHsT5Ff7LuJoLmJHtZl2yJx8wI5yeze+OoB54z5TqlhqngPxDZav4euZYGjbzLaePkqR1VxjHI4ZckEHuOB4U1SzLmjHSpH/yZf193ofQ5Rm3tUqNV+9+f/B/M++ASQSQfpnrTwOfxrzn4OfE/TviJooIEVrrluv8Aptju5XnHmJnkof8Ax0nB7E+iDPb7ueK8SUXFuMlZo+jT6mX4r0RPEGhXGnmdraVikkFygBa3mRg8cgHcq6qcd8Y71zDS3/ibwta6xZ2yQeMNFldJLVJAuZ0IE9sSScRTBRtLdmikxkLXe55wPxrhvEsdx4d8RrrFgxig1kLp938oMcd1jFtcNxxk4hY990XZazlorsbdlex1mg6rZ67o1pqenSeZaXKB0JGCPVWHZgQQQeQQQeRU9tHkzSF2YSvuUHOFAAAAB+mfxrivPuPDevTwTiCx0nX5j9kcuWa31B85QqAVAkA3AggeYHzkyCuvmeUKLazGHCjMj5IjXpn3b2/Oovdq/wDX9ak86eti9gZ9/wCVGKihQRRKoZ2x/E7ZJp5Jz/OtTRPQdjmgDnNNPT/69Lz3oC4rDNLTQfxo569qQXHCigUUFEbf6wcGkAyRhRx79KUsQ+O3Y0nbBJ9eKozYnUjv657ClU84wOOOtGMkZzgD0pFIJIAIx6GgB4JyRimZPylV64zk9qcfTrSY3HIJx9aAPG9K06fQvF9xqNn4H8W6jqEM93IL6a8s41m89lLcLIodfkXbuyQMD+FQvUDxh4obYU+HGubNueb+zU+wx5v/AOqu9G3OOM+lUdT1O30yKJpyzSynbBbxjdJM2CdqL3OOfQDkkAE1LSWt/wAv8ioxlN2W7OB1rXvEOoFHm+HOt28ts5a2vE1GyEkBK8sMy4xjOQcqcAHrgZfgfxp4pbSbtrT4eX9xCb2Vg0N/aohLHcxAaTPLMzcEr83BwK6zX7O4vre3j1VIjeXUyrY6fGwaOFx83nS5x5pTBcj7vAABOGPWaVZRafp0FrAZWSMfflJLuxOSzHuxJJJ9Sa5knOomtLff/X9aXOyb5KPI3dt/JW/r033OH/4TDxvtP/FsdQ3YHH9sWeM/XfXK/D3xL4z03w9PYWnw5u7v7PqF6GYaxaIEZ7mSQoQW/hDgZ6HGRwa9tPTFcr4HjWHU/F8K4+TWmJPu9tbydO33/wAevetuV23f4f5HLeyt/XU+ff2iNM8VeK9Eh1zUfh1c6RNpKnz75dTt7n/RuSQyIdxAYhsj7o3npk185qj4YcH+E85H+f8APTNfpdqSW8mnXcV7GJLNoXWZGHDIVO4flX536n4bu9Cu4bW/IxNZ210jEFQ8c0YdceuMlSQSNyn2z9PkWK3w8n5r9UYYjRcxWsLRn5ZPm4x8ygnj0P8AP17E9PQvC+lAgs8W/LbmG4huh+6MjgfXPOM9TWP4Y01rmQRoDujAEZZe+MZGDkjr09eoPFek6VYiO2hwQbaJjKB1LtjggnjaAT0GOh7ce9UqWR8hm2M+wmaFhbBUXaEycYyAMZXHOcdATyffpVu8J2MiNhiSW5IJ54z3zwTg8/UgURkq6qjsMEfMueDjI49e3179SacsjFGCqm0DBGQMA59+mMe2PTIz85mmMVNW7nzSTZSfeDggMWODwMHtn/P596inWK4sJLadfMt5cMwx3HORk8HGRn0z07vuGUFzJnk44ABPfn06nn+fSo7dyFY4BAHU8dvbr/iB3wa/P62OqUa6qwdpJ3/r16m9NcuxyF14e1PwrrUPiHwq7wXFo3mxGJtwUcDn1QglWU/TPQH2/wCHvxj8Q+NzcW2k+E9Ke/tVUzRS62YWYcAyqhhJ2Z9zjgHqM8MkxhzvIdOPlK5zgD/P09qyJ9HaC/g17w3cSWGsWTmWKSMc7uM5XABUjcGB4K5GOMV9jh8dhs7hp7tVee9un9fkfQ5fnUqTVPEbdz6DOvfEHgL4G0gDbnnxB/8AaKh1ybxvrGmXmm6h4K0Keyuo2t5U/t9xuRsgkH7OCOOncdetSfCj4hW/jKzltL+NLHxLZIpvbIEhSOgmizyYzn6qTg9ifQOF654H5Vxyg4ScZKzXr/mfWQkpxUou6fp/keKrqfj3X9MuPDmqaBo019YFLa9nTWXhlLGIPFdx4hOz5hlXGfnVgACpxr+G/Enj+4Fzpw0Dwqb7TGS2uYV1aWMqSoKyBfKbEbg7l5JxkHkEDa8eRHR7y08WQoWhtkFpq6bmUGxZ8mYAA/NCx8wHshlHUin+JxJolzH4qs7cPPZp5GrRRSnElkWLGUKB87x5MijGcNKoyWxXO0oysvzf+Y7Wen9fgIl/8R2RyfD3hdG7BtYn9vS3rO16D4n6zpz2Fqnh3Q5pTGRqNrqE0zwbWBYiNoQHyAw2kgc9a9FtrhbiJZF43DIGc5HqPUHsfepCatcstV+ppd7p/kYvhqy1jT7e9TXNXGpyTXTy27C3WL7PCQNsHH39pB+c4JzzWyMcUuOgoA5GaokUeuKF6UnAIAHenAYwO1BQDpS0d6KRQ0g5yKaB8oAOKf3pvXnt25zmmS0JtzjnGOaAo2kZ9uKXcMj9c07oP8KLhZDdp9aNvPFOB57UAjOKAshu35s56VXWytor97xY0F1JGInlx8xRckDPYAkmrX1NQXttFe20ttcoJIJkMciE8MpGCPxpFJ26mN4dc6tdya8zObadPKsEZdu2DOTJjrmQgNz/AAhOAd1b6gjqcn6UBQqBUAAAwAOgFKvTj9amKsiqkueV+gVxfhC8kb4g+PbFo1EUVxZ3CvggsZLVFPsQPKHvkn2rta5Kyk2fFLW4t4LSaPYOFPH3Z7sHH/fQz+HrVWM20tzR8dXU1h4J8Q3lq5juLfTriWNwAdrLGxB546jvXkPxj8EpL8N/DuqyQTpqGiWcFtcKhBAhKqrFxySEbDcHgb+vWvUfihN9n+HPiZ/MEbNp08aMTxuZCq/TJI5rpJokkieJxmNl2keoPBFa0ajpTVSO6JqR548r2Z8i6HpSrCQwWOUkgo27oD04IK9Tg/7pGQMjp4Qiw/dyBkkuOD6n06/h9OQbV9on/CP67qGknB8hv3LMcs1uRlCeMYAGDgdVb6VSkkPKI4ByFGwde2D3z+Ocg9cZr6evjY+z9otnqfmWLhUhWlCpunYjnkGCH3eZj1HH169/x9e2KmdsO7oHwcL2/nnv/TvguHIZV3EADuAR/hjn6c9hURkC8birjj7oGOOc/wCfw7V+e5pjHUu7u5ildjG27T0OeAAe2MdPw7/p/FHI/wC7XrkcjOOvb9Mf5wKex3oFTJAHQAcHHHI/z79MNkDmMg7QAvJwDwR/k/5Jr5mrNylfzNd9ERIS6+vHXr/n/PfNOBaKVSWRcc8H7uPp/n+ZuWqq1wqT+aFY7FwMHptzzjoePw/Al7DcfZrMW1m90006pl5RH5cZ4Zgf48HGB3J47CiFWVOXNDR3NYUXU0IxuuL21u7S6bT9Ws2MltexY3RPjoezIRwyn5WHHHAHufw18dReKIXsdSSKz8SWsSvd2iZ2OmSPOhLctGT2+8hO1ucE+CzwNBM4fBXnJx35685HQ/lnnk1Zhlk321xFcTW1/ayCW0u4eZLd+mQOjIQcMh+Vhwf4a+swOcxxUOTEaSXX9H/X4HoZbmU8FPkqawf4ea/r/g/VDKskZR1V1YYYEZBB6g+1cL4NlTw3Pf8Ahq9EzHS4vOsp5JPMa509mO3HJZjCcxkHJACH/loBVn4c+OIfFUT2l0iWuuWsavcW6EmORTwJoWI+aMnI9VPDAcE3vHFjfNZ22r6Ghk1XSpPPjhXAN1Ccedb5wfvqMr0/eJGScA16E1dW6/1/XmfbwnGrFSg7p7Mo+EFHhrWpvCcqn7EI3utGkJLD7Nld9uSehiZhtGf9WyYztbHaduv5965jWbKDxX4b06/0C6RJofL1LSLpSyoH2HZuA6xujsjLjO12xg4I0vDOtQ+INFt9Rto5IS+5JYJlKvBKjFZI2BAOVYMp9cZGRg0J/iUagyaARuPPNKRz2x9KQkEjDDB7VQCrnPP4Yp2cc0gJHoaByaRQopaQUtIaENHNBIHJOMUZFAB2560vNNyB3wPSlyMZ7UAFAHtRkUUAFB6g0fjSEdAPXmmIdRSAev50Uhi965KeHyfivYzjcRdaLPG2TwDFPCRgep85s/7orrDx2Ncd4huJ7f4j+DXjgJguYr+zkkZCQuUjlAz2YmDgHqA3pQDelv63G/GGUx/DzUgoLGWS2g2DA377iNNuT03bsZ7ZzXZ1x/xSh+1+HbKz2h/tWradGYzxvUXcTuM9vkVj+HHOK68Z68j2oFrc4H4t6YraTDrUagvYNifLhF8liNzkkj7hw3Ucbu5rxq4nyQDw6gq2/kDB7j8u2Og74H1FJGkkbRyKrxuCGVhkMD1BHpXzd4t0JvD2rXemYka3h2+QzZAaFgfL+Y9SMOpx/cJwBmscXiJQo2vofK8RYLbFQXk/0f6fcYZ3SDILbsYK5/Ie56n169Tmol2gHBZu5JwB06DH+ee2Ml5DKAQWB5zjB9sD/Of0y2TgKWTCAnJx6+/H+f0+QxFXmf3HzCV0PVSSdnQKW4HUDnp9D+XscU8I2EbpjOCV/Dnv17+vTJGKjkZlG5slmBJJxx6/kf6++bsUJ3btzNuU7iFBK+vQ8AjHIPAIHfJ8+clFuxpTjd6FuytWdXZGChSOCgOfVvvY6enUccfeGlZwLJIkcRVZ48mSSNMhRtG0cDuFPA7AnocUtlbi5kYzmQxCMlxGudoHQn1U8854OfTbV63sru4v4lAdEk3sxgiKqoLbjxn5sYHGTyPXJPNUbab/AFPaoUdFZX/r8DM8RaI1vMGVCIpV3ZY5yQSGIPQ8kDA6DHfArnbuFQrsG3RMWMYUg8DHPXsDn1/Mkez61okV1oypEv2d1U7FVAAcDoR0HA6DpyM4NeUanp0kBw8Tq7E7gc4RgduBx0znPXOOgxg3h6zltowzTAewldLRmZbzyQXFtc21xJb3lnIZraeLO6FsY+jK2drKeGGQcdT718OPHMfiiGWxv0jtfEFooa5t03bJUJwJ4S3JjPcHlCdrdi3hYTYHDoEO7KLz6rjvx6/48ERIZhc29zZXEtpeWz+bbXUBAeBgOT6Mp6Mp+VlznA5H0eDzSVGXJV2MMszKWClyPWD6dvNf5HvmhhvDPiu40Apt0nUjJf6a4UBY5Sxa4tuvXLGVeOQ0g6R0avu8LeJY9WhVjpOrzR2+oooOIJ8bIrrjs2Eif28tsgI2eb0rXo/iR4dk012h03xppLJfQp82xZoyRHPHnloWOUcdQHZG5IJ7bQtTsPGnhITy2pNveRPbXllOpDRuMpNA4IByrBlPHb0NfTRmpq6ejPtqc41IqcHdM3znPFJj061zHgq7nt2u/DmrXT3OqaSEAnlPz3dq2fJnPqflZGPd42OACK6g9e9UncrcATilH0ooPp/WmMVc96WkAwc0tItDW5yP6U0dsUp6k0g4X7wNMhgeTzn2peOxpOhx+VLmmIPxo4yOtGPTFAOehGKQwB5HI56UucUnPrinUAg645paSjIxSKCub8WgLrfg+ViAE1VgSxwPms7lR+OSB+NdIK5jx2Vii0G5clRBrFrh8AgGRjCMj383bx3YHtQxPZjvGcC3Nz4ZhZsA6vG+3ON5SKWQD8CgP/AcV0ua5nxVcxJ4k8H2rMwml1CaRFGcEJaT5yRx/EvB/pXTUB1AnC5zxXnnxh0Jr/QE1W3iBuNPyZVJA3W5xvycfw4D9f4T1zg+h5FMmjSWF4pY0kjcFWRxkMD1BHcVM4KcXCXUzrUY16cqc9mrHylIhSfaZBk5yVYYB/8ArfXHocc1E23JA6qCOB19f/14/Drne8YaMfD2vXmmbStvF+8gIyB5DZ8sDOc4ClSe5QnHOKyQk+WKqTxng9x34P1wfbjnmvh8TCVKpKnPdH5xWoSo1HSlumEWGBU4Z/u/N/D0xgDnH6/jitnTLAyTxxrIoRsFVc53HrtUnGCeRzx1OR1Fa2hjJJwFyuPlIB9yc8HIYDjjnBwOvRWUTqUEgRXMZXEuDvQEEbffjpwTgc54rzqk+up2YagpO7/r+v67CyCSD90INkUbgOAcnODtYnsMr6AcDrnnQ8MtIt4rbXjaBPLjWVcKT90E8/d5B44/MCoVtyJA0O1ZwCP3bbMhfUZPHJ78fhuGt4ZijnnhlMarGwI3Fd44BXauScYHB6nrknrXLO0YSbXQ9vD05OtGz6/1+h0mpXRsmhmk3ncCJlAJUAjk46dj+eOpFc34z0O2WCTULdEAUgeWynYCOcgd+p4HXPByeZfGtwFVkG0Oo25AGT/9bkf/AKt1M8H65a3thJb3jLKpVt2VyoAClh+vHfpk8iuROUPfSPs8VlP1rBqVjynTfDU2gWdxZ+ddXBkuXnJucF1L7SVJwM4wc5A5OcDusi5LcjJyGAJ4yccj1GPr06nivY38OWF/HII5VnSRvl8obfJ7E8Hn0IPPJ9xXJ6x4VmgRRHGojZlG9cYBz/Eew6jjjAGegz6ax0atRuVrs/P8fk2IptzaucEBNbTW15YXX2TULV/NtriIEtE/GTjoyspKlScMuRxw1ei+C/iDZw+I7q91JodMXUUQ6pbMx2xXKrtjvIsnmGVUEZ4BV44wcliTxWoaX9mKPuiw+GUF+cHoSOo+vQ9s8gcd46mubbw7d3Fhu+1Ro3lyBcuqswDEHt8pPT09ea9zLcdUpyUItNS/B9/8ycnxVXD11hn8Mnt28z6Y13UbXWTFrfg66ttS1vRNzm3ik+a5t3A823PuwCsvYSJHnjIPY6de22padbX9hKs9pdRLNDIOjowyp/I1+e3wM1jUdK+LPhqXT7toTc38VvcFnwskTuFcNng8E4z3xjnFfcmkxSeGvFNzpyxgaHqzvdWRHAguiC00GM8B8NMvH3vNz/CK+uhzpe+1fy0/V/16H2b8zrx6+9H1xmgUHOa0AUcjilpB0paRSGN14603jpnNObdk4xRg0yGhMDp/Sl46Aj8qMHGMAUEE4BwaBC8cUDrRg0m3j6dM0DAGjgf/AKqcAc0cigLAwyKQLznP6U6ikVYTFcT8ZWvIPh7f3enBftNlcWl6CSAAsNzFKzc8HCoxx1OMDJxXb1znxIi874e+Jo9ocnTbkgH1EbEfrQ9hNaFTXYVn+InhMSKjGCC/uk3dVYCKPcPwlYY9G9q6zHNctcS/aPiPohQkouj3khBBGN81rtPT0VutdXTuCG7fpRjjFOpAMdBikOxwHxj0iG58MTaqsDNdaeu4um4kQblMnA6gAb+5+U464Pj8ETJneXKL84aMjeQeOvvkfp14x9OkEghsEHtXhGt6RcaP4insWIVVnEtoYxhTGzfu8g91G9Tg4+XPAJr5/PcP7irx6aP9P8vmj57OMEpNYiO+z/R/15FTRLMrdW/Mksef91sjkFTjBwN2c5HLd8iugEUqWbHYo2oSoY7RtAJUgk5AwSAQOWXsOabpllIU82XYXjZEPlY3BWPzHeOAAVyT0z17Zuy+csDRKUAUgqxUuq4c8Fs4HO717YOTx8VOSlK7ZGHw/s6exmvbieZxajMalA8jovVQf4uCRjd07HB4rrNDidZJZmKhDk7tgxJlg24H0+Yg/hnnNc2irtidpJGO8kbvlZQW7dc8cHrn6g10cmoWOkaMbvULuJNw5dGB39Pugdu5wKyre9HlSvoenldB1K1orU43xvcx7pGSRh87E7Oc9SB6Hgnp6Yz0B84hvNRmuJNN0O8ghvbv/Vm4BkCxhgZCBjLHB9B97tkgWfFHia61y5l/sUNbGRSouZ0EmDjrs6Yxg4OecdtoHY/DTwdZRXNt4h1W3dtQs1ZYbiUlTHuXa2QGAycnnBxuPfk9UIrDUuaa16LfXpfpa+/l07/qVRf2bgP3sbNpdfv26rp8tdztfCmnS2VgtxeTzDbh+WUjGT8vB4+g9cZPNY3izXne7ijt5ysaMsiLggcfNluzKeufbjuRF4q8RjyY/LGIZIgBCcAkMeWIBxgggg57Z4zXATzSyNukLdQo564yeR3OSffPbtXNhsNKT55Lc/JM/wA+lXk4x/Affzi5uVfzpHB2qCxJY4HXP5+n4DOaTREoV2sQ2Ay5ySOhH8vzHthYonkcBFMjcYXnkA8cen5/XPNP0+6tric2dkZL682kpa2MLXMoKjkEJwvB4LlR79TX1GXYGVeUUtNP0PiV7StO0Fd+RFZaDpsKSeXYWkaTIUlKwqBIpyCGwORx759jnGvqPjz+ydNGkaneXV5pDgeWQ5a6spFdWjmhkb75jcBtjn0AYgBW6DT/AIf+MNXjlR4rTQLZiyiW9l+03ABUfOIom2DnjmQ9ORgAHq9F+CfhS0YTa2lz4guhg7tRfMSkekKhU/ME+9foGHhgsPR9nNcz+78f+Br5n0WV5fj4VfbTlyp7pu9/X+ro2vhb4/0nx7orS6feQz6jZbYr+OJHVUkORuTcMmNirFT1x1wQQO1rO0rRdM0lpn0vT7WzM3lrJ9niCBhGgRBgdlUBQOwGK0a4EraH1ivbUUdKWkBzS0FIaTzS54oPXvSAUxAW4yOR7Uc4PUUED0+lHQe1AaiigUgHJPalpDCjPSgDpSdxxQIdQORSGlAxQMO1Z/iG1N7oGp2gRXM9rLEFbo25CMH860KRlDKQwBB6g0Ia8zzTwPftrPjHSL1XaSH/AIRK0uAWwu03EhOQvYsIeeuNo/H0yvLvgxChbftUSWuiafp3cFRE9yNvOeORz1POa9RpLYiG1/62Cm4ByRS4oxwaZQn4VxXxO05DpSa2hSObTQTLK4yFtiytKTyOF2LJ3OEOAScHrL+9tNOtJLrULmC0to+XmnkCIv1JOBXB3fxT0ieONfD1pc6wJOPPYfZrcccZeXBYMOhRXHrisMVKiqco1mkmupjVcFBqo7J/195j+C7rStZ0iKfw/LDqdsZykjqPlDIxBzuIyOAVHo2T1zWq9pHa3kKTymBZItpVGwpU5XaxPHA5475POKp/DK31ex8NXdrq8umfu7phYxadnyre22rsiBZQSVO7qCfUnmsHxzqd9YafJf3NvLLJDykCTR+a+GwUChhn8PTI5ANfmNSLlXdOk7q+j/Lt+R0YLA4VpOtNRiurdv6/rQu+O7LQ7PTLCa6urnzba5ivoY4JQBPJCwKrJ2KZ2NtGD8gIIArz2/8A7Y8Xak1xchtjOdu3gAZJ6Z9V69OR7E6+mDT9Y1RWkvptVulQEWelQyXHlxggYzjaMEqMk+/TIrvtKsNbtTBHo/hOWHzj81zf3kUaQKOR8i72ycD+HIz+A9CjgsXypU6cm7aNqy/GyPewuZ5flUP9k9+p3Suvk1p/mcLrfhu78K+DbjW4LCC9ltMTT2bsVaWMcvsYHhgCzcg9G4BJrK0/43+GdX0q1srRptGuQVDxXaL5Zwc4Djj0+8ACMjb6etS+EPFGsl017WNMtbZlx5VjbNKyk5Bw8hAxgkcp7143B+zDdQeMNSuo7u0m0S2kWbT7a7LZu/usYpSmNi/eXcMnocdq9nBcPe0p/wC2r3r3TT/B7r9Twsbjq+Y8yqXimMm1Jb3UPs1u0t/qcpD/AGaxiNxNkd2VAdgGcktgZxz1x0+k/DbxZqinfZ2ehQ7x+81CQTyEYHKwxNt6ZHzSDp0716/4A1HSZ9LfTtK02PRbjTyIrrSVjWNrVzz0UAMp5KuOGHOeoHTbcEEHjv3r18NkuHopc3vP7l93/BZ4FLI6EXzVW5P8DzfS/g7oMbb9au9S1lmBDxXEwigY+8UQVTgZHzZ6mvRLK0ttPs4bSxt4ra1hURxQwoERFHAAA4AA7VNQce9epGMYK0VZHrUqNOjHlpxSXkGeOlIffIpx+lJ+dUaMTt6UfhRk7unHrmgEZ96AHDpS0i9KWkUhDR+NBGSD6UDpxzQAtFFFAwooooAKKKKACiiigApKPrXnHx51C9sPBIWydo0uJ1hmZR1Qqx257ZIH5Y700rux04LCvGYiFCLtzOxW+CE4b/hKrd7iF5LfWLmCFFbnyFkZkIB5KfOQG6dh0r1BmVELMwCgZJJwAK+OPCd/qem+IrCfQpI01EyrHD5ilkYsdu1lBBKnOCAc+nNe1ar8HL3xRv8A+E28e+INTR/vW1oI7S14bK/ucOvHPJyTxzxWs6ShLlb0PSz3J1lNWMIy5lJX7HS3/wAT/DsRuI9JkudcnhcRsmlxeam44+XziViDYOcF8/jxXnOtfFbXdRvjZaffaRpRmYRwQWLf2hesxzjsUUn02MOD81eiaT8JvBem28cX9iRXqx5C/wBoO11gHsBISAPYDFdlY2Fpp8JisLWC1iznZBGEGfoBU1I0nGyb9dF/mfLVaWJqtpTUF5K7+96fckfPFz4R8T6vfDU7nRNU1O9Cfu5r6WNZI1z91RKyhOcnCgevPFdLo/w08SSsk17e2OlnO4iN3upB1yM4QA4wQeQOR3zXtWOKTtXnrL8Pe8o8z822cscnoc3PUcpS7t/8MecJ8J9NeXN9rWuXEAOTbC4WKMnGOdihs9TkMOtdLpXgrw3pMkctlo1os8eSk0iebIuQQcO+SOCR16cdKx/i547m8DaJaz6fpn9q6ndSssNmJNhZEjaSR84PCqh49xSv8TNH+x6HJZ22o6ldatZDUIbTT7czSpDgZdhwAAWC+pPAGa6oUqdP4IpeiS/I7qeFo09YQS+R26jYAowFHQAYpRyOtcSPiZohvbyJLfVJLSxO29v0s2NvaMI95WRuoIUjPBwTg4NZVr8a/CEmnajeSSX1slnDFcFJrfDzRSOER0AJ4LEDnBGecVZ0WPTPxoPXrXnFx8YNAtorDzLLVxdXpkMNr9nXzGVMbnB3bSvIHysSTnA4NaEvxO0CPXU0uRNQU/aYbKS6a2YQQXEqhkhkbqHOR2wCcEigDU8UeGhq0lvqOnXX9m6/aKVtr9E3fLnmORf44z3U9OoIIBpvhbxP/aVzNpOr2407xDaoHnsi+5XToJoW/jjJ79QeGANYy/Ffw4WkPl6qttDff2fLdtYyLbxzeb5WDKRt+9joTgHNS39zofjnw5darazXcH9kXFwLbUoV2SxSRZV5Ij/GhIIIOVYAgg0AdwB75OOtLn3rz3w78UdH1G0VCmpy3S6UNUR2sTF9tiGA7wqSf4j90nvwSOayNQ+N+jLozX2k6XqF7NFqVvp1xa7QrxGXo2V3q3AOADyeOKAsetfjSV5TbfGC2tvE+safrmm31vZW19bWkNzFZuVi86NGX7Qx4RtzYwOfat3/AIWl4YF/bWU11LDcTXV3Z7ZYiPLktgDIH9ByMHvkUA0dwB6k0uMNnpnivN9W+MXhvSdN0rUb+DU4tP1G3juo7k242KjsVUnLZJ4zhQSAQT1FbI+ImgnWv7I33J1L+1P7K+z+Ud/meX5m/H/PPbzuoCx2ApaBRSKQUlLRQAnOR6UtFFABRRRQAUmKWigBMUooooAQ8iquqadaarYTWWoQJcWsy7XjfoR/Q+45q1S0Di3FqUdGjh/DHwx8PeHdW/tG1S5nuF5i+0uHWI+qgAc+5zXcUUU5Scndm2JxVbFT568nJ+YUY7UUUjATFGOKWkoEcl4p+HuheK/EFnqviCKa+FnbPbw2cjjyELsC0mAN28hQv3sY7d6w9N+D+kaTa2Eejazr+nXFjHNbw3VvcRiUQSyeY0JzGVKBuRkZB716VSd6AOEHwx0pbq/Mep61Hp+osXv9OW5H2e8do/LdpMrvywA3YYAkc1T0/wCEel2GlXWnW+s62LaaFbdQzW5MSBg20fufnHygHzN/FekUUDPJ5fgT4ZfQ10kXuqpZGWWaaMG3KyvIV3NtMRWM4VQDEEwBxWwPhP4fTV4ruKbUorNLmC8bTVnBtpZ4VCxyMCpckBVyN2CQCQa9AooA888QfDmI/DLxN4Z0Nlml1aSe5VtRkwiTSvv3ZRMgK3I4J4GT3rb0XwomifDiHwxYMmYdPa1EjZAeRkIZz9WJY/WuoooA8i8OfBWwXwkmn+KdRv7+/fSE0l2S4Hl2sYIZhb/IuAWVTlwxIGDxkHRj+DmiLYapbvqmtPNqFxaXTXRkhWSKS2GImQLEEHA5BUj6V6Z3ooA4K6+F+kXdrq8NzfapK2qXdre3ErSR7zJbhApHyYAOwFuO5xiqHiD4L+GNcvfEd1cy6lDNrjRvK0EqL9ndCpZocodpfYN2c59q9MooA8y8VfBfw74ikcyXmq2MUlhDp0kVpJHtaGI5QfPGxUjj7pAOOQat2vw/x8a77xvcraiE2CWtskbMZGl6PK4IAB2YQYJ4znFehUUAFFFFABRmijFABmiiigAoopCKAFozSYpaACig0UAFFFFABRRR1oAT9KXNFFAgooooGFFFFABRRRQAUdqKKAEzRzmlooABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electroanatomic antegrade mapping in the left anterior oblique view during sinus rhythm shows that the earliest activation (red) is near the coronary sinus (black dot), representing a right posteroseptal accessory pathway. The orange dot is the His-bundle location and the purple dot is the location of the inferior vena cava.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     With permission Worley, SJ, Pacing Clin Electrophysiol 1998; 21:1636.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_32_42511=[""].join("\n");
var outline_f41_32_42511=null;
